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Abstract 
Controlling lineage specific differentiation of stem cells is crucial for functional tissue 
engineering, and current methods have drawbacks and limitations. Histone 
deacetlyase (HDAC) proteins are key to cellular epigenetics, and a number of 
studies have shown that their inhibitors (HDACis) can control stem cell fate. The 
aim of this study was to investigate the effect of a novel HDAC2 and HDAC3 
selective inhibitor, MI192, on human adipose derived stem cells (ADSCs), exploring 
the potential of utilising MI192 in controlling the osteogenic differentiation of 
ADSCs, with the long term goal of improving the efficacy of bone tissue 
engineering. MI192 was synthesised in house and characterised with NMR 
analysis. The effect of MI192 was explored on commercially (Life Technologies) 
available ADSCs. It was found that 1 µM to 100 µM MI192 was cytotoxic and 
reduced ADSC viability, with a dose response observed. Using propidium iodide 
staining, it was demonstrated that MI192 halted the cell cycle in the G2M phase. 
FACs analysis showed that MI192 altered the stem cell marker expression profile of 
ADSCs; increasing expression of some markers (CD34 and CD146) and 
decreasing some (CD29, CD44, CD73, CD105, CD166). When utilised in a pre-
treatment strategy in 2D models, MI192 improved the osteogenic differentiation of 
ADSCs, strongly increasing production of alkaline phosphatase protein, with 2 days 
of 30 µM pre-treatment being the optimal concentration and treatment length. 
MI192 pre-treatment also increased ADSC mineralisation (calcium accumulation 
stained with Alizarin Red and mineral nodule formation stained with Von Kossa) 
and increased osteogenic gene expression (BMP2, RUNX2, COL1 and ALP). The 
adipogenic differentiation of the ADSCs was inhibited by MI192 pre-treatment, with 
reduced lipid droplet accumulation (stained with Oil Red O) and adipogenic gene 
(PPARγ and ADIPOQ) expression seen. Increased osteogenic differentiation was 
further demonstrated in 3D models, using Am silk scaffolds. Cell attachment was 
assessed with live cell labelling, and collagen production, mineralisation and protein 
production analysed with histology and immunohistochemistry. Finally, TaqMan® 
Gene Expression Array Cards were utilised to investigate how two days of MI192 
treatment altered the expression of 96 different genes. Some key Wnt related 
genes, as well as other key osteogenic genes such as BMP2 were up-regulated, 
providing some mechanistic explanation for the increase in osteogenic 
differentiation potential seen with MI192 pre-treatment. This thesis demonstrates 
the potential of utilising MI192 to improve bone tissue engineering strategies.  
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Chapter 1: Literature Review 
This chapter reviews the literature relevant to this thesis, providing an introduction to 
the relevant topics. The review firstly provides an explanation of epigenetics and the 
role of HDAC enzymes in the human body. This is followed by an introduction to 
HDAC inhibitor compounds, the design of these inhibitors and their current uses. 
Further discussion focuses on the potential of these inhibitors in tissue engineering, 
more specifically bone tissue engineering, as well as introducing the current 
approaches and state of play in these fields. It finishes with thoughts on potential 
future directions for the field. 
 
1.1 Background 
There is a largely unmet clinical need for the repair and regeneration of human 
tissues and organs. In 2011, the total healthcare expenditure in the UK alone was 
£142.8 billion (Payne 2013). Due to the limitations of conventional clinical therapies, 
tissue engineering, a multidisciplinary area of research, has come to the fore. Tissue 
engineering aims to produce functional tissue and organs, essentially by the delivery 
of cells onto biomaterials, in a three dimensional (3D) structure, along with the 
necessary stimulus (be that chemical, mechanical or environmental) (Naderi et al. 
2011) to generate the tissue/organ of interest. Some early successes have been 
achieved by transplanting relatively simple tissues or organs such as the trachea 
(Orlando et al. 2011) and the bladder (Atala et al. 2006). The excitement 
accompanying these early accomplishments demonstrates the huge potential of 
using tissue engineering approaches to restore tissue and organ function, although 
much more research is needed, especially for transplants to be fully functional, and 
for more complicated organs and tissues to be generated (Dai et al. 2012; Evans 
2011; Bertino & Otterson 2011). 
 
Stem cells are a key cell source for tissue engineering purposes, with the potential to 
be differentiated into the specific lineages required for the repair and restoration of 
functional tissues. Increased reporting of the limitations of current methods of using 
stem cells in tissue engineering has galvanised research investigating new methods 
of controlling stem cell fate (Vater et al. 2011; Wilson 2009; Reya et al. 2001). 
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Environmental stimuli and chemicals/growth factors/proteins etc that stem cells 
come into contact with can affect their fate (Vunjak-Novakovic et al. 2010; Baker & 
Chen 2012). Researchers currently have many options to utilise growth factors, 
bioactive molecules and genetic modifications/therapies to control the differentiation 
of stem cells for tissue engineering purposes (Hochedlinger & Plath 2009). A review 
collating examples of different culture conditions utilised to influence the in vitro 
differentiation of mesenchymal stem cells down multiple lineages (including 
osteogenic, chondrogenic and adipogenic) is an excellent source for understanding 
how wide the range of conditions available is (Vater et al. 2011). However, current 
protocols for effectively controlling stem cell proliferation and differentiation are ill 
defined, challenging, have side effects and can be very time consuming, expensive 
and unreproducible on the large scale.   
 
It is well documented that both a cell’s genetic and epigenetic make-up can affect 
how it behaves. For many years, research was primarily focused on genetics 
(Tollervey & Lunyak 2012), but more recently it has become apparent that 
‘epigenetics’ plays a massive role in cell fate and controlling the cell’s properties. 
More specifically, research has discovered that modifications to the histone proteins 
in a cell, such as those by histone deacetylation enzymes, affect chromatin 
structure, and thus stem cell properties like potency and differentiation potential 
(Tollervey & Lunyak 2012; Hochedlinger & Plath 2009; Kretsovali et al. 2012a). 
Knowledge and understanding of this may be crucial for improving tissue 
engineering and cell-based therapies. Work on the inhibition of histone deacetylase 
enzymes as a tool for affecting cell properties technically began in the late 1970s, 
when Sodium Butyrate (NaB) was found to affect leukaemia cells. However, work 
only really took off in the late 1990s, and  since then, two small molecular inhibitors 
of  histone deacetylase enzymes (HDACis), Vorinostat and Romidepsin, have found 
FDA approval for the treatment of T-cell lymphoma (Marks & Breslow 2007; Bertino 
& Otterson 2011). In 2015, Panobinostat (Farydak) was approved by the FDA for the 
treatment of multiple myeloma (U.S. Food and Drug Administration n.d.). 
 
While the main focus of work with HDACis remains in cancer therapeutics, work has 
begun to investigate these elsewhere, such as in HIV therapeutics (Barton et al. 
2014), in inflammatory diseases such as rheumatoid arthritis (Gillespie et al. 2012), 
as drugs to treat or prevent cardiac diseases (McKinsey 2011) and key to this thesis, 
in combination with stem to improve tissue engineering. For example, inhibition of 
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histone deacetylation enzymes has been utilised to improve in vitro expansion 
methods of human hematopoietic stem cells (Elizalde et al. 2012), to improve the 
differentiation of stem cells into bone cells (Boer et al. 2006), to increase the 
efficiency of generation of induced pluripotent stem cells (iPSCs) (Hochedlinger & 
Plath 2009), and to increase efficiency of cellular therapies (Lee et al. 2007). 
 
1.2 Epigenetics  
1.2.1 Introduction to Epigenetics 
Genetics is the study of the primary structure of nucleic acids, deoxyribonucleic acid 
(DNA), the information they code for and how this information is utilised and 
transferred from one generation of cells to the next. Epigenetics describes the post-
genetic modifications made to the DNA sequence; the chemical functional groups 
such as methyl or acetyl on DNA, the protein scaffolds that DNA is wrapped around, 
or other proteins involved with DNA in the cell. These post-genetic modifications 
made to the DNA sequence are in the form of chemical functional groups, such as 
methyl or acetyl. The actual base genomic code remains unchanged with the 
epigenetic modifications. These epigenetic changes are potentially heritable and can 
be passed down to daughter cells during cell division, which is potentially important 
when considering stem cell fates. Although it is questionable whether epigenetic 
modifications are always heritable, and whether heritability is a defining property of 
epigenetics. A number of different definitions of epigenetics exist; for example, in a 
key early paper it was described as “the structural adaptation of chromosomal 
regions so as to register, signal or perpetuate altered activity states” (Tollervey & 
Lunyak 2012; Bird 2007).  
 
Epigenetic modifications include, but aren’t limited to, methylation, acetylation, 
phosphorylation, ubiquitination, sumoylation, citrullination and Adenosine 
diphosphate ribosylation (Spivakov & Fisher 2007). Research has demonstrated that 
external environmental influences can alter the levels of these modifications in 
human cells. For example, alterations have been seen as a result of microbial 
infection (Minárovits 2009), pollution (Silveyra & Floros 2012), alcohol consumption 
(Agudelo et al. 2012), smoking (Hillemacher et al. 2008) and diet (Burdge et al. 
2012). How these changes come about, and how they influence DNA, cells and the 
overall effects on the human body, is the subject of much investigation. This is of 
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particular interest to medical researchers, because a cell’s epigenome is the key 
cellular level influencing factor behind a number of diseases, perhaps most notably 
cancers (Ropero & Esteller 2007) and inflammatory diseases (Shakespear et al. 
2011), although it has become apparent that many other diseases also have 
epigenetics as a key mediator (Dinarello et al. 2011).  
 
1.2.2 Human DNA 
DNA in its most basic form exists as the famous double helix. DNA can be packed 
into further assembly levels (Figure 1.1) where charge, polarities and structural 
interactions are controlled in complicated and highly regulated processes (Verreault 
2000). This DNA packing results in tight, but flexible assemblies; the flexibility 
allowing the structures to be altered constantly, resulting in the correct parts of the 
DNA being utilised in DNA transcription, replication or repair (Hondele & Ladurner 
2011). The hierarchical order of DNA assemblies, from small to large, is DNA  
Chromatin  Nucleosome-core particles  Nucleosomes  Chromosomes. 
 
Chromatin is the term for the complex of DNA and the proteins which form the 
nucleosomes in eukaryotic cells. Nucleosomes are the repeating units of chromatin, 
and the main genetic component of cell nuclei. These nucleosome structures are 
formed from DNA when the 145-147 base unit structures wrap twice around two 
copies of each type of histone protein – H2A, H2B, H3 and H4 (Shahbazian & 
Grunstein 2007). A whole single unit is known as the nucleosome-core particle 
(Figure 1.1), and these particles are further assembled into chromosomes (Figure 
1.2).  
 
Histone proteins are highly abundant proteins in cell nuclei and under normal 
physiological conditions contain a high proportion of amino acids with positively 
charged, basic, side chains. It is these positive charges and their ionic interaction 
with the negative regions of the DNA backbone that account for the ease of 
assembly of DNA. Other interactions, such as hydrogen bonding, account for the 
remainder of the bonding energy between histones and DNA (Hondele & Ladurner 
2011). 
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Figure 1.1 - The crystal structure of the nucleosome-core-particle. The 146 
base pair DNA ribbon structure is in brown and turquoise. It is wrapped around 
the eight histone protein backbone chains (H3 is blue, H4 green, H2A yellow 
and H2B red). The left view is down the DNA superhelix axis, and 
perpendicular to the axis on the right. Reprinted with permission from (Luger et 
al. 1997). 
 
 
Figure 1.2 – Diagram showing how DNA wraps around the histone proteins, 
then the formation of a chromosome particle. Reprinted with permission 
from (Zaidi et al. 2010). 
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Chromatin’s higher order structure, i.e. how the chromatin is folded, is governed by 
interactions between nucleosomal histones, DNA, neighbouring nucleosomes and 
other non-histone proteins. In the cell, the structure of the chromatin is dependent on 
cell-cycle, the level of gene activity and the region of the chromosome involved. Post 
translational modifications (PTMs) made to the histone are key controlling factors. 
PTMs are modifications made to the DNA or related proteins after it has been 
synthesised/translated, and epigenetic modifications are an example of PTMs. The 
majority of PTMs have been shown to be reversible (Tollervey & Lunyak 2012).  
 
The epigenetic makeup of the cell affects this chromatin higher-order structure 
(Jones 2012). Chromatin states are dynamic, but when simplified, chromatin can 
transition between an open and relaxed, or a compact and folded form. The 
compaction level affects the accessibility of the DNA, which has wide reaching 
cellular consequence. The epigenetic makeup affects three key chromatin 
properties: 1) The positioning of specific nucleosomes, 2) The higher order structure 
of chromatin, 3) The compartmentalisation of the chromatin sections. These can 
subsequently affect how the DNA is read and translated, and thus how genes are 
expressed in cells, with wide ranging consequences (Eberharter & Becker 2002). 
 
Furthermore, epigenetics has an impact on the chromatin assembly processes, 
which take place in the S phase of the cell cycle (Verreault 2000). Due to the 
potential for large numbers of unwanted interactions between different parts of DNA, 
the histone proteins themselves, and other specialist proteins known as histone 
chaperones, control the assembly of DNA onto the histones. The full mechanism by 
which histones and histone chaperones assemble the nucleosome is not fully 
understood, but it is believed that epigenetic modifications to the histones, which 
alter the charges on the DNA, histone proteins and assembly proteins, may play a 
role. Consequently, epigenetics may affect how histone chaperones assemble the 
cell’s DNA in the first place, as well as how the DNA is read (Shahbazian & 
Grunstein 2007). 
 
1.2.3 Acetylation 
Two especially critical epigenetic modifications are the addition (acetylation) or 
removal (deacetylation) of acetyl groups to chromatin’s histone lysine residue(s). 
This is one of the most abundant post translational modifications and genome wide 
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analysis of cells has shown that acetylation is a modification at least as frequent as 
phosphorylation (Filippakopoulos & Knapp 2012; Kretsovali et al. 2012a). Acetylation 
is a key epigenetic modification, with levels affecting processes such as the 
previously mentioned chromatin folding and the assembly of the nucleosome by 
histone-chaperones.  
 
 
Figure 1.3 - An Acetyl group, a chemical group with the chemical formula 
COCH3. A small chemical motif consisting of a methyl group single bonded to a 
carbonyl group, which is a carbon and an oxygen joined by a double bond. It is 
sometimes shortened to 'Ac'. 
 
In biochemical terms, there are two key ways in which the addition of an acetyl 
group (Figure 1.3) to a histone tail alters the properties of the tail. Firstly, the acetyl 
group neutralises the positive charge that was previously present on the lysine 
residue, potentially resulting in the electrostatic interactions of the nucleosomes with 
anionic DNA (or anything else it is interacting with) being weakened, leading to a 
more open chromatin structure (Uciechowska et al. 2009). Secondly, the acetyl 
group prevents further epigenetic modifications, blocking the site and effectively 
chemically locking them from further/alternative epigenetic modifications (Sadoul et 
al. 2008). This change is only temporary as these groups can also be removed. 
 
It has been shown that the acetylation of lysine residues allows them to act as 
docking sites for the binding of other regulatory ‘reader’ proteins where the acetyl 
group is essential for this interaction. These reader proteins can measure and ‘read 
out’ the histones acetylation level, potentially mediating transcription and any other 
chromatin dependent processes. As this is a board remit, by definition, the enzymes 
controlling acetylation levels are classified as both co-activators and co-repressors 
(Reichert et al. 2012). A class of proteins called bromodomains are currently the only 
known interaction modules that specifically recognise and read the acetylation of the 
N-terminal of histone lysine residues (Dhalluin et al. 1999), playing a key epigenetic 
role and may be interesting therapeutic targets (Filippakopoulos & Knapp 2012). 
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However, they fall outside the scope of this review due to their entirely different 
mechanism of action to HDACs and different inhibitor/activator 
compounds/mechanisms.  
 
1.2.4 HDACs and HATs 
While the histone code can be “read” by proteins such as bromodomains, it can also 
be written and erased. The acylation levels of histone proteins are predominantly 
controlled by two groups of cellular enzymes; classified as histone deacetylases 
(HDACs) and histone acetyltransferases (HATs). If proteins such as bromodomains 
are the acetylation ‘readers’, HATs are the ‘writers’, and HDACs the ‘erasers’ 
(Filippakopoulos & Knapp 2012). HATs mediate the transfer of acetyl groups onto 
the lysine residues, and the actions of HDACs remove those acetyl groups. HDAC 
inhibitor (HDACi) compounds inhibit the action of HDACs, generally resulting in 
increased acetylation levels of proteins. 
 
1.2.5 Non-histone acetylation  
Lysine amino acid residues are found in many cellular proteins, not just as part of 
histones. HATs and HDACs have multiple targets, they don’t just simply modify the 
acetylation level of histone proteins (Martínez-Balbás et al. 2000). Evolutionary 
studies suggest that HDAC enzymes actually pre-date the evolution of histone 
proteins themselves. Some functions of these enzymes are not even related to 
histones; for example, HDAC6 interacts with tubulin proteins and HDAC1 on 
transcription factors such as the tumour suppressor p53 (Gregoretti et al. 2004). 
Despite containing histone in their names, non-histone proteins may actually 
constitute the majority of substrates affected by HATs and HDACs (Choudhary et al. 
2009). This huge range of targets results in the wide-ranging cellular consequences 
of altering or affecting the HAT and HDAC proteins, and why they are considered so 
important (Duncan et al. 2011; Buchwald et al. 2009; Spange et al. 2009; Sadoul et 
al. 2008). 
 
With this in mind, Balasubramanian et al. have argued it is actually technically 
incorrect to name these classes of enzymes/proteins HATs and HDACs. It may be 
more accurate to refer to them as lysine acetylases/deacetylases, or the more 
commonly referenced alternative  protein acetylases/deacetylases (LATs and 
LDACs, or ATs and DACs, with corresponding inhibitors as LDACis and DACis) 
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(Balasubramanian et al. 2009). Another review states that HDACs should be named 
KDACs (Reichert et al. 2012). While the huge range of targets of these compounds 
must be understood, the nomenclature convention of HATs, HDACs and HDACis will 
be adhered to here, as this is the standard in the majority of the literature (Spange et 
al. 2009). 
 
1.2.6  HDAC isoforms  
There are 18 distinct human enzymes known to have deacetylation activity, 
conventionally numbered 1–18 (for example, HDAC8). Based on molecular 
phylogenetic analysis of protein primary structures, and their homology to yeast 
enzymes, these 18 HDACs are grouped into two categories – classical and sirtuins 
(Bertrand 2010), which can be further subdivided into four classes (Bradner et al. 
2010): classes I, II and IV are classical HDACs and class III are sirtuins. The activity 
of the classical HDACs depends on zinc (Zn2+) ions, whereas the sirtuin class utilise 
nicotinamide adenine dinucleotide: NAD+ - a phosphate linked dinucleotide 
coenzyme. As they have entirely different mechanisms of action, structure and 
inhibitors, sirtuins fall outside the scope of this review (Uciechowska et al. 2009). 
 
Different HDAC enzymes can have highly specific functions; often two or more 
isoforms can function together in unison, and some isoforms have overlapping 
functions. While the full physiological roles of each individual HDAC isoform are not 
known, studies inhibiting individual isoforms, or knock out studies of specific 
isoforms have provided some insight to their function (Kretsovali et al. 2012a). 
Summaries of such mouse development studies can be found elsewhere (Witt et al. 
2009; Reichert et al. 2012). Table 1-1 contains summary of the known cellular 
location of, tissue distribution and biological functions of HDACs.  
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Table 1-1 - A summary of the zinc dependent HDAC isoforms. 
 
 
HDAC 
Cellular 
Location 
Tissue Distribution Known Biological Functions 
 
 
 
 
 
 
 
 
 
Class I 
 
 
 
 
 
 
 
HDAC1 
Nucleus 
(de Ruijter et 
al. 2003) 
Ubiquitous (Yang et al. 
1997). 
 
Cellular proliferation (Lagger et al. 2002; Zupkovitz et al. 2010). 
Cell cycle regulation and haematopoiesis (Wilting et al. 2010; Yamaguchi et al. 
2010). 
DNA damage response (Miller et al. 2010). 
Cardiac development (Montgomery et al. 2007; D.-F. Lu et al. 2014). 
Oligodendrocyte, glial cell, synapse and neuronal cell development and function 
(Montgomery et al. 2009; Ye et al. 2009; MacDonald & Roskams 2008; D. Kim et al. 
2008; Akhtar et al. 2009; Humphrey et al. 2008). 
Regulating Schwann cells (Jacob et al. 2011; Chen et al. 2011). 
Osteogenic and skeletal muscle development (Maroni et al. 2012; Moresi et al. 
2012). 
Modulating T Cell response (Grausenburger et al. 2010). 
Epidermal formation (Leboeuf et al. 2010). 
Adipogenesis (Haberland et al. 2010). 
Cartilage formation (Hong et al. 2009). 
HDAC2 
Nucleus  
(de Ruijter et 
al. 2003) 
Ubiquitous (Yang et al. 
1997). 
 
Cell cycle regulation (Yamaguchi et al. 2010). 
Cardiac development (Montgomery et al. 2007; Trivedi et al. 2007). 
DNA damage response (Miller et al. 2010).  
Oligodendrocyte, glial cell, synapse and neuronal cell development and function 
36 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Class I 
(Montgomery et al. 2009; Ye et al. 2009; MacDonald & Roskams 2008; Guan et al. 
2009; Jawerka et al. 2010; Akhtar et al. 2009; Humphrey et al. 2008).Regulating 
Schwann cells (Jacob et al. 2011; Bai et al. 2005). 
Skeletal muscle development (Moresi et al. 2012). 
Epidermal formation (Leboeuf et al. 2010). 
Adipogenesis (Haberland et al. 2010). 
Regulating cartilage structure (Hong et al. 2009). 
HDAC3 
Nucleus and 
cytoplasm  
(de Ruijter et 
al. 2003)  
Ubiquitous (Yang et al. 
1997). 
Cell cycle regulation (Bhaskara et al. 2009; Jiang & Hsieh 2014). 
Osteogenic development (Maroni et al. 2012; Schroeder et al. 2004; Hesse et al. 
2010; Lamour et al. 2007). 
Liver function (Knutson et al. 2008; Feng et al. 2011). 
Cardiac function (Trivedi et al. 2008; Montgomery et al. 2008) 
Bone mass and formation,(McGee-Lawrence et al. 2013; Razidlo et al. 2010; Hesse 
et al. 2010; Maroni et al. 2012; Schroeder et al. 2004) including osteoclast 
suppression (Pham et al. 2011). 
Chondroprogenitor differentiation to cartilage (Razidlo et al. 2010). 
Brain memory function (McQuown et al. 2011). 
Neural stem cell proliferation and differentiation (Jiang & Hsieh 2014; Sun et al. 
2007). 
Hematopoietic stem cell growth (Elizalde et al. 2012). 
HDAC8 
Nucleus and 
cytoplasm  
(de Ruijter et 
al. 2003)  
Ubiquitous (Yang et al. 
1997). 
Craniofacial and skull bone in embryonic development (Haberland et al. 2009). 
Mediates the osteogenic differentiation of stem cells (Fu et al. 2014). 
     
[Type a quote from the document or the summary of an interesting point. You can position the text box anywhere in the document. Use 
the Drawing Tools tab to change the formatting of the pull quote text box.] 
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Class IIa 
 
 
 
HDAC4 
 
 
Nucleus and 
cytoplasm (de 
Ruijter et al. 
2003) 
Brain, heart and skeletal 
muscle (Verdin et al. 2003; 
Zhao et al. 2001), 
prehypertrophic 
chondrocytes (Vega et al. 
2004) retina (Chen & Cepko 
2009), neurons (Bolger & 
Yao 2005; Bolger et al. 2007; 
Chawla et al. 2003). 
Myofibroblast development (Glenisson et al. 2007). 
Chondrocyte hypertrophy and endochondral ossification (Vega et al. 2004). 
Retinal neuronal function (Chen & Cepko 2009). 
Regulates neuronal activity, cell death and survival (Bolger & Yao 2005; Bolger et al. 
2007). 
Muscle differentiation (Zhao et al. 2001). 
HDAC5 
Nucleus and 
cytoplasm (de 
Ruijter et al. 
2003)  
Heart, skeletal muscle and 
brain (Verdin et al. 2003; 
Mckinsey et al. 2000), 
neurons (Chawla et al. 
2003). 
Myocardial and endothelial functions (Mckinsey et al. 2000). 
Differentiation of neural stem cells (Sun et al. 2007) and neuronal activity (Chawla et 
al. 2003). 
Memory function (Agis-Balboa et al. 2013). 
HDAC7 
Nucleus and 
cytoplasm (de 
Ruijter et al. 
2003)  
Thymus (Dequiedt et al. 
2003), heart, muscle and 
lung (Verdin et al. 2003). 
In embryonic development found in endothelial cells of developing heart, blood 
vessels, and mesenchyme and myocardial layers of heart and in lung tissue (Chang 
et al. 2006). 
Role in developing thymocytes (Dequiedt et al. 2003; Ji et al. 2010). 
Osteoclast activity (Pham et al. 2011). 
Inflammatory macrophages (Shakespear et al. 2013). 
HDAC9 
Nucleus and 
cytoplasm (de 
Ruijter et al. 
2003)  
Heart, skeletal muscle and 
brain (Verdin et al. 2003; 
Zhou et al. 2001). 
Redundant role in heart development (Chang & McKinsey 2004). 
Motor innervation in muscles (Méjat et al. 2005). 
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Class IIb 
 
 
HDAC6 
Mainly the 
cytoplasm (de 
Ruijter et al. 
2003) 
Muscle (Balasubramanian et 
al. 2014), brain (d’Ydewalle 
et al. 2012) heart (Zhang et 
al. 2014), liver (Gradilone et 
al. 2014), kidneys (Liu et al. 
2012), testes (Zhang et al. 
2008). 
Involved in Cellular response to stress (Boyault et al. 2007; Kwon et al. 2007)  and 
macro-autophagy (J.-Y. Lee et al. 2010). 
Muscle differentiation (Balasubramanian et al. 2014). 
Tubulin acetylation, minor role in bone mass regulation and immune response 
modulation (Zhang et al. 2008). 
Neuroprotective and neurodegenerative functions (d’Ydewalle et al. 2012). 
Arterial modelling (Zhang et al. 2014). 
Platelet activation (Sadoul et al. 2015). 
HDAC10 
Nucleus and 
cytoplasm (de 
Ruijter et al. 
2003)  
Liver, spleen and kidney 
(Kao et al. 2002), skin (Lai et 
al. 2010). 
Promotes autophagy-mediated cell survival in neuroblastoma cells (Oehme et al. 
2013). 
Role in melanin production in the skin (Lai et al. 2010). 
Class IV HDAC11 
Nucleus and 
cytoplasm (de 
Ruijter et al. 
2003)  
Brain (Liu et al. 2008), heart, 
skeletal muscle, and kidneys 
(Gao et al. 2002). 
Influences immune activation versus immune tolerance (Villagra et al. 2008). 
Expressed in the developing brain within neural oligodendrocyte cells (Liu et al. 
2008). 
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1.2.7 HDAC structure and mechanism of deacetylation  
Each HDAC isoform has a (sometimes subtly) different structure. However, full 
structural data on HDACs is limited; X-ray crystal structures are very difficult to obtain 
and only a few HDAC enzymes have been isolated, typically by co-crystallisation with 
an inhibitor or a signalling molecule, giving an indicator of how the enzyme potentially 
forms complexes, or its enzymatic function, in the cell. To date, the structures of 
HDAC7, HDAC4, HDAC3, HDAC2 and HDAC1 have been established, and HDAC8 
has been characterised most prolifically (Wagner et al. 2013). 
 
It was pioneering work by Finnin et al. (1999) that lead to the first description of a 
histone-deacetlyase-like protein (HDLP, Protein Data Bank code 1C3P) (Figure 3) 
(Finnin et al. 1999). HDLP was isolated from the bacterium Aquifex aeolicus, and 
today this is still considered a good HDAC structural model, with a 35% homology to 
HDAC1. While, HDLP is only a homologue of human HDAC enzymes, it still provides 
a framework for further research into the mechanisms of catalytic activity and 
inhibition. As well as this structure, Finnin and co-workers also suggested a 
mechanism of action of HDAC enzymes (Summarised in Figure 1.5), and while a 
number of mechanisms of deacetylation by the HDAC active site have since been 
proposed (Vanommeslaeghe, De Proft, et al. 2005; Corminboeuf et al. 2006), this is 
still considered possibly accurate today.   
 
Figure 1.4 – Space filling diagram. A ‘space filling’ representation of HDACi TSA 
bound in the active site, (a sock shaped cavity), of HDLP. Reprinted with 
permission from (Finnin et al. 1999). 
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Figure 1.5 – Mechanism of action. The relevant residues and molecules involved in 
a proposed HDAC1 active site of HDLP, along with a proposed mechanism for 
the deacetylation of an acetylated lysine residue. Adapted from (Finnin et al. 
1999).  
 
The active site of this HDLP consists of an 11 A°-deep sock-shaped cavity or tunnel, 
comprising of around 390 amino acids. In this, a Zn2+ ion sits bound at the ‘heel’ of 
the sock. The internal cavity walls are hydrophobic, consisting of lipophilic amino 
acids that differ depending on the class of HDAC. While there may be differences in 
residues and pocket shape between HDAC classes, this catalytic zinc ion is common 
to all zinc dependent HDAC proteins (Jones 2012), and researchers are confident 
this is essential to the deacetylation process.  
 
Until 2004/5, the HDLP model was the only source of structural information about the 
active sites of HDAC enzymes. This changed when X-Ray structures of human 
HDAC8 with an inhibitor bound in the catalytic pocket were published, proving that 
the catalytic site was in fact very similar to that of HDLP (Somoza et al. 2004; Vannini 
et al. 2004). As of 2015, 29 different crystallographic structures of human zinc-
dependent HDACs have been logged in the Protein Data Bank. However, crystal 
structures are only a snapshot of the structure of a protein. When in solution (as they 
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are naturally in the cell), the structure could be very different, as well as being 
dynamic and constantly changing. This is problematic for researchers attempting to 
design compounds to bind to proteins, as they have to work from potentially 
inaccurate crystal structures (Deschamps et al. 2015). 
 
Much important work is ongoing in the field of structural determination, as these 
studies can reveal the structural relation between the enzymes and their higher-order 
complex partners, the role of potential signalling molecules on complex formation and 
enzymatic function, and how inhibitor compounds actually bind and cause a loss of 
enzymatic function (Silvestri et al. 2012; Deschamps et al. 2015). While the full 
enzyme structures are not known, researchers can still utilise what they know in 
design of inhibitors of these enzymes.  
 
1.2.8 The effects of histone acetylation levels on chromatin 
The way in which chromatin is organised and read affects all nuclear processes 
involving DNA. This in turn has an effect on gene expression, with far reaching 
consequences. With regards to stem cells, important properties such as pluripotency, 
differentiation and reprogramming are all affected by the “epigenetic landscape” 
(Tollervey & Lunyak 2012). 
 
Generally, histone acetylation results in a more open and more transcriptionally active 
chromatin; acetylation reduces interactions between the nucleosomes and the 
histone tails are released from the linker DNA, causing it to open up. Deacetylation 
leads to a more condensed and transcriptionally silenced chromatin, increasing the 
number of possible interactions as less sites are blocked by acetyl groups, and 
resulting in a repression of transcription (Grunstein 1997). However, this is a 
simplification, and it is not always productive to talk in simplified terms of acetylation 
causing more transcriptionally active chromatin and vice versa. It is often not just a 
case of on or off, open or closed, active or inactive, permissive or repressive 
chromatin structures. In some cases epigenetic modifications can silence some 
sections of the chromatin, while simultaneously causing the area to actually become 
more transcriptionally active. In the literature, these silent but transcriptionally 
available sections of chromatin are sometimes referred to as bivalent domains, a 
third, “poised” state (Mikkelsen et al., 2007). It was originally thought that these 
bivalent markers were a feature of only pluripotent stem cells. However, these 
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regions also exist in several different animal cell populations (Tollervey & Lunyak 
2012; Mikkelsen et al. 2007). 
 
1.3 HDAC Inhibitors 
HDACis are typically small molecular compounds that can bind to and block the 
action of HDAC enzymes. They can be isolated from natural sources, such as 
Trichostatin A (TSA, isolated from antifungal bacteria) (Tsuji et al. 1976), or designed 
using medicinal chemistry tools and synthesised in a laboratory (Hahnen et al. 2008). 
Interestingly, the HDACi valproic acid (VPA) has been used in psychiatry and 
neurology for several decades, and its mechanism of action was only discovered to 
be inhibition of HDACs in 2001 (Phiel et al. 2001; Göttlicher et al. 2001; Hahnen et al. 
2008).  
 
High levels of deacetylation activity can be linked to tumour pathology. These high 
levels deacetylation activity repress the activity of certain genes, which are in turn 
known to repress cancer cells (Bertrand 2010). Due to this, and other mechanisms of 
action, to date, HDACis have primarily been associated with cancer therapeutics 
(Ropero & Esteller 2007). Three HDACis have achieved FDA approval for use in 
cancer treatments; Vorinostat, also known as Suberoylanilide Hydroxamic Acid 
(SAHA) or Zolinza (Richardson et al. 2008), Romidepsin (Bertino & Otterson 2011) 
and Panobinostat (Prince & Bishton 2009). At the end of 2012, a review found that at 
least 20 structurally different HDACis were found in various stages of anti-cancer 
clinical trials, as either monotherapies or in combination with other anti-cancer agents 
(Nebbioso et al. 2012). Typically they have been applied to the treatment of 
haematological malignancies, as the response of solid tumours to HDACis doesn't 
appear to be translatable, athough they are being explored in a number of 
combination therapies (West & Johnstone 2014). 
 
More recently, research has diversified, and HDACis have been discovered as 
potential tools in many different therapeutic areas, such as inflammatory diseases 
(Bode & Dalpke 2011), diabetes (Christensen et al. 2011), arthritis (Buckland 2011; 
Gillespie et al. 2012) and tissue engineering (Boer et al. 2006). 
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Different papers characterise current HDACis differently. However some major 
categories are common to most reviews (Nebbioso et al. 2012). These major 
categories are hydroxamic acids, natural cyclic peptides, short-chain and aromatic 
fatty acids, benzamide based and electrophilic ketones and thiols. Very few HDACis 
don’t fit into one of these categories, although occasionally an ‘other HDACis’ 
category is used to account for these. 
 
1.3.1 Mechanism of HDAC inhibition 
Hydroxamic HDACis block the HDAC active site, with the zinc ion coordinating to the 
two oxygen atoms of the hydroxamic acid section of the HDACi. There are potentially 
other disrupting interactions, such as the active site changing shape, which can 
account for the inhibition action. These all depend on the structure of the HDACi. The 
aliphatic chain region of the HDACi occupies the channel, where hydrophobic 
interactions strengthen the binding energy between the HDACi and the enzyme. The 
capping group, often an aromatic ring, blocks access to the pocket, reducing the 
potential for any competitive binding. The rim of the catalytic pocket is usually where 
the structural differences between HDAC isoforms can be found, so it is often here 
that efforts are often focussed when designing isoform specific inhibitors (Deschamps 
et al. 2015).  
 
1.3.2 Specific HDACis compared to panHDACis 
To date, research has largely focused on non-specific/unselective HDACi compounds 
(panHDACis), which are broad spectrum HDACis that target multiple HDAC isoforms 
at once (Balasubramanian et al. 2009). Most first generation HDACis, such as SAHA 
and Romidepsin (Bertino & Otterson 2011; Richardson et al. 2008), are relatively 
unselective (Jones 2012). However, conflicting findings have been reported, for 
example Bradner et al. (2010) have demonstrated that some such HDACis can be 
selective to certain HDAC isoforms. Discrepancies in this field can arise due to a lack 
of knowledge of HDAC structure and problems with currently utilised screening 
techniques, such as the isolated enzymes mentioned previously, which can have 
different structures to the enzymes naturally (Bradner et al. 2010; Madsen & Olsen 
2012). The chemical structures of some of the key HDACis in the field can be seen in 
Figure 1.6. 
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Figure 1.6 - Structures of HDACis commonly found in the literature. Clockwise 
from top left – Sodium butyrate, Valproic Acid, Trichostatin A, Romidepsin, 
Entinostat (MS-275) and Vorinostat (SAHA). 
 
While some panHDACis have proven to be effective drugs (Richardson et al. 2008; 
Bertino & Otterson 2011), research is beginning to move away from this unselective 
approach, to explore isoform selective inhibitors. The broad spectrum of targets of the 
panHDACis means that it is hard to fathom the mechanism of action of the HDACi, 
and leads to a greater potential for side effects. It has been be argued that targeting 
specific HDACs is key to the development of future HDAC therapeutics 
(Balasubramanian et al. 2009; Jones 2012; Witt et al. 2009). This is easier said than 
done, as the structural differences between different HDAC isoforms are often subtle, 
with most of the features of the enzyme catalytic pocket being conserved between 
isoforms (Deschamps et al. 2015).  
 
1.3.3 Design of HDACis 
Computational studies can be undertaken to aid in the design of HDACis, where 
researchers can model the binding sites of inhibitors on HDAC enzymes. These 
binding pockets can then have libraries of compounds virtually docked into the 
binding site, modelling how well different chemicals bind into the catalytic pockets. 
Known HDACis or ligands for the enzymes can also be bound, so benchmark values 
can be generated to validate the models. Interactions such as hydrogen bonds, Van 
Der Waals interactions and metal chelation forces are taken into account. 
Quantitative structure activity relationship models have been developed for HDACs 
and HDACis, which relate the chemical structure of compounds to their biological 
activity (Nair et al. 2012). This is just one illustrative example of potential 
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computational models for compound design, it is a very broad subject (Wang 2009; 
Pontiki & Hadjipavlou-Litina 2011). 
 
Computational designers can produce whole libraries of potentially useful compounds 
(Xiang et al. 2012; Tang et al. 2009), or individual design motifs of HDACis, such as 
the zinc binding group, can be investigated (Vanommeslaeghe, Loverix, et al. 2005). 
Chemical libraries are collections of chemical compounds that have been grouped for 
a purpose. Only a very limited number of HDACi compound libraries have been 
reported so far, and thus there is a highlighted need for further development in this 
field (Nair et al. 2012). However, this work relies on improvements to the detailed 
structural knowledge of HDACis.  
 
1.3.3.1 The HDACi Design Pharmacophore 
Computational studies have led to a set of design principles being adopted for 
HDACis, which typically result in them having three key domains. When designing 
compounds, this is known as the pharmacophore (Figure 1.7, where SAHA is given 
as an example). The International Union of Pure and Applied Chemistry (IUPAC) 
defines a pharmacophore to be “an ensemble of steric and electronic features that is 
necessary to ensure the optimal supramolecular interaction with a specific biological 
target and to trigger or block its biological response” (Wermuth et al. 1998).  
The following three components make up the most common HDACi design 
pharmacophore (Pontiki & Hadjipavlou-Litina 2011; Sternson et al. 2001): 
1) A metal binging group, which interacts with the zinc ion in active site at the 
heel of the HDAC pocket.  
2) A linking domain, which occupies the majority of the HDAC pocket. This can 
be cyclic or chain like, and links the metal binder and the capping domain. 
3) A surface recognition or capping domain, which typically interacts with 
residues on the rim of the HDAC tunnel. 
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Figure 1.7 – Molecular pharmacophore of HDACis. SAHA is given as an example, 
adapted from (Pontiki & Hadjipavlou-Litina 2011). 
 
Within each of these three major pharmacophore components, there is much scope 
for chemical diversity, and each component can have its own set of design rules 
(Bertrand 2010). This pharmacophore has developed because the three domains are 
known to either interact with, or facilitate other parts of the compound to interact with 
the previously described catalytic pocket or tunnel of the HDAC enzyme. X-Ray 
crystallography studies of HDACis interacting with HDAC catalytic pockets, such as 
the previously mentioned by Finnin et al. lead to these deductions (Finnin et al. 
1999). These can be represented by space filling diagrams, where computational 
modelling has predicted the size and shape of the catalytic pocket, and the space can 
be filled by a chemical molecule (Figure 1.4).  
 
1.3.3.2 Isoform Specific HDACis and their design 
Considering the advanced stage of research and trials that some of these HDACis 
have reached, it is remarkable how little is known about selectivity and the 
mechanism of action of HDACis. The previously mentioned report of HDACi 
selectivity are conflicting and Bradner et al. demonstrated that a large proportion of 
the well investigated compounds widely perceived as non-selective, panHDACis, 
actually had an unexpectedly high level of selectivity for certain HDAC isoforms, most 
usually HDAC1 and HDAC2 (Bradner et al. 2010). A summary of their findings can be 
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seen in Figure 1.8. For example, SAHA, which has been reported elsewhere to be 
selective for HDAC7 in 14 different cell types (Dokmanovic et al. 2007), was found to 
be selective only for HDAC1, HDAC2, HDAC3 and HDAC6 (Bradner et al. 2010).  
 
Therefore, research is moving towards the design of selective HDACis, creating a so 
called ‘second generation’ of HDACis. The development of these second generation 
HDACis may have advantages for some applications, but it is worth noting there are 
still advantages with panHDACis, especially considering that from a regulatory 
perspective, many of these are close to reaching FDA approval (Jones 2012; 
Balasubramanian et al. 2009; Bieliauskas & Pflum 2009). 
 
While cancer is still the main focus of research in this area, the rise of HDAC specific 
enzymes (especially driven by the fact that specific HDACs may be highly expressed 
in certain cancers (Balasubramanian et al. 2009) is helping push the field of HDACis 
in new directions (McKinsey 2011).                                         .
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Figure 1.8 - Chemical phylogenetic analysis of HDACs; the binding affinity of HDACis for different HDAC isoforms. a) Hierarchical 
clustering of HDACs with a representative panel of HDACi compounds binding affinity for different HDAC isoforms, with an indication of 
inhibitor potency (Ki); b) and c) Dendrogram representative diagrams, with the chemical structure and enzymatic selectivity profiles of MS-
275 (b) and SAHA (c), overlaying molecular phylogeny. The circles are representative of Ki on a logarithmic scale. Reprinted with permission 
from (Bradner et al. 2010).  
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1.4 The Effect of HDACis on Cancerous and Normal Cells 
Cancerous cells are understood to have an abnormal epigenetic make up, 
compared to normal cells in the human body (Tsaniras et al. 2014; Reya et al. 
2001). It has been reported that HDACi compounds can kill or damage cancerous 
cells, while leaving normal cells relatively unharmed (Qiu et al. 2000; Bose et al. 
2014). This is especially advantageous when compared to other cancer treatments, 
such as chemotherapy and radiotherapy, which are known to be very damaging to 
normal cells. This specificity for cancerous tissue is a major advantage for HDACis 
in cancer therapeutics.  
 
HDACis are found to be selective for tumour cells over normal cells (that are often 
reported as resistant to the effects of HDACis) at clinically utilised concentrations 
(Nebbioso et al. 2005; Dokmanovic et al. 2007). This can be through several 
possible mechanisms. For example, on HDACi treatment, normal cells experience 
an increase in the levels of thioredoxin, a protein that acts to resistance to reactive 
oxygen species (ROS) accumulation. This increase in thioredoxin is not seen in 
cancerous cells and the high levels of ROS can cause the death of cancer cells 
(Ungerstedt et al. 2005). Interestingly, some of the effects of HDACis have been 
observed to be reversible (J. H. Lee et al. 2010), thus it is vital researchers reach a 
better understanding of how HDACis affect normal cells. 
 
HDACis can have wide ranging effects on both normal and cancerous cells, 
causing alterations to the cell-cycle, differentiation potential, proliferation, gene 
expression, reactive oxygen species accumulation and normal cell death pathways. 
The effects of HDACis on cancerous cells are depicted pictorially in Figure 1.9. The 
effects are dependent on the cell type, choice of HDACi and application factors 
such as exposure time and concentration of inhibitor (Xu et al. 2007). For example, 
SAHA has been found to have negative effects on normal cells in mouse in vivo 
models (McGee-Lawrence et al. 2011). The full range of individual mechanisms 
related to each of these effects are difficult to isolate and describe, and the effects 
are often happening in synergy with each other.  
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Figure 1.9 – A schematic showing the standard properties of a tumour cell 
blocked by treatment with a HDACi. Tumour cells can undergo many 
processes under normal physiological conditions, and this diagram shows 
some of the processes that HDACis are known to stop, with red lines through 
the arrows. Apoptosis is typically favoured, hence the green arrow. Adapted 
from (New et al. 2012). 
 
1.4.1 Cell Death and Related Responses to HDACis 
As it is typically the aim of the therapy, the effects of HDACis on cell death in 
cancerous cells is well explored. How these translate into normal cells is of much 
interest to researchers looking to explore the side effects of HDACis, or utilise them 
elsewhere.  
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1.4.1.1 Apoptosis, Necrosis, Necroptosis and Autophagic Cell Death 
Apoptosis is the controlled, programmed cell death that occurs without outside 
stimulus,resulting in minimal inflammation. It is the most studied and evolutionarily 
conserved form of programmed cell death, and alternations in this can lead to 
cancerous cells developing. In contrast, necrosis is passive cell death occurring due 
to a stimulus from the outside environment, resulting in the release of inflammatory 
cellular contents (Fink et al. 2005). Necroptosis is another form of non-apoptotic cell 
death, usually occurring when the caspase proteins triggering apoptosis are 
inhibited. Autophagic cell death usually takes place as a result of stress conditions, 
and is often linked to other cell death pathways. It is a lysosome-dependent process 
utilised normally in the cell to degrade unnecessary or dysfunctional cellular 
components, but can also be part of a programmed cell death pathway. However, 
there is a debate as to whether autophagy is simply as a result of other cell death 
pathways, or separate in its own right. Cells can die via other caspase-dependent 
death pathways such as pyroptosis, and also caspase-independent cell death 
pathways (Tait et al. 2014). 
 
Many different death resulting phenotypes can form as a result of HDACi treatment 
(Xu et al. 2007), including apoptotic pathway activation (Frew et al. 2009), 
autophagic cell death (Shao et al. 2004; Robert et al. 2011) and mitotic cell death 
(Atadja et al. 2004; Dowling et al. 2005). Cancerous cells have abnormal cell death 
pathways, which is one of the key reasons uncontrolled tumour growth can occur. 
HDACi treatment of cancerous cells results in an increase in pro-apoptotic and a 
decrease in anti-apoptotic proteins (Xu et al. 2007; Dell’Aversana et al. 2012; Bose 
et al. 2014). 
 
Most of the work related to the effect of HDACis on cell death has been carried out 
on cancerous cells. Despite reports of normal cells being resistant to HDACis, it is 
incorrect to assume that normal cells are not going to suffer cell death from HDACi 
treatment. A study undertaken in 2009 showed that at clinical concentrations, SAHA 
activates the mitochondrial apoptosis pathway in normal cells. The cells resisted the 
apoptotic effect of SAHA for 24 hours, but 60% of cells had died after 72 hours of 
exposure (Brodska et al. 2009). This is despite having received clinical approval, 
with strong claims that normal cells are not affected (Richardson et al. 2008). 
Furthermore, necrosis and apoptosis have been observed in normal peripheral 
blood lymphocytes (as well as in a cancerous lymphocyte line) when treated with 
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SAHA (and NaB) (Brodská & Holoubek 2011). In another study, SAHA has been 
shown to induced apoptotic cell death in normal human lymphocytes (Kuzelová et 
al. 2010), and SAHA and MS-275 increased apoptotic pathways in bone marrow 
derived stem cells (Di Bernardo et al. 2009). This just serves to highlight some 
examples of SAHA’s potential to cause cell death. Due to its clinical approval, it is 
one of the more explored compounds in this field. 
 
1.4.1.2 Reactive Oxygen Species Accumulation  
As well as the above cell death pathways, HDACis are also known to cause cell 
death through the disruption of mitochondrial membrane proteins, resulting in 
increased levels of reactive oxygen species (ROS) in the cell (Ruefli et al. 2001; 
Rosato et al. 2003). It has been reported that normal cells have a resistance to this 
effect (Qiu et al. 1999; Atadja et al. 2004; Kelly et al. 2003). However, that isn’t to 
say that researchers utilising HDACis shouldn’t be aware and monitor this, 
especially as there is evidence of this happening in normal human cells (Brodská & 
Holoubek 2011). 
 
1.4.1.3 HDACi Effect on the Cell Cycle, DNA Damage Response, 
Proliferation and Mitotic Cell Death 
The cell cycle is the name given to the normal series of events that a cell will go 
through to prepare for and undergo cell division prior to the processes of 
proliferation and differentiation. In normal cells this is monitored with checkpoints in 
between phases, which can be activated to halt the cell cycle, and in turn cell 
division, when needed (Majdzadeh et al. 2008; Jiang & Hsieh 2014). When the 
DNA is damaged, the spindles on that DNA is damage or not aligned correctly, or 
the previous cell cycle does not finish correctly, and so checkpoints will be activated 
and prevent the progression of the cell cycle. If possible DNA will be repaired and 
the cycle will continue as normal. This prevents the transmission of a mutated 
genome to future generations of the cell. Any loss or damage to the cell cycle 
checkpoints, such as is common in tumour cells, results in a growth advantage for 
tumour cells and a loss in protective mechanisms. A halt in the cell cycle also halts 
the proliferation of the cells, and a lack of this halting is what causes uncontrolled 
cell division in cancers (Bose et al. 2014; Qiu et al. 2000).  
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Cancerous cells have disrupted cell cycle checkpoints, but on treatment with 
HDACis, cell cycles in cancerous cells can be halted at the either G1 or the G2 
phase of the cell cycle. Halting these cells at the cell cycle checkpoints can then 
result in the cell’s normal apoptotic mechanism being activated (Johnstone 2002). 
The lack of cell cycle arrest at the G1 phase in cancerous cells has been linked to a 
specific gene – p21WAF1 (Chen et al. 2004). When the acetylation of histones 
associated with p21WAF1 increased with HDACi treatment, there was a resulting drop 
in HDAC1 bound to the p21WAF1 promoter region, and consequential cell-cycle 
arrest at the G1 point (Gui et al. 2003). This is a slow cell death pathway. Cells can 
also arrest at the G2 checkpoint and undergo an aberrant mitosis (Qiu et al. 2000; 
Burgess et al. 2004). 
 
Alterations in cell cycle is one of the key anti-cancer mechanism of HDACis, and a 
key factor in determining the specificity of HDACis for normal cells (Burgess et al. 
2004; Qiu et al. 2000), and is an effect observed utilising HDACIs with many types 
of cancers, for example in colon cancer (Wilson et al. 2006; Jackson & Evers 2009; 
Gum et al. 1997). 
 
As with many of the effects of HDACis on cells, the effects of HDACis on the cell-
cycle are found to be less for normal cells than transformed cells. The cell-cycle is 
still affected in normal cells, but because normal cells have intact cell-cycle 
checkpoints, the effects are less pronounced (Schroeder & Westendorf 2005).  
Normal cells have fully functioning cell-cycle arrest points, typically not possessed 
by cancerous cells (Qiu et al. 2000). Studies on normal cells such as osteoblasts 
found the cell cycle of such cells to be uninterrupted on treatment with HDACis 
(Schroeder & Westendorf 2005). However, the opposite has been found in other 
cell types, such as epithelial cells (Davis et al. 2000). Human bone marrow MSCs 
treated with HDACis MS-275 and SAHA were arrested at the G1 phase of the cell 
cycle. With the MS-275 treated cells, there was a reduction in the S phase, which 
was not seen in the SAHA treated cells. In the SAHA treated cells, a G2/M 
reduction was observed, which was not seen in the MS-275 cells (Di Bernardo et al. 
2009). This may be due to the inhibitors acting upon different HDAC isoforms.  
 
HDACis can also induce a forced cellular senescence (Xu et al. 2005). Although it 
has been reported that normal cells treated with HDACis showed no evidence of 
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senescence (Xu et al. 2005), this contrasts with a study with human MSCs and the 
MS-275 and SAHA, where different effects on senescence and death pathways 
were observed (Di Bernardo et al. 2009).  
 
A number of studies have shown that the effect of HDACis on the cell cycle in turn 
affects the proliferation capacity of the cells. HDACis can halt proliferation of the 
cancerous cells and subsequent cell death, but importantly cancerous cells that are 
not proliferating are also targeted and die; although the death effect takes longer to 
begin. In contrast, the cell cycle and proliferation of normal cells are stopped by 
HDACis, but it is reported that they do not die as a consequence of this (Qiu et al. 
2000; Burgess et al. 2004). A summary of this can be seen in Figure 1.10. 
 
Investigating specific HDAC isoforms linked to the cell cycle, HDAC1 and HDAC2 
are known to be of particular importance. In several studies, it was found that 
inhibiting HDAC1 induced a partial G1/S cell-cycle arrest, resulting in reduced cell 
proliferation (Lagger et al. 2002; Zupkovitz et al. 2010). The complete deletion of 
HDAC1 has no effect on proliferation; however, deletion of both HDAC1 and 
HDAC2 leads to a stronger G1 cell cycle arrest. It is known that both HDAC1 and 
HDAC2 (that have overlapping effects), and the p21 and p57 genes, are key to the 
regulation of the G1-to-S-phase transition in a normal cell cycle (Yamaguchi et al. 
2010; Wilting et al. 2010). It appears, when HDAC1 is deleted, HDAC2 can 
compensate, probably due to overlapping functions. HDAC1 and HDAC2 were 
found to be key to the cell cycle progression of renal fibroblast cells (Pang et al. 
2011). Silencing of HDAC2, but not HDAC1 resulted in an increased protein level of 
p27, a negative cell cycle regulator. It was also found that the down-regulation of 
HDAC1 and HDAC2 both had an effect on the signal transducer and activator of 
transcription 3 (STAT3) signalling pathway. HDAC1 and HDAC2 are essential to the 
activation of these pathways, which affect the proliferation of these cells (Pang et al. 
2011). Finally, in the previously mentioned study, the HDAC1, HDAC2 and HDAC3 
specific MS-275 was found halt the cell cycle at the G1 checkpoint, and a reduction 
of cells in the S phase of the cell cycle (Di Bernardo et al. 2009). This is cell type 
dependent; however, with variance found between different cell lines (Senese et al. 
2007).  
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As well as HDAC1 and HDAC2, HDAC3 has also been found to play a role in the 
progression of cell cycle. In a study with HeLa cells, a cancerous cell line, 
researchers found that a HDAC3 complex is essential in the regulation of cellular 
spindle function and microtubule attachment during mitosis (Ishii et al. 2008). When 
HDAC3 was deleted in a mouse model, Bhaskara et al. found it resulted in early 
embryonic lethality. This lead them to examine cells derived from the HDAC3 
deficient mouse embryos, finding the cells died by an apoptotic pathway. However, 
unlike the mitotic catastrophe effect of a halted cell cycle, this was due to DNA 
damage and inefficient repair of the DNA double strand breaks. In transformed and 
cancerous cells, HDAC3 inhibition/deletion results in mitotic catastrophe apoptosis, 
which is likely because it’s combined with these DNA damaging effects. In normal 
cells, these DNA damage effects are repairable, so HDAC3 inhibition does not 
result in cell death (Bhaskara et al. 2009).  
 
For even greater detail in this area, reviews have been undertaken into the exact 
pathways and ways by which different HDACs affect the cell cycle and cellular 
proliferation (Reichert et al. 2012; Gabrielli et al. 2011). 
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Figure 1.10 – Effects of HDACi on the cell cycle. When treated with a low 
concentration of a HDACi, normal cells continue the normal cell cycle and 
pass the G2/M checkpoint to survive the treatment. When treated with a 
HDACi, during the late G1 and S phase, tumour cells undergo aberrant 
mitosis and a rapid apoptotic effect results. When treated during the G1 
phase, there is a G1 arrest, and a delayed but eventual apoptosis. Adapted 
from (Burgess et al. 2004; Johnstone 2002) 
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1.4.2 DNA Alteration and its Effects on Mitosis 
Another way HDACis can affect cells, which is different to, but related to the effects 
on the cell cycle, is by altering the cell’s DNA. This can be either by causing direct 
damage or by targeting the cell’s mitotic DNA replication processes (Eot-Houllier et 
al. 2009). Some researchers believe this induced genomic instability is often 
overlooked in clinical trials (Eot-Houllier et al. 2009). For example, HDACis such as 
SAHA can directly damage DNA (Petruccelli et al. 2011). To make matters worse, 
HDACis, by multiple mechanisms, can also inhibit DNA repair mechanisms (Bose et 
al. 2014). HDACis can also effect the centromere (the central linking part of the 
chromosome), which can lead to catastrophic cell death (Zhang et al. 2010). 
 
Lee at al. (2010) found that SAHA caused damage to the DNA of both cancerous 
and normal cells; however, this was found to be reversible in normal cells (J. H. Lee 
et al. 2010). This is not always the case, as when treated with SAHA, VPA, MS-275 
and NaB, normal human fibroblast cells demonstrated a reduced double strand 
break repair capacity (Purrucker et al. 2010). This effect on DNA often reported as 
not relevant in normal cells, and that damage may be reversible, but there as this 
evidence suggests, this is not always the case. 
 
While the majority of studies in the past have focused on the effects of HDACis on 
cancerous cells, an increasing number investigate the effects of HDACis on normal 
cells. It is not only the proliferative capacity, cell cycle and DNA damage response 
of the cell that is altered by HDACi treatment; the differentiation capacity can also 
be altered. The ability of compounds such as HDACis to alter, and potentially 
control, stem cell fate is a very attractive prospect for researchers. Stem cells 
therapies and their applications, such as tissue engineering, may benefit greatly 
from this increased control. 
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Figure 1.11 – The four key pillars of tissue engineering. From left to right: Cells, Environmental Stimuli. Chemical cues and scaffolds, with 
examples listed, and pictures of each. All pictures are the author’s own. 
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1.5 Tissue Engineering of Bone 
Tissue engineering comprises of four (sometimes simplified to three) key pillars: 
cells, scaffolds, growth factors/bioactive molecules and environmental/mechanical 
stimulation (Figure 1.11) (Kessler & Grande 2008).   
 
1.5.1 The Clinical Need and Current Practices 
There is a major clinical need to regenerate tissues and organs (Naderi et al. 2011; 
Payne 2013). In developed countries, such as the United States, the expenditure on 
functional bone grafts is expected to double between 2012 and 2020, to meet the 
increased and aging population. Expenditure was over $2.5 billion annually in 2012. 
Tissue engineered bone grafts are needed for fracture repair and the restoration of 
bone lost due to injury, congenital disorders and degenerative diseases. There is 
the potential for tissue engineering to provide some solutions to this; however, the 
field is still currently struggling to produce actual functional tissue regeneration 
(Amini et al. 2012).  
 
Tissue engineered devices should mimic the natural biology of the bone, allowing 
for ingrowth of bone (osteoconduction), or the promotion of new bone formation 
(osteoinduction and osteogenesis). For this to take place successfully, implants 
should be able to integrate into the natural environment, allowing for diffusion of 
cells, natural growth factors, chemicals and signals that will promote 
osteoconduction/osteoinduction. In bone, these processes involve extracellular 
matrix deposition, mineralisation, vascularisation and a controlled and minimal 
inflammatory response to the newly implanted material. The implant should ideally 
degrade at the same rate new bone is being deposited. As all bones in the body 
have a structural, supportive function, the mechanical integrity of any tissue 
engineered material is also key (Ericka M. Bueno & Glowacki 2011; McMahon et al. 
2013; Xiadou Wang et al. 2010). 
 
Currently, allografts and autografts are used in the clinic for bone tissue repair. 
Allografts of bone from sources such as cadavers do not have a good integration 
with the host tissue, as well as having a relatively high risk of infection. 
Furthermore, the tissue quality harvested for these grafts can be very variable.  
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Autografts, which are currently considered the gold standard, have superior 
integration in the site, primarily due to them being fully vascularised on 
transplantation.  However, with autografts, the tissue source is much more limited 
and there are associated complications with donor site morbidity (McMahon et al. 
2013; Xiadou Wang et al. 2010).  
 
Theoretically, tissue engineered constructs could be transplanted in patients to 
replace the need for autografts and allografts. There has been limited exploration of 
these in the clinic, with the majority of reports being a single component of cells, 
scaffolds or growth factors, not a combination of two or three. Therefore, currently, 
there is much scope to develop combined approaches for bone tissue engineering, 
utilising cells, scaffolds growth factors and environmental stimuli (Liu et al. 2013).  
 
1.5.2 The Biology of Bone 
1.5.2.1 Bone function 
Bone has four main functions in the human body (Pocock & Richards 2006): 
1) Protection and support for the body, through supporting tissues such as 
muscle, tendons and ligaments. 
2) Supporting movement of the body by being able to articulate at the joints. 
3) A homeostatic role providing a mineral deposit for the body. 
4) Storage of bone marrow, thus playing a role in repair and regeneration of 
other tissues in the body, such as through haematopoietic stem cells 
forming blood and immune system cells. 
 
1.5.2.2 The Structural Constituents of Bone 
Bone is often crudely thought of as simply a rigid, inert, mass of hard tissue. 
However, on closer inspection bone is actually much more complicated than this. 
Bone is a living, dynamic structure, a specialist connective tissue, which will 
respond to the conditions that it is subjected to (Pocock & Richards 2006; D.L. 
Bartel et al. 2006). Bone is a very complex structure, with several quite distinct 
hierarchical levels. In the main skeleton, (i.e. not craniofacial bone that can have a 
different structure), there are two types of bone; cortical and trabecular. At a lower 
level, both are comprised of a composite of mineralized collagen matrixes.  
 
- 61 - 
  
Cortical bone is mainly located on the outside of long bone structures, forming a 
shell. Trabecular bone is found towards the centre of the cortical bone shells and 
towards the end of joints, where its more elastic properties aid in it acting in a load 
absorbing capacity. The articulating ends of the bone are covered in growth 
cartilage, a flexible but strong tissue that allows for bone growth (covered later) 
(Mackie et al. 2008). The outer layer of the bone is covered in the periosteum, a 
tough fibrous connective tissue with an inner layer capable of forming bone tissue. 
Long bones also contain a marrow cavity, where fatty yellow marrow is located, 
which is typically not involved in haematopoiesis. Haematopoiesis takes place in 
the red marrow, which is found in small, flat, irregular bones such as the sternum 
and ilium. A diagram of a typical long bone can be seen in Figure 1.12 (Pocock & 
Richards 2006).  
 
When studying the material properties of bone, at the underlying hierarchical 
material level (0.5 – 1 mm scale), cortical and trabecular bone actually have similar 
structures. Both are made of lamellar bone structures. Lamellar bone is formed 
from a regular, highly organised, pattern of the collagen fibres. At a micrometre 
scale, cortical bone is comprised of many sheets of lamellar bone formed around 
the Haversian Canals. These canals provide the essential blood supply to the bone, 
necessary for essential functions such as nutrition supply and waste disposal. In 
contrast, trabecular bone (sometimes called spongy bone) at the micrometre scale 
is a more highly porous bone structure, in which the lamellar are arranged in less 
well organised packets than in cortical bone. Trabecular bone consists of rods and 
plates with irregular geometries, giving it a more porous structure than cortical bone 
(Donald L. Bartel et al. 2006; Pocock & Richards 2006).  
 
A key difference between cortical and trabecular bone is the increased levels of 
new bone formation and bone remodelling in trabecular bone. This newly formed 
bone is less mineralised than the older cortical bone. Although, this may not always 
be the case, as trabecular bone has a more varied structure than cortical bone, 
which is largely dependent on the anatomical site as bone structure varies a lot 
between different anatomical sites. The age, lifestyle and medical history of the 
individual person from which the bone is being studied must also be considered 
(Donald L. Bartel et al. 2006). 
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Figure 1.12 – The structure of a typical long bone. Adapted from (Pocock & 
Richards 2006). 
 
1.5.2.3 The Cellular Constituents of Bone 
There are three major cell types in bone: osteoblasts, osteoclasts and osteocytes 
(Pocock & Richards 2006; Gilbert 2000): 
 
Osteoblasts – Located primarily on the bone surface and lining marrow cavities. 
These cells are responsible for bone formation, secreting bone constituents such as 
collagen, glycol proteins and also mineralise the newly formed bone by calcifying it. 
Calcification occurs when osteoblasts secrete a collagen-proteoglycan matrix. This 
is able to bind calcium and calcium salts, calcifying the osteoid bone matrix. In 
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tissue engineering, creating osteoclast-like cells is often the goal of researcher, due 
to the bone forming ability of these cells.  
 
Osteocytes – Mature bone cells, which are terminally differentiated osteoblasts. 
They are trapped in lacunae, small spaces in-between the laid down mineralised 
bone matrix. They are responsible for movement of calcium through the bone, via 
tiny channels linking osteocyte cells to each other (canaliculi).  
 
Osteoclasts – Larger than the other bone cells, they are responsible for bone 
resorption during bone growth and remodelling. They are found near bone surfaces 
where bone erosion is occurring.   
 
1.5.2.4 Bone formation  
Bone forms from two different processes, endochondral ossification and 
intramembrane ossification. Long bones are formed from endochondral ossification, 
which is via a cartilage intermediate. Flat bones form by intramembrane 
ossification, where cells condense to form bone directly, without a cartilage 
intermediate (Chen et al. 2012). How and when these processes take place 
depends on the physical environment of the site of formation and the biochemical 
cues present. Mesenchymal stem cells (MSCs) and/or other progenitor cells are 
key, as they can form a number of cells necessary to these processes, most 
importantly osteoblasts and chondrocytes. These formation processes are 
regulated by a number of complicated signalling pathways, including  bone 
morphogenetic protein (BMP), Transforming growth factor beta (TGF-β), Indian 
hedgehog and Wnt signalling pathways (Chen et al. 2012; Mackie et al. 2008; 
Zhang et al. 2013).  
 
1.5.3 Stem Cells 
Stem cells, such as MSCs, are a key cell source for tissue engineering with the 
potential to be controlled, resulting in cells of the specific lineages required for 
creating and/or regenerating functional tissues, such as bone. Theoretically, stem 
cells will respond to virtually any stimuli they are subjected to, whether that be from 
scaffolds, growth factors, mechanical stimulation or any other external factors 
(Drummond-Barbosa 2008).  
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Control of the key pathways of stem cells to bone cells, such as the Wnt or BMP 
signalling pathways, could lead to improved osteogenic differentiation protocols, 
mimicking the environment in the body where bone is formed. Currently, chemicals 
such as dexamethasone, ascorbic acid and phosphate sources (El-Gendy & Yang 
2012; Saha et al. 2013) are utilised, as well as osteogenic growth factors such as 
BMPs, to stimulate osteogenic differentiation of stem cells toward bone forming 
cells (Yang et al. 2003). These MSC derived, osteoblast-like cells can produce 
collagen matrix and modulate matrix mineralization and maturation (Vater et al. 
2011). However, the current technologies either have limited efficacy, financial 
restrictions, ill-defined protocols or detrimental associated side effects, resulting in 
the search for additional or alternative approaches to enhance bone tissue 
engineering (Liu et al. 2013; Ericka M. Bueno & Glowacki 2011; Tollervey & Lunyak 
2012). 
 
1.5.3.1 What are Stem Cells? 
Stem cells are a type of cell found in niches in the human body, capable of 
differentiating into other cell types. Differentiation is the process by which stem cells 
move down a cell lineage or derivation pathway, to progenitor-like cells, and finally 
to adult (somatic) cells. This more differentiated a cell is, the more limited the 
number of potential future cell divisions it has. The key, defining, property of stem 
cells is their ability to self-renew. Self-renewal is asymmetric cell division, where 
one of the resulting daughter cells is an identical copy of the original stem cell, while 
the other is a more differentiated cell (Gronthos et al. 2002; Hochedlinger & Plath 
2009; Tollervey & Lunyak 2012). 
 
It is important to understand the different classifications used for stem cells. One 
method of classification is related to cell potency; the ability of the stem cell to 
differentiate into different tissue types (Preynat-Seauve & Krause 2011). In order of 
most differentiation potential, to the least, cells can be classified as omni/totipotent, 
pluripotent, multipotent or unipotent. Totipotent cells, such as zygote cells, can 
differentiate to form every cell type in an organism. Embryonic stem cells are 
classified as pluripotent, because they can form all cells from the embryo, and 
consequently all adult tissues (just not the embryonic tissues). Multipotent cells are 
less potent and can give rise to usually just one lineage of cells; most adult stem 
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cells are classified as multipotent. Finally, unipotent cells can only maintain one cell 
type or lineage, and are considered terminally differentiated (Hochedlinger & Plath 
2009). A schematic representation of stem cells losing their potency can be seen in 
Figure 1.13, whereas the stem cells move down the hills, they lose their potency 
and differentiate into other cell types.  
 
Stem cells can also be categorised according to their origin, most simply either 
‘embryonic’ or ‘adult’. However, the more recently discovered induced pluripotent 
stem cells are considered as a third major category (Takahashi et al. 2007; Park et 
al. 2008). Also to be considered is the emerging category of ‘neonatal’ stem cells, 
as well as all the populations associated with germ cells (Turnpenny et al. 2006). 
Furthermore, within the category of ‘adult stem cells’, further classification terms 
such as mesenchymal or hematopoietic can be used. These usually depend on the 
origin of the cells, or lineage that can result from them. Classifications such as 
totipotent and multipotent are not mutually exclusive; for example, hematopoietic 
stem cells are classified as multipotent stem cells. Poor characterisation of stem 
cell biochemical and molecular characteristics makes the classification of stem cells 
a difficult and constantly evolving process, and researchers are often at odds about 
how to classify them. In particular, the property of ‘stemness’, or differentiation 
potential, is difficult to describe and characterise. The indicator genes, biomarkers 
etc. responsible for this potential are not consistent across different stem cell 
populations. For example, compounding the problem, even the methods of 
determining stem cell genes and overlapping gene populations are not consistent 
(Ramalho-Santos et al. 2002). The exact definition of stem cells is often bought into 
question, as some researchers even question the property of self-renewal truly 
being a defining property of stem cells (Grafi & Avivi 2004). Epigenetic analysis and 
further understanding of epigenetics may hold some of the solutions to these 
difficulties. 
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Figure 1.13 – Schematic summary of cells decreasing in differentiation 
potential. ‘The hills of differentiation potential’. As cells fall down to lower hills 
they lose their differentiation potential, becoming less stem cell like.  
 
1.5.3.2 Mesenchymal Stem cells 
The term ‘mesenchymal stem cell’ (MSC) is used to collectively describe 
multipotential stromal cells that can differentiate into a number of different tissues. 
However, the term is a confusing one, sometimes, particularly historically, used 
solely to describe bone marrow stem/stromal cells, the cells isolated only from bone 
marrow. However, the term has also evolved to be used to describe a variety of 
multipotential cells from different tissues, for example adipose (Zuk et al. 2001), 
synovial membrane (De Bari et al. 2001), skeletal muscle (Zammit & Beauchamp 
2001) and dental pulp (Gronthos et al. 2000; Gronthos et al. 2002; Tomlinson et al. 
2015). The multipotential of such cells has been demonstrated by generating a 
number of different tissue types, including those of the classic tri-lineage 
differentiation potential test; bone, cartilage and adipose tissues (Jones & Yang 
2011; Lindner et al. 2010; Dudakovic et al. 2015). These cells don’t just differentiate 
into cells of the mesoderm; however, there has been work to demonstrate their 
differentiation into other lineages derived from other embryonic layers, such as 
neuronal (Zhao et al. 2002) and lung tissue (Ortiz et al. 2003), demonstrating the 
wider potential of these cells. However, there are limited examples of this, often 
with a lack of in vivo validation, along with a lack of evidence of these cells 
demonstrating lifelong self-renewal in vivo (Bianco et al. 2009). For these reasons, 
researchers are still debating if it is correct to name these cells multipotential cells, 
or perhaps even stem cells.  
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It is useful to compare MSCs to other stem cell populations for context. ESCs can 
differentiate into all embryonic tissues (of the endoderm, mesoderm and ectoderm), 
are relatively easily isolated from embryos, and have been extensively 
characterised with in vivo testing to prove their plasticity. However, there are a 
plethora of ethical and legal issues associated with ESCs. Hematopoietic stem cells 
can be found in a well-defined niche (a simple schematic of this can be seen in 
Figure 1.14) in the bone marrow, and their differentiation into all blood cell types 
has been demonstrated (Moore & Lemischka 2006; Keller 2005). Whereas cells 
currently classified as MSCs can be found in multiple different tissues/organs, and 
their niches are undefined in comparison. 
 
These different cell populations are often collectively referred to as MSCs due to 
their ability to adhere to plastic (a property exploited in the routine tissue culture 
experiments carried out in laboratories), and their fibroblast like morphology. There 
have been attempts to find common surface markers among different MSC 
populations, and to fully characterise these, but there is still a lack of consensus 
this. This is why sometimes in the literature, these cells are referred to by other 
names, such as ‘multipotent adult progenitor cells’ (Lindner et al. 2010; Jacobs et 
al. 2013). 
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Figure 1.14 - Hematopoietic stem cell nice. A diagram of hematopoietic stem 
cells in the bone marrow niche they can be found. Adapted from (Moore & 
Lemischka 2006; Wang & Wagers 2011). 
 
 
1.5.3.3 Adipose Derived MSCs 
Human adipose derived stem cells (ADSCs) were discovered in subcutaneous fat, 
and isolated as a by-product of liposuction surgery (hence they were originally 
Processed Lipoaspirate Cells, or PLA cells) cells. Their multi-lineage potential was 
demonstrated in vitro (Zuk et al. 2001). Since then, ADSCs have been identified as 
one of the most promising sources of MSCs, largely due to their ease of harvesting 
compared to other MSCs from other sources such as bone marrow. ADSCs can 
also be isolated from alternative fat sources to subcutaneous fat (Dragoo et al. 
2003), and have shown multilineage differentiation potential comparable to the 
current gold standard of bone marrow MSCs, with ADSCs being able to differentiate 
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into bone (Levi & Longaker 2011), cartilage (Erickson et al. 2002), nerve (Golipoor 
et al. 2010), endothelial (Planat-Benard et al. 2004) and cardiac (Lee & Kemp 2006) 
lineages. Controlling and improving upon these differentiation protocols is the focus 
of much research today, due to their huge potential for both autologous and 
allogenic treatments.  
 
1.5.3.4 Epigenetics Markers and Stem Cells 
There are strong links between epigenetic markers and the differentiation properties 
of stem cells. Epigenetics plays a key role in the differentiation potential of stem 
cells, and its role has been described elsewhere as “staggeringly complicated” 
(Tollervey & Lunyak 2012). Until relatively recently, when stem cells were analysed 
and discussed, it was usual for only the transcriptional regulation and factor 
networks to be focused upon. However, it has become apparent that the 
differentiation states and the potency of stem cells are linked to the cell’s 
“epigenetic landscape”. Epigenetics is key to defining the molecular base of 
pluripotency, reprogramming and early human development (Tollervey & Lunyak 
2012; Teven et al. 2011). Different genes are switched on or off as cell potency 
changes, which is controlled by expression of different transcription factors and also 
processes linked to epigenetic control, such as chromatin remodelling. The fact that 
epigenetic modifications are heritable allows for the potential for modifications to 
early stage stem cells to have long lasting effects, and to possibly be utilised control 
stem cell lineages all the way from pluripotent cells to terminally differentiated adult 
cells.  
 
Tollervey et al. define three classic cornerstones of epigenetics that orchestrate 
gene activity and pluripotency as (Tollervey & Lunyak 2012): 
1. Chromatin remodelling and chromatin modifications. 
2. DNA methylation of CpG dinucleotide (a cytosine nucleotide occurring next 
to a guanine nucleotide) regions of DNA. 
3. The activity of non-coding RNA. 
 
The effect of compounds such as HDACis directly and indirectly on chromatin 
modelling, one of the three key pillars, is therefore of interest to those looking to 
control stem cells. Studies have shown that as cells become less potent, they 
typically become more transcriptionally restrained, due to condensation of the 
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chromatin and an increase in heterochromatin levels. Levels of, and specific 
epigenetic markers can actually be used to assess potency of stem cells (Tollervey 
& Lunyak 2012; Stancheva 2011). 
 
The vast and complicated pattern of epigenetic modifications has a role to play in 
stem cell pluripotency, differentiation and reprograming (Tollervey & Lunyak 2012; 
Kretsovali et al. 2012b; Liang et al. 2010). As more and more research is conducted 
into stem cells with the aim of producing cellular therapies, disease models and in 
tissue regeneration and creation, the fundamentals of stem cells need to be better 
understood. If this research is to be recreated on a larger, commercial scale, or 
improved to make more of an impact on the clinic, tools such as epigenetics need 
to be harnessed.  
 
1.5.4 Epigenetics and HDACis as Tools in Tissue Engineering 
HDACis can have a wide range of effects on cells, some desirable but some 
undesirable, as discussed previously. In theory, HDACis may be able to alter the 
differentiation properties of stem cells, allowing greater control of their fate. The 
advance of some HDACis to cancerous clinical trials has led to research 
investigating the side-effects of HDACis on naturally occurring stem cell populations 
that reside in the body, such as MSCs. For example, SAHA and MS-275 were 
found to reduce the stem cell like properties of human MSCS, as well as the 
previously mentioned effects of inducing cell cycle arrest, an increase in apoptotic 
death pathways and increased cellular senescence (Di Bernardo et al. 2009). 
These findings may not necessarily be a bad thing; a reduction in the differentiation 
potential, combined with the movement of a cell down a single lineage, may be 
beneficial.  
 
From a translational research perspective, a number of alternative properties of 
HDACis on cells may make them a promising tool for the translation of tissue 
engineering. Potentially useful effects of HDACis include pain relief (Li et al. 2012; 
Naguib et al. 2012; Denk & McMahon 2012; Chiechio et al. 2009; Z. Zhang et al. 
2011), anti-microbial (Steinmann et al. 2009), immune response modulatory 
(Schildberg et al. 2010; Kinugasa et al. 2008; Reddy et al. 2004; Choi & Reddy 
2011), and anti-inflammatory properties (Shakespear et al. 2011; Bhavsar et al. 
2008; Choi & Reddy 2011; T.-I. Kim et al. 2013). 
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Recently, more and more studies have emerged exploring the use of HDACis in 
bone tissue engineering. As well as bone, which will be covered in detail in the 
following sections, work has begun attempting to utilise HDACis for the 
regeneration of different tissues, such as cardiac (Ohtani & Dimmeler 2011), 
neural/nervous (Hsieh et al. 2004), adipose (Catalioto et al. 2009), dental (Duncan 
et al. 2011; Duncan et al. 2012), liver (Niki et al. 1999; Snykers et al. 2009; Knutson 
et al. 2008; Kurinna & Barton 2011), skin (Glenisson et al. 2007), pancreatic 
(Avrahami & Kaestner 2012), muscle (M.-S. Kim et al. 2008) and cartilage (Hong et 
al. 2009). 
 
1.5.5 HDACis and Bone tissue Engineering 
1.5.5.1 A brief history 
Research into the effect of HDACis on bone really first began in the 1990s, when 
NaB was found to promote bone formation by osteoblast cells (Iwami & Moriyama 
1993). Due to initial concerns about the side-effects of HDACis utilised in cancer 
therapies on bone tissue, several early studies also investigated the effect of 
HDACis on bone densities (Nissen-Meyer et al. 2007; Senn et al. 2010; McGee-
Lawrence et al. 2011; Pratap et al. 2010). SAHA was found to have a number of 
worrying effects on bone cells in animal models, including the reduction of 
osteoblast numbers, harmful effects on mature osteoblasts, DNA damage and an 
overall loss of bone mass in animal models (McGee-Lawrence et al. 2011; Pratap 
et al. 2010). Similar concerns were held with  VPA (Nissen-Meyer et al. 2007; Senn 
et al. 2010). 
 
However, allaying the fears of some clinicians, a study published in 2013 found that 
while SAHA inhibited the proliferation of bone related cell populations, such as 
human bone marrow MSCs, it also increased their osteogenic differentiation 
potential in vitro. This indicates that perhaps SAHA didn’t have a negative effect on 
bone cells, and that it could be a promising tool for both oncological and tissue 
engineering applications (Xu et al. 2013). However, problems can arise using 
animal models to draw conclusions about the effect of HDACis, as some species 
may be affected by HDACis in different ways (Senn et al. 2010). The exposure 
dose and length are also key factors when studying HDACis, therefore human 
clinical trials are needed to closely monitor the potential side effects.  
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1.5.5.2 HDAC isoforms and their links with bone cells 
High levels of HDAC acetylation were found to block vitamin D stimulation of 
osteocalcin production and thus osteoblast differentiation (Montecino et al. 1999). It 
has been suggested that several specific HDAC isoforms are linked to osteoblast 
activity. In particular, HDAC3 is thought to be closely linked to bone tissue formation 
(Schroeder & Westendorf 2005; Schroeder et al. 2004; Razidlo et al. 2010; McGee-
Lawrence et al. 2013). HDAC3 interacts with Runx2, supressing osteocalcin 
production and regulating progenitors differentiation into osteoblasts (Schroeder et 
al. 2004; Hesse et al. 2010; Lamour et al. 2007). During the differentiation of 
osteoblasts, HDAC3 activity is reduced, resulting in acetylation of histones 3 and 4. 
This balance of acetylation can be altered in cells by over or under expressing 
Nuclear Factor of Activated T Cells (NFAT) signalling (Choo et al. 2009). In vivo 
HDAC3 knockout reduced osteoblast levels and increased fatty deposits in bone 
marrow, seriously compromising skeletal health in mice (Razidlo et al. 2010). 
Another study found HDAC3 to be essential for bone maintenance during aging; 
when knocked down the mouse bone mass was reduced (McGee-Lawrence et al. 
2013).  
 
Of the other class 1 HDAC isoforms, similarly, HDAC1 is downregulated during 
differentiation of osteoblasts, making it another potentially interesting bone linked 
HDAC isoform to specifically target with inhibitors to induce osteoblast 
differentiation (Lee et al. 2006). Often overlooked as a class 1 HDAC, there has 
been a recent investigation into the role of HDAC8 in osteogenic differentiation, 
where it was discovered HDAC8 suppressed osteogenic-related genes expression, 
and inhibition of this with VPA promoted osteogenic expression of rat bone marrow 
stromal cells (Fu et al. 2014). 
 
Jointly HDAC4 and HDAC5 have been found to play a role in osteoblast 
differentiation (Kang et al. 2005; Jeon et al. 2006). HDAC4 also specifically controls 
chondrocyte hypertrophy, which is involved in endochondral ossification during 
bone formation (Vega et al. 2004). Moreover, HDAC6 is linked to the differentiation 
of mesenchymal stem cells into osteogenic lineages (Huang et al. 2012). 
 
Moving on from osteoblasts linked effects, both class I and class II HDAC isoforms 
are required for osteoclast differentiation (Cantley et al. 2011), and Romidepsin, 
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which preferentially inhibits class 1 HDACs, inhibits osteoclastogenesis (Nakamura 
et al. 2005). HDAC3 and HDAC7 appear to have opposite effects: suppression of 
HDAC7 accelerates osteoclast differentiation, while suppression of HDAC3 inhibits 
osteoclast differentiation (Pham et al. 2011). Similarly, other researchers have 
suggested that HDAC5 and HDAC6 activity will reduce osteoclast differentiation (J. 
H. Kim et al. 2011). 
 
1.5.5.3 Current status of the potential of HDACis in in vitro bone tissue 
engineering 
Although the specificity of different HDACis are questionable (Bradner et al. 2010), 
it is clear that there are obvious differences in effects between different HDACis on 
bone related cells. Lee et al. (2006) demonstrated that both NaB and TSA can 
increase osteogenic activity in rat cell lines, including upregulation of osteoblast 
marker genes (Lee et al. 2006). It has also been reported that NaB can also 
promote osteogenic differentiation of periodontal ligament fibroblasts (with the 
added benefit of modulating inflammatory reactions) (T.-I. Kim et al. 2013). 
Similarly, TSA, MS-275 and VPA have been shown to upregulate pre-osteoblasts 
osteogenic gene expression (Schroeder et al. 2007). However, others suggest that 
TSA may not actually induce osteoblasts maturation (Schroeder & Westendorf 
2005; Iwami & Moriyama 1993). Other studies have found that HDAC1, HDAC2 and 
HDAC3 specific MS-275 stimulates bone regeneration both in vitro and in vivo (H.-
N. Kim et al. 2011; Kim et al. 2012). Another HDACi, Largazole, was found to 
increase the in vitro osteogenic potential of C2C12 cell line cells, believed to be due 
to an increased expression of RUNX2 and BMPs (Lee et al. 2011). Thus, reports 
are conflicting, and the effects of HDACis on bone tissue engineering are still 
unclear and require further study. 
 
It is clear that the choice of HDACi, delivery system and the length of time that cells 
are exposed to the HDACis may be vital (Jung et al. 2010). Several in vitro studies 
demonstrate the importance of controlling the length of time cells are exposed to 
the HDACis, often developing pre-treatment strategies to effect differentiation 
(Maroni et al. 2012; Xu et al. 2009; Cho et al. 2005). 
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1.5.5.4 Current status of the effect of HDACis on Osteoclasts 
HDACis, such as Trichostatin A (TSA) and NaB, inhibit osteoclast differentiation 
(Iwami & Moriyama 1993; Rahman et al. 2003; Takada et al. 2006). In 2007, Yi e al. 
reported that TSA can actually cause osteoclast death (Yi & Baek 2007), and Kim 
et al. (2012) suggested that HDAC1, HDAC2 and HDAC3 specific inhibitor (MS-
275) can reduce bone absorption by having a negative impact on osteoclast 
differentiation (Kim et al. 2012). These inhibitory effects on osteoclasts could be 
utilised to prevent bone loss in inflammatory disease (Cantley et al. 2012). 
Although, contradictorily, it has also been shown that TSA promoted the expression 
of RANKL, a ligand integral to osteoclast formation, function and survival (Fan et al. 
2004). 
 
1.5.5.5 Current status of the potential of HDACis in in vivo bone tissue 
engineering 
In one of the key first studies utilising HDACis in bone tissue engineering, it was 
reported that the panHDACis TSA and NaB increased osteogenic differentiation of 
MSCs in vitro and ex vivo (Cho et al. 2005). However, these results could not be 
recreated in in vivo conditions (Boer et al. 2006). 
 
In 2010, Hung HM et al observed an increased osteoblast differentiation over 
controls, when the α-calcium scaffolds loaded with TSA and NaB were placed in rat 
bone defect models (Jung et al. 2010). Elsewhere NaB and VPA have been used in 
combination with reduced oxygen environments and ADSCs to achieve the 
regeneration of bone tissue both in vitro and in vivo (Xu et al. 2009). Similarly Lee 
et al. demonstrated that collagen scaffolds soaked in Largazole solution could 
improve mouse bone formation in two models (Lee et al. 2011). 
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1.6 Introduction Synopsis 
The actions of histone deacetylases (HDACs) remove the acetyl groups from lysine 
residues, leading to the formation of a condensed and transcriptionally silenced 
chromatin. HDACis block the action of HDACs, resulting in hyperacetylation of 
histones, thereby affecting gene expression. The use of these compounds has so 
far mostly been limited to cancer treatments, due to their profound effect on cancer 
cells while usually leaving normal cells unaffected.  
 
However, research has begun to explore their use in other applications, such as 
tissue engineering. Different HDAC isoforms can be linked to different tissue types, 
such as bone. There is a highlighted clinical need to improve bone tissue 
engineering, leading to some research into how HDACis affect formation of bone 
and with the potential to utilise this in bone tissue engineering 
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1.7 Thesis Aims and Objectives  
The aim of this study was to investigate the effect of HDACi MI192 on the 
behaviour of adipose derived stem cells, with the long term goal of improving the 
efficacy of bone tissue engineering. 
 
The main objectives of the study: 
1) To synthesise and characterise MI192. 
2) To investigate the effect of MI192 on the general properties of ADSCs. 
3) To investigate the effect of MI192 on the differentiation (osteogenic and 
adipogenic) of ADSCs, in 2D. 
4) To investigate the effect of MI192 on in vitro 3D models of bone tissue 
engineering.  
5) To investigate the effect of MI192 on the gene expression of ADSCs, 
without any induction of differentiation.  
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Chapter 2: General Materials and Methods 
This chapter describes all of the general materials and methods that apply to the 
subsequent chapters. Those individual chapters also have methods specific to those 
chapters where relevant. 
2.1 General reagents 
All reagents (e.g. hydrochloric acid (HCl), dimethyl sulfoxide (DMSO) and ethanol 
(EtOH)) were purchased from Sigma-Aldrich, unless otherwise stated. 
 
Tissue culture flasks and plates were purchased from Corning. General reagents 
used for cell culture were phosphate buffered saline (1x PBS, pH 7.4 without Ca or 
Mg, Lonza, Cat. no: BE17-516F), Alpha minimal essential medium (α-MEM, without 
L-Glutamine, Lonza, Cat. no: BE12-169F), fetal calf serum (FCS, Sigma, Cat. no: 
F9665), penicillin-streptomycin (P/S, Sigma Cat. no: P4333), L-glutamine (L-G, 
Sigma, Cat. no: G7513) and 0.25 % (w/v) trypsin-EDTA (Ethylenediaminetetraacetic 
acid ) solution (T/E, Sigma-Aldrich, Cat. no: T4049). ‘Basal medium’ refers to α-MEM 
supplemented with 10 % FCS, 1 % P/S (10,000 units/mL penicillin, 10 mg/mL 
streptomycin) and 1 % L-G (200 µM). 
 
2.2 MI192 
Unless otherwise stated, MI192 used was the batch synthesised in Chapter 3: The 
Chemical Synthesis of MI192. HDACi MI192 was dissolved in DMSO to make a 10 
mM stock solution (3.8148 mg in 1 mL DMSO). The stock was then added directly to 
culture medium to make the desired concentration. All media containing MI192 were 
made fresh to use, never stored, to avoid any MI192 degradation in solution. The 
concentration of DMSO in cell culture was always below 0.5 %, so as to have a 
minimal cytotoxic effect on cells. The effect of DMSO on ADSCs was investigated to 
ensure that the concentrations used in this thesis were not having an adverse effect 
on the ADSCs. The results can be seen in the Appendix (A3 - Investigation of the 
effect off 1% – 0.01% DMSO has on ADSC cell number and viability). 
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2.3 Cell Culture 
All cell incubations were carried out in an incubator at 37 °C, 5 % CO2 and greater 
than 90 % humidity. All cell culture experiments were carried out aseptically in a class 
II biological safety laminar flow hood. 
 
2.3.1 Cell detachment and seeding 
To detach cells, medium was aspirated and cells were washed twice with 1x PBS 
prior to being incubated in T/E for 5-10 minutes, until complete cell detachment was 
observed (confirmed under a light microscope). The resulting cell suspension was 
centrifuged at 1100 RPM for 5 minutes, the supernatant was aspirated and the cell 
pellet was re-suspended in the appropriate culture media. Cells were counted and 
seeded at different densities according to experimental design.  
 
2.3.2 Cell Counting 
To determined cell numbers, a mixture of a 40 l cell suspension with equal volume 
of trypan blue (Sigma-Aldrich, Cat. no: T8154) was added in both sides of a 
haemocytometer, and the cell number was manually counted under a light 
microscope. Any cells stained dark blue were determined dead or not viable, and 
were not counted. The total viable cells in 4 corner squares (of the 9 squares in one 
side’s full grid) were counted and from the average cell number in 1 square was 
calculated. This was undertaken for both sides of the haemocytometer and the 
average of these was used for the cell count. Each square was 1 mm x 1 mm so the 
total area was 1 mm2. The depth of each square was 0.1 mm, so the final volume of 
each square was 100 nL. The total number of cells could then be calculated by 
multiplying the cell count by the trypan blue dilution factor, then by 10,000 and finally 
by the total volume of cell suspension: 
 
𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠
=  𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑥 10,000 𝑥 𝑡𝑜𝑡𝑎𝑙 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 
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2.3.3 Human Adipose Derived Stem Cells  
Unless otherwise stated, human adipose derived stem cells were purchased from Life 
Technologies (STEMPRO® Human Adipose Derived Stem Cells, Cat. no: R7788-
110/R7788-115)1. The cells are isolated from human adipose tissue collected during 
liposuction procedures and cryopreserved from primary cultures. Before 
cryopreservation, the ADSCs were expanded for one passage in MesenPRO RS™ 
Medium. Each lot of ADSCs originates from a single donor of human lipoaspirate 
tissue. Cells are prepared from low-passage (passage 1) adherent human adipose-
derived primary cell cultures. Cells express a flow-cytometry cell-surface protein 
profile positive for CD29, CD44, CD73, CD90, CD105, and CD166 (> 95 %), and 
negative for CD14, CD31, CD45, and Lin1 (< 2 %). Unless otherwise stated, cells 
from 1 donor (Lot: 2118, cells isolated from the Abdomen of a 45 year old female) 
were used for all experiments.  
 
2.3.4 In vitro expansion of ADSCs 
All ADSCs were expanded in an ‘expansion medium’, MesenPRO RS™ Basal 
Medium (Life Technologies, reduced serum medium for long term culture of MSCs, 
Cat. no: 12746-012) supplemented with 1 % P/S. This was recommended for ADSC 
expansion by Life Technologies. The medium was changed every 3-4 days. Cells 
were passaged when approaching 90 % confluency. Cells of passage 5 were used 
for all experiments. To prove their multi-differentiation potential, P5 ADSCs from this 
donor underwent tri-lineage differentiation (osteogenic, adipogenic and 
chondrogenic). A summary of this can be seen in the appendix (A2 - Confirmation of 
tri-linage differentiation potential of ADSCs). 
 
2.3.5 Osteogenic Induction Culture 
Two different media were used for the osteogenic differentiation of ADSCs. Both 
media were changed every 3 – 4 days. 
 
                                               
1 Manufacturer’s information for these cells can be found at 
http://tools.lifetechnologies.com/content/sfs/brochures/stempro-adsc-manual.pdf. 
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‘Osteogenic induction medium’ was used for short term induction experiments (1 - 10 
days) to induce the early osteogenic differentiation of cells. This was ‘Basal medium’, 
as above, supplemented with 100 µM L-Ascorbic acid 2-phosphate sesquimagnesium 
salt hydrate (Sigma-Aldrich, Cat. no: A8960) and 10 nM dexamethasone (Sigma-
Aldrich, Cat. no: D4902). It contained no mineral additional source.  
 
‘Mineralisation medium’ (commercial name: StemPro® Osteogenesis Differentiation 
Media, Life Technologies, Cat. no: A10072-01) was used for long term induction 
experiments (over 10 days), to induce extracellular matrix mineralisation. The full 
contents are not disclosed by the manufacturer, but it presumably contains a mineral 
source. Manufacturer’s information states it contains a low glucose level, GlutaMAX™ 
glutamine source, standard serum level (10 %), no phenol red or HEPES buffer and 
sodium phosphate inorganic salts.  
 
2.3.6 Adipogenic Induction Culture 
To induce adipogenic lineage differentiation, the Zen Bio adipogenic culture protocol 
was followed, where two media were used sequentially. Firstly, cells were cultured in 
‘adipogenic induction medium’ (Zen Bio, Cat. no: DM-2) for 7 days. After this, 
according to the protocol, a fixed amount (e.g. for a 12 well plate, 1.2 mL of the 2 mL 
total medium) of this induction medium was removed, then a fixed amount of 
‘adipocyte maintenance medium’ (Zen Bio, Cat. no: AM-1) was added (e.g. for a 12 
well plate, 1.6 mL was added). Cells were then cultured for a further 7 days before 
assessment.  
 
2.3.7 Chondrogenic Induction Culture 
For chondrogenic differentiation, cell pellets (2.5 x 105 cells per pellet) were cultured 
in chondrogenic induction media, which is serum free α-MEM supplemented with 1 % 
L-G, 1 % P/S, 0.1 µM dexamethasone, 10 ng/mL Human TGF-β-3 Recombinant 
Protein (Cambridge Bioscience, Cat. no: GFH109-2), 50 µg/mL L-Ascorbic acid 2-
phosphate sesquimagnesium salt hydrate (Sigma Aldrich, Cat. no: A8960) and 1 % 
100x insulin transferrin selenium solution (ITS–G, Life Technologies, Cat. no: 
41400045), for 3 weeks. The medium was changed every 3 days.  
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2.4 Biochemical assays 
Cells for biochemical assays were washed twice with 1x PBS and stored in a –80 °C 
freezer in a fixed volume per well of 0.1 % Triton X-100 (Fisher Scientific, Cat. no: 
BPE151-500) for a maximum of two weeks until needed. Cells were lysed when 
undergoing three freeze-thaw cycles of –80 °C and 37 °C, with scraping in-between. 
 
2.4.1 PicoGreen® DNA quantification assay  
After the cells were lysed in Triton X-100, DNA quantity was then assessed by Quant-
iT™ PicoGreen® (Invitrogen, Life Technologies, Cat. no: P7581) DNA quantification 
assay. PicoGreen® reagent is an ultrasensitive fluorescent nucleic acid stain, which 
detects double stranded DNA in solution.  
 
A 10 mg/mL DNA stock standard was prepared by adding 10.47 mg of DNA sodium 
salt from herring testes (Sigma-Aldrich, Cat. no: D6898) to 1047 µL of 1x Tris-EDTA 
(1x TE, Sigma-Aldrich, Cat. no: 93302) buffer and incubating for 60 minutes at 37 ºC 
on a shaker. The DNA concentration was checked on a Thermo Scientific ND1000 
Nanodrop spectrophotometer. DNA standards were then prepared by adding this to 
1x TE buffer; prepared standards ranged from 1 ng/mL to 1 µg/mL. 
 
For the assay, 10 µL – 30 µL of cell lysate solution (prepared as above) was added to 
70 µL – 90 µL of 1x TE buffer (giving a total volume of 100 µL). 100 µL of 
PicoGreen® reagent (a 1:200 dilution in 1x TE buffer) was then added to every 
sample and  each standard, and was incubated at 37 ºC in the dark for 5 minutes. 
Three technical repeats of each biological repeat were performed. Blank reading 
wells of 100 µL of TE buffer, with addition of 100 µL of the PicoGreen® reagent, were 
also created, for background readings. The fluorescence was then measured in a 
Varioskan Flash Multimode Microplate Reader (Model 3001, Thermo Scientific) by 
exciting the samples at 480 nm, with emission reading set at 520 nm. The unknown 
value of DNA was then calculated using the standard curve generated, to give the ng 
of DNA. The total µg of DNA per well was calculated from the ng DNA per mL 
calculated and Triton X-100 harvest volume from each well. 
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2.4.2 Alkaline Phosphatase (ALP) Quantitative Assay 
ALP quantity was assessed using the 4-nitrophenyl colourmetric phosphate liquid 
system.  Standards (100 µM – 5 µM) for the ALP activity assay were prepared by a 
serial dilution of 4-nitrophenyl (10 mM solution, Sigma-Aldrich, Cat. no: N7660) in an 
assay buffer solution (60 µL 2 % aq. solution of Tergitol® type NP-40, Sigma-Aldrich, 
Cat. no: NP40S, in 10 mL 1.5 M alkaline buffer solution, Sigma-Aldrich, Cat. no: 
A9226, and 20 mL dH2O). 10 µL of cell lysate solution was incubated in a 96 well 
plate with 90 µL of 4-nitrophenol phosphate liquid system (Sigma-Aldrich, Cat. no: 
4264-83-9), along with the standards, for 45 - 60 minutes at 37 °C. Blank wells of 10 
µL of cell lysis solution, with no cells, and the 4-nitrophenol phosphate liquid system 
were also set up, for background readings. Three technical repeats of each biological 
repeat and standard were performed. The reaction was stopped by addition of 100 µL 
of 1 M NaOH, (including addition to the standards), and the absorbance was read at 
405 nm. The unknown value of ALP was then calculated using the generated 
standard curve, to give the mmol of ALP. The net (nmol/hour/well) ALP activity was 
then calculated from the mmol ALP multiplied by 1000, total Triton X-100 harvest 
volume, assay volume and time length of the ALP reaction (incubation time): 
 
𝑛𝑒𝑡 𝐴𝐿𝑃𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
(
(𝑚𝑚𝑜𝑙 𝐴𝐿𝑃 𝑥 1000)𝑥 𝑡𝑜𝑡𝑎𝑙 𝑇𝑟𝑖𝑡𝑜𝑛 𝑋 − 100 ℎ𝑎𝑟𝑣𝑒𝑠𝑡 𝑣𝑜𝑙𝑢𝑚𝑒
𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒 )
𝑎𝑠𝑠𝑎𝑦 𝑣𝑜𝑙𝑢𝑚𝑒
  
   
 
2.4.3 Alkaline Phosphatase Specific Activity (ALPSA) Calculation 
Alkaline phosphatase specific activity (ALPSA) for each well was calculated using the 
total ALP quantity divided by the total DNA content of the same well (nmol 
ALP/hour/µg of DNA): 
 
𝐴𝐿𝑃𝑆𝐴 =
𝑇𝑜𝑡𝑎𝑙 𝐴𝐿𝑃 𝑝𝑒𝑟 ℎ𝑜𝑢𝑟 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 (𝑛𝑚𝑜𝑙)
𝑡𝑜𝑡𝑎𝑙 𝐷𝑁𝐴 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 (µg)
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2.5 2D Histological Staining 
2.5.1 Alkaline Phosphatase Staining 
Samples were washed twice in 1x PBS, fixed in 10 % neutral buffered formalin (NBF, 
Cellpath, Cat. no: BAF-0010-01A) for 60 seconds and washed with three washes of 
distilled water (dH2O). The sample was then stained for ALP using the 
SIGMAFAST™ BCIP®/NBT kit (Sigma-Aldrich, Cat. no: B5655). One tablet from the 
kit was dissolved in 10 mL of dH2O, and the cells stained with this solution for 30 
minutes to 1 hour 37 °C in darkness. Cells were then washed with dH2O, left to air dry 
and observed under a Leica DMI6000 B inverted microscope. A blue coloured stain 
indicates ALP protein. 
 
2.5.2 Alizarin Red Staining for Calcium Accumulation 
Samples were washed twice with 1x PBS, fixed in 10 % NBF for 1 hour and then 
washed three times with dH2O. The samples were then incubated with Alizarin Red 
solution (40 mM at pH 4.1 +/- 0.1, Millipore (UK) Limited, Cat. no: TMS-008-C) for 15 
minutes at room temperature, followed by three washes of dH2O and one further 1 
hour wash in dH2O on a rocking device. Cells were then air dried and observed under 
a Leica DMI6000 B inverted microscope. A red coloured stain indicates calcium 
deposition. The stain was then destained by adding 1 mL of 10 % cetylpyridinium 
chloride (Sigma, Cat. No: C0732) in 0.1 M phosphate buffer (pH 7.0) to each well and 
placing the plate on a rocking device for 1 hour, allowing the stain to dissolve into the 
solution. 10 µL extracts from each well were diluted with 90 µL dH2O, and the 
absorbance was read on a plate reader at 550 nm. Blanks were prepared from 10 µL 
10 % cetylpyridinium chloride and 90 µL dH2O. 
 
2.5.3 Von Kossa Staining for Mineral Nodule Formation  
Samples were washed twice with 1x PBS, fixed in 10 % NBF for 1 hour and then 
washed three times with dH2O. The samples were then incubated with a 1 % aq. 
silver nitrate (Sigma-Aldrich, Cat. no: S6506) solution at room temperature in a U.V. 
light box for 15 minutes. This was followed by three dH2O washes and one wash with 
5 % sodium thiosulfate (Sigma-Aldrich, Cat. no: S7026). Cells were then air dried and 
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observed under a Leica DMI6000 B inverted microscope. A brown/black colour stain 
indicates mineral deposition. 
 
2.5.4 Oil Red O Stain for Lipid Droplets 
Samples were washed twice with 1x PBS, fixed in 10 % NBF for 1 hour, washed 
three times with dH2O, and then washed once with 60 % i-propanol (Sigma-Aldrich, 
Cat. no: 190764). The samples were then incubated with an Oil Red O Stain (20 µM 
pore filtered 0.3 % weight in 60 % i-propanol Oil Red O powder stain, Sigma-Aldrich, 
Cat. no: O0625) for 15 minutes. Cells were then washed with 60 % i-Propanol and 
then three washes of dH2O. Cells were then air dried and observed under a Leica 
DMI6000 B inverted microscope. Red colour stain indicates lipid droplet 
accumulation. The stain was then destained by adding 500 µL of 100 % i-Propanol to 
each well and placing the plate on a rocking device for 1 hour, allowing the stain to 
dissolve into the solution. The absorbance at 500 nm of 100 µL extracts from each 
well were read on a plate reader. Blanks were made from 100 µL 100 % i-Propanol.  
 
2.6 Histology of 3D samples 
2.6.1 Paraffin Embedding and Sectioning 
All 3D samples for histological analysis were processed in a VIP Tissue processor 
(Sakura) through 70 % EtOH, 90 % EtOH, 4 changes of 100 % EtOH, 3 changes of 
100 % xylene and 3 changes of wax, prior to be embedded in paraffin. 5 µM sections 
were cut using a Leitz rotary microtome and mounted on glass slides using a 40 °C 
water bath. Slides used for histological staining were Superfrost™ Plus Microscope 
Slides (Fisherbrand™, Cat. no: 12-550-15) and slides used for immunohistochemical 
staining were Silane Adhesion Whitecoat slides (CellPath, Cat. no: MDC-0102-54A).  
 
2.6.2 Taking Slides to Water 
Prior to any histological staining or immunohistochemistry, paraffin sections on slides 
were ‘taken to water’ to remove the wax and hydrate the sections. This was done by 
immersing the slides in a bath of 100 % xylene (VWR, Cat. no: VWRC28975) for 5 
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minutes, two 100% EtOH baths for 5 minutes each and washing in running tap water 
bath for 5 minutes.  
 
2.6.3 Haematoxylin and Eosin (H+E) Staining 
After being taken to water, slides were stained with Harris’s Haematoxylin (Shandon, 
Cat. no: 6765002) for 3 minutes, washed in a running tap water bath for 2 minutes, 
developed in Scott’s tap water (Leica Microsystems, Cat. no: 02901) for 3 minutes, 
washed in a running tap water bath for 2 minutes and stained with 1 % aq. eosin 
(Leica Microsystems, Cat. no: 01592E) for two minutes. The slides were then 
immersed in a running tap water bath for 5 minutes, and two 100 % EtOH baths, for 5 
minutes each, and in xylene for 2 minutes before mounting in DPX (p-xylene-bis (N-
pyridinium bromide), Agar Scientific Cat. No: R1340). The stains were then observed 
under an Olympus BX50 microscope.  
 
2.6.4 Weigert’s Haematoxylin, Picrosirius Red and/or Alcian Blue 
Staining 
After being taken to water, slides were then stained with Weigert’s haematoxylin (an 
equal part mix of Haematoxylin Weigert’s Solution A and Haematoxylin Weigert’s 
Solution B, TCS Biosciences, Cat. nos: HS375-500 and HS380-500) for 15 minutes, 
then washed in a tap water bath for 10 minutes. Then the slides were (if required) 
stained with Alcian Blue (1 % w/v in 3 % acetic acid, TCS Biosciences, Cat. no: 
HS116-500) for 10 minutes, washed in a tap water bath prior to staining with a 
Picrosirius Red Stain Kit (Polysciences, Inc, Cat. no: 24901), following the 
manufacturer’s instructions. Slides were immersed in solution A for two minutes, 
washed in tap water for 1 minute, immersed in solution B for 60 minutes and finally in 
solution C for 1 minute. Slides were then blotted dry, washed in two 100 % EtOH 
baths, for 5 minutes each, and washed in 100 % xylene for 2 minutes before 
mounting in DPX (p-Xylene-bis (N-pyridinium bromide), Agar Scientific Cat. No: 
R1340). The stains were then observed under an Olympus BX50 microscope. 
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2.6.5 Van Gieson Staining 
After being taken to water, slides were then stained with Van Gieson Stain (Thermo 
Scientific Cat. no: 12688636) for 5 minutes, then washed in a tap water bath for 5 
minutes. Slides were then washed, mounted and observed as in 2.6.4: Weigert’s 
Haematoxylin, Picrosirius Red and/or Alcian Blue Staining. 
 
2.6.6 Von Kossa Staining 
After being taken to water, slides were then placed in a U.V. light box and stained 
with 1% silver nitrate (Sigma Aldrich Cat no: 209139) in dH2O for 10 minutes. Slides 
were then washed in 5% Sodium Thiosulfate: (Sigma Aldrich Cat no: 217263) for 5 
minutes, before washing in running tap water for 10 minutes, and counter staining in 
Van Gieson Stain for 1 minute. Slides were then washed, mounted and observed as 
in 2.6.4: Weigert’s Haematoxylin, Picrosirius Red and/or Alcian Blue Staining. 
 
2.7 Polymerase chain reaction (PCR) 
Prior to quantitative real-time polymerase chain reaction (qRT-PCR), Ribonucleic acid 
(RNA) was isolated from cultured cells and reverse transcribed into complementary 
DNA (cDNA). 
 
2.7.1 RNA Isolation 
To extract RNA, cells were lysed by incubation for 10 minutes at room temperature 
with 600 µL per well (for a 12 well plate) of Trizol® reagent (Life Technologies Cat. 
no: 15596-026). Lysates were stored at -80 °C for a maximum of 14 days before RNA 
was extracted using an RNAase mini kit with an additional DNase digestion step 
(Qiagen, Cat. nos: 74104 and 79254) following the manufacturer’s instructions. 
Briefly, the kit utilises a silica gel membrane column to bind RNA in the presence of 
high concentrations of salts. The RNA is loaded onto the column, where it attaches. 
The RNA attached to the column then goes through multiple wash steps, any 
genomic DNA contaminate is digested by the DNAse kit, and the RNA is finally eluted 
using UltraPure™ DNase/RNase-Free Distilled Water (Life Technologies, Cat. no: 
10977035). 
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RNA quality and concentration was measured at 260 nm using a Thermo Scientific 
ND1000 Nanodrop spectrophotometer, and the purity calculated and checked using 
the 260:280 nm ratio. Ratios above 1.8 were considered of good purity, any below 
were treated with caution. RNA was frozen and stored at -80 °C until required. 
 
2.7.2 Reverse Transcription 
200 ng of RNA was then was transcribed to cDNA using a high capacity RNA-to-
cDNA Kit (Applied Biosystems, Cat. no: 4387406), following the manufacturer’s 
instructions. Briefly 200 ng of the RNA dissolved in water, 1 µL enzyme and 10 µL of 
10x buffer were made to a total volume of 20 µL with nuclease-free water, and then 
reactions performed on a F. Hoffmann-La Roche Ltd. MJ Research PTC-100 
ThermoCycler at 37 °C for 1 hour, followed by an enzyme denaturing step at 95 °C 
for 5 minutes. cDNA was stored at - 20 °C (for a maximum of 3 months) before use. 
Based on the manufacturer’s recommendations, it was assumed that the reverse 
transcription reaction was 100 % efficient, so cDNA synthesised was the same 
amount as the RNA inputted. 
 
2.7.3 qRT-PCR 
Expression levels of different genes were determined by qRT-PCR using TaqMan 
gene expression assays. All reactions were carried out in 96 well semi-skirted PCR 
plates for a Roche LightCycler (Starlab Cat. no: I1402-9909), in TaqMan® Gene 
Expression Master Mix (Life Technologies Cat. no: 4369016) and UltraPure™ 
DNase/RNase-Free Distilled Water. The TaqMan® Assays have been optimised to 
be 100 % efficient by the manufacturer. Amplification curves were obtained using a 
LightCycler 480 real time QPCR system. All samples underwent a 10 minute 95 °C 
pre-incubation step, followed by 45 cycles of 10 seconds at 95 °C, 30 seconds at 60 
°C and 1 second at 72 °C. Samples were cooled to 40 °C at the end of the 45 cycles. 
The cycle threshold (Ct) value was generated for each sample and the comparative 
Ct method (2-∆∆Ct) was used to quantify gene expression levels, relative to a 
housekeeping gene. 
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2.7.4 Generation of standard curves 
Optimal cDNA concentration for assays, and probe efficiency was investigated by 
plotting standard curves for each probe using known cDNA concentrations. The 
details and the standard curves can be found in A5.2 - Standard Curves for qRT-PCR 
Assays. Serial dilutions of cDNA were run with each primer/probe set to produce the 
standard curves. Values were generated from a day 0 sample of cells, against 
resulting Ct values for reactions where all other variables (water, master mix and 
probe used) all stayed the same. No template controls were also run to check for 
unwanted reactions. All reactions were run in triplicate and the average Ct value for 
each Log10 concentration of cDNA was plotted, to give the standard curve. cDNA 
concentration was determined suitable at 5 ng/reaction and all probes were found to 
be of sufficient efficiency for experiments. 
 
2.7.5 Optimisation of Housekeeping Genes  
For all experiments, it is standard practice to use an endogenous control 
housekeeping gene in qRT-PCR analysis, to normalise the expression of target 
genes. This housekeeping gene should expressed at a constant level in all samples, 
and is essential to act as a reference, reducing error in cDNA concentrations or 
reaction volumes (Rubie et al. 2005; Ragni et al. 2013). The more stable the 
housekeeping gene, the better for determining the change in expression of other 
genes. Glyceraldehyde-3-phosphate (GAPDH) is a commonly utilised housekeeping 
gene; however, it is believed that there are more stable genes available. Previous 
work in the department, and a journal article on the topic (Ragni et al. 2013), 
suggested that tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein (YWHAZ) may be a more stable gene, especially in differentiation protocols.  
 
To assess this, a comparative study between GAPDH and YWHAZ was undertaken 
to determine the most stable housekeeping gene. For four different conditions from 
the adipogenic differentiation experiment outlined in Chapter 5: (5.2.5: Assessment of 
the effect of MI192 pre-treatment on the adipogenic gene expression of ADSCs) the 
expression of the two genes was calculated, in biological triplicate and with three 
technical repeats for a total of n = 18 for each condition. Graphs of the mean ± SE 
was plotted and the statistical significance was determined by Kruskal-Wallis 1 way 
ANOVA test of variance, using Graphpad Version 5. The graphs and statistical 
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analysis can be found in the Appendix (A5.1 - Choice of Housekeeping Gene for 
qRT-PCR Assays). There was a lower variance with the YWHAZ housekeeping gene 
between samples that resulted in this being selected for all qRT-PCR experiments.                             
.
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Chapter 3: The Chemical Synthesis of MI192  
 
This chapter introduces the key HDACi utilised in this thesis, MI192. The key property 
of MI192 is its selective for HDAC isoforms HDAC2 and HDAC3. The design of the 
compound is briefly discussed, along with the work undertaken involving the 
synthesis and characterisation of MI192 by the author in the Department of 
Chemistry, University of Leeds. 
3.1 Introduction 
MI192 was the most potent inhibitor found in a library of HDACis designed to be class 
1 HDAC specific. It was discovered by the Grigg group in 2008 as part of a series of 
tetrahydroisoquinolines created by Martin Inham. MI192 was designed by M. Inham in 
silico in Accelrys Accord. Libraries of designed inhibitors were screened and then 
docked of the inhibitors into HDAC homology models, based on known HDAC 
structures, in AutoDock docking program (Zhu et al. 2010). Docking and enzyme 
binding was evaluated in SPROUT 6.2 (Morris et al. 1998).  
 
MI192 has low molecular weight, microsomal stability and CYP450 inhibition, 
meaning it should have excellent drug like properties (Ogu & Maxa 2000). It is 
believed that MI192 is a slow binding HDACi (Boissinot et al. 2012). Boissinot et al. 
(2012) undertook an experiment to determine the inhibition activity of MI192 for all 
HDAC isoforms, in HeLa cell nuclear extracts (Table 3-1) (Boissinot et al. 2012). The 
IC50 value is the half maximal inhibitory concentration, and is a measure of the 
effectiveness of the compounds in the assay. This technique is commonly used to 
investigate how the strength of HDAC inhibition by HDACis (Sebaugh 2011).  
 
The overall HDACi inhibition with HeLa cell extracts showed that TSA is a stronger 
HDAC inhibitor when considering all HDAC isoforms (Table 3-1). MI192 had 
comparable HDAC inhibition levels to MS-275.  
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Also undertaken was recombinant human HDAC isoform specificity profiling, as part 
of a collaborative effort with Cancer Research Technology 
(http://www.cancertechnology.co.uk/), undertaken by Amphora Discovery Corp, NC, 
USA (http://www.tekprotocol.com/amphora/#hdac), now part of Caliper Life Sciences 
(http://www.caliperls.com). The results generated from this give an indicator of the 
specificity of MI192, compared to some commercial inhibitors (Table 3-1). 
 
The results from the HDAC isoform screen (Table 3-2) demonstrated the key 
characteristic of MI192, that it is specific for HDAC2 and HDAC3. The inhibition of 
HDAC3 by MI192 is ~60-140 fold stronger than MS-275 and Mocetinostat 
(MGCD0103). The inhibition of HDAC2 by MI192 is 40 fold more effective than 
MS275 and is comparable to that of MGCD0103. However, MI192 has ~26-140 less 
strength of binding to HDAC1 than MS-275 and MGCD0103. Therefore they found 
that MI192 is selective for HDAC2 and HDAC3, in contrast to commercial HDACis 
MGCD0103, TSA and MS-275 (Boissinot et al. 2012). 
 
To date, there only two papers focusing on MI192, related to rheumatoid arthritis and 
leukaemia research (Gillespie et al. 2012; Boissinot et al. 2012). MI192 was found to 
be a very effective potential compound in both of these fields. These successes lead 
to further research avenues being explored for MI192, resulting in the collaboration 
between Leeds School of Dentistry and Department of Chemistry, exploring the effect 
of MI192 on stem cell differentiation.  
 
The synthesis of MI192 has yet to be published; however, the route was established 
by the Grigg group, and a schematic of this approach can be seen in Figure 3.1. The 
synthesis of MI192 was undertaken by the author; the full synthesis route is explained 
in the materials and methods. The compound synthesised was characterised by 
NMR, compared to control batches of the compound and deemed pure, for biological 
experiments.  
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Table 3-1 - The inhibition of HDAC activity in HeLa cell nuclear extracts by 
MI192, MS-275 and TSA (Boissinot et al. 2012). 
 
Compound HDAC inhibition (IC50 µM) 
TSA 0.005 ± 0.0005 
MS-275a 3.0 ± 0.2 
MI192 1.5 ± 0.5 
 
Table 3-2 – HDAC isoform specificity information for HDACis MI192, TSA, MS-
275 and MGCD0103, for HDAC isoforms HDAC1, HDAC2, HDAC3, HDAC8, 
HDAC4, HDAC6 and HDAC7 (Boissinot et al. 2012). 
 
HDAC TSA MS-275a MGCD0103a MI192 
HDAC1 0.0047 0.18 ± 0.06 0.034 ± 0.017 4.8 
HDAC2 0.0084 1.2 ± 0.13 0.034 ± 0.008 0.030 
HDAC3 0.0023 2.3 ± 0.80 0.998 ± 0.431 0.016 
HDAC8 1.3 > 10 > 10 > 10 
HDAC4-CAT 0.0074 > 10 > 10 5.0 
HDAC6 0.0036 > 10 > 10 > 10 
HDAC7 0.0057 > 10 > 10 4.1 
a Values for MS-275 and MGCD0103 taken from the literature (Khan et al. 2008). 
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Figure 3.1 – The complete synthesis scheme of MI192. Compound 1 - 4-(4,6-
Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium tetrafluoroborate, 
compound 2 - 4-((Tert-butoxycarbonylamino)methyl)benzoic acid, compound 3 - 
tert-Butyl 4-(2-aminophenylcarbamoyl)benzylcarbamate, compound 4 - 4-
(Aminomethyl)-N-(2-aminophenyl)benzamide.  
 
 
 
 
 
 
 
 
 
 
O 
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3.2 Materials and Methods  
All chemicals were obtained from Sigma Aldrich. 1H NMR spectra were recorded at 
300 Mhz on a Bruker DPX300 instrument. The deuterated solvents used for each 
compounds were recorded with the spectra. Chemical shifts are given in parts per 
million () downfield from tetramethylsilane (0.00 ). The following abbreviations are 
used: s – singlet; d – doublet; dd – double doublet; m – multiplet (n > 6). Column 
chromatograpghy was performed on silica gel 60 (Merck, 230-400 mesh). Full NMR 
spectra can be found in the Appendix (A.1 - NMR Spectra). 
 
All reaction steps, except the final MI192 synthesis step, were first undertaken on a 
small, ~100 mg, pilot scale, to test and optimise the synthesis, before the large scale 
reactions were undertaken. 
 
3.2.1 Synthesis scheme of 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium tetrafluoroborate (compound 1) 
 
Figure 3.2 – Synthesis scheme of 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium tetrafluoroborate (compound 1). 
 
To a stirred suspension of 7.39g of 2-chloro-4,6-dimethoxy-1,3,5-triazine in 100 mL of 
water (1 eq., 41.4 mmol) was added 5 mL N-methylmorpholine (1.1 eq., 45.6 mmol). 
After stirring for 25 mins at room temperature the solid had dissolved to give a 
colourless solution. Then, 5.57 g of sodium tetrafluoroborate (1.2 eq., 49.7 mmol) 
dissolved in water (150 mL) was added dropwise over 5 minutes, causing a white 
precipitate to form. The resulting suspension was stirred for 1 hour further. The 
precipitate was collected by vacuum filtration and washed sequentially with water 
(two washes of 20 mL) and methanol (1 wash of 40 mL). The material was dried in 
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vacuo to give compound 1, 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium 
tetrafluoroborate, (Figure 3.2), as a colourless solid (11 g, 81%). 
 
3.2.2 Synthesis of 4-((Tert-butoxycarbonylamino)methyl)benzoic 
acid (compound 2) 
 
Figure 3.3 - Synthesis scheme of 4-((Tert-butoxycarbonylamino)methyl)benzoic 
acid (compound 2). 
 
6.04 g 4-Aminomethybenzoic acid (1 eq., 40 mmol) and 17.4 g di-tert-butyl 
dicarbonate (2 eq., 80 mmol) were stirred in a mixture of dioxane (200 mL) and water 
(132 mL). The mixture was adjusted to pH 9 by drop wise addition of sodium 
hydroxide solution (10%). The resulting colourless solution was stirred for 1.5 hours 
at room temperature and then reduced to 1/3 volume in vacuo by removing 2/3 of the 
organic solvent. The residue was acidified to pH 3, at 0 °C, with drop wise addition of 
HCl (37%). The resulting colourless precipitate was collected by vacuum filtration and 
dried in vacuo at 80 °C overnight to give compound 2, 4-((Tert-
butoxycarbonylamino)methyl)benzoic acid (Figure 3.3), as a colourless solid (8.23 g, 
81.85%). 
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3.2.3 Synthesis of tert-Butyl 4-(2-
aminophenylcarbamoyl)benzylcarbamate (compound 3) 
 
Figure 3.4 – Synthesis scheme of tert-Butyl 4-(2-
aminophenylcarbamoyl)benzylcarbamate (compound 3). 
 
To a stirred solution of 7.306g of compound 1 (1 eq., 22.3 mmol) and 5.591g of 
compound 2 (1 eq., 22.2 mmol) in 66 mL DMF, 2.887g of o-phenylenediamine (1.2 
eq., 26.7 mmol) was added. The solution turned from yellow to green in five minutes 
and was stirred for 4 hours at room temperature. The mixture was then diluted with 
200 mL of water, extracted with two changes of EtOAc (30 mL each), the combined 
organics were washed with H2O (one wash of 20 mL), filtered and concentrated in 
vacuo. The thick, oily orange residue was triturated with 50 mL of Et2O for 1 hour at a 
time, three times. The resulting precipitated titrates were combined, vacuum filtered 
and dried overnight in vacuo to give compound 3, tert-Butyl 4-(2-
aminophenylcarbamoyl)benzylcarbamate (Figure 3.4), as a yellow solid (5.46 g, 
71.3%).  
 
3.2.4 Synthesis scheme of 4-(Aminomethyl)-N-(2-
aminophenyl)benzamide (compound 4) 
 
Figure 3.5 - Synthesis of 4-(Aminomethyl)-N-(2-aminophenyl)benzamide 
(compound 4). 
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1 g of compound 3 (3 mmol) was stirred in a 1:1 mixture of TFA (10 mL) and 
chloroform (10 mL) for 2 hours. The mixture was then concentrated in vacuo, taken 
up in EtOAc (20 mL), then sequentially washed with 10% sodium hydroxide (two 
washes of 20 mL), followed by saturated sodium chloride solution (20 mL) and 
concentrated in vacuo, to give compound 4 (4-(Aminomethyl)-N-(2-
aminophenyl)benzamide (Figure 3.5), as a solid yellow product (453 mg, 64%).   
 
3.2.5 Synthesis of MI192 
 
Figure 3.6- Synthesis scheme of MI192.  
 
Methyl 2-iodobenzoate (1.0 mol eq.), compound 4, (1.1 mol eq.), Pd2dba2 (0.025 mol 
eq.), tri-2-furylphosphine (0.1 mol eq.), K2CO3 (2.0 mol eq.) and DMF (10 mL / mmol) 
were combined in a Schlenk tube with a stirrer bar, subjected to three liquid nitrogen 
freeze-pump-thaw cycles and charged under pressure with allene gas (0.5 bar). This 
was then allowed to thaw to room temperature and stirred at 80 °C for 24 hours. The 
reaction was then cooled to room temperature, diluted with H2O (20 mL) and 
extracted with EtOAc (3 x 20 mL), dried with MgSO4, gravity filtered and concentrated 
in vacuo. The resulting orange oil was purified by column chromatography (12.5 g 
silica, gradient of 10% EtOAc in hexane to 70% EtOAc:Hexane) to yield MI192 as an 
orange powder. Two reactions of 133 mg of compound 4 yielded 177 mg of product, 
46.2 %. 
 
 
 
 
 
O 
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3.3 Results 
All compounds in the scheme were synthesised and satisfactory yields were 
obtained. Yields were at least comparable to, or better than previously described 
(unpublished data from lab books). All compounds were characterised by NMR, 
confirming the expected products had been obtained. The NMRs can be found in the 
Appendix (A.1 - NMR Spectra) and the peak descriptions can be seen below, 
describing each compound:   
 
Compound 1, 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium 
tetrafluoroborate (Figure 3.2) : 1H NMR (300 MHz; DMSO) H 3.45 (3H, s, N-CH3), 
3.75-4.35 (2H, m, N-CH2-CH2-O), 4.1 (6H, s, O-CH3). 
 
Compound 2, 4-((Tert-butoxycarbonylamino)methyl)benzoic acid (Figure 3.3): 1H 
NMR (300 MHz; DMSO) H 1.3 (9H, s, C-CH3 Boc group), 4.2 (2H, d, NH-CH2), 7.3 
(2H, d, aromatic CH), 7.55 (1H, t, NH), 7.9 (2H, d, aromatic CH). 
 
Compound 3, tert-Butyl 4-(2-aminophenylcarbamoyl)benzylcarbamate (Figure 3.4): 
1H NMR (300 MHz; DMSO) H 1.4 (9H, s, C-CH3 Boc group), 4.2 (2H, d, NH-CH2), 4.8 
(2H, d, NH2), 6.6 (1H, dd, aromatic CH), 6.8 (1H, d, aromatic CH), 6.95 (1H, dd, 
aromatic CH), 7.25 (1H, d, aromatic CH), 7.35 (2H, d, aromatic CH), 7.5 (1H, t, CH2-
NH), 7.95 (2H, d, aromatic CH), 9.65 (1H, s, O=C-NH). 
 
Compound 4, 4-(Aminomethyl)-N-(2-aminophenyl)benzamide (Figure 3.5): 1H NMR 
(300 MHz; MeOD) H 3.65 (2H, d, NH2-CH2), 6.8 (1H, dd, aromatic CH), 6.9 (1H, d, 
aromatic CH), 7.1 (1H, dd, aromatic CH), 7.2 (1H, d, aromatic CH), 7.5 (2H, d, 
aromatic CH), 7.95 (2H, d, aromatic CH). 
 
MI192 (Figure 3.6): 1H NMR (300 MHz; CDCl3) H 3.75 (2H, broad s, C-NH2), 4.15 
(1H, s, N-CH2), 4.8 (2H, s, N-CH2), 5.15 (1H, s, C=CH), 5.6 (1H, s, C=CH), 6.85 (2H, 
m, aromatic CH), 7.1 (1H, dd, aromatic CH), 7.35 (1H, d, aromatic CH), 7.5 (5H, m, 
aromatic CH), 7.8 (3H, m, aromatic CH and O=C-NH), 8.2 (1H, d, aromatic O=C-CH). 
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3.4 Discussion 
The Grigg group has a history of utilising allene gas in neat and effective chemical 
synthesis reactions (Elboray et al. 2012). Without the use of the gas, the synthesis of 
MI192 would be many more steps and a very laborious process. The already 
optimised route was adhered to for the synthesis of MI192, with improvements made 
where possible.  
 
The first step, Figure 3.2, consists of forming the coupling reagent, for use in the third 
reaction step. 2-chloro-4,6-dimethoxy-1,3,5-triazine and N-methylmorpholine reacted 
to give the coupling reagent, which was then stabilised with addition of sodium 
tetrafluoroborate salt, allowing the reagent to be stored and used in subsequent 
reactions (Kamiński et al. 2005). The yield was high, at 81% on a gram scale. 
 
Secondly, the tert-butyl carbamate (boc) protection of a primary amide was 
undertaken, Figure 3.3. Without protection the free amine may interfere in the second 
step, a coupling reaction. Once the pilot study was successful, the boc protection 
took place on a gram scale with a 82% yield, which were comparable to the work 
being followed (80%).  
 
Thirdly, Figure 3.4, the coupling reaction was undertaken. This reaction was the first 
step where some optimisation of the methods was necessary. The trituration wasn’t 
successful on a small scale, and the product did not precipitate out on the first 
attempt. A more vigorous stirring technique and the use of less Et2O resulted in some 
successful product isolation. A second trituration also yielded some product; however, 
on a small 1 mmol starting material scale the yield was only 50.6%. Because the 
starting materials were cheap and a large amount of them had been synthesised, a 
larger scale coupling was undertaken anyway, despite the poor yield. On an 11 mmol 
starting material scale (10 x the pilot) the yield improved to 63.9% and on doubling 
the scale again (the scale reported in the materials and methods) the yield was 
71.3%. Either the reaction or the work up process is improved on a larger scale. In 
the optimised work the expected yield was 70%, so this was another slight 
improvement. 
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In the Boc deprotection step, Figure 3.5, the supplied method used addition of 36% 
HCl (aq.) to the product stirred in water. The work up process involved use of hot 
THF, which appeared to react with the product, resulting in a loss of product and a 
low yield of 41%. On a gram scale this yield of 41% was deemed unsatisfactory, so 
an alternative deprotection method from the literature was attempted (Hooker et al. 
2010). On a 100 mg scale a 1:1 mixture of TFA and chloroform gave a 73.2% yield, 
and on a larger scale a 64% yield. While not as good as the 87% yield expected from 
the optimised work, this was more acceptable than the 41% yield obtained when this 
was repeated. Enough compound was synthesised when optimising the step, so 
further optimisation work was not undertaken.  
 
Problems were also encountered with the synthesis of MI192, Figure 3.6. Due to the 
expense of the gas, at least £100 per reaction, optimisation of this reaction was 
limited by cost, not time or availability of the reagents. Initially a method using 
caesium carbonate as the base was followed; however, on several repetitions, 
including with different batches of starting materials and meticulous degassing of the 
reaction mixture using liquid nitrogen freeze thaw cycles, no product was even seen 
in crude reaction NMR spectra. On switching to potassium carbonate as a base two 
parallel reactions were successful. MI192 was produced in a 46.2% yield. This yield 
was below that reported previously (~ 60%); however, enough product was obtained 
from these two reactions, and due to the cost of the gas, further optimisation or 
reactions were not undertaken. The NMR spectra for the MI192 synthesised was 
compared to a batch synthesied in the group previously, as well as a batch obtained 
as part of a collaboration with Cancer Research Technology UK 
(http://www.cancertechnology.co.uk/) as part of a separate collaborative project. 
 
This MI192 synthesised was sufficient for a large number of biological testing 
experiments, due to the very low amounts of compound used. The compound was 
stored in the dark in a -20 °C freezer and used as needed.                         .
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Chapter 4: The General Effects of MI192 on Adipose Derived 
Stem Cells Cultured in Monolayer 
 
The aim of this chapter is to investigate the general, non-differentiation related effects 
of MI192 on ADSC cells in monolayer. The objectives are to investigate the effects of 
MI192 on ADSC morphology, cell number, cytotoxic effects and if the ADSC viability 
changes over while treated with MI192. Also investigated was the effect of MI192 
treatment on the cell cycle, HDAC activity and stem cell markers of ADSCs. 
 
4.1 Introduction 
HDACis are small molecular compounds that inhibit the deacetylation action of HDAC 
enzymes in the cell. Since acetylation/deacetylation is a key epigenetic process, and 
stem cell fate is closely linked to a cell epigenetic landscape, HDACis can potentially 
drastically affect stem cell fate (Tollervey & Lunyak 2012). Researchers have 
explored the prospect of using HDACis such as NaB (Iwami & Moriyama 1993), TSA 
(Boer et al. 2006), VPA, (Schroeder et al. 2007) and MS-275 (H.-N. Kim et al. 2011) 
to improve the osteogenic potential of cells. 
 
There are 18 HDAC isoforms in the human cell, and, to date, most inhibitors target a 
large number of these. However, to try and narrow down side effects and control the 
functions of HDACis more carefully, researchers are looking to utilise HDACis to 
target specific HDAC isoforms. For example, as described in Chapter 3: The 
Chemical Synthesis of MI192, MS-275 is a HDACi that specifically targets HDAC1, 
HDAC2 and HDAC3 (Bradner et al. 2010). The inhibitor this study is focused upon is 
MI192, which is specific for HDAC2 and HDAC3, and believed to be the only one of 
its kind in the world. This ability to target just these isoforms is an exciting prospect.  
 
As discussed in depth in the literature review, HDAC3 in particular is an important 
isoform when considering bone tissue, it is key to bone formation (Schroeder & 
Westendorf 2005; Schroeder et al. 2004; Razidlo et al. 2010; McGee-Lawrence et al. 
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2013; Hesse et al. 2010; Lamour et al. 2007; Choo et al. 2009; Shen et al. 2002). In 
comparison, there are less links with HDAC2 and bone. 
 
Adipose tissue is an abundant, very promising source for easily isolatable MSCs (Zuk 
et al. 2001; Zuk et al. 2002). ADSCs are commercially available from a number of 
sources, and are known to have the potential to differentiate into multiple lineages 
(Levi & Longaker 2011; Erickson et al. 2002; Planat-Benard et al. 2004; Golipoor et 
al. 2010). However, many of these methods of inducing differentiation are not very 
effective, thus researchers are seeking ways to improve protocols. Therefore 
HDACis, with their ability to affect stem cell fate, could help researchers in achieving 
this goal.  
 
However, before looking at how the differentiation potential of these cells is altered, it 
is very important and interesting to investigate firstly the more general effects of 
MI192 on ADSC properties, such as viability and function.  
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4.2 Materials and Methods 
4.2.1 Assessment of Cell Morphology 
ADSCs were seeded in two 12 well plates (1 x 105 cells per well) and cultured in 
basal medium for 24 hours. The medium was then replaced with medium containing 
different concentrations of MI192 (50 µM, 30 µM and 5 µM in 1 mL basal medium) 
and TSA (10 µM in 1 mL basal medium). Basal medium alone (untreated wells) was 
used as a control. The sample size was three (n=3) for all groups. Cells were 
observed under a Leica DMI6000 B inverted microscope at 12, 24, 48 and 72 hour 
time points and cell morphology was assessed. Plates were not washed before 
observation to prevent cells being washed away. 
 
4.2.2 Effect of MI192 on ADSC DNA quantity (as an indicator of cell 
number) 
ADSCs were seeded in three 24 well plates (5 x 104 cells per well) and cultured in 
basal medium for 24 hours. The medium was then replaced with medium containing 
different concentrations of MI192 (10 µM – 100 µM in 500 µL basal medium). Basal 
medium alone (untreated wells) was used as a control. The sample size was three 
(n=3) for all groups. At 24, 48 and 72 hour time points, one plate of cells was washed 
with twice 1x PBS (to wash away dead/detached cells), lysed in  0.1 % Triton-X 100 
and then stored in a –80 °C freezer for DNA quantification by a PicoGreen® assay.  
 
4.2.3 Cytotoxic effect of MI192 on ADSCs 
ADSCs were seeded in three 96 well plates (1 x 104 cells per well) and cultured in 
basal medium for 24 hours. The medium was then replaced with medium containing 
different concentrations of MI192 (10 µM – 100 µM in 100 µL basal medium). Basal 
medium alone (untreated wells) was used as a control. The sample size was three 
(n=3) for all groups. At 24, 48 and 72 hour time points, one of the plates was stopped 
for a cytotoxicity assay. The CytoTox 96® Non-Radioactive Cytotoxicity Assay 
(Promega, Cat. no: G9260) was used according to the manufacturer’s instructions. 
Briefly, the prepared reagent (100 µL per well) is added directly to the medium of the 
plate, with addition also to controls containing no cells for blank background readings. 
The plate was then incubated for 30 minutes at 37 °C and the fluorescence was then 
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measured in a Varioskan Flash Multimode Microplate Reader (Model 3001, Thermo 
Scientific), by exciting the samples at 488 nm with emission reading set at 520 nm. 
 
The CytoTox-Fluor Assay is a single-reagent addition assay that measures the 
relative number of dead cells in a cell population. A fluorogenic peptide substrate 
(bis-alanyl-alanyl-phenylalanyl-rhodamine 110) reacts with proteases that have been 
released from the dead cells in the population. The peptide cannot penetrate the 
membrane of live cells so no signal is generated from these. 
 
4.2.4 Effect of MI192 on ADSCs viability 
ADSCs were seeded in three 96 well plates (1 x 104 cells per well) and cultured in 
basal medium for 24 hours. The medium was then replaced with medium containing 
different concentrations of MI192 (10 µM – 100 µM in 100 µL basal medium). Basal 
medium alone (untreated wells) was used as a control. The sample size was three 
(n=3) for all groups. At 24, 48 and 72 hour time points, one of the plates was stopped 
for a cell viability assay. The CellTiter-Glo Luminescent Cell Viability Assay 
(Promega, Cat. no: G7570) was used according to the manufacturer’s instructions. 
Briefly, the plates were equilibrated to room temperature for 30 minutes, prepared 
reagent (100 µL per well) was added directly to the medium of the plate, with addition 
also to controls containing no cells, for blank background readings. The plate was 
then mixed on a rocker for 2 minutes and then incubated for 10 minutes at room 
temperature to stabilise the luminescent signal. The luminescence was then 
measured on a Varioskan Flash Multimode Microplate Reader (Model 3001, Thermo 
Scientific). 
 
The CellTiter-Glo assay determines the number of viable cells in a population based 
on quantification of the ATP levels present, as ATP activity is a sign of metabolically 
active cells. The assay reagent lyses the cells and the presence of ATP catalyses a 
reaction involving a thermostable luciferase (Ultra-Glo™ Recombinant Luciferase) to 
generate a luminescent signal.  
 
4.2.5 Effect of MI192 on the HDAC specific activity of ADSCs 
ADSCs were seeded in two 24 well plates (5 x 104 cells per well) and cultured in 
basal medium for 24 hours. The medium was then replaced with MI192 containing 
105 
 
 
medium (30 µM and 10 µM in 500 µL basal medium). Basal medium alone (untreated 
wells) was used as a control. The sample size was three (n=3) for all groups. At 24 
and 48 hour time points the HDAC activity of the cells was measured using an in situ 
HDAC activity fluorometric assay kit (Biovision Cat. no: K339-100), according to the 
manufacturer’s instructions. Briefly, the cells were lysed with scraping and two freeze-
thaw cycles of –80 °C and 37 °C. To ensure no protein degradation, the assay was 
carried out straight away. 
 
20 µL of cell lysate was added to 65 µL of UltraPure™ DNase/RNase-Free distilled 
water and 10 µL of the supplied 10x Assay buffer (giving a total volume of 95 µL). As 
well as the test groups, a series of standards from a provided deacetylated sample 
were also plated. A positive control of provided HeLa nuclear extract was tested, 
along with a negative control of provided TSA added to nuclear extracts of untreated 
ADSCs. For the reaction, 5 µL of the fluorometric substrate was added and the plate 
was mixed on a rocker for 2 minutes, prior to incubation at 37 °C for 30 minutes. 
Then, 10 µL of the lysine developer was added and the plate incubated for a further 
30 minutes at 37 °C. The fluorescence was measured in a Varioskan Flash 
Multimode Microplate Reader (Model 3001, Thermo Scientific) by exciting the 
samples at 368 nm with emission reading set at 442 nm. Total DNA content in the 
same samples was quantified with a PicoGreen® assay. The unknown value of 
HDAC activity was then calculated using the generated standard curve to give the µg 
HDAC activity, and the value per well was calculated from Triton X-100 harvest 
volume and volume of lysate used for the assay. The µg of DNA per well was 
calculated in the same way, and the HDAC specific activity per well was calculated by 
dividing the µg HDAC activity by the total DNA content in the same well. 
 
The HDAC activity assay measures the deacetylation ability of the HDAC enzymes in 
cells. The substrate contains an acetylated lysine side chain that HDAC enzymes will 
deacetlyase. A developer is then added that produces the fluorophore from 
deacetylated HDAC substrate, with a greater reading indicating a larger HDAC 
enzyme activity in cells.  
 
4.2.6 Effect of MI192 on ADSC Cell Cycle 
ADSCs were seeded in three 6 well plates (1 x 105 cells per well) and cultured in 
basal medium for 72 hours, to ensure normal cell cycle function was initiated. The 
106 
 
 
medium was then replaced with medium containing MI192 (30 µM and 10 µM in 2mL 
basal medium), and TSA (10 µM in 1 mL basal medium). Basal medium alone 
(untreated wells) was used as a control. The sample size was three (n=3) for all 
groups. At 12, 24 and 48 hour time points the cells were harvested; the medium was 
aspirated, cells washed 3 times with 1x PBS and then detached with T/E for 5 - 10 
minutes. The resulting cell suspensions were centrifuged at 1100 RPM for 5 minutes, 
the supernatant was removed and 500 µL ice cold 70 % (v/v) ethanol/PBS was added 
drop wise, with gentle vortexing. Cells were then stored at -80 °C for no more than 
one week. 
 
For propidium iodide staining, the cells were centrifuged at 1100 RPM for 5 minutes, 
the supernatant carefully decanted, the cells washed in 500 µL 4 °C FACS buffer (1x 
PBS with addition of 0.1 % (w/v) bovine serum albumin (Sigma-Aldrich Cat. no: 
A2058) and 0.1 % TWEEN-20 (Sigma-Aldrich Cat. no: P9416)) and then centrifuged 
at 1100 RPM for 5 minutes. The supernatant was decanted and the cells re-
suspended with gentle pipetting in 500 µL of freshly made staining solution, 20 µg/mL 
propidium iodide (Sigma-Aldrich, Cat. no: P4170) and 200 µg Ribonuclease A 
(Sigma-Aldrich Cat. no: R6513). Cells were incubated at room temperature for 20 
minutes, placed on ice and events were collected with a 2 laser (blue and violet) 
Attune NxT Flow Cytometer (Life Technologies). Ideally at least 5000 events for each 
sample was logged, (although for the smaller cell counts 2000 events was logged), 
then samples were analysed with the standard procedures for cell cycle analysis 
using the ModFitLT software version 3 (Becton Dickinson). 
 
Briefly, events were gated to account only for intact cells (gate 1 – by forward scatter 
against side scatter), then to account only for material related to intact nuclei (gate 2 
– by BL3 area against forward scatter area) and finally to remove any doublets or 
abnormal cells, i.e. diploid cells (gate 3 – by BL3 height against BL3 area) (Figure 
4.1). Gates were then applied to all samples and histograms of the BL3 area against 
count were created, with two distinct peaks representing the G0/G1 phase and the 
G2/M phase, with the area in between the S Phase of the cell cycle. The area under 
the peaks was then measured to give the percentage of events in each cycle, with a 
confidence value. All confidence values were between 3.48 and 7.78, with the 
majority falling below 5.5, indicating a good confidence in the data.  
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Figure 4.1 – Gates created in flow cytometry analysis of ADSCs stained with PI 
for cell cycle analysis. Representative gates shown, which were created in 
ModFit software to account for intact cells (Gate 1), material related to intact 
nuclei (Gate 2) and for single cells (Gate 3). 
 
4.2.7 Effect of MI192 on ADSC Stem cell Markers 
The cell culture was carried out by the author, cell labelling and flow cytometry 
analysis was carried out by Dr. Matthew Tomlinson (Leeds School of Dentistry) and 
data analysis jointly by Dr. Tomlinson and the author. 
 
ADSCs were seeded in two T75 flasks (1 x 106 cells per flask) and cultured in basal 
medium for 24 hours. The medium in one flask was then replaced with MI192 
containing medium (30 µM in 10 mL basal medium) with an un-treated control flask, 
where the medium was changed to 10 mL of basal medium. At 48 hours the cells 
were harvested by aspiration of the medium, 3x washes in 1x PBS and detached with 
T/E for 5 - 10 minutes. The resulting cell suspension was centrifuged at 1100 RPM for 
5 minutes to give a pellet. Cells were then resuspended in 1x PBS and 10 μL Fc 
receptor blocking solution (Miltenyi Biotec Cat. No: 130-059-901) before incubation 
with various antibodies (5 μL per 1×106 cells unless stated) in a total volume of 100 
μL for 20 min at room temperature in the dark. Following labelling, 900 μL of PBS 
was added to each sample before centrifugation at 1100 RPM and resuspension in 
500 μL 1x PBS. For each marker, untreated and treated cells were labelled three 
times (n=3), for three technical repeats. Samples were analysed using a BD LSRII 
flow cytometer (BD Biosciences) running BD FACSDiva 8 software and subsequent 
data analysis was performed using Kaluza (Beckman Coulter Inc.). 
 
        Gate 1                      Gate 2      Gate 3 
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Antibodies used were as follows: CD29-Alexa Fluor 488, CD34-FITC, CD44-FITC (10 
μL per 1×106 cells), CD45-PE, CD73-PE (2 μL per 1×106 cells), CD90-APC, CD105-
PE, CD146-Alexa Fluor 488 and CD166-PE (10 μL per 1×106 cells). All antibodies 
were purchased from Biolegend (Cat. nos: See Table 4-1). Propidium iodide (Miltenyi 
Biotec, Cat. no: 130-093-233) was used as a viability dye. 
 
All threshold values for flow cytometry were obtained by analysing both 
autofluorescence of non-labelled ADSCs and reactivity of isotype matched controls. 
Events were gated based on forward and side scatter, to account only for intact cells 
(Gate 1, an example of which is shown below in Figure 4.2 –). Colour compensation 
was performed for each panel and applied equally to all markers. The intact cell 
events were then grid gated so that the percentage of positive and negative cells 
could be counted for each marker (Gate 2, an example of which is shown below in 
Figure 4.2). Histograms were produced showing cell count for each marker for both 
untreated and treated cells, compared to a negative control. Comparative histograms 
were also produced comparing the untreated and treated cell populations. The 
percentage of labelled cells for each technical repeat was also recorded. 
  Gate 1                       Gate 2 
 
Figure 4.2 – Representative pictures of gates created in Kaluza software. Gate 1 
- to account for intact cells. Gate 2 - to count the percentage of intact cells 
marked positive with FITC and PE. Intact cells marked positive with both FITC 
and PE shown in the top right quadrant, B++.  
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Table 4-1 - Cell surface markers used in analysis of ADSCs. Each marker is 
detailed with alternative names, distribution, a summary of understanding of 
function, relevant references and conjugate and catalogue number. 
 
Marker Distribution and function References 
Conjugate 
(Biolegend 
Catalogue 
number) 
CD29 / 
Integrin β1 
Involved in cell-cell and cell-matrix, 
tissue repair and immune response. 
Used as part of haematopoietic and 
stromal MSC marker panels. 
(Hynes 1992; 
Tomlinson et al. 
2015; Baboolal et 
al. 2014) 
CD29-Alexa Fluor 
488 
(303016) 
CD34 / 
Platelet 
endothelial 
cell adhesion 
molecule-1 
(PECAM-1) 
Function is not fully understood, 
potentially enhances proliferation and 
halts the differentiation of progenitor 
cells. Also possibly promotes the 
adhesion of lymphocytes to the 
vascular endothelium in lymphoid 
tissues. Used as a marker of 
hematopoietic stem cells (HSCs) to 
isolate them for bone-marrow 
transplantation. Also been employed 
as a marker to identify other stem 
cells. 
 
(Nielsen & 
McNagny 2008) 
CD34-FITC 
(350006) 
CD44 
Cell adhesion protein involved in 
matrix-dependent migration, which 
binds hyaluronan and other matrix 
proteins. Involved in many cellular 
processes, including the regulation of 
growth, survival, differentiation and 
cell motility. 
 
 
(Baboolal et al. 
2014; Ponta et al. 
2003) 
CD44-FITC 
(103022) 
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CD45 / 
Leukocyte 
Common 
Antigen (LCA) 
Expressed highly in hematopoietic 
cells, is an essential regulator of T- and 
B-cell antigen receptor signalling. 
Present on all leukocytes, therefore it 
can be used to separate HSCs from 
MSCs 
 
(Trowbridge & 
Thomas 1994) 
CD45-FITC 
(304038) 
CD73 / Ecto-
5’-
nucleotidase 
Expressed on epithelial and stromal 
cells and bone marrow MSCs. It 
hydrolyses extracellular nucleoside 
monophosphates into bioactive 
nucleoside intermediates. Involved in 
angiogenesis, hypoxic response, 
endothelial tissue barrier function. 
Especially used as a positive marker 
for bone marrow MSCs. 
 
(Baboolal et al. 
2014; Battula et 
al. 2009; Lv et al. 
2014; Colgan et al. 
2006) 
CD73-PE 
(344004) 
CD90 / Thy-1 
Glycoprotein involved in signal 
transduction, found on hematopoietic 
and bone marrow stem cells, neurons, 
all thymocytes, and peripheral T-cells, 
but not on B-cells. It is involved in 
lymphocyte activation, and 
proliferation, inflammatory responses 
and differentiation of hematopoietic 
stem cells. 
 
(Baboolal et al. 
2014; Mayani & 
Lansdorp 1994; 
Kisselbach et al. 
2009) 
 
 
CD90-APC 
(328114) 
CD105 / 
Endoglin 
High expressed in angiogenic 
endothelial cells and in the blood 
vessels of tumour tissues. Associated 
with proliferation of endothelial cells 
and hypoxic conditions. Receptor for 
transforming growth factor (TGF) -1 
and -3 and modulates TGF- signalling. 
(Duff et al. 2003) 
CD105-PE 
(323206) 
CD146 / 
Melanoma 
Highly expressed in blood vessels, 
smooth muscles and pericytes, 
(Robey 2011; 
Covas et al. 2008) 
CD146-Alexa Fluor 
488 
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Cell Adhesion 
Molecule 
(MCAM) 
although its function is not well 
understood. It is thought to be 
involved in interactions of MSCs and 
other cells with endothelial cells. It is a 
commonly used marker of multipotent 
mesenchymal stromal cells. 
 
(342008) 
CD166 / 
Activated 
Leukocyte Cell 
Adhesion 
Molecule 
(LCAM) 
Mediates both heterophilic and 
homophilic cell-cell interactions. 
Expressed in MSCs, growing or 
migrating dynamic tissues, including 
neural, organ development, 
haematopoiesis and immune 
responses, namely T-cells. 
 
(Swart 2002) 
CD166-PE 
(343904) 
 
4.2.8 Statistical Analysis 
 
All statistical analysis undertaken with Graphpad Prism 5. Method used: ANOVA 
multiple comparisons test with Tukey modification. For all graphs: ns = P > 0.05, * = ≤ 
0.05, ** = P ≤ 0.01  *** = P ≤ 0.001 and **** = P ≤ 0.0001. 
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4.3 Results 
4.3.1 Effect of MI192 on ADSC Morphology 
Representative in situ pictures were taken at 12, 24, 48, 72 and 96 hours of cells 
cultured with 5 µM, 30 µM and 50 µM of MI192, 10 µM of TSA and a basal control 
group (Figure 4.3, Figure 4.4 and Figure 4.5). 
 
At the 12 hour time point (the earliest time point), the cells in basal medium culture 
group are showing a typical phenotype for these stem cells (fibroblast like) (Figure 4.3 
A, top left image). The cells in the 5 µM MI192 pre-treated group have become clearly 
smaller and more circular (Figure 4.3 A, top right image), and the cells in the 30 µM 
and 50 µM MI192 pre-treated groups are clumping together in clusters with distinctive 
bridges between the clusters (Figure 4.3 A, bottom two images), when compared with 
the untreated basal medium controls. A morphological change is especially clear in 
the picture of the cells in the lowest dose (5 µM), where more cells are visible, due to 
less cell detachment.  
 
At the 24 hour time point, the cells in the basal medium culture group are showing a 
higher cell density, with cells beginning to grow to over confluency, and 
demonstrating a continuation of the fibroblast like morphology (Figure 4.3 B, top left 
image). The cells in the 5 µM MI192 pre-treated group are showing an increase in cell 
density over the previous time point, although less than the basal group, indicating 
the cell proliferation may have slower or halted. They have the same smaller and 
more circular morphology as at 12 hours (Figure 4.3 B, top right image) when 
compared to the basal control. The photographs of cells in the 30 µM and 50 µM 
MI192 pre-treated group show some small white dots (Figure 4.3 B, bottom two 
images), which indicates cell death/detachment compared to that in the 5 µM MI192 
concentration and the basal medium control groups. The cells are also showing a 
lower cell density. 
 
At the 48 hour time point, there is little change in the cells in the basal medium culture 
group, as they have reached over confluency and have nowhere to grow (Figure 4.4 
A, top left image). The cells in the 5 µM MI192 pre-treated group have the same 
smaller and more circular morphology as at 12 and 24 hours (Figure 4.4 A, top right 
image), along with a similar cell density (indicating a lack of proliferation) to the 5 µM 
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MI192 cells at other two time points. Some cell death is visible, indicated by small 
white dots. The photographs of cells in the 30 µM and 50 µM MI192 pre-treated group 
have a large number of small white dots (Figure 4.4 A, bottom two images), which 
indicates higher cell death/detachment compared to that in the 5 µM MI192 
concentration and the basal medium control groups.  
 
At the 72 hour time point, the basal group remains unchanged (Figure 4.4 B, top left 
image). A similar level of cell death/detachment in the 5 µM MI192 pre-treated group 
(Figure 4.4 B, top right image), to the 48 hour time points visible There is a high level 
of cell death/detachment visible in the 30 µM and 50 µM MI192 pre-treated groups 
(Figure 4.4 B, bottom two images). The 30 µM group has a higher cell density than 
the 50 µM treated group, indicating a lower loss of cells. 
 
At the 96 hour time point, the basal group remains unchanged (Figure 4.5 A, top left 
image). A higher level of cell death is visible in the 5 µM MI192 pre-treated group 
(Figure 4.5 A, top right image) than in the previous time points, indicating MI192 may 
now be having a cytotoxic effect. There are very few attached cells in the 30 µM and 
50 µM MI192 dosed groups (Figure 4.5 A, bottom two images), indicating the well is 
approaching 100 % cell death.  
 
Culture with 5 µM TSA has a different effect on the cells (Figure 4.5 B). Compared to 
the 5 µM MI192 pre-treated cells, the 5 µM TSA dosed cells have become more 
elongated, with a fibroblast-like morphology. There is very minimal cell death 
observed throughout the time points and the pattern of cells is similar to that of the 
basal controls.  
 
114 
 
 
 
 
 
Figure 4.3 - Phase contrast images of ADSCs treated with MI192 for 12 (A) and 
24 (B) hours. Cells dosed with MI192 (5 µM, 30 µM and 50 µM) and compared 
to a basal control with no MI192 dose. Scale bars = 100 µM. 
5 µM 
50 µM 30 µM 
Basal 
Basal 5 µM 
50 µM 30 µM 
A: 
B:
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Figure 4.4 - Phase contrast images of ADSCs treated with MI192 for 48 (A) and 
72 (B) hours. Cells dosed with MI192 (5 µM, 30 µM and 50 µM) and compared 
to a basal control with no MI192 dose. Scale bars = 100 µM. 
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Figure 4.5 - Phase contrast images of ADSCs treated with MI192 for 96 hours 
(A) and ADSCs treated with TSA for a range of time points (B). A - Cells 
dosed with MI192 (5µM, 30 µM and 50 µM) and compared to a basal control 
with no MI192 dose. B – Cells dosed at the same time but with 10µM TSA for 
the same time points. Scale bars = 100 µM. 
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4.3.2 Effect of MI192 on ADSC DNA quantity (as an indicator of cell 
number) 
After 1 day of treatment with different concentrations of MI192 (10 µM - 100 µM), only 
the ADSCs treated with the lowest concentration of MI192 (10 µM) showed no 
statistically significant (P > 0.05) reduction in total DNA content, comparted to the 
untreated basal medium control (Figure 4.6). There was a statistically significant (P ≤ 
0.05) reduction in the total DNA content in the higher concentration (20 µM - 100 µM) 
groups compared to the basal medium control. There was no significant difference in 
the total DNA content between the higher concentration of MI192 groups, compared 
to each other (P > 0.05). 
 
After 2 days, there was an increase in cell number (although not statistically 
significant, P > 0.05) in the untreated basal medium control compared to the day 1 
samples. In contrast, in all concentrations of MI192 (10 µM - 100 µM) there was a 
statistically significant (P ≤ 0.001) reduction in total DNA content, compared to the 
untreated basal medium control. The reduction was down to a similar level to that 
seen in the day 1 treated group. It could be  result showing cellular proliferation 
halting. There was a statistically significant reduction in the 100 µM group compared 
to 10 µM group (P ≤ 0.05), with no statistical significant (P > 0.05) difference between 
the other groups. 
 
After 3 days, there was another increase in cell number (although not statistically 
significant, P > 0.05) in the untreated basal medium control compared to the day 1 
and day 2 samples. In all concentrations of MI192 there was a reduction in total DNA 
content, compared to the untreated basal medium control. Except in the 10 µM MI192 
treated cells, this reduction was lower than the previous time points, indicating cell 
death or detachment, as the cell numbers are reducing over time. The reduction 
compared to the untreated basal medium control was highly significant in all groups 
(P ≤ 0.001). Comparing the 10 µM MI192 and 100 µM MI192 treated cells, there was 
a highly significant difference (P ≤ 0.001), and a dose response (although not 
statistically significant, P > 0.05) between the doses of MI192, indicating a higher 
concentration results in a lower total DNA content. The total DNA content for the 10 
µM MI192 treated cells stayed similar across all three time points. These results 
indicate that MI192 has a cytotoxic, and/or proliferation halting effect on ADSCs, at all 
concentrations, with a dose response visible. 
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Figure 4.6 - Quant-iT™ PicoGreen® analysis of ADSCs treated for 1 day, 2 days 
and 3 days with a range of doses of MI192. Results expressed as mean ± SD 
(n=3). A selected sample of significance levels are shown, * = P ≤ 0.05, ** = P ≤ 
0.01 and **** = P ≤ 0.0001 
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4.3.3 Cytotoxic effect of MI192 on ADSCs  
After 1 day of treatment with different concentrations of MI192 (1 µM - 50 µM), no 
statistically significant (P > 0.05) cytotoxic effect of MI192 was seen in the test groups 
compared to the untreated basal control group (Figure 4.7). 
 
After 2 days of treatment with MI192, the 50 µM and 100 µM groups showed 
extremely statistically significant (P ≤ 0.001) cytotoxic marker release compared to 
the untreated basal control group. There were also statistically significant cytotoxicity 
markers measured in the lower concentrations, with 30 µM (P ≤ 0.01), 20 µM (P ≤ 
0.05) and 10 µM (P ≤ 0.05) all showing a measured cytotoxic effect compared 
untreated basal control group. However, there was no statistical significant difference 
between the 1 µM group and the untreated basal control group (P ≥ 0.05). The 
cytotoxic effect was not statistically significant different between most groups (P > 
0.05); however, there was a dose response visible, with a higher cytotoxic effect 
visible in the higher doses of MI192. 
 
After 3 days of treatment with MI192, all groups showed an increase in the cytotoxic 
marker release compared to the untreated basal control group. 1 µM MI192 showed a 
statistically significant cytotoxic marker release (P ≤ 0.01) and all other groups (10 µM 
- 100 µM) had an extremely high difference compared to the control (P ≤ 0.001). 
There was a lower cytotoxic effect seen in the lower MI192 doses (1 µM and 10 µM), 
with the higher doses (20 µM - 50 µM) all having a comparable cytotoxic effect.  
 
MI192 was found to have a cytotoxic effect on ADSCs, which was suggested 
previously by the reduction in cell number (Figure 4.6). At all treatment concentrations 
of MI192, the cytotoxic effect of MI192 can be seen in the release of cytotoxicity 
markers, with an increase in treatment length and dose size.  
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4.3.4 Effect of MI192 on ADSCs viability 
After 1 day of treatment with different concentrations of MI192 (1 µM - 50 µM), a 
statistically significant reduction (P ≤ 0.001) in cell viability was observed in all 
treatment groups (P ≤ 0.001), except at 1 µM, which had no statistically significant (P 
≥ 0.05) reduction, compared to the untreated basal control group (Figure 4.8). The 
reduction was to a similar level in all groups. 
 
After 2 days of treatment with MI192, all MI192 treatment groups showed a 
statistically significant reduction in cell viability (P ≤ 0.001) compared to the untreated 
basal control group. The higher doses (40 µM and 50 µM) showed the greatest 
reduction in cell viability compared to the untreated basal control group. There was a 
clear dose response, with the lower doses showing the least reduction in cell viability 
compared untreated basal control group. 
 
After 3 days of treatment with MI192 all groups showed a statistically significant 
reduction (P ≤ 0.001 for all treatment groups except 1 µM, which was P ≤ 0.01) in cell 
viability, compared to the untreated basal control group. A dose response was visible; 
in the higher doses (50 µM, 40 µM and 30 µM) the cell viability was near 0, with the 
lower doses (20 µM, 10 µM and 1 µM) having higher overall level of viable cells.  
 
MI192 was found to have an effect on the viability of ADSCs, at all doses and dose 
lengths, except 1 day of 1 µM MI192. At all doses, except 1 µM, a reduction in cell 
viability was seen with increasing dosage time. 1 µM showed a reduction after 2 days 
of treatment, with the same level of reduction seen at 3 days, compared to the 
untreated basal controls.  
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Figure 4.7 - CytoTox-Fluor™ analysis of ADSCs treated with a range of MI192 
doses (50 µM, 40 µM, 30 µM, 20 µM, 10 µM and 1 µM) for 1 day, 2 days and 
3 days. Results expressed as mean ± SD (n=3) Significance levels shown are 
the sample compared to the basal control for that time point, i.e. A 40 µM dose 
for 2 days compared to basal control at 2 days. * = p ≤ 0.05, ** = p ≤ 0.01 and 
*** = p ≤ 0.001. 
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Figure 4.8 - CellTiter-Glo® analysis of ADSCs treated with a range of MI192 
doses (50 µM, 40 µM, 30 µM, 20 µM, 10 µM and 1 µM) for 1 day, 2 days and 
3 days. Results expressed as mean ± SD (n=3). Significance levels shown are 
the sample compared to the basal control for that time point, i.e. A 40 µM dose 
for 2 days compared to basal control at 2 days. * = P ≤ 0.05, ** = P ≤ 0.01 and 
*** = P ≤ 0.001. 
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4.3.5 Effect of MI192 on the HDAC specific activity of ADSCs 
Treatment of ADSCs for both one and two days with two doses of MI192 (30 µM and 
10 µM) lead to a statistically significant (P ≤ 0.01) reduction in the HDAC specific 
activity of the cells, compared to untreated controls (Figure 4.9). There was no 
observable difference between the two different doses at both time points.  
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Figure 4.9 – HDAC activity of ADSCs treated for 1 day and 2 days two of doses 
of MI192. Results expressed as mean ± SD (n=3), ** = P ≤ 0.01 
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4.3.6 Effect of MI192 on ADSC Cell Cycle 
Representative histograms show the number of cells in different stages of the cell 
cycle (Figure 4.10). The average exact % of each group was calculated (Table 4-2).  
 
After 12 hours, 92.05 % of the cells in untreated basal medium group were in the 
G0/G1 phase, 3.25 % of the cells were in G2/M phase and 4.76 % of the cells were in 
S phase. In contrast, both MI192 treatment groups showed an increase in the G2/M 
phase (11.32 % for 30 µM and 7.03 % for 10 µM) compared to that of the basal 
control (3.25 %). There is also an increase in the S phase in the treated groups (9.22 
% for 30 µM and 6.39 % for 10 µM) compared to that of the basal control (4.76 %). 
The 10 µM TSA group showed a similar increase at G2/M phase (8.96 %), but a 
slight drop in the S phase (2.68 %) compared to the basal controls. 
 
After 24 hours, 68.65 % of the cells in basal medium group were in the G0/G1 phase, 
17.13 % of the cells were in G2/M phase and 14.22 % of the cells were in S phase. 
Again, both MI192 treatment groups showed an increase in the G2/M phase (23.56 % 
for 30 µM and 21.98 % for 10 µM) compared to that of the basal control (17.13 %). 
There were less cells found in the S phase of the cell cycle in the treated groups 
(7.30 % for 30 µM and 8.51 % for 10 µM), compared to the basal medium group 
(14.22 %). The 10 µM TSA group also showed a increase G2/M phase (23.47 %), but 
a higher percentage of cells in the S phase (12.65 %) than the MI192 treated groups. 
 
After 48 hours, 56.3 % of the cells in untreated basal medium group were in the 
G0/G1 phase, 9.46 % of the cells were in G2/M phase and 40.86 % of the cells were 
in S phase. Again, both MI192 treatment groups showed an increase in the G2/M 
phase (11.97 % for 30 µM and 18.59 % for 10 µM) compared to that of the untreated 
basal medium group (9.46 %). In the S phase the MI192 treated groups had a lower 
percentage of cells (33.81 % for 30 µM and 8.153 % for 10 µM) than the untreated 
basal medium group (40.86 %). The 10 µM TSA group showed a similar increase at 
G2/M phase (18.72 %), and a lower percentage of cells in the S phase (10.43 %) 
than the basal control, with a level comparable to the 10 µM MI192 treated group.  
 
MI192 treatment was found to increase halting of the ADSC cell cycle of in the G2/M 
phase, with the results showing a similar trend with TSA treatment.  
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Figure 4.10 – Representative histograms of the flow cytometry analysis of the cell cycle distribution for ADSCs dosed with 30 
µM and 10 µM MI192 and 10 µM TSA with untreated controls, for 12, 24 and 48 hours. Representative histograms from each time 
point and test group shown, the experiment was carried out in biological triplicate, and histograms are representative of at least 2000 
events. The first large peak represents the population of cells in the G0/G1 phase, the second small peak the population of cells in the 
G2/M phase, with the area in between the S Phase.                                                                  .
  
  
  
12 hours 
24 hours 
48 hours 
Basal 30 µM MI192 10 µM MI192 10 µM TSA 
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Table 4-2 – Table of data for the flow cytometry analysis of the cell cycle 
distribution for ADSCs. Cells were dosed with 30 µM and 10 µM MI192, 10 
µM TSA and untreated controls, for 12, 24 and 48 hours. Average percentage 
of cells for each of the three calculated phases of the cell cycle shown, with the 
standard deviation (SD) for each. 
 
 
G0/G1Phase 
Mean % 
SD 
G2/M Phase 
Mean % 
SD 
S Phase 
Mean % 
SD 
1
2
 h
o
u
rs
 
Basal 92.05 2.74 3.25 1.14 4.76 1.68 
30 µM MI192 79.46 6.47 11.32 2.07 9.22 2.07 
10 µM MI192 86.61 1.91 7.03 1.24 6.39 2.95 
10 µM TSA 88.36 0.39 8.96 1.53 2.68 1.22 
2
4
 h
o
u
rs
 
Basal 68.65 7.81 17.13 0.96 14.22 8.75 
30 µM MI192 69.15 1.44 23.56 1.09 7.30 1.10 
10 µM MI192 69.50 3.38 21.98 0.44 8.51 3.05 
10 µM TSA 63.88 4.91 23.47 1.02 12.65 4.04 
4
8
 h
o
u
rs
 
Basal 56.3 5.42 9.46 3.94 40.86 9.36 
30 µM MI192 54.22 3.62 11.97 0.40 33.81 4.01 
10 µM MI192 73.26 3.25 18.59 0.49 8.153 2.87 
10 µM TSA 70.86 6.88 18.72 1.09 10.43 5.81 
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4.3.7 Effect of MI192 on ADSC Stem Cell Markers  
The expression of 9 commonly used stem cell markers (see Table 4-1 for full details) 
was investigated in ADSCs treated with 30 µM MI192 for 2 days, compared to 
untreated basal medium controls. Markers were assessed as a group of three 
(CD29/CD73/CD90) and three groups of two (CD34/CD45, CD44/CD166 and 
CD146/CD105). Representative dot plots of the events (after gating for intact cells) 
were produced for the groups of markers for both the untreated ADSCs and are 
shown in the Appendix (A4 - Effect of MI192 on ADSC Stem Cell Markers: FACs plots 
and autofluorescence comparison histograms). Also produced and shown in the 
Appendix were histograms showing the expression of the marker compared to the 
negative autofluorescence readings for the cells, for both untreated and MI192 
treated ADSCs. This was to account autofluorescence when analysing the markers, 
and to ensure there was no overlap with the expressing populations.  
 
The events in the treated cells were more spread than in the untreated controls, so to 
understand if the spread of data was just due to a size alteration on the death of the 
cells, a propidium iodide stain of the MI192 treated cells was analysed (Figure 4.11). 
The cells were washed several times before detachment and labelling, so cells that 
were already dead should not have been labelled. However, the PI staining indicates 
that only 84.25 % of the cells labelled were alive, so some cells labelled will be close 
to death and likely did not just detach with the wash. These dead cells were gated out 
when analysing the stem cell markers. The PI staining indicates two populations of 
cells, so these were gated (Figure 4.11 D) and then the spread of these cells was re-
assessed. Figure 4.11 C shows that the cells in this sub-population had a spread of 
size similar to that of the whole population (Figure 4.11 A). This showed that the sub 
population of cells that has appeared is not solely due to the cells being a different 
size, or dying, the population appears to be a distinct one, of live cells. 
 
To show the difference in stem cell marker expression in cells treated with MI192, 
compared to untreated controls, representative histograms were  produced (Figure 
4.12, Figure 4.13 and Figure 4.14), along with a table illustrating the average 
percentage (of the three technical repeats) of the total population of cells labelled with 
the marker, for the untreated and MI192 treated cells (Table 4-3). The treatment of 
ADSCs with MI192 clearly causes an increase in expression of CD34 and CD146 
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(Figure 4.12 B and Figure 4.14 B), when compared to the untreated controls. This 
was a +35.46 % increase for CD34 and an increase of +35.02 % for CD146. After 
MI192 treatment, cells with lower expression of CD29, CD44, CD73, CD90, CD105 
and CD166 can be seen when compared to the controls (Figure 4.12 A and C, Figure 
4.13 B and C and Figure 4.14 A and C). For some markers, there was a large 
decrease; -20.61 % for CD29, -7.94 % for CD73, and -40.29 % for CD105 (Figure 
4.12 A, Figure 4.13 B and Figure 4.14 A). There was only a smaller decrease in 
CD44 (-2.84 %) and CD166 (-4.53 %) (Figure 4.12 C and Figure 4.14 C). In contrast, 
and virtually no change in the expression level of CD45 and CD90 (Figure 4.13 A and 
C) remained similar level compare to the untreated group (+0.66 % and -0.12 % 
respectively).  
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Figure 4.11 - Representative histograms showing flow cytometric analysis of PI 
staining of MI192 treated ADSCs. A – Gate 1, gating for intact cells, B – Gate 
2 (box D on the plot) – gating for the subpopulation of cells, C – size analysis of 
the subpopulation of cells from Gate 2 (D on the plot). D – Statistical analysis of 
the gates. 
 
 
D. 
A. B. 
C. 
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Figure 4.12 – CD29, CD34 and CD44. Representative histograms and graphical 
representation of flow cytometric analysis of stem cell markers in MI192 treated 
compared to untreated ADSCs. Error bars represent SD of technical repeats (n 
= 3). A – CD29, B – CD34, C – CD44. Untreated ADSCs (red colour) compared 
to MI192 treated (green colour). Note the y axis is a different scale for each 
graph. 
A. 
B. 
C. 
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Figure 4.13 – CD45, CD73 and CD90. Representative histograms and graphical 
representation of flow cytometric analysis of stem cell markers in MI192 treated 
compared to untreated ADSCs. Error bars represent SD of technical repeats (n 
= 3). A – CD45, B – CD73, C – CD90. Untreated ADSCs (red colour) compared 
to MI192 treated (green colour). Note the y axis is a different scale for each 
graph. 
A. 
B. 
C. 
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Figure 4.14 – CD105, CD146 and CD166. Representative histograms and graphical 
representation of flow cytometric analysis of stem cell markers in MI192 treated 
compared to untreated ADSCs. Error bars represent SD of technical repeats (n 
= 3). A – CD105, B – CD146, C – CD166. Untreated ADSCs (red colour) 
compared to MI192 treated (green colour). Note the y axis is a different scale 
for each graph. 
C. 
B. 
A. 
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Table 4-3 – The percentage of untreated and MI192 treated ADSCs positive for 
stem cell markers CD29, CD34, CD44, CD45, CD73, CD90, CD105, CD146 
and CD166. The percentage change on treatment was calculated. 
Marker Untreated Treated Change 
CD29 99.84 % 79.23 % - 20.61 % 
CD34 1.66 % 37.12 % + 35.46 % 
CD44 99.96 % 97.12 % - 2.84 % 
CD45 0.39 % 1.05 % + 0.66 % 
CD73 99.74 % 92.10 % - 7.94 % 
CD90 99.73 % 99.61 % - 0.12 % 
CD105 99.69 % 59.67 % - 40.29 % 
CD146 7.42 % 42.44 % + 35.02 % 
CD166 99.96 % 95.43 % - 4.53 % 
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4.4 Discussion 
In recent years, the possibility of utilising HDACi compounds to control the osteogenic 
potential of cells for tissue engineering applications has been explored (Iwami & 
Moriyama 1993; Schroeder et al. 2007; H.-N. Kim et al. 2011). In many publications 
exciting findings such as improvements to differentiation protocols (Maroni et al. 
2012; Boer et al. 2006), are reported, but often avoid the reporting of side effects to 
using the HDACis, such as cytotoxicity or proliferative halting effects. 
 
Thus, it is important to gain an understanding of the effect of HDAC2 and HDAC3 
selective MI192 on general cellular properties before looking at its effects on 
differentiation. Cytotoxic effects and alterations to cell properties such as changing 
the cell cycle or stem cell marker expression may have implications for how these 
compounds are utilised.  
 
It has been reported in the literature that HDACis halt the proliferation of cells (Khan 
et al. 2008), particularly MSCs (Lee et al. 2009; Kurihara & Suzuki 2014). While it has 
been reported that low doses of TSA (10 nM – 100 nM) stimulate the proliferation of 
dental pulp derived MSCs (Jin et al. 2013), another paper reported that TSA halted 
the proliferation of murine dental pulp cells (Duncan et al. 2012). This is likely due to 
HDACis halting the cell cycle, but this is discussed later. This proliferation halting 
effect may be being observed in the images taken throughout MI192 treatment 
(Figure 4.3, Figure 4.4 and Figure 4.5). These show that cells treated with MI192 
become smaller and more rounded, which can be seen as early as 12 hours, and 
most clearly in the lower, 5 µM MI192 doses (Figure 4.3 A). Cells will often clump 
together in clusters, sometime detaching as clusters (Figure 4.3 A). It is clear that 
MI192 has an effect on the cell phenotype, with cell death also visible at higher 
doses. This is in contrast to TSA, where cell death is not visible, and the cells have a 
different, although still distinct morphological change. When treated with TSA, the 
cells become more elongated. This cell morphology change may be due to the TSA 
dosage halting proliferation of the ADSCs, potentially causing the cells to become 
more elongated rather than pushing against each other as in the basal controls. Also 
relevant, and although no data is shown, when seeding cells, MI192 clearly inhibited 
cell attachment and caused high levels of cell death.  
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Assessment of the total DNA content, indicating cell numbers, gave a quantitative 
measurement of the cell death or proliferative halting effect observed previously. As 
dead cells were washed away, the total DNA content correlates to the total number of 
live cells. The total DNA content is reduced over 1, 2 and 3 days when cells are 
treated with MI192 (Figure 4.6). This could be a combination of, or one of, cellular 
proliferation being halted or cell death. At least some of this must be due to cell 
death, as the DNA content, especially in the groups with the higher doses (30 µM – 
50 µM), drops below the initial basal level of cells (if it was purely a proliferation 
halting effect, the DNA content would be the same as at seeding). A dose response 
can also be seen, with the lower doses having the lowest reduction in DNA content. It 
is clear that the longer the treatment time, the more cell death. 
 
It is important to know if any compound utilised with cells is going to have a cytotoxic 
effect, or an effect on cell viability, as this may have implications for how (or if at all) 
the compound is utilised. This is especially important given the drop in cell numbers 
observed previously. In the literature, HDACis are often utilised at low concentrations, 
and are often reported not to be cytotoxic to normal cells, or affect cell viability (for 
example in Duncan et al. 2012; Paino et al. 2014; Xu et al. 2013). This is the opposite 
of typical reports with cancer cells, where the aim is usually to utilise HDACis to kill 
cancerous cells (Frew et al. 2009). The results in this chapter (Figure 4.7) show that 
after two days of treatment, high concentrations of MI192 had a cytotoxic effect on 
ADSCs. The effect was dose dependent, and it was even more pronounced after 
three days of treatment. 
 
A simple one reagent addition ATP assay was chosen to show the effect of MI192 on 
cell viability (Figure 4.8), as this is the most widely used assay for high throughput 
screening and is regarded as being a fast and reliable method of determining cell 
viability (Riss et al. 2004). In the literature, this method has been utilised to assess 
the effect of SAHA on leukaemia cells (Petruccelli et al. 2011). 
 
There was a visible loss in cell viability after just one day of treatment with MI192. 
This effect was dose and time dependent. By day 3, there was very few (5 % – 20 % 
of the basal control) viable cells in the 50 µM – 20 µM groups. It is worth noting that 
the cell viability assay only measures ATP activity in cells, which is associated with 
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cell viability, but does not measure if the cells are able to recover to a viable state. 
The assay works on the principle that when dying cells lose membrane integrity their 
ability to synthesise ATP will cease and endogenous ATPases will remove any ATP 
present in the cells. However, if all of the cells not generating viable ATP signals were 
dead in this assay, a much larger reduction in cell number (total DNA content) would 
be observed previously in these cells with MI192 treatment (Figure 4.8). More than 5 
% of cells remained after 3 days of treatment with 30 µM MI192, and therefore not all 
can be dying. It may be that the alteration of the epigenetic makeup of the cell may 
affect the cell’s ability to produce ATP, which may not have any other adverse or long 
term effects. Indeed, there are established links between ATP fuelled transporters 
and HDAC enzymes and inhibition, and this may be a side effect of that (Ni et al. 
2015).  
 
An alternative viability assessment method was also undertaken with propidium 
iodide, in combination with the assessment of stem cell makers. It is a commonly 
used tool for assessment of cell viability, for example used in the literature to assess 
peripheral blood lymphocytes treated with SAHA (Brodská & Holoubek 2011). PI 
staining confirmed that 84.25 % cells remained viable after two days of 30 µM MI192 
treatment, although this didn’t measure include dead cells that had been washed 
away prior to staining. 
 
These results all together indicate that ADSCs should not be exposed to MI192 for 
longer than 2 days and/or to high doses of MI192 (over 10 µM), at least without 
appreciating there will be a loss of cell number and/or viability.  
 
It is important to explore the effect of MI192 on the HDAC activity of the ADSCs. As 
discussed in Chapter 3: The Chemical Synthesis of MI192, it has been reported that 
MI192 reduces the activity of HeLa cells, to a comparable or better level than other 
HDACis (Boissinot et al. 2012). Elsewhere, a fluorometric assay sold by Biovision has 
been used to show that HDACis (e.g. MS-275) reduce the HDAC activity of cells (Kim 
et al. 2014; Zhang et al. 2012). The assay contains a substrate with an acetylated 
lysine side chain, which HDAC enzymes will deacetylate, resulting in a product that 
can be developed with a developer to produce a fluorescence signal. 
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In this study, the same assay was used to demonstrate that MI192 reduces the 
HDAC activity of ADSCs. After 1 and 2 days treatment, both doses of MI192 (30µM 
and 10 µM) reduced ADSC HDAC activity. These reductions were similar in both 
doses of MI192 and at both time points. It is known that MI192 is specific for HDAC2 
and HDAC3, and has a much lower inhibition of other HDAC isoforms (Boissinot et al. 
2012). Therefore, uninhibited HDAC enzymes could still act to deacetylate the 
substrate and some activity should still be observed in cells. This study confirmed that 
MI192 has a HDAC inhibitory effect function after 24 hours. The fact that the two 
doses are showing the similar levels of HDAC activity indicates that both doses of 
MI192 will reduce HDAC activity, and that the differences in effects, such as 
cytotoxicity, may be due to other effects of MI192. Alternatively, cells may metabolise 
MI192, or it may unbind, and in the higher concentrations there is more opportunity 
for MI192 to rebind, having a longer period affecting cells. Also, MI192 may have a 
short half-life in the medium, and a higher concentration of MI192 results in there 
being a greater amount of MI192 available over time.  
 
In a normal functioning cell, the cell cycle is the sequence of events that takes place 
leading to cell division, and it is essential to normal cell function and the processes of 
proliferation and differentiation (Majdzadeh et al. 2008; Jiang & Hsieh 2014). A 
number of studies show that HDAC2 and HDAC3 are both involved in the regulation 
of the cell cycle (Yamaguchi et al. 2010; Bhaskara et al. 2009; Jiang & Hsieh 2014). 
Thus, disrupting their action could have an effect on the cell cycle that in turn could 
help to control cell function. It has been reported that SAHA reduced the number of 
MSCs in the G2/M phase, MS-275 reduced the number of MSCs in the S phase, and 
both of them halted the cells in the G1 phase of the cell cycle (Di Bernardo et al. 
2009). 
 
In this study, MI192 was shown to reduce cell numbers in the S phase of the cell 
cycle, but it increased numbers in the G2/M phase (Table 4-2 and Figure 4.10), which 
doesn’t mirror the results seen with MS-275 or SAHA (Di Bernardo et al. 2009). A 
similar effect was also seen in the TSA treated group, where the cells halted the cell 
cycle in the G2/M phase. This indicates that MI192 and TSA may have a different 
mechanism of action compared to MS-275 and SAHA. The standard deviation of the 
S phase was especially high, at later time points, and the histograms show the fact 
that the software had a harder time picking the peaks at the later time points. This is 
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likely due to a greater spread in the cell cycle as a mixed stromal population of cells 
diverges from a set point (i.e. when they are seeded) more over a longer period of 
time.  
 
Although reports can vary, MS-275 is thought to be relatively HDAC1, HDAC2 and 
HDAC3 selective (Bradner et al. 2010; Khan et al. 2008; Boissinot et al. 2012). Jiang 
et al. (2014) demonstrated that in HDAC3 mouse knock down models, cells cannot 
progress through the G2/M phase of the cell cycle (Jiang & Hsieh 2014); HDAC3 
controls this progression through stabilisation of the G2/M cyclin dependent kinase 1 
(CDK1). Therefore, the inhibition of HDAC3 may result in an induction of cycle arrest 
in G2/M, an effect seen in this study. The G2/M cell cycle check point is where the 
cell checks for DNA damage. Some HDACis are known to cause damage to DNA 
(McGee-Lawrence et al. 2011; Petruccelli et al. 2011), therefore it may be that the 
high level of cells at the G2/M checkpoint is in response to this DNA damage, and 
that cells are halting here and exiting the cell cycle via controlled apoptosis. This 
could explain the high level of cell death observed in the MI192 treated cells. 
 
Stem cell markers are a general term, referring to genes or proteins that can be 
utilised to isolate and/or identify stem cells (Baer & Geiger 2012; Churchman et al. 
2012; Nielsen & McNagny 2008). The effect of HDACis on these markers may reflect 
on their role in stem cell fate. HDACis have the potential to promote stem cell self-
renewal or increase the stem cell properties of cells (Kretsovali et al. 2012). In mouse 
ES cells, it has been shown that HDACis (such as VPA, NaB and TSA) improved 
transfection protocols and had no effect on stem cell markers (pluripotency marker 
Oct4, was tested) (Y. Kim et al. 2013), although these were different markers to those 
tested here. There is very little literature precedent for this work, and no studies test 
the stem cell markers before and after HDAC treatment. The ADSCs used in this 
thesis were sorted by the manufacturer (Life Technologies) to be positive for CD29, 
CD44, CD73, CD90, CD105 and CD166, and negative for CD45. The results 
demonstrate that at passage 5, the cells are still maintaining their stem cell markers.  
 
Treatment of cells with MI192 may have resulted in a subpopulation of cells forming, 
with a different stem cell marker profile was observed. The testing of the cells with 
propidium iodide, which will only penetrate cells when they are dead, demonstrated 
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that this sub-population of cells that has formed was not just due to cell death, and 
when the size of the cells in the sub-population of cells was investigated, the sub-
population was not just due to a change in the cell size (which is observed in the cell 
phenotype changing with MI192 treatment). The sub-population of cells had a large 
increase of expression of CD34 and CD146, with a decrease in expression of CD29, 
CD44, CD73, CD105, CD166, with no change in the expression of CD45 and CD90. 
 
Regarding the markers that were up-regulated with MI192 treatment, CD34 is a 
commonly utilised marker of HSCs, and can be used to separate these cells from 
bone marrow MSCs (Trowbridge & Thomas 1994; Tomlinson et al. 2015; Nielsen & 
McNagny 2008). CD146 is highly expressed in blood vessels and pericytes, structural 
cells of the vascular system. While CD34 is classified as a marker of hematopoietic 
lineage, it is expressed in early ADSCs, and is lost with increased cell culture time. 
CD146 is also reported to decrease with culture time, but is expressed in CD34 
negative cells, and not in CD34 positive cells (Mitchell et al. 2006; Baer & Geiger 
2012). The increased expression of both of these on treatment with MI192 is very 
interesting.  
 
It has been suggested that HSCs may actually be progenitor cells for ADSCs (Sera et 
al. 2010), so the increase of these stem cell markers may indicate the ADSCs, which 
survive the treatment with MI192, are more immature. This may mean that they have 
greater differentiation potential. Alternatively, they may be primed to differentiate 
down the lineages that HSCs are specialist for, such as the blood, lymphatic and 
immune systems. The treatment of ADSCs with MI192 may be priming these cells to 
behave like HSCs, or may just be making the cells more “stem cell like” and/or 
immature ADSC like. Although the topic is controversial and conclusions are not fully 
drawn. Reportedly, CD34 positive cells have greater colony forming ability and 
proliferative capacity, but less ability to differentiate into osteogenic and adipogenic 
lineages (Suga et al. 2009). This could have implications for the differentiation 
potential of the MI192 treated ADSCs. 
 
The down-regulation of the CD29, CD44, CD73, CD105 and CD166 could have a 
wide range of consequences. Markers such as CD29 are also markers of HSCs, 
while others, e.g. CD73 was more used as bone marrow MSC markers. The 
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reduction in these was quite small, in the range of (3 % - 8%, and the cells still 
expressed these markers to a reasonably high percentage (except CD105 which had 
a 40 % reduction). It is well known that CD105 is highly expressed in angiogenic 
endothelial cells and in the blood vessels of tumour tissues, which means that these 
cells may be losing angiogenic potential (Duff et al. 2003). However, CD34 is also a 
marker of angiogenesis, and expression was increased on MI192 treatment, so 
picture is a slightly confusing one. The alteration of these markers could have 
implication for their applications, as vascularisation of tissues is becoming more of a 
highlighted issue for generating functional tissue as tissue engineering evolves       
(Liu et al. 2013).                                                                                                     .
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Chapter 5: The Effects of MI192 on the Differentiation of 
Adipose Derived Stem Cells in 2D 
 
The aim of this chapter is to investigate effects of MI192 on the differentiation of 
ADSCs, and primarily to address how the osteogenic differentiation potential of 
these cells is affected. The objectives are to investigate how MI192 pre-treatment 
and treatment for the whole experiment affects the alkaline phosphatase (ALP) 
activity of ADSCs, how the pre-treatment with MI192 affects the ALPSA of ADSCs 
compared to TSA, the effect of MI192 on ALP activity in cells from four different 
donors and with two different batches of MI192, and how the effect of pre-treatment 
with MI192 with two different osteogenic mediums affects ALP production over time. 
Further objectives are to investigate the effect of MI192 pre-treatment on 
osteogenic gene expression, and mineralisation through Alizarin Red and Von 
Kossa staining. Finally, the effect of MI192 pre-treatment on the adipogenic 
potential of the ADSCs was investigated, through Oil Red O staining and 
assessment of adipogenic gene expression.  
5.1 Introduction  
The clinical need for bone tissue engineering could be met by the appropriate 
combination of stem cells, scaffolds, suitable mechanical stimuli and optimal growth 
factors. Cells can be taken either from the patient, or obtained from an allogenic 
source, engineered to differentiate down an osteogenic lineage and implanted into 
the patient. The potential for using ADSCs in bone tissue engineering has been well 
documented both in vitro and in vivo (Levi & Longaker 2011; Halvorsen et al. 2001; 
Zheng et al. 2006; Colnot 2011). 
 
Reports of HDACis being utilised in bone related research primarily began with 
studies into the side-effects of HDACis being utilised in cancer therapies (Witt et al. 
2009). SAHA and VPA have been reported to have a negative impact on bone 
density in patients, as well as a damaging effect on osteoblasts (McGee-Lawrence 
et al. 2011; Pratap et al. 2010). For example, VPA has been found to increase the 
neurogenic differentiation capacity of canine ADSCs, while reducing the late stages 
of adipogenic and osteogenic potential of these cells (Kurihara & Suzuki 2014). 
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SAHA was found to decrease osteoblastic gene expression, induce cell cycle arrest 
and cause DNA damage in in vitro tests with mouse bone marrow MSCs. 
Interestingly, mature osteoblast cells were not affected (McGee-Lawrence et al. 
2011).  
 
In contrast, Dudakovic et al. (2015) reported that SAHA enhanced ADSC 
expression of some key stem cell pluripotency markers (NANOG, OCT4/POU5F1, 
and SOX2), which may indicate that SAHA induces a more immature pluripotent 
state in ADSCs (Dudakovic et al. 2015). Also, Xu et al (2013) suggested that while 
high doses of SAHA are toxic to human bone marrow MSCs, lower doses will 
increase the osteogenic potential of these cells (increasing ALP activity, mRNA 
expression of osteogenic markers, and matrix mineralisation). Furthermore, it has 
been shown that when mice were dosed with clinically relevant doses of SAHA, 
there was no sign of loss in bone density (Xu et al. 2013). This study highlights the 
importance of dose optimisation when using compounds such as SAHA, with 
potentially very harmful side effects, as this can be the crucial to find a balance 
between negative and positive effects.  
 
As well as investigating the side effects of HDACis on cells within cancer 
therapeutics, researchers have begun to investigate their effect on stem cells, for 
tissue engineering purposes. Early successes with mouse derived bone marrow 
MSCs (Cho et al. 2005; Schroeder & Westendorf 2005) preceded similar findings 
with human bone marrow MSCs, where TSA was found to improve their osteogenic 
differentiation (Boer et al. 2006). Similarly, SAHA and VPA have been shown to 
increase the osteogenic potential of human bone marrow MSCs, with no negative 
effect on bone in mouse animal models (Xu et al. 2013). There are other studies 
also demonstrating the potential of HDACis to increase the osteogenic potential of 
other cell populations, such as human periodontal ligament fibroblasts (T.-I. Kim et 
al. 2013) and mouse dental pulp-derived cells (Duncan et al. 2012). 
 
More specifically regarding this study, researchers have also investigated the effect 
of HDACis on ADSCs. However, the picture can be a confusing one, as there is 
evidence to suggest that HDACis can both increase and reduce the osteogenic 
differentiation potential of ADSCs. The majority of findings in field support the 
potential for HDACis to have a positive impact on the osteogenic potential of 
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ADSCs. At varying oxygen concentrations, both VPA and NaB have been found to 
increase the osteogenic potential of mouse adipose derived stem cells, promoting 
gene expression, Alizarin Red staining and ALP activity, while also decreasing the 
adipogenic potential of the cells (Xu et al. 2009). Also, TSA and NaB can enhance 
rat ADSCs osteogenic gene expression, ALP activity and mineralisation levels of 
the cells (Hu et al. 2014; Hu et al. 2013).  
 
Isoform specificity is becoming particularly interesting to researchers, as outlined in 
depth in the introduction of Chapter 4: The General Effects of MI192 on Adipose 
Derived Stem Cells Cultured in Monolayer. In 2012, Maroni et al. investigated the 
effect of blocking HDAC1 and HDAC3 on the differentiation potential of ADSCs, and 
suggested that specific targeting of HDAC isoforms may improve the differentiation 
potential. Pre-treatment of cells with TSA before osteogenic induction increased the 
osteogenic potential of the ADSCs (assessed by measurement of ALP activity, 
Alizarin Red staining and assessment collagen production) (Maroni et al. 2012). 
This is in line with the aforementioned study by Boer et al. (2006), where it was 
reported that TSA increased the osteogenic potential of human bone marrow MSCs 
(Boer et al. 2006). Maroni et al. also found that the genetic blocking of HDAC1 and 
HDAC3 with small interfering RNAs (siRNAs) activated the osteogenic 
differentiation pathway of the ADSCs, with increased RUNX2 and decreased 
PPARγ expression (respectively the osteogenic and adipogenic master 
transcription factors) (Maroni et al. 2012). siRNAs have also been utilised to block 
HDAC6, which was found to activate the osteogenic differentiation pathway of 
human ADSCs, by increasing RUNX2 and decreasing PPARγ expression (Huang 
et al. 2012). Aside from ADSCs, MS-275, allegedly a HDACi specific to HDAC1 
HDAC2 and HDAC3 improved the osteogenic differentiation potential of mouse 
primary osteoblast precursor cells (Kim et al. 2012; H.-N. Kim et al. 2011). 
 
MI192 is an isoform specific HDACi, specifically targeting HDAC isoforms HDAC2 
and HDAC3. The aim of this study was to investigate the effects of MI192 on the 
differentiation potential of ADSCs, with particular attention paid to the effect on the 
osteogenic differentiation potential of the cells.  
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5.2 Materials and methods 
 
5.2.1 The effect of MI192 on the early osteogenic differentiation of 
ADSCs  
Alkaline phosphatase activity can be stained histologically or measured in a 
biochemical assay and normalised to total DNA content of the cells, giving the 
quantitative alkaline phosphatase specific activity (ALPSA) of the cells. See 2.4: 
Biochemical assays for the ALPSA methods. ALP is a useful marker for measuring 
early stage osteogenic differentiation of cells. They were used in a number of 
experiments investigating MI192 and its effect on the osteogenic differentiation 
potential of ADSCs. 
 
5.2.1.1 The effect of MI192 pre-treatment on the alkaline phosphatase 
staining levels of ADSCs 
ADSCs were seeded in a 12 well plate (1 x 105 cells per well) and cultured in basal 
medium for 24 hours. The medium was then replaced with MI192 containing 
medium (100 µM and 30 µM in 1 mL basal medium). Basal medium alone 
(untreated wells) was used as the negative control group. After 48 hours of pre-
treatment, the cells in all groups were washed twice with 1x PBS. The medium for 
the test groups (MI192 pre-treated cells) and the osteogenic positive control group 
was changed to osteogenic induction medium, and the negative basal control group 
changed to fresh basal medium. n=3 for all groups. After 7 days of culture, the cells 
were washed twice with 1x PBS, stained for alkaline phosphatase, observed under 
a Leica DMI6000 B inverted microscope and photographed using a macro camera 
(HTC One Mini 2 Phone camera). 
 
5.2.1.2 The effect of MI192 pre-treatment dose and time period on the 
ALPSA of ADSCs 
ADSCs were seeded in three 24 well plates (5 x 104 cells per well) and cultured in 
basal medium for 24 hours. The medium was then replaced with MI192 containing 
medium (50 µM, 40 µM, 30 µM, 20 µM and 10 µM in 500 µL basal medium), with 
untreated cells as the controls. After 24, 48 and 72 hours of pre-treatment, the cells 
in all groups on one plate at each time point were washed twice with 1x PBS. The 
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medium for the test groups (MI192 pre-treated cells) and the osteogenic positive 
control groups was changed to osteogenic induction medium, and the negative 
basal control group changed to fresh basal medium. n=3 for all groups. The cells 
were cultured for 7 days. The cells were then washed twice with 1x PBS, lysed in 
200 µL of Triton X-100 per well then stored at –80 °C for a quantitative alkaline 
phosphatase specific activity (ALPSA) assay. 
 
5.2.1.3 A comparison of MI192 pre-treatment and continuous treatment 
on the ALPSA of ADSCs 
ADSCs were seeded in two 24 well plates (5 x 104 cells per well) and cultured in 
basal medium for 24 hours. 
 
For one plate, the medium was then replaced with MI192 containing medium (30 
µM, 20 µM, 10 µM, 5 µM, 1 µM and 750 nm MI192 in 500 µL basal medium), with 
untreated cells as the controls. After 48 hours of pre-treatment, the cells in all 
groups on this plate were washed twice with 1x PBS. The medium for the test 
groups (MI192 pre-treated cells) and the osteogenic positive control groups was 
changed to osteogenic induction medium, and the negative basal control group 
changed to fresh basal medium. n=3 for all groups. The cells were cultured for 7 
days. The cells were then washed twice with 1x PBS, lysed in 200 µL of Triton X-
100 per well then stored at –80 °C for an ALPSA assay. 
 
For the other plate, the medium in the test group was replaced with MI192 
containing medium (10 µM, 7.5 µM, 5 µM, 2.5 µM, 1 µM and 750 nm MI192 in 500 
µL osteogenic induction medium). The medium in the untreated positive controls 
group was replaced with fresh osteogenic induction medium and that in the 
untreated negative controls was replaced with basal medium. The cells were 
cultured for 7 days. The cells were then washed twice with 1x PBS, lysed in 200 µL 
of Triton X-100 per well then stored at –80 °C for a quantitative alkaline 
phosphatase specific activity assay.  
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5.2.1.4 A comparison of pre-treatment with two different batches of 
MI192 on the ALPSA of ADSCs 
MI192 from two different batches was used in this experiment. ‘Batch 1’ was the 
MI192 synthesised in Chapter 3: The Chemical Synthesis of MI192, which was 
used for all other experiments in the thesis, and ‘Batch 2’ was synthesised by 
Cancer Research Technology UK (http://www.cancertechnology.co.uk/) as part of a 
separate collaborative project. 
 
ADSCs were seeded in two 6 well plates (5 x 105 cells per well) and cultured in 
basal medium for 24 hours. The medium was then replaced with two separate 
mediums containing the two different batches of MI192 (30 µM in 2 mL basal 
medium), with untreated cells as the controls. After 48 hours of pre-treatment, the 
cells in all groups were washed twice with 1x PBS. The medium for the test groups 
(MI192 pre-treated cells) and the osteogenic positive control groups was changed 
to osteogenic induction medium. The medium in one of the groups of the batch 1 
MI192 pre-treated cells and the negative basal control group were changed to fresh 
basal medium. n=3 for all groups. The cells were cultured for 7 days. The cells were 
then washed twice with 1x PBS, lysed in 200 µL of Triton X-100 per well then stored 
at –80 °C for an ALPSA assay. 
 
5.2.1.5 A comparison of pre-treatments with either MI192 or TSA on the 
ALPSA of ADSCs 
ADSCs were seeded in two 24 well plates (5 x 104 cells per well) and cultured in 
basal medium for 24 hours. The medium was then replaced with MI192 containing 
medium (50 µM, 40 µM 30 µM, 20 µM, 10 µM, 5 µM MI192 and 10 µM, 5 µM 1 µM 
TSA in 500 µL basal medium), with untreated cells as the controls. After 48 hours of 
pre-treatment, the cells in all groups were washed twice with 1x PBS. The medium 
for the test groups (MI192 and TSA pre-treated cells) and the osteogenic positive 
control groups was changed to osteogenic induction medium, and the negative 
basal control group changed to fresh basal medium. n=3 for all groups. The cells 
were cultured for 7 days. The cells were then washed twice with 1x PBS, lysed in 
200 µL of Triton X-100 per well then stored at –80 °C for an ALPSA assay. 
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5.2.1.6 A comparison of MI192 pre-treatment on the ALPSA of ADSCs 
from four donors 
ADSCs from 4 different donors (Information in Table 5-1) were seeded in four 24 
well plates (5 x 104 cells per well) and cultured in basal medium for 24 hours. For 
every donor, the medium was then replaced with MI192 containing medium (30 µM, 
and 10 µM in 500 µL basal medium), with untreated cells as the controls. After 48 
hours of pre-treatment, the cells in all groups were washed twice with 1x PBS. The 
medium for the test groups (MI192 pre-treated cells) and the osteogenic positive 
control groups was changed to osteogenic induction medium, and the medium in 
the negative basal control group was changed to fresh basal medium. n=3 for all 
groups, for each donor. The cells were cultured for 7 days. The cells were then 
washed twice with 1x PBS, lysed in 200 µL of Triton X-100 per well then stored at –
80 °C for an ALPSA assay. 
 
5.2.1.7 The effect of MI192 pre-treatment on the ALPSA of ADSCs 
across multiple time points and with two different osteogenic 
media 
ADSCs were seeded in four 24 well plates (5 x 104 cells per well) and cultured in 
basal medium for 24 hours. For a plate for each time point, the medium was then 
replaced with MI192 containing medium (30 µM in 500 µL basal medium), with 
untreated cells as the controls, with two groups of each condition on each plate. 
After 48 hours of pre-treatment, the cells in all groups were washed twice with 1x 
PBS. The medium in the MI192 pre-treated cells and the osteogenic positive control 
groups was changed to osteogenic induction medium and osteogenic mineralisation 
medium, with a MI192 pre-treated group and a osteogenic positive control for each 
media type, and the medium in the negative basal control group was changed to 
fresh basal medium. n=3 for all groups, for each media at each time point. The cells 
were cultured for 3, 5, 7 and 9 days. At each time point, one plate of cells was 
washed twice with 1x PBS, cells were lysed in 200 µL of Triton X-100 per well then 
stored at –80 °C for an ALPSA assay. 
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Table 5-1 – ADSC donor information. 
Donor 
Company 
(Catalogue number) 
Manufacturer donor / lot 
number 
Donor(s) age / Sex / 
Tissue location 
1 Life Technologies (R7788110) 2118 45/Female/Abdomen 
2 Life Technologies (R7788110) 2117 49/Female/Abdomen 
3 Life Technologies (R7788110) 2033 
63/Male/Breast and 
Abdomen 
4 Lonza (PT-5006) 407088 
46/Female/Abdomen 
(assumed) 
 
5.2.2 Assessment of the effect of MI192 pre-treatment on the 
osteogenic gene expression of ADSCs   
ADSCs were seeded in five 12 well plates (1 x 105 cells per well) and cultured in 
basal medium for 24 hours. The media was then replaced with MI192 containing 
medium (30 µM in 1 mL basal medium), with untreated cells as the controls. After 
48 hours of pre-treatment, the cells in all groups were washed twice with 1x PBS. 
The medium for the test groups (MI192 pre-treated cells) and the osteogenic 
positive control groups was changed to StemPro® Osteogenesis Differentiation 
Medium, and the negative basal control group changed to MesenPRO RS™ growth 
medium. The medium was changed every 4 days. n=3 for all groups. Cells were 
cultured for 3, 5, 7, 14 and 21 days, with one plate stopped at every time point by 
harvesting in Trizol® reagent. RNA isolation and cDNA conversions were carried 
out according to the methods described in Chapter 2: General Materials and 
Methods. 
  
qRT-PCR was utilised to analyse gene expression of commonly utilised osteogenic 
markers, according to the methods described in Chapter 2: General Materials and 
Methods. qRT-PCR was performed using TaqMan gene expression assays (Life 
Technologies) and the full list of genes and assays can be found in Table 5-2. 
Standard curves for each gene can be found in the Appendix (A5.2 - Standard 
Curves for qRT-PCR Assays). Gene expression level was normalised to 
148 
 
 
housekeeping gene YWHAZ, statistical analysis undertaken, and then further 
normalised to the gene expression of the basal sample of the respective time point. 
 
Table 5-2 - TaqMan gene expression assays used in 5.2.2, the assessment of 
the effect of MI192 pre-treatment on the osteogenic gene expression of 
ADSCs 
Gene 
symbol 
Description 
TaqMan assay 
identification 
YWHAZ 
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein 
Housekeeping gene 
Hs00237047_m1 
RUNX2 Runt-related transcription factor 2 Hs00298328_s1 
BMP2 Bone morphogenetic protein 2 Hs00154192_m1 
ALPL Alkaline phosphatase Hs01029144_m1 
COL1A1 Collagen, type I Hs00164004_m1 
OCN/BGLAP 
Osteocalcin / PMF-bone gamma-
carboxyglutamate (gla) protein 
Hs00609452_g1 
SPP1/OPN 
Osteopontin / secreted 
phosphoprotein 1/ bone 
sialoprotein I 
Hs00959010_m1 
 
5.2.3 The effect of MI192 pre-treatment on the calcium 
accumulation and mineralisation of ADSCs  
ADSCs were seeded in two 12 well plates (1 x 105 cells per well) and cultured in 
basal medium for 24 hours. The medium was then replaced with MI192 containing 
medium (30 µM in 1 mL basal medium), TSA containing medium (10 µM in 1 mL 
basal medium) with untreated cells as the controls. After 48 hours of pre-treatment, 
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the cells in all groups were washed twice with 1x PBS. The medium for the test 
groups (MI192 and TSA pre-treated cells) and the osteogenic positive control 
groups was changed to osteogenic mineralisation medium and the negative basal 
control group was changed to MesenPRO RS™ growth medium. n=3 for all groups. 
The cells were cultured for 28 days, with the medium being changed every 4 - 5 
days. Cells were then fixed in 10% NBF for 1 hour, washed in dH2O three times and 
stained for calcium accumulation with Alizarin Red staining or mineral nodule 
formation with Von Kossa staining according to the methods described Chapter 2: 
General Materials and Methods. 
 
5.2.4 The effect of MI192 pre-treatment on the Oil Red O staining 
(adipogenic differentiation) of ADSCs 
ADSCs were seeded in a 12 well plate (1 x 105 cells per well) and cultured in basal 
medium for 24 hours. The medium was then replaced with MI192 containing 
medium (30 µM and 50 µM in 1 mL basal medium), with untreated controls. After 48 
hours of pre-treatment, the cells in all groups were washed twice with 1x PBS. The 
medium for the test groups (MI192 pre-treated cells) and the adipogenic positive 
control groups was changed to adipogenic induction medium and the adipogenic 
differentiation protocol (2.3.6: Adipogenic Induction Culture) was followed. The 
negative basal control group medium was changed to fresh basal medium. n=3 for 
all groups. The cells were cultured for 14 days. The cells were then washed with 1x 
PBS and stained for lipid droplets with Oil Red O Stain. 
 
5.2.5 Assessment of the effect of MI192 pre-treatment on the 
adipogenic gene expression of ADSCs  
ADSCs were seeded in four 12 well plates (1 x 105 cells per well) and cultured in 
basal medium for 24 hours. The medium was then replaced with MI192 containing 
medium (40 µM, 30 µM and 20 µM in basal medium), with untreated cells as the 
controls. After 48 hours of pre-treatment, the cells in all groups were washed twice 
with 1x PBS. The medium for the test groups (MI192 pre-treated cells) and the 
adipogenic positive control groups was changed to adipogenic induction medium, 
and the negative basal control group changed to MesenPRO RS™ growth medium. 
n=3 for all groups. Cells were cultured for 5 and 14 days, following the adipogenic 
induction protocol, with two plates stopped at each time point. At each time point 
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cells were harvested in Trizol® reagent for RNA isolation and cDNA conversions 
according to the methods described in Chapter 2: General Materials and Methods. 
 
qRT-PCR was used to analyse gene expression of cells for commonly used 
adipogenic markers, according to the methods described in Chapter 2: General 
Materials and Methods. qRT-PCR was performed using TaqMan gene expression 
assays (Life Technologies) and the full list of genes and assays can be found in 
Table 5-3. Standard curves for each gene can be found in the Appendix (A5.2 - 
Standard Curves for qRT-PCR Assays). Gene expression level was normalised to 
housekeeping gene YWHAZ, statistical analysis undertaken, and then further 
normalised to the gene expression of a day 0 sample. 
 
Table 5-3 - TaqMan gene expression assays used in 5.2.5, the assessment of 
the effect of MI192 pre-treatment on the adipogenic gene expression of 
ADSCs 
Gene 
symbol 
Description 
TaqMan assay 
identification 
YWHAZ 
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein 
Housekeeping gene 
Hs00237047_m1 
PPARγ 
Peroxisome proliferator-activated 
receptor gamma 
Hs01115513_m1 
ADIPOQ Adiponectin Hs00605917_m1 
 
5.2.6 Statistical Analysis 
 
All statistical analysis undertaken with Graphpad Prism 5. Method used: ANOVA 
multiple comparisons test with Tukey modification. For all graphs: ns = P > 0.05, * = 
≤ 0.05, ** = P ≤ 0.01  *** = P ≤ 0.001 and **** = P ≤ 0.0001. 
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5.3 Results  
5.3.1 The effect of MI192 pre-treatment on the alkaline 
phosphatase staining levels of ADSCs 
ALP was stained in ADSCs pre-treated with 100 µM and 30 µM of MI192 for 2 days.  
 
After 2 days pre-treatment with MI192 followed by a further 7 days of culture in 
osteogenic induction medium, the ALP levels of ADSCs were measured with ALP 
staining (Figure 5.1). The positive control group (osteogenic medium alone, Figure 
5.1B) had stronger blue ALP staining than the negative control group (basal 
medium alone, Figure 5.1A). The cells pre-treated with 100 µM MI192 (Figure 5.1C) 
had very low ALP staining, levels comparable to the other groups. The cells pre-
treated with 30 µM MI192 had the strongest ALP staining (Figure 5.1D). The cell 
density was lower in both of the MI192 pre-treated groups, with the lowest in the 
100 µM MI192 pre-treated group. Cells treated with M192 also showed a different 
morphology to that of the basal and osteogenic controls.  
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Figure 5.1 – ALP Staining of ADSCs treated with MI192 then cultured in 
osteogenic induction medium. A – Basal medium control; B – Osteogenic 
medium control; C – 100 µM pre-treatment for 2 days with MI192 then 7 days 
in osteogenic medium; D – 30 µM pre-treatment for 2 days with MI192 then 7 
days in osteogenic medium. Cells stained blue for ALP. Macro image of the 
well of the plate shown, as well as phase contrast and bright field images 
showing detailed cell staining. Scale bars = 100 µM. 
D: 
C: 
B: 
A: 
Phase contrast Bright field 
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5.3.2 The effect of MI192 pre-treatment dose and time period on 
the ALPSA of ADSCs 
The Alkaline Phosphatase (ALP) levels in ADSCs pre-treated with a range (50 µM – 
20 µM) of MI192 doses for different treatment periods (1 - 2 days) was assessed 
with a biochemical assay, and normalised to DNA content, giving the ALP specific 
activity (ALPSA) (Figure 5.2). The total DNA content is not shown as the same 
trend as in Chapter 3:The Chemical Synthesis of MI192 was seen.  
 
In the 1 day pre-treatment groups, the osteogenic medium positive control group 
showed a statistically significant increase (P ≤ 0.05) in ALPSA over the basal 
medium negative control group (Figure 5.2). However, there was no significant 
difference between the MI192 pre-treated groups and the osteogenic medium 
positive control, or between the different doses (P > 0.05) in the 1 day pre-
treatment groups. After two days of pre-treatment, all MI192 pre-treated cells have 
a statistically significant increase of ALPSA over the osteogenic medium positive 
control (40 µM P ≤ 0.05, 30 µM P ≤ 0.001 and 20 µM P ≤ 0.01). 30 µM of MI192 
pre-treatment for two days had the highest level of ALPSA of all groups, and was 
statistically significantly higher than the other groups in one day pre-treatment (P ≤ 
0.01), most notably the same dose. However, there were no significant difference 
(P > 0.05) between 30 µM and 40 µM, 20 µM pre-treated for two days cells, but the 
highest ALPSA was seen in the 30 µM group. 
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Figure 5.2 – ALPSA of ADSCs pre-treated with MI192 then cultured in osteogenic 
induction medium. ADSCs were pre-treated with 50 µM, 40 µM, 30 µM and 20 
µM MI192 for one and 2 days, before culture in osteogenic induction medium for 7 
days, with basal medium and osteogenic medium controls. Results expressed as 
mean ± SD (n=3). Statistical significance was determined using a one-way 
ANOVA. * = P ≤ 0.05, ** = P ≤ 0.01 and *** = P ≤ 0.001. 
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5.3.2.1 A comparison of MI192 pre-treatment and continuous treatment 
on the ALPSA of ADSCs 
ADSCs were either pre-treated with a range (30 µM – 750 nM) of MI192 doses for 
two days, or treated with MI192 (10 µM – 750 nM) for the whole culture period, of 
the same total length. 
 
5.3.2.2 Total DNA content  
The DNA quantification (Figure 5.3 A) showed that there was a reduction in the 
DNA, and therefore cell numbers, in all groups compared to basal medium negative 
control group (Figure 5.3 A). The osteogenic medium positive control group 
reduced total DNA content compared to the basal control, although not significantly 
(P > 0.05). The MI192 pre-treated groups showed a dose dependent trend in 
reduction of total DNA content, although no results were statistically significantly 
lower than the controls (P > 0.05). With the continuous MI192 treatment, the higher 
doses (10 µM, 7.5 µM, 5 µM MI192 and 2.5 µM) significantly reduced total DNA 
content compared with the osteogenic medium control group (P ≤ 0.001, P ≤ 0.001, 
P ≤ 0.001 and P ≤ 0.05 respectively). There was no significant difference between 
the lower doses (1 µM and 750 nm MI192) groups and the osteogenic medium 
control group (P > 0.05).  
 
5.3.2.3 ALPSA 
For the continuous treatment with MI192, all doses showed an increase in the 
ALPSA compared to the controls (Figure 5.3 B). The increase was statistically 
significantly higher (P ≤ 0.05) for the 10 µM and 7.5 µM whole time groups. The 
increase in ALPSA in the pre-treated cells was much higher, and with a similar 
trend seen in Figure 5.2. The 30 µM and 20 µM pre-treated groups showed the 
greatest increase over the osteogenic medium positive control group (P ≤ 0.001). 
The lower doses of pre-treatment (1 µM and 750 nM) had a much smaller increase 
in specific ALP activity than the higher doses (not statistically significant and P ≤ 
0.05 respectively). 
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Figure 5.3 - PicoGreen® DNA quantification (A) and ALPSA (B) of ADSCs pre-
treated with MI192 then cultured in osteogenic induction medium, 
compared to ADSCs treated continuously with MI192 in osteogenic 
medium. A – Total DNA content of ADSCs pre-treated with 30 µM - 750 nM 
MI192 and cultured in osteogenic induction medium, compared to the DNA 
content of cells cultured in osteogenic induction medium containing 10 µM - 
750 nM MI192 continuously; B – ALPSA of the same ADSCs. For both, 
significance level shown is compared to osteogenic control, along with a 
selection of other values. Results expressed as mean ± SD (n=3). Statistical 
significance was determined using a one-way ANOVA. * = P ≤ 0.05 and *** = 
P ≤ 0.001. 
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5.3.2.4 A comparison of pre-treatment with two different batches of 
MI192 on the ALPSA of ADSCs 
The difference between the ALPSA of ADSCs pre-treated with two different 
compound batches of MI192 for two days was investigated. In this experiment a 
group where ADSCs were pre-treated with MI192 and then cultured in basal 
medium negative control was also included, to investigate if this lead to a rise in 
ALPSA (Figure 5.4).  
 
After two days of pre-treatment with two batches of MI192 (30 µM) followed by 
culture in osteogenic medium positive control group for one week, both pre-treated 
groups significantly enhanced ALPSA compared to the osteogenic control (P < 0.01 
and P < 0.001 respectively) and the basal control (P ≤ 0.01 and P ≤ 0.001 
respectively, not shown on the graph). There was no significant difference between 
the two batches, and the error bars overlapped.  
 
The basal medium ADSCs treated with MI192 showed an enhancement of ALPSA; 
however, there was no significant difference compared to the positive control and 
basal medium control groups (P > 0.05) (Figure 5.4).  
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Figure 5.4 – ALPSA of ADSCs pre-treated with two different batches of MI192 
then cultured in osteogenic induction medium and basal medium. The 
specific ALP activity of cells pre-treated with 30 µM of MI192 for 2 days, 
before culture in osteogenic induction, or basal medium for 7 days, with basal 
medium and osteogenic medium controls. Results expressed as mean ± SD 
(n=3). Statistical significance was determined using a one-way ANOVA.  *** = 
P ≤ 0.001. 
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5.3.2.5 A comparison of pre-treatments with either MI192 or TSA on the 
ALPSA of ADSCs 
The ALPSA of ADSCs pre-treated with a range (50 µM – 10 µM) of MI192 doses for 
two days was compared to the ALPSA of ADSCs pre-treated with a commercially 
available HDACi TSA (10 µM – 1 µM) (Figure 5.5).  
 
The osteogenic medium positive control group showed an increase in ALPSA over 
the basal medium negative control group, although this was not statistically 
significant. This was similar to the results from other experiments as described 
earlier (e.g. Figure 5.2 and Figure 5.3 B). 10 µM and 5 µM TSA pre-treatment group 
showed enhanced ALPSA compared to that of the basal and osteogenic control 
groups, however this was not significant (P > 0.05). The ALPSA was much higher in 
all of the MI192 pre-treated groups. When comparing the 10 µM MI192 pre-
treatment group and the 10 µM TSA pre-treatment group, the ALPSA was strongly 
and statistically significantly higher (P ≤ 0.001).  
 
5.3.2.6 A comparison of MI192 pre-treatment on the ALPSA of ADSCs 
from four donors 
 
To test for donor variability, the ALPSA levels of ADSCs from 4 different donors 
were compared after pre-treatment with two doses of MI192 (30 µM and 10 µM) 
(Figure 5.6) In all four donors the osteogenic medium positive control group had 
higher ALPSA than the basal medium negative controls of the same donor. 
However, there was only one donor with a significantly higher ALPSA (P ≤ 0.05). 
Four 30 µM and two 10 µM MI192 pre-treatment groups showed an extremely 
significant increase in the ALPSA compared to both basal and osteogenic controls 
of the same donor (P ≤ 0.001). In two out of four donors, 30 µM MI192 pre-
treatment groups had significant higher ALPSA compared to that of 10 µM MI192 
pre-treated groups in the same donor, as seen in the previous experiments, with the 
same donor (in 5.3.2) The other two donors had comparable ALPSA levels in both 
the 30 µM MI192 and 10 µM MI192 pre-treatment groups (P > 0.05).  
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Figure 5.5 - ALPSA of ADSCs pre-treated with MI192 and TSA. The specific 
ALP activity of cells pre-treated with MI192 and TSA for 2 days. Significance 
level for every group compared to osteogenic control shown above the bar. 
Results expressed as mean ± SD (n=3). Statistical significance was 
determined using a one-way ANOVA. *** = P ≤ 0.001. 
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Figure 5.6 – ALPSA of ADSCs from 4 different donors pre-treated with MI192. 
The specific ALP activity of cells pre-treated with 30 µM and 10 µM MI192 for 
2 days. Results expressed as mean ± SD (n=3). Statistical significance was 
determined using a one-way ANOVA. * = P ≤ 0.05 and *** = P ≤ 0.001 
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5.3.3 The effect of MI192 pre-treatment on the ALPSA of ADSCs 
across multiple time points and with two different 
osteogenic media 
Two different osteogenic media were used in this thesis. The ‘osteogenic induction 
medium’ was used for all previous osteogenic differentiation experiments in this 
chapter, and contains no additional mineral source(s). But, to ensure maximum 
osteogenic differentiation, StemPro® Osteogenesis Differentiation Medium, which 
contains additional mineral sources, and is recommended for use with these cells, 
was used in long term experiments, where mineralisation, or gene expression 
linked to mineralisation, was measured. This is the ‘osteogenic mineralisation 
medium’. This was not used initially in optimisation experiments due to the massive 
increased cost (£85 for 100 mL) of the StemPro® Osteogenesis Differentiation 
Medium.  
 
Firstly, the two media was compared, to ensure that the effect of MI192 was seen 
with the osteogenic mineralisation medium’ as well as the ‘osteogenic induction 
medium’. Discussion of the content of both media can be found in this chapter’s 
discussion. The ALPSA of ADSCs pre-treated with MI192, across 4 time points, 
with both osteogenic media – the osteogenic induction medium (Figure 5.7 A) and 
the osteogenic mineralisation medium (Figure 5.7 B) was assessed. This study 
aims to compare the effect these two osteogenic media on the ADSCs ALPSA over 
time and their effect of cell response to MI192 pre-treatment.  
 
The ‘osteogenic induction medium’ significantly increased the ALPSA of the 
osteogenic positive controls ADSCs at day 5, day 7 and day 9, although not 
statistically significantly (P > 0.05), when compared to that of the basal medium 
negative control group at the same time points. There was a trend of increasing 
ALPSA over the time points. For all time points, there was a statistically significant 
increase in the ALPSA in the 30 µM MI192 pre-treated group compared to that of 
the osteogenic induction medium group at the same time point (day 3: P ≤ 0.01, day 
5: P ≤ 0.001, day 7: P ≤ 0.001 and day 9 P ≤ 0.05). The highest ALPSA levels in the 
MI192 pre-treated groups was at day 7. 
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The ‘osteogenic mineralisation medium’ significantly increased the ALPSA of the 
osteogenic control ADSCs at day 3, day 5, day 7 and day 9, although not 
statistically significantly (P > 0.05), when compared to that in the basal controls at 
the same time points. There was a trend of increasing over the time points. For all 
time points, there was an increase in the ALPSA in the 30 µM MI192 pre-treated 
group compared to that of the osteogenic induction medium group at the same time 
point (day 3: P ≤ 0.01, day 5: P ≤ 0.001, day 7: P ≤ 0.05 and day 9 P > 0.05). The 
highest ALPSA levels in the MI192 pre-treated groups was at day 5. 
 
With the osteogenic mineralisation medium (Figure 5.7 B) a similar trend to the 
osteogenic induction medium was seen (Figure 5.7 A). In both media, at all time 
points there was an increase in the ALP levels of the positive osteogenic control 
over the basal control. For the 30 µM MI192 pre-treated group, there was an 
increase in ALP at every time point, with the osteogenic induction medium having 
peak ALPSA at day 7 and the osteogenic mineralisation medium at day 5. The 
increase in ALP result was successfully repeated with the osteogenic mineralisation 
medium, so it was utilised for all subsequent experiments. 
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Figure 5.7 - ALPSA of ADSCs, pre-treated with MI192, across 4 time points, 
with the osteogenic induction (A) and osteogenic mineralisation (B) 
media. The ALPSA of cells pre-treated with 30 µM for 2 days, before culture 
in osteogenic mineralisation or osteogenic induction media for 3, 5, 7 and 9 
days, with basal medium and osteogenic medium for both. Results expressed 
as mean ± SD (n=3). Statistical significance was determined using a one-way 
ANOVA. * = P ≤ 0.05, ** = P ≤ 0.01 and *** = P ≤ 0.001. 
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5.3.4 Assessment of the effect of MI192 pre-treatment on the 
osteogenic gene expression of ADSCs   
To better understand the mechanism by which MI192 affects the osteogenic 
differentiation of ADSCs, the expression of osteogenic marker genes at multiple 
time points (3 days, 5 days, 7 days, 14 days and 21 days) was assessed by qRT-
PCR (Figure 5.8, Figure 5.9 and Figure 5.10).  
 
5.3.4.1 RUNX2 
The expression of RUNX2 in the osteogenic medium positive control group was 
consistently statistically significantly higher (P ≤ 0.001) than the basal medium 
negative control group in the same group at all time points (Figure 5.8 A). Initially, at 
day 3, the RUNX2 expression in the MI192 pre-treated cells was at basal levels, 
and statistically significantly lower than the osteogenic control (P ≤ 0.001). At day 5, 
the RUNX2 expression of MI192 pre-treated cells was similar to that of the 
osteogenic control (P >0.05), and statistically significantly (P ≤ 0.001) higher than 
the basal control. However, there was extremely significantly higher RUNX2 
expression in the MI192 pre-treated cells compared to the osteogenic control at 
days 7 and 14 (P ≤ 0.001). At day 21, the RUNX2 expression level drops back 
down in both osteogenic control and the test group although there was still a 
significant difference compared to the basal control (P ≤ 0.001 and P ≤ 0.05 
respectively). However, there was no significant difference between the MI192 pre-
treated group and the osteogenic control (P > 0.05) at day 21.  
  
5.3.4.2 BMP2 
The expression of BMP2 in the osteogenic medium positive control group was 1.3 – 
2.2 times higher compared to that of the basal medium negative control group of 
the same day at every time point except day 5 (where expression was at the basal 
level), although this was never statistically significant (P > 0.05) (Figure 5.8 B).       
 
The expression of BMP2 in the MI192 pre-treated cells was highest at day 3, which 
was statistically significant higher than the basal control (P ≤ 0.001); however, not 
statistically significantly higher than the osteogenic control (P > 0.05). This may due 
to a huge standard deviation (and when extra technical repeats were undertaken 
independently, the results of which are not included, here n still equals 3, the results 
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were the same). Similarly, BMP2 expression in the MI192 pre-treated cells was 
higher than the osteogenic control at day 5 and at day 7 (P > 0.05). At days 14 and 
21, the BMP2 expression level in the MI192 pre-treated cells was lower, and the 
same level as the osteogenic control (P > 0.05).  
 
5.3.4.3 ALP 
ALP expression in the osteogenic medium positive control group increases steadily 
over the time points (Figure 5.9 A). Initially, expression is only 3 times greater than 
basal medium negative control group, and not statistically significant (P > 0.05), but 
this rises to 10 times greater by day 14 and day 21, becoming statistically 
significantly different (P ≤ 0.001). 
 
ALP expression in the MI192 pre-treated cells was initially slightly lower than the 
osteogenic control, at day 3 (although not statistically significantly, P > 0.05). But at 
day 5 there is a huge spike and expression is much higher than the osteogenic 
control, statistically significantly (P ≤ 0.001). The expression in the MI192 pre-
treated cells remains higher than the osteogenic control at day 7, although there 
was no statistical significance (P > 0.05), before dropping down to basal levels at 
day 14 and 21. The expression level is down as low as it was at day 3, and at day 
14 and day 21 is not statistically significantly higher than the basal controls. The 
osteogenic control has ALP expression much higher, statistically significantly (P ≤ 
0.001) than the MI192 pre-treated cells at day 14 and day 21. 
 
5.3.4.4 COL1 
COL1 expression in the basal medium negative control group increased steadily 
with culture, with high levels by day 21. It is still normalised to 1 for the graph 
(Figure 5.9 B). Compared to the basal control, there was a spike expression of 
COL1 at day 3 and day 7 in the osteogenic medium positive control group, both 
statistically significantly (P ≤ 0.001). In the osteogenic control, the expression at day 
5 and 14 was comparable to the basal control, with no statistically significant 
difference (P > 0.05) and at day 21 it was statistically significantly lower than the 
basal control (P ≤ 0.001). 
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The MI192 pre-treated cells had COL1 expression levels lower than basal and 
osteogenic control at day 3 (both statistically significantly, P ≤ 0.001). At day 5 the 
expression levels in all three groups were comparable. At day 7 the MI192 pre-
treated cells had a huge peak in COL1 expression, with statistically significant (P ≤ 
0.001) increase over the osteogenic control (which also had a peak in expression, 
albeit lower than the MI192 pre-treated group) and basal control. The expression of 
COL1 drops off in the MI192 pre-treated cells and is statistically significantly (P ≤ 
0.01) lower than the basal at day 14 and statistically significantly (P ≤ 0.001) lower 
than both the basal and osteogenic controls at day 21. 
 
5.3.4.5 OCN/BGLAP 
OCN/BGLAP expression was relatively low in all samples, with only small peaks in 
the osteogenic medium positive control groups compared to the basal medium 
negative control groups at day 3 (not statistically significantly, P > 0.05) and day 14 
(statistically significantly, P ≤ 0.01) (Figure 5.10 A). The expression in the 
osteogenic control was lower than the basal control at day 5, the same at day 7 and 
only slightly higher at day 21. 
 
In the MI192 pre-treated cells the expression of OCN/BGLAP was actually 
statistically significantly (P ≤ 0.001) below the basal controls at day 3 and day 5, 
indicating MI192 may be inhibiting OCN/BGLAP expression. At day 7 the 
expression in the pre-treated cells was slightly higher than the osteogenic control, 
although not statistically significantly (P > 005). In the MI192 pre-treated cells, the 
expression was higher in the basal control at day 14, although below the osteogenic 
control (although not statistically significantly, P > 0.05) and expression was lower 
than the basal and osteogenic control at day 21 (also not statistically significantly, P 
> 0>05). 
 
5.3.4.6 SPP1/OPN 
Expression of SPP1/OPN was highest in the basal medium negative control groups 
at every time point (the highest levels were at day 5 and day 7). The expression of 
SPP1/OPN in the osteogenic medium positive control group was consistently 
statistically significantly (P ≤ 0.001) lower than the basal control, except at day 14 
when a small peak in expression was observed, and there was still a reduced 
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expression compared to the basal control (although it was not statistically 
significant, (P > 0.05), unlike at every other time point).  
 
In the MI192 pre-treated cells, there was a consistently lower expression of 
SPP1/OPN than the basal control (P ≤ 0.001 at every time point) and the 
osteogenic control (P ≤ 0.001 at day 3, day 5 and day 14, P ≤ 0.01 at day 7 and not 
significantly, P > 0.05 at day 21) indicating that MI192 is actually inhibiting the 
expression of SPP1/OPN, even more so than the osteogenic control.  
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Figure 5.8 – Quantitative expression of RUNX2 (A) and BMP2 (B) in ADSCs. 
Cells were pre-treated with 30 µM MI192 for 2 days, then cultured in 
osteogenic medium. Gene expression was analysed at day 3, day 5, day 7, 
day 14 and day 21. Results expressed as mean ± SD (n=3). Statistical 
significance was determined using a one-way ANOVA. Only the significance 
levels between the conditions at each time point shown. * = P ≤ 0.05, ** = P ≤ 
0.01 and *** = P ≤ 0.001. 
A 
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Figure 5.9 – Quantitative expression of ALP (A) and COL1 (B) in ADSCs. Cells 
were pre-treated with 30 µM MI192 for 2 days, then cultured in osteogenic 
medium. Gene expression was analysed at day 3, day 5, day 7, day 14 and 
day 21. Results expressed as mean ± SD (n=3). Statistical significance was 
determined using a one-way ANOVA. Only the significance levels between 
the conditions at each time point shown. * = P ≤ 0.05, ** = P ≤ 0.01 and *** = 
P ≤ 0.001. 
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Figure 5.10 – Quantitative expression of OCN/BGLAP (A) and SPP1 (B) in 
ADSCs. Cells were pre-treated with 30 µM MI192 for 2 days, then cultured in 
osteogenic medium. Gene expression was analysed at day 3, day 5, day 7, 
day 14 and day 21. Results expressed as mean ± SD (n=3). Statistical 
significance was determined using a one-way ANOVA. Only the significance 
levels between the conditions at each time point shown. * = P ≤ 0.05, ** = P ≤ 
0.01 and *** = P ≤ 0.001. 
 
A 
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5.3.5 The effect of MI192 pre-treatment on the calcium 
accumulation and osteogenic mineralisation of ADSCs 
The effect of 30 µM MI192 pre-treatment on the mineralisation levels of ADSCs, 
compared to pre-treatment with 10 µM of TSA, was assessed with an Alizarin Red 
stain for calcium (Figure 5.11) and a Von Kossa stain for mineral nodule formation 
(Figure 5.13).  
 
5.3.5.1 Alizarin Red Staining 
A red stain indicates calcium deposition. After 2 days pre-treatment with MI192 or 
TSA followed by 28 days of culture in osteogenic mineralisation medium. Alizarin 
Red staining showed negative staining in the basal medium negative control group 
(Figure 5.11 A). In contrast, the osteogenic positive control had a much stronger red 
coloured Alizarin Red positive staining (Figure 5.11 B) than the basal negative 
control. The overall staining level in the 30 µM MI192 treated group (Figure 5.11 C) 
was lower than the osteogenic control (Figure 5.11 B). However, in the MI192 pre-
treated group, the staining was more indicative of mineral nodule formation, where 
large clumps of mineralisation had occurred, not just a low level staining of lots of 
cells as seen in the osteogenic control. Also, in the MI192 pre-treated group, there 
were very few areas without staining (the white areas being where there were no 
cells), which is a similar trend to the ALP staining (Figure 5.1). The osteogenic 
control had large areas of cells not stained, and thus not all cells were accumulating 
calcium. The TSA pre-treated group (Figure 5.11 D) had overall weaker staining 
levels than the osteogenic control.  
 
The stain was destained using a 10% cetylpyridinium chloride solution, to give a 
quantitative reading for each group (Figure 5.12). This supported the qualitative 
observations of the staining intensity. The basal control group had a lower reading 
than all other groups, and the osteogenic control had the highest staining. The 
MI192 pre-treated group had a higher staining level than the basal control, although 
lower than the osteogenic control. The TSA pre-treated group had a small increase 
in staining level compared to the MI192 pre-treated group, although it was still lower 
than the osteogenic control.  
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5.3.5.2 Von Kossa Staining 
Von Kossa staining is utilised to stain not just the calcium accumulated in the cell, 
but functional mineral nodules, by acting to replace the calcium in mineral nodules 
with silver nitrate that binds to an anion such as phosphate or carbonate. Therefore 
a positive Von Kossa stain indicates functional mineral nodules, containing other 
anions bound to calcium, not just the pure calcium that may have accumulated in 
the cell. Black/brown staining indicates mineral nodule formation. 
 
The strongly stained nodules only show up as small black dots, which are hard to 
visualise in the macro photos. There was no positive staining in the basal control 
group (Figure 5.13 A). Phase contrast images show a low level of brown staining in 
the osteogenic control (Figure 5.13 B), with spots of black, when compared to the 
basal control, which is a sign of a low level of mineralisation in nodules. The 30 µM 
MI192 pre-treated group (Figure 5.13 C) has several large areas of intense black, 
positive Von Kossa staining. The staining is clearer and there are more and larger 
mineral nodules observed in the MI192 pre-treated cells, indicating that more 
functional mineralisation is taking place. The TSA pre-treated group had a higher 
level of brown staining than the osteogenic control, with evidence of some small 
black stained nodules. This was weaker than that in the 30 µM MI192 pre-treated 
group. 
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Figure 5.11 - ADSCs treated with MI192 then cultured in osteogenic 
mineralisation medium, before staining for calcium with Alizarin Red 
staining. A – Basal medium control, B – Osteogenic medium control, C – 30 
µM pre-treatment for 2 days with MI192, D – 10 µM pre-treatment for 2 days 
with TSA. Red staining indicates calcium accumulation. Macro image of the 
well of the plate shown, as well as two phase contrast images showing 
detailed cell staining. Scale bars = 100 µM. 
D: 
C: 
B: 
A: 
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Figure 5.12 – Quantitative measurement of Alizarin Red stain. Stain destained 
from ADSCs pre-treated with MI192 then cultured in osteogenic medium, 
before staining for calcium with Alizarin Red staining. Stain was destained and 
quantified from a basal medium control, an osteogenic medium control, cells 
pre-treated with 30 µM of MI192 and 10 µM TSA (same cells as pictures in 
Figure 5.11). Average absorbance of readings taken 550 nm. Results 
expressed as mean ± SD (n=3). Statistical significance was determined using 
a one-way ANOVA. Only the significance levels between compared to the 
osteogenic control shown. * = P ≤ 0.05. 
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Figure 5.13 - ADSCs pre-treated with MI192 then cultured in osteogenic 
mineralisation medium, before staining for mineralisation with Von 
Kossa staining. A – Basal medium control, B – Osteogenic medium control, 
C – 30 µM pre-treatment for 2 days with MI192 then 28 days in osteogenic 
medium, D – 10 µM pre-treatment for 2 days with TSA then 28 days in 
osteogenic medium. Brown and black staining indicates calcium 
accumulation, black being a stronger stain. Macro image of the well of the 
plate shown, as well as two phase contrast images showing detailed cell 
staining. Scale bars = 100 µM. 
 
D: 
C: 
B: 
A: 
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5.3.6 The effect of MI192 pre-treatment on the Oil Red O staining 
(adipogenic differentiation) of ADSCs 
To investigate the effect of MI192 pre-treatment on the adipogenic differentiation of 
ADSCs, the lipid accumulation in ADSCs were assessed by an Oil Red O staining 
for lipid droplets (Figure 5.14). 
 
There was no positive Oil Red O stain in the basal medium negative control group 
(Figure 5.14 A). In contrast, the positive adipogenic control group (Figure 5.14B) 
showed an increased level of red staining. 
 
The Oil Red O staining in cells pre-treated with 10 µM, 20 µM and 50 µM of MI192 
(Figure 5.14 C, D and E) and 10 µM and 20 µM of TSA (Figure 5.14 F and G) 
followed by culture in adipogenic differentiation medium showed a weaker positive 
staining for Oil Red O compared to that of the positive adipogenic control (Figure 
5.14 B). Lower concentration of the pre-treatment (10 µM MI192 and 10 µM TSA, 
Figure 5.14 C and F) groups showed slightly stronger positive staining than the 
basal control, although the staining is much lower than the positive adipogenic 
control (Figure 5.14 B). The staining was much weaker in the higher doses of 
MI192 and TSA groups.  
 
The stain was destained using 100% isopropanol, to give a quantitative reading for 
each group (Figure 5.15). The results were similar to the qualitative analysis of the 
stain made by eye. Staining intensity was higher in the adipogenic control than the 
basal control. The MI192 pre-treated groups had lower staining level than the 
adipogenic control (P ≤ 0.001), although all groups were slightly higher than the 
basal control. The TSA pre-treated groups had a slightly lower staining level than 
the MI192 pre-treated groups, also much lower than the adipogenic control P ≤ 
0.001).  
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Figure 5.14 - ADSCs pre-treated with MI192 then cultured in adipogenic 
medium, before staining for lipid droplet accumulation with an Oil Red O 
stain. A – Basal medium control; B – Adipogenic medium control; C, D, E, F, 
G – Cells pre-treated with HDACis MI192 and TSA then cultured in 
adipogenic medium for 14 days. Cells pre-treated with C: 10 µM MI192; D: 20 
µM MI192; E: 50 µM MI192; F: 10 µM TSA; G: 20 µM TSA. Red staining 
indicates lipid droplets. Macro image of the well of the plate shown, as well as 
two phase contrast images showing detailed cell staining. Scale bars = 100 
µM. 
G F E 
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Figure 5.15 - Quantitative measurement of Oil Red O stain, destained from 
ADSCs pre-treated with MI192 then cultured in adipogenic medium, 
before staining for lipid droplet accumulation with an Oil Red O stain. 
The stain was quantified from a basal medium control, an adipogenic medium 
control, cells pre-treated with 50 µM, 30 µM and 10 µM of MI192 and 20 µM 
TSA and 10 µM TSA (same cells as pictures in (Figure 5.14). Average 
absorbance of readings taken 500 nm. Results expressed as mean ± SD 
(n=3). Statistical significance was determined using a one-way ANOVA. Only 
the significance levels between compared to the adipogenic control shown. *** 
= P ≤ 0.001. 
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5.3.7 Assessment of the effect of MI192 pre-treatment on the 
adipogenic gene expression of ADSCs   
To better understand the mechanism by which MI192 affects the adipogenic 
differentiation of ADSCs, cells were pre-treated with 3 doses (40 µM, 30 µM and 20 
µM) of MI192 for two days, cultured in adipogenic induction medium for 3 days and 
14 days. Gene expression was assessed by qRT-PCR (Figure 5.16).  
 
5.3.7.1 PPARγ 
The expression of PPARγ was over 5 fold, statistically significantly (P ≤ 0.001), up-
regulated in ADSCs in the adipogenic control group compared to the basal medium 
negative control group at day 3. At day 14 it was over 9 fold greater (P ≤ 0.001). 
Comparing the two time points, in the adipogenic culture groups, the PPARγ 
expression level in ADSCs at day 14 was significantly higher than at day 3 (P ≤ 
0.001) 
 
At day 3, PPARγ transcript levels for the ADSCs pre-treated with MI192 (20 µM - 40 
µM) were the same as the basal controls. This expression was statistically 
significantly lower than the adipogenic medium control group (P ≤ 0.001). At day 14, 
the PPARγ expression level in the three MI192 pre-treated groups were higher than 
the basal control group (P ≤ 0.001), but still lower than the adipogenic control. 
There was a dose response visible for PPARγ expression in the MI192 pre-treated 
groups, where the higher doses inhibited the PPARγ transcription the most. The 
PPARγ expression level in the 40 µM and 30 µM MI192 pre-treated groups were 
significantly lower than that of adipogenic control group (P ≤ 0.001). The expression 
of  PPARγ was statistically significantly up-regulated in the 20 µM MI192 pre-
treated group, compared to the higher concentrations of MI192 pre-treatment (40 
µM : P ≤ 0.001  and 30 µM : P ≤ 0.05) and was similar to that of the adipogenic 
control group.  
 
5.3.7.2 ADIPOQ 
Expression of ADIPOQ was undetected in the basal medium negative control group 
at both time points, which was expected given that when attempting to generate a 
standard curve for ADIPOQ it was undetected at all concentrations of cDNA. 
However, this shows that it was detected once adipogenic differentiation was 
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induced in the cells. At both day 3 and day 14 the expression of ADIPOQ was 
higher in the adipogenic positive controls (statistically significantly, P ≤ 0.001). 
 
At day 3, the pre-treatment of the cells with MI192 supressed expression of 
ADIPOQ. Only a very small amount of ADIPOQ was expressed in the 20 µM MI192 
pre-treated cells, and it was statistically significantly lower than the adipogenic 
control cells (P ≤ 0.001). At the 14 day time point some expression was seen in the 
MI192 pre-treated cells, which was a similar level in all groups (P > 0.05). However, 
the expression in the MI192 pre-treated groups was statistically significantly lower 
than the adipogenic medium controls (P ≤ 0.001 for the cells pre-treated with 40 µM 
and 20 µM MI192, and P ≤ 0.01 for the cells pre-treated with 30 µM MI192). 
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Figure 5.16 - Quantitative expression of PPRγ (A) and ADIPOQ (B) in ADSCs 
pre-treated with 40 µM, 30 µM and 20 µM of MI192 for 2 days, then 
cultured in adipogenic medium for 14 days. Gene expression was 
analysed at day 3 and, day 14. Results expressed as mean ± SD (n=3). For 
ADIPOQ (B) the graph is on a log scale and undetermined genes were set at 
an expression value of 1, where the Day 3 Basal ADIPOQ value was 
undetermined. Statistical significance was determined using a one-way 
ANOVA. Only the significance levels between the conditions at each time 
point shown. * = P ≤ 0.05, ** = P ≤ 0.01 and *** = P ≤ 0.001. 
A 
B 
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5.4 Discussion 
The effect of MI192 on the osteogenic and adipogenic differentiation of ADSCs was 
explored in this chapter. HDAC inhibitors can be broadly placed into one of two 
categories; panHDACis, which target all zinc ion dependent HDAC isoforms (those 
being the class I isoforms HDAC1, HDAC2, HDAC3 and HDAC8, and class II 
isoforms HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10, and Class IV 
isform HDAC11), and isoform specific HDACis, which target only one, or a small 
number, of HDAC isoforms. The use of isoform specific HDACis holds great 
potential for researchers, whether they are applied to cancer therapeutics 
(Balasubramanian et al. 2009) or other fields such as nerve tissue engineering 
(Rivieccio et al. 2009). While panHDACis, such as SAHA and NaB, have 
demonstrated potential to be applied to bone tissue engineering scenarios (Xu et al. 
2013; Xu et al. 2009), researchers are beginning to look to more isoform selective 
HDACis, to address clinical needs. 
 
To date, studies exploring the potential of isoform specific HDACis in bone tissue 
engineering are limited. MS-275 is an important HDACi, and specifically inhibits 
HDAC1, HDAC2 and HDAC3. It has shown the potential to improve the osteogenic 
potential of mouse primary osteoblast precursor cells (Kim et al. 2012; H.-N. Kim et 
al. 2011). It is particularly interesting that MS-275 is a specific HDAC, with a 
demonstrated potential for improving bone tissue engineering. Although there are 
some reports it also targets HDAC9 (Balasubramanian et al. 2009), it is still 
relatively specific compared to panHDACis and most studies find it certainly targets 
HDAC1, HDAC2 and HDAC3. The improvements made to the differentiation 
potential may be due to its HDAC3 specificity.  
 
HDAC3 is an important HDAC isoform when considering bone tissue, as it is 
involved in bone formation (Schroeder & Westendorf 2005; Schroeder et al. 2004; 
Razidlo et al. 2010; McGee-Lawrence et al. 2013; Hesse et al. 2010; Lamour et al. 
2007; Choo et al. 2009; Shen et al. 2002). Interestingly, inhibition of HDAC3 (along 
with HDAC1) with siRNAs in ADSCs resulted in an increase in osteogenic 
differentiation in the cells (Maroni et al. 2012). Comparatively, there are only 
minimal links with HDAC2 and bone. A specific link between HDAC2 and bone was 
made in 2014, when the silencing of HDAC2 in human dental pulp stem cells was 
found to increase OPN expression and bone sialoprotein levels, while decreasing 
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OCN expression. Separately, but in the same cells, VPA was found to decrease 
OCN expression, believed to be as a result of the inhibition of HDAC2 (Paino et al. 
2014). Therefore, the effect on the differentiation potential of cells when treated with 
a HDACi specific to HDAC2 and HDAC3 in combination, such as MI192, would be 
interesting. 
 
The results from Chapter 4: The General Effects of MI192 on Adipose Derived 
Stem Cells Cultured in Monolayer indicate that long exposure to MI192 results in 
high levels of cell death, so the possibility of a pre-treatment strategy was explored. 
Cells would be pre-treated, or primed, with MI192, before undergoing differentiation. 
This pre-treatment with HDACi strategy has been used in the literature (see Table 
5-4) (Xu et al. 2009; Cho et al. 2005). TSA is known to improve the osteogenic 
differentiation of MSCs. Therefore, it was used as a control in some relevant 
experiments (Hu et al. 2014; Hu et al. 2013). Maroni et al. (2012) utilised a pre-
treatment strategy (similar to that employed in this chapter) pre-treating ADSCs with 
1 – 2.5 µM of TSA for 2 days. Therefore lower concentrations (1 µM – 20 µM) of 
TSA than MI192 were typically employed as a control; similar to levels utilised in the 
literature (Maroni et al. 2012).  
 
Table 5-4 – Summary of pre-treatment strategies in the literature with HDACis 
and MSCs  
Paper HDACi(s) Cells/aim Strategy 
Maroni et al. 
2012 
TSA 
ADSCs / investigating bone 
and adipogenic differentiation 
potential 
Pre-treatment of cells for 2 
days with 1 µM TSA 
Xu et al. 
2009 
NaB and VPA 
Mouse ADSCs / osteogenic 
differentiation 
Pre-treatment of cells for 2 
days with NaB and VPA 
Cho et al. 
2005 
VPA 
Bone marrow MSCs and 
ADSCs / osteogenic 
differentiation 
Pre-treatment of cells for 1, 
2 and 4 days with VPA 
 
In this chapter two different osteogenic media were used. The ‘osteogenic induction 
medium’ was a combination of basal medium (10% FCS in α-MEM) supplemented 
with ascorbic acid 2-phosphate, which promotes extracellular matrix formation 
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(Vater et al. 2011), and dexamethasone, which, although the exact mechanism of 
action is unknown, is thought to activate osteogenic transcription factors and is an 
often utilised promoter of osteogenic differentiation (Hildebrandt et al. 2009). The 
concentrations utilised were based on a review article suggesting that 10 nM of 
dexamethasone and 100 µM L-Ascorbic acid 2-phosphate were optimal for 
osteogenic differentiation (Hoemann et al. 2009). In this chapter it was shown that 
this medium strongly stimulated ALP production in ADSCs, so was used for the 
early osteogenic induction of ADSCs. The second medium, the ‘osteogenic 
mineralisation medium’ is discussed later.  
 
ALP is found in elevated levels in osteoblasts. It is produced in pre-osteoblast cells 
and thus is an early stage indicator of osteogenic differentiation. Generally an 
increase in ALP activity is commonly associated with the osteogenic differentiation 
of stem cells (Boer et al. 2006; Vater et al. 2011). A number of studies show ALP 
levels to be elevated, in several different cell types, when investigating the effect of 
HDACis on osteogenic differentiation (Boer et al. 2006; Xu et al. 2013). When 
investigating ALP expression levels in ADSCs, pre-treatment with 30 µM MI192 
(with subsequent osteogenic culture) was increased the ALP staining of ADSCs 
(Figure 5.1). The higher dose of MI192 (100 µM), did not result in an increase in 
ALP staining. This high a dose of MI192 is known to have a high cytotoxic effect on 
the ADSC and resulted in massively reduced cell numbers, as well as no ALP 
expression.  
 
To quantify ALP activity, the total ALP was normalised to the total DNA content of 
the same well. The effect of a range of doses of MI192, with two different pre-
treatment periods (1 and 2 days), was investigated (Figure 5.2). Due to the 
cytotoxic effects, longer pre-treatment lengths were not investigated. The 
normalised ALPSA levels account for the cell loss due to the cytotoxic effect of 
MI192 and there was an increase over the controls for every dose in both time 
points. For the two days of treatment there was a dose response, which suggested 
that 30 µM pre-treatment for two days was the optimal dose and treatment length. 
This result was confirmed with several experimental repeats. This can also be seen 
in other experiments in the chapter (e.g. Figure 5.3 B). A two day 30 µM treatment 
was chosen as the optimal dose for future experiments. Cell numbers in the MI192 
pre-treated groups were lower, but still around 70% of the osteogenic controls, so 
sufficient cells are surviving the treatment.  
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In the literature, one study demonstrated that the specific knockdown of HDAC3 
with siRNAs has been shown to increase different bone marker levels, although not 
ALP, in cell lines (Schroeder et al. 2004). Therefore, it may be the inhibition of 
HDAC2 specifically, which is responsible for the huge increase in ALP levels in 
these cells. That being said, in colon cancer cells the specific silencing of HDAC3, 
when compared to HDAC1 and HDAC2, increased ALP levels in the cells (Wilson 
et al. 2006). The reports vary depending on the cell type and the experimental 
parameters, therefore it could be the combination of inhibition of HDAC2 and 
HDAC3, or the isoforms individually, which causes this. 
 
To ensure the pre-treatment strategy was the optimal strategy, the treatment of 
ADSCs for the “whole time” of the experiment was also investigated (Figure 5.3). 
Lower doses of MI192 were used for the “whole time” treatment, and compared to 
pre-treatment with the same doses, as well as the optimised 30 µM (and 20 µM, for 
comparison) dose. The cytotoxic effect of MI192 was seen in the cells treated for 
the whole 7 days with higher doses of MI192, the total DNA content was very low. 
Although the cell numbers in the lower doses (2.5 µM – 750 nm) were comparable 
to the pre-treatment groups. The ALPSA was elevated over the osteogenic controls 
in the “whole time” MI192 treatment groups, but the 30 µM pre-treatment had the 
highest ALPSA overall. It was also important to investigate pre-treatment with the 
lower doses of MI192. However the results show that to see the greatest increased 
ALPSA, the higher concentrations of MI192 are necessary. A lower dose for a 
longer time would be better if there was a lower level of cell loss due from the 
cytotoxic effect; however there was still significant cell death with extended culture 
with lower MI192 doses. Therefore, the advantages of the increased osteogenic 
potential with the higher doses, with the caveat of the increased cell death, was 
investigated in the majority of this thesis.  
 
To investigate if MI192 alone, without any additional osteogenic induction, had any 
effect on the ALPSA levels in ADSCs, cells were pre-treated for two days with 30 
µM and subsequently cultured in basal medium, not osteogenic medium (Figure 
5.4). There was only a slight increase in the ALPSA over the positive osteogenic 
control, and the increase was not significant enough to warrant further investigation. 
This indicated that MI192 treatment alone is not sufficient; that osteogenic induction 
is needed. 
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Different batches of MI192 were available for the project, one synthesised by the 
author (outlined in Chapter 3: The Chemical Synthesis of MI192) and one provided 
by a commercial partner. NMR spectroscopy indicated both compounds were pure 
and chemically identically (NMR data for the commercially provided MI192 not 
shown). However, to investigate if any differences were present on a biological level 
(perhaps due to impurities or different rates of degradation of the compounds), the 
effect of pre-treatment with 30 µM for two days on ALPSA levels of the ADSCs was 
investigated. While there was a difference in ALPSA, likely due to experimental 
error or variability due to low number of biological repeats, there was no statistical 
difference between the ALPSA of the ADSCs pre-treated with the two different 
batches, and the error bars over lapped.  
 
Maroni et al. utilising a 2 day 1 – 2.5 µM TSA pre-treatment strategy to improve the 
osteogenic differentiation potential of ADSCs (Maroni et al. 2012). However, when 
the effect of pre-treatment with TSA on ADSC ALPSA was investigated, there was 
only a very small increase (P > 0.05) in the ALP levels of the ADSCs, compared to 
the controls (Figure 5.5). This was unexpected, because the ADSCs used by 
Maroni et al. were primary ADSCs from human donors, similar to those cells used 
in this thesis. A dose range was utilised, to investigate if higher concentrations of 
TSA would increase the osteogenic potential of ADSCs; however, in doses 10 times 
higher than those used in the literature no significant effect was seen. This may be 
due to the purer nature (they are sorted for stem cell markers) of these cells, or 
perhaps the increase seen would be comparatively large to the controls if MI192 
treatment was not included. 
 
Properties such as the differentiation potential and proliferation of cells can vary 
depending on the donor from which the cells are sourced. With MSCs, this does 
not, as often only reported, always correlate to age or gender (Siddappa et al. 
2007). Donor variability can cause problems with commercialisation of stem cell 
related products. For practical reasons, the majority of experiments in this thesis 
investigate the effects of MI192 on cells from a single donor. This was a 
representation of how the inhibitor could be utilised in a clinical setting. To 
investigate donor variability, and to ensure the increase in ALPSA wasn’t donor 
dependent, the effects of MI192 on ALPSA of cells from 4 donors were tested 
(Figure 5.6). For all four donors, a large, statistically significant (P ≤ 0.001 to ≤ 0.05) 
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in ALPSA was seen in cells pre-treated with MI192, over the osteogenic controls, 
mirroring the trend from previous experiments (Figure 5.2). There was a slight 
difference between donors in the dose response, which may be because of subtle 
difference in cells between donors. From this data it can be concluded that the 
increase in osteogenic potential in ADSCs is not donor dependent. The assumption 
was made that the results from the one main donor are representative of all ADSCs 
from all donors (processed in this way). It is worth noting that three of the four 
donors were female and all were over the age of 45, so this is not totally 
representative of all possible donors, but these were the donors available from the 
manufacturers at the time. 
 
For the long term experiments, an ‘osteogenic mineralisation medium’ was utilised, 
which is a commercial medium from Life Technologies. The exact composition is 
unknown, but it causes a strong mineralisation of ADSCs, so at least likely contains 
a mineral source. Firstly, it was tested and compared to the ‘osteogenic induction 
medium’, to ensure the same effects with MI192 were seen (Figure 5.7). Any 
difference in ALPSA levels across 4 time points, with both media, was also 
investigated. The same increase in ALPSA levels with the osteogenic mineralisation 
medium as with the osteogenic induction medium was seen, although the ALP 
levels peaked earlier (at day 5 not day 7). The mineralisation medium likely has a 
quicker effect than the ‘osteogenic induction medium’; it may contain stronger 
acting osteogenic differentiation inducing compounds, such as BMP2. MI192 having 
the same effect with the mineralisation medium lead to further, long term, 
experiments with the osteogenic mineralisation medium. 
 
Gene expression is coordinated by the epigenetic make up of cells, and HDACis 
are known to affect the osteogenic gene expression of cells (for examples, see 
(Schroeder et al. 2007; Paino et al. 2014; Cho et al. 2005)). The effect of MI192 
pre-treatment on ADSC osteogenic gene expression was investigated. Measuring 
gene expression levels can provide an indication of multiple different changes to the 
cell, over multiple time points, in one experiment; indicating how the cells are 
responding to stimuli. However it is important to note that changes in gene 
expression are not always representative of what actually happens in the cell, as it 
only measures transcript levels, not actual proteins produced.  
 
188 
 
 
RUNX2 is an early osteogenic transcription factor, which the initially high 
expression of drops over time in the osteogenic positive controls (Figure 5.8 A). 
This was expected, as it is an early stage marker, transcript levels should drop over 
time. In the MI192 pre-treated cells, expression is initially lower than the osteogenic 
controls, but peaks at day 14 when it is higher than the osteogenic controls. This 
lag in expression indicates that MI192 actually inhibits RUNX2 expression initially, 
with expression at the level of the basal controls at day 3 and day 5. Runx2 protein 
is known form complexes with HDAC3 (Hesse et al. 2010; Schroeder et al. 2004), 
and it has been reported that inhibition of HDAC3 (along with HDAC1) with siRNAs 
in ADSCs activated RUNX2 expression, across several time points (Maroni et al. 
2012). HDAC3 is involved in the mediation of Runx2 protein by zinc finger protein 
521 (Zfp521); Zfp521 recruits HDAC3 into a transcriptional repression complex with 
Runx2 (Hesse et al. 2010). The lag in expression may be evidence of an effect of 
the HDAC2 inhibition by MI192. HDAC2 may be necessary for stimulation of 
RUNX2 expression. Alternatively, the inhibition of HDAC3 may mean that no 
RUNX2 transcripts are necessary, as any already present but otherwise occupied 
Runx2 protein bound to HDAC3 could be released when HDAC3 is inhibited. 
Therefore the cells don’t need to increase RUNX2 gene expression, whereas in the 
osteogenic control expression increases in response to the medium.   
 
BMP2 encodes for bone morphogenetic protein 2 (BMP2), and is perhaps the most 
explored protein in the osteogenic differentiation pathway, as it is widely reported 
treating cells with BMP2 induces osteogenic differentiation of the cells (Carragee et 
al. 2011). BMP2 is known to induce osteoblast differentiation through increasing 
expression of ATF6, a transcription factor that is dependent on Runx2. BMP2-
induced osteoblast differentiation mediates ATF6, and in turn regulates expression 
of further osteogenic differentiation related genes such as ALP (Jang et al. 2012). 
MI192 pre-treatment increase expression of BMP2 (Figure 5.8 B), at several time 
points. This increased BMP2 expression, especially at the early day 3 time point, 
may in turn result in the observed increases in ALP levels in ADSCs. BMP2 and 
HDAC proteins are all part of a complicated regulatory network that can result in the 
osteogenic differentiation of stem cells (Scholl et al. 2012; Jeon et al. 2006). Here, 
HDAC2 and HDAC3 inhibition lead to an increase in expression of BMP2, at least 
initially. 
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ALP encodes alkaline phosphatase, and ALP levels have been measured in 
multiple experiments in this chapter. Increased levels of ALP protein were observed 
in cells pre-treated with MI192, therefore an increased gene expression was 
expected. In the M192 pre-treated cells, the ALP expression is much greater than 
the osteogenic controls at day 5. This increased gene expression likely results in 
the increased protein levels seen in the ALPSA experiments (for example Figure 
5.9 A). ALP expression peaks at day 5 in the MI192 pre-treated cells, and 
expression decreases down to a level of the basal controls after day 7, while in the 
osteogenic control it continues to increase. This indicates that the cells pre-treated 
with MI192 initially produce a large amount of ALP, but then stop. This increase 
may be caused by the spike in BMP2 expression at day 3. The cells pre-treated 
with MI192 seemingly produce enough ALP protein from this spike in expression 
and gene expression reduces back down to a near basal level afterwards. 
 
Another gene that shows a spike in cells pre-treated with MI192 treatment is COL1. 
COL1 is the main gene responsible for formation of type 1 collagen, the primary 
type of collagen associated with bone cells and an mid-stage marker of osteogenic 
differentiation (Schroeder & Westendorf 2005). The levels of COL1 are high, and in 
the basal culture controls, increase consistently with time, an apparent effect of 
culturing the cells in the MesenPRO RS™ growth medium (Figure 5.9 B). COL1 
expression peaks at day 7 in both the osteogenic control and the MI192 pre-treated 
cells, although expression is statistically significantly higher (P ≤ 0.001) in the 
MI192 pre-treated cells. The pattern is similar in both the controls and the MI192 
pre-treated cells, except for a peak at day 3 in the osteogenic controls over the 
MI192 pre-treated cells. At the later time points COL1 expression drops off, 
although this is compared to the basal control where expression keeps increasing. 
This lag in expression may be linked to the suppression of RUNX2 in the MI192 
pre-treated cells. The increase in COL1 expression is similar to findings in the 
literature, where HDAC inhibition, with VPA and NaB has been found to increase 
COL1 expression increase in mouse ADSCs (Xu et al. 2009) and TSA was found to 
accelerate COL1 expression in a MC3T3-E1 mouse preosteoblast cell line 
(Schroeder & Westendorf 2005). However, not all HDACi treatment results in 
increasing COL1 expression; the treatment of mice with SAHA was found to down-
regulate COL1 in mouse tibia (McGee-Lawrence et al. 2011). The increase in COL1 
expression in the MI192 pre-treated cells over the osteogenic control is another 
indicator that MI192 pre-treatment improves the osteogenic differentiation potential 
of ADSCs. 
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OCN/BGLAP encodes osteocalcin/bone gamma-carboxyglutamic acid-containing 
protein, a non-collagenous protein found in bone, often utilised as a later stage 
marker of osteogenic differentiation (Schroeder & Westendorf 2005). OCN 
expression is initially inhibited by MI192 treatment, to a level below that even of the 
basal culture cells (Figure 5.10 A). This is likely as a result of the inhibition of 
RUNX2 expression, as Runx2 is a known promoter of OCN expression (Fu et al. 
2014; Vrtačnik et al. 2013). In the MI192 pre-treated cells at day 7 expression of 
OCN increases over the osteogenic control; however, it is only a slight increase and 
expression is less at day 14 and day 21 in the MI192 pre-treated cells. Importantly, 
Paino et al. (2013) discovered that the silencing of HDAC2 decreases OCN 
expression in a Saos-2m bone osteosarcoma cell line, making it likely HDAC2 is 
key for OCN expression (Paino et al. 2014). Reports of the importance of HDAC3 
with regards to OCN are conflicting; deletion of HDAC3 resulted in no effect on 
OCN levels in vivo (Razidlo et al. 2010; McGee-Lawrence et al. 2013), but in vitro 
with osteoblasts it was found that HDAC3 had a suppressive effect on OCN, 
believing its deletion of inhibition would result in increased OCN expression 
(Lamour et al. 2007). An increase in OCN expression with TSA treatment has been 
observed in some of the literature (Schroeder & Westendorf 2005; Jin et al. 2013; 
Hu et al. 2013), although the treatment of mice with SAHA was found to down-
regulate OCN in mouse tibia (McGee-Lawrence et al. 2011), and treatment of 
human osteoblasts and human dental pulp stem cells with VPA reduced OCN 
expression (Paino et al. 2014). There are clear differences in HDACis here, likely 
due to different HDAC isoforms being targeted. Here, it would appear HDAC2 and 
HDAC3 inhibition combined may negatively affect OCN expression. This could just 
be due to the HDAC2 inhibition. The lack of OCN expression may be a problem for 
the long term differentiation prospects of these MI192 pre-treated cells, as OCN is a 
key bone protein. 
 
SPP1 encodes osteopontin (OPN), a structural extracellular protein found in 
osteoblasts, forming part of the organic component of bone. It is found in several 
other tissues, such as the lung and vasculature, and plays a role in controlling 
mineralisation, coupling of bone formation and bone resorption (Subramani 2015), 
although its full function is not completely understood. While being found 
abundantly in bone, it appears to modulate the formation of hydroxyapatite, 
preventing crystal growth, ensuring that they grow in the correct locations (Hunter 
2013). The addition of exogenous OPN to cells actually inhibited mineralisation 
(Addison et al. 2007). Here, expression of SPP1 was consistently down-regulated in 
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the osteogenic control, and the pre-treatment of ADSCs with MI192 resulted in an 
even greater down-regulation (Figure 5.10 B). This trend was consistently seen 
across all time points. The only notable change in the pattern of expression was at 
day 14 in the osteogenic controls, where there was a peak in OPN expression. 
OPN protein is a target of Runx2, but the increase in RUNX2 expression in these 
cells does not seem to correlate to an increase in SPP1 expression. The down-
regulation of SPP1 may enable the MI192 pre-treated cells to mineralise more 
freely. In the literature, expression of SPP1 was also seen to be down-regulated in 
the tibia of mice treated with SAHA (McGee-Lawrence et al. 2011). In human 
osteoblast cells, treatment with VPA reduced SPP1 expression, although in dental 
pulp stem cells, SPP1 expression was increased with VPA treatment (Paino et al. 
2014). 
 
The effect of MI192 pre-treatment on the mineralisation of ADSCs was next 
explored, with an Alizarin Red stain for calcium accumulation and a Von Kossa 
stain for mineral nodule formation (Figure 5.11, Figure 5.12 and Figure 5.13). MI192 
pre-treatment resulted in more mineral nodules forming in the cells. Overall calcium 
accumulation in the cells was lower, although this was not normalised to cell 
number and may just be as a result of a lower cell number. Indeed, almost all the 
cells visible had calcium deposition, whereas in the osteogenic control there were 
areas of negative staining (Figure 5.11). The Von Kossa stain was strongest with 
MI192 pre-treatment, indicating these cells were forming more functional mineral 
nodules, and not just accumulating minerals such as calcium and not actually 
functionalising them or doing anything with them, as may be happening in the 
osteogenic controls. Typically in the literature, treatment of cells with HDACis 
increases their mineralisation potential (Xu et al. 2013; Paino et al. 2014), although 
pre-treatment of ADSCs with TSA has actually been show to decrease 
mineralisation (Maroni et al. 2012). It was also found that inhibition of HDAC3 (with 
siRNAs) will increase the speed at which cells mineralise (Schroeder et al. 2004), 
and has been shown to increase Alizarin Red staining of ADSCs (Maroni et al. 
2012). The down-regulation of SPP1 expression seen above may explain why the 
mineralisation was greater in the MI192 pre-treated cells, as SPP1 can inhibit the 
formation of mineral nodules. 
 
Osteogenic differentiation and adipogenic differentiation regulatory machinery is 
closely linked (Ducy et al. 2000). The effects of MI192 on adipogenic differentiation 
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were explored, to see if different lineages of differentiation were affected, either 
positively or negatively, with MI192 treatment. 
 
Accumulation of fat droplets is an indicator of adipogenic differentiation. Staining 
with Oil Red O for lipid droplets found that pre-treatment with MI192 inhibited the 
adipogenic differentiation of ADSCs. Staining was strong in the adipogenic controls, 
but was statistically significantly weakened (when destained) with MI192 treatment. 
There are reports that HDACi inhibition will promote adipogenic differentiation of 
cells. Treatment of a 3T3-L1 mouse fibroblast/adipocyte cell line with several 
HDACis found that adipogenic activity was stimulated (Fajas et al. 2002), and a 
further study by Yoo at al. (2006) also found that treatment of 3T3-L1 cells with NaB 
resulted adipogenic differentiation (Yoo et al. 2006). They also found that 
specifically knocking down HDAC1 also stimulated adipogenesis. Furthermore, 
Jiang at al. (2013) found that HDAC3 inhibition promoted PPARγ mediated 
adipogenic differentiation in the same 3T3-L1 cells (Jiang et al. 2013). Peroxisome 
proliferator activated receptors (PPARs) are nuclear receptor proteins that function 
as transcription factors regulating the expression of genes, with the gamma (γ) type 
being a regulator of adipogenic differentiation and metabolic response to the 
external environment (Lehrke & Lazar 2005). However, the findings in these studies 
were all with the same cell line. With primary ADSCs, Maroni et al. found that 
silencing of HDAC3 with siRNAs inhibited PPARγ expression (Maroni et al. 2012). 
The study by Maroni et al. was undertaken with ADSCs, so the most applicable to 
this study, although they did not explore the effects of the inhibition on the actual 
adipogenic differentiation of the ADSCs. In this study, it would seem that these 
findings are in line with those of Maroni et al., and the inhibition of HDAC3 (and 
HDAC2) inhibits the adipogenic differentiation of these cells. PPARγ gene 
expression in ADSCs undergoing adipogenic differentiation after MI192 pre-
treatment was investigated. Also investigated was ADIPOQ, which encodes 
adiponectin, a protein involved in regulating glucose levels and fate storage in the 
body, which can be used as a later stage marker of adipogenic differentiation 
(Haberland et al. 2010). 
 
On analysing the adipogenic gene expression changes with MI192 treatment, 
PPARγ and ADIPOQ expression was down-regulated. This is in line with the 
findings of Maroni et al., where PPARγ was down-regulated (Maroni et al. 2012). 
The fact that the findings are different to those found in the 3T3-L1 cells, which may 
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indicate a difference in the use of species (mouse vs human) or the fact that the 
3T3-L1 cells are transformed (Yoo et al. 2006). The creation of the HDAC3-PPARγ 
complex in the ADSCs, if it has an oppressive effect on adipogenic differentiation, 
and why the inhibition of HDAC3 appears to down-regulate PPARγ expression and 
not leave the protein free to induce adipogenic differentiation as in the 3T3-L1 cells 
is unclear from these initial experiments.  It is clear; however, that MI192 inhibits 
adipogenic gene expression.   
194 
 
 
 
Chapter 6: The Effects of MI192 on Bone Tissue Engineering 
using Adipose Derived Stem Cells and Three Dimensional 
In Vitro Models 
The aim of this chapter was to investigate the effect of MI192 treatment on the 
osteogenic differentiation of ADSCs, using scaffolds cast from silk fibroin extracted 
from Antheraea mylitta silk worms. The objectives were to assess how cells attached 
and spread on the scaffolds with live/dead cell labelling and to assess the ADSCs 
ability to lay down extracellular matrix, their ability to mineralise and their formation of 
proteins known to be important in bone cells through histology and 
immunohistochemistry. 
  
6.1 Introduction 
It was well known that cells cultured in monolayer on tissue culture plastic are forced 
to act atypically (Baker & Chen 2012; Griffith & Swartz 2006), which therefore can 
only tell a part of a story. A huge amount of early research into cells behaviour has 
been undertaken in monolayer; however, this is not representative of how cells are 
located, and therefore act, in vivo. That being said, 2D cell culture systems are still a 
useful tool in research. They are standardised, still mimic the condition of the body to 
some degree and are easily used and set up. Naturally, in the body, cells are found in 
complicated, three dimensional (3D) environments, usually surrounded by cells of 
many different types, naturally occurring chemicals, signals and constantly changing 
conditions (Baker & Chen 2012), i.e. not just at a steady temperature of 37 °C, with 
5% CO2 and constantly defined nutrient source (tissue culture medium). When 
cultured in 2D, the morphology of cells is altered causing an alteration in the cell 
properties (Baker & Chen 2012; Griffith & Swartz 2006). Perhaps most significantly, 
cells cultured in 3D culture models are able to interact with other cells much more 
naturally, not just by touching at the edges. This is a potential issue with 2D culture 
that has been recognised for decades (Vondermark et al. 1977). A summary of the 
difference between 2D and 3D culture systems can be seen in Figure 6.1. When 
195 
 
 
 
trying to tissue engineer complex 3D tissues, it is important to investigate cell 
behaviour in 3D.  
 
 
Figure 6.1 – Depictions of cells in 2D and 3D culture systems. An illustration of 
the difference in cell morphology, and therefore adhesive, topographical, 
mechanical and soluble cues between 2D and 3D culture systems. Reprinted 
with permission from (Baker & Chen 2012). 
 
‘Scaffolds’ form one of the four key pillars of tissue engineering, (Chapter 1:Literature 
Review, Figure 1.1), providing a 3D template and the microenvironment to support 
cell growth, extra cellular matrix deposition and tissue formation. 3D culture models 
utilising scaffolds have been extensively explored for bone tissue engineering (Laino 
et al. 2006; El-Gendy & Yang 2012; Amini et al. 2012). The goal when utilising these 
scaffolds is typically to have them integrate into the surrounding bone and heal the 
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defects, or strengthen weakened bone (Amini et al. 2012; Ericka M. Bueno & 
Glowacki 2011). 
 
For the purposes for tissue engineering, researchers look to design scaffolds that are 
biocompatible, economically viable, inductive for the tissue of choice and which 
support cell growth and differentiation (Ericka M Bueno & Glowacki 2011). To date, 
many different scaffolds have been utilised in bone tissue engineering, including 
Bioglass® (W. Lu et al. 2014), peptides (Sfeir et al. 2014) and bioresorbable polymer 
based scaffolds, such as those based on lactic acid or other copolymers (which have 
FDA approval in surgical applications and as drug delivery systems (Howard et al. 
2002)). Due to the need for a high mechanical strength, in bone tissue, glass-
ceramics, such as Apatite-Wollastonite (Dyson et al. 2007), have also been explored.  
 
Regarding utilising HDACis in bone tissue engineering, there has been very little work 
utilising HDACis in combination with scaffolds. Some researchers jumped straight 
from 2D in vitro validation, to in vivo studies, where they investigated bone healing 
utilising injection of a cell suspension, without any 3D experiments with scaffolds (Xu 
et al. 2009). Others will utilise scaffolds but implant them in vivo without first reporting 
or undertaking in vitro validation, moving directly onto in vivo models utilising the 
scaffolds. For example, Boer et al. (2006) utilised biphasic calcium phosphate 
ceramic granules as a scaffold to investigate the effect of TSA and NaB on bone 
formation in a subcutaneous mouse model. However, the results from this were 
inconclusive, perhaps because the authors missed out the 3D in vitro testing, which 
can be very important step prior pre-clinical and clinical assessments (Boer et al. 
2006). 
 
Lee et al. (2011) utilised two different animal models to investigate the in vivo 
osteogenic activity of Largazole: 1) collagen sponge scaffolds doped with Largazole 
were implanted calvaria bones, and 2) macroporous biphasic calcium phosphate 
scaffolds were also doped with Largazole in a rabbit calvaria bone defect model. The 
results showed that Largazole improved osteogenic healing in both models (Lee et al. 
2011). In another study, Jung at al. (2010) combined TSA and NaB with calcium 
sulphate scaffolds during the setting process. These HDACi doped scaffolds were 
found to have increased osteoinductive capability, improving the osteogenic 
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differentiation of a murine MC3T3-E1 pre-osteoblast cell line (while simultaneously 
inhibiting the osteoclastic potential of these cells), unusually with the 3D results 
validated both in vitro and in vivo (Jung et al. 2010). These studies are the sum total 
of the literature surrounding this topic, so there are very few studies to compare 
results with in this chapter.  
 
Silk scaffolds are a type of scaffold that have shown much promise for multiple areas 
of tissue engineering, including cartilage (Saha et al. 2013), cardiac (Patra et al. 
2012) and nervous tissue engineering (Allmeling et al. 2008). Silk is an abundant 
natural polymer biomaterial, which can be farmed in large amounts from spiders or 
silk worms. Silk fibroin protein has been utilised in oral surgeries, wound healing and 
has FDA approval as a material for ligament and tendon approval (marketed as 
Serica, by Allergan) (Kundu et al. 2013). As well as being abundant, silk has the 
advantage of being a biocompatible natural material, which will elicit a low immune 
response on implantation. Silk is also mechanically robust and biodegradable, at a 
rate typically useful for implantation. Another beneficial property of silk is that it can 
be easily cast into shapes, or electro spun, to create scaffolds of a desired shape, 
size and physical properties. Finally, typically scaffolds formed from silk are porous, 
allowing good cell ingrowth (Saha et al. 2013; Kundu et al. 2013; Omenetto & Kaplan 
2010). Silk scaffolds have been utilised in multiple bone tissue engineering studies. 
For example, Meinel et al. (2005) demonstrated that they can heal critical sized bone 
defects in mouse models (Meinel et al. 2005). Scaffolds can be coated, for example 
with apatite (Zhao et al. 2009) or have growth factors incorporated (Saha et al. 2013), 
to enhance their osteogenic induction properties.  
 
The majority of studies utilising silk from silk worms investigate silk from the Bombyx 
mori (Bm) silk worm, which is a mulberry silk, (where mulberry refers to the plants the 
worms eat). Silk produced from Am worms is a non-mulberry silk and the worm is 
found almost exclusively in the north eastern parts of India. The silk produced from an 
Am worm has slightly different properties to that of a Bm worm, as can be seen in 
comparative studies of the two. Reports are conflicting as to which is the more 
osteoinductive, with S. Saha of Oral Biology, and Miyamoto  et al. (2013) finding that 
Bm is more osteoinductive (Miyamoto et al. 2013; Saha et al. 2013), but Sahu et al. 
finding Am to be more so ( Sahu et al. 2015). Because they were the most 
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abundantly available from collaborators, and they were found to be osteoinductive in 
the latest study carried out with them, Am silk scaffolds were used for these studies. 
 
3D scaffolds produced from Indian tropical Antheraea mylitta (Am), in the laboratory 
of Professor S. C. Kundu of the Indian Institute of Technology Kharagpur, were 
utilised to investigate the aims of this chapter. To fully investigate the potential of 
these, a number of experimental designs were investigated. A schematic explaining 
these can be seen in Figure 6.2.                                        . 
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Figure 6.2- Schematic representing the three different experimental designs for the scaffold studies covered in 
this chapter. Design 1: Where the cells were pre-treated with MI192 once seeded onto the scaffolds. Design 2: 
Where the cells were pre-treated with MI192 in monolayer, had a 7 day osteogenic induction period in monolayer, 
then seeded onto the scaffold for further osteogenic induction. Design 3: Where the cells were pre-treated with 
MI192 in monolayer and seeded straight onto the scaffold.  
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6.2 Materials and Methods 
Scaffolds used in this chapter were created in the laboratory of Professor S. C. 
Kundu, of the Indian Institute of Technology (IIT) Kharagpur, as part of a collaborative 
project between Leeds School of Dentistry and IIT Kharagpur. Scaffold production 
(6.2.1) was carried out in India, but the scaffold preparation (crosslinking, sterilisation 
and FCS treatment) was carried out by the author in Leeds (6.2.2). 
 
6.2.1 Silk protein fibroin extraction and 3D scaffold production 
Briefly, silk larvae from the Indian tropical Antheraea mylitta were obtained from the 
Tasar Sericulture Farm, West Midnapur, West Bengal State, India. After washing with 
dH2O, the glands of Antheraea mylitta larvae were dissected and silk protein fibroin 
was collected by squeezing it out of the glands. The extract was dissolved in 1% (w/v) 
Sodium dodecyl sulfate (SDS) aqueous solution containing 10 mM Tris (pH 8.0) and 
5 mM EDTA. To then remove any traces of solvents, the fibroin solution was 
extensively dialyzed against dH2O. This was then cast in moulds (5 mm diameter 2 
mm thickness) and lyophilised to obtain 3D silk scaffolds, with a slow pre-cooling step 
of – 20 °C to obtain scaffolds with uniform and interconnected pores (Saha et al. 
2013; Patra et al. 2012). All scaffolds used in this chapter were this size and were 
produced in this way. They are referred to as ‘Am silk scaffolds’ throughout.  
 
6.2.2 Scaffold preparation before experiments 
Prior to cell seeding, dried scaffolds were crosslinked and sterilised in 70 % EtOH for 
30 minutes at 37 °C, washed three times with 1x PBS, (30 minutes per wash) and 
then incubated in 20 % FCS α-MEM over night at 37 °C. Prior to cell seeding the 
scaffolds were washed twice in plain medium.  
 
6.2.3 Dynamic seeding of cells on 3D silk scaffolds 
Cells were dynamically seeded onto scaffolds using an in house dynamic seeding 
device (Figure 6.3). Briefly, 1.5 mL cell suspension containing the appropriate cell 
number was placed in a sterile 2 mL Eppendorf tube with a hole pieced in the lid. The 
sterilised, crosslinked and FCS pre-treated silk scaffold was then placed in each tube, 
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in the cell suspension. The lid was shut and the hole was covered with a layer of 
Opsite (Smith & Nephew, Cat. No: 4630), a transparent, adhesive polyurethane film, 
used in surgeries and wound healing, which allows gas exchange in and out of the 
tube, while keeping the contents sterile.  
 
The tubes were then placed in the rotating seeding device (Figure 6.3) that was kept 
in a standard cell culture incubator for the seeding duration. The seeding device turns 
at a constant rate, of around 10 rotations per minute, thereby increasing the 
opportunity for cells to come into contact with and seed onto the scaffolds.  
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Figure 6.3 – Photographs of the in house dynamic cell seeding device. A – 
Unloaded device. Arrows indicate the black bars which rotate when the device 
is turned on, which causes the seeding device to rotate. B – Empty seeding 
device loaded onto the cell seeder.  C – Seeding device with an empty tube in, 
indicating how tubes sit in the device.  
A 
 
B 
 
C 
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6.2.4 Live and dead cell Labelling 
Live/dead cell labelling can be utilised for the in situ imaging of cells in culture. 
Labelling and imaging were carried out with ascetic technique, so culture can be 
continued after imaging. 
 
CellTracker™ Green CMFDA (5-chloromethylfluorescein diacetate) dye 
(ThermoFisher Scientific, Cat. no: C7025) can be utilised as a live cell label. The dye 
can be absorbed freely across cell membranes, reacts with cellular components and 
is converted to cell-impermeable products. These products emit fluorescence for at 
least 24 hours and can be passed to daughter cells through several generations, 
while not being transferred to any adjacent cells, or leaving the cells. CMFDA emits 
green fluorescence (excitation/emission maxima ~492/517 nm). Ethidium homodimer 
I (EthD-1, Sigma, 2 mM in DMSO, Cat. no: E1903) dye can be utilised as a dead cell 
maker. EthD-1 is an intact membrane-impermeable dye, which will only be absorbed 
into dead cells due to their disrupted membranes. EthD-1 binds to DNA in dead cells 
and emits red fluorescence (excitation/emission maxima ~528/617 nm). 
 
Scaffolds were immersed for 30 minutes in basal medium containing the dyes 
prepared according to the manufacturer’s instructions. For CFMDA, 10 µL DMSO 
was added to 1 vial containing 50 µg of CFMDA, which was then diluted in 5 mL of 
culture medium to a final concentration of 10 µg/mL medium. For EthD-1, 20 µL of the 
dye (which came prepared by the manufacturer at 2 mM in DMSO) was added to the 
same 5 mL of culture medium, to a final concentration of 6.8 µg/mL medium. Labelled 
scaffolds were then washed in basal medium for 30 minutes, before placing in fresh 
basal medium for imaging. 
 
6.2.5 ADSCs seeded onto 3D silk scaffolds prior to MI192 
treatment (Expt 1)  
ADSCs were dynamically seeded (1 x 105 cells per scaffold), as described above 
onto Am scaffolds in basal medium for 48 hours. Then, the cell-scaffolds constructs 
were cultured in basal medium for further 24 hours. The medium was then replaced 
with MI192 containing medium (30 µM in 1 mL basal medium per scaffold), with 
untreated control scaffolds. After 48 hours, the scaffolds were carefully washed in 1x 
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PBS. The medium for the test groups (MI192 pre-treated scaffolds) and the 
osteogenic positive control group was changed to osteogenic mineralisation medium. 
The sample size was three for both groups (n=3). The medium was changed every 4-
5 days. After 6 weeks of culture, live cells on two of the scaffolds from each group 
were labelled with CellTracker™ Green CMFDA Dye and the scaffolds were imaged 
under a Leica DMI6000 B inverted confocal microscope. Following imaging at 6 
weeks, the cell density was observed to be too low to stop the experiment, so the 
scaffolds were cultured for a further 3 weeks. After 9 weeks culture, live cells on the 
same two scaffolds from each group were labelled with CellTracker™ Green CMFDA 
Dye and imaged under a Leica DMI6000 B inverted confocal microscope. Scaffolds 
were then fixed in 10 % NBF for 24 hours, before being paraffin embedded, sectioned 
and histologically stained with a Van Gieson’s stain, to visualise tissue formation.  
 
6.2.6 ADSCs treated with MI192 followed by 7 days of osteogenic 
induction prior to seeding on 3D silk scaffolds (Expt 2) 
ADSCs in T175 tissue culture flasks were washed with 1x PBS and the medium then 
replaced with medium containing MI192 (10 µM and 30 µM in 25 mL basal medium 
per flask), with cells in one other flask untreated, as a control. After 48 hours, the 
flasks were carefully washed in 1x PBS. The medium for the test groups (MI192 pre-
treated) and the osteogenic positive control groups was changed to osteogenic 
mineralisation medium and the negative basal control group was changed to 
MesenPRO RS™ growth medium. The ADSCs were then cultured for 7 days, with 
the medium changed at day 3. The ADSCs were detached and then dynamically 
seeded onto Am silk scaffolds (2.5 x 105 cells per scaffold) for 48 hours, in osteogenic 
mineralisation or MesenPRO RS™ growth medium as appropriate. The sample size 
was four for all groups (n=4). After 24 hours of culture, live cells on two of the 
scaffolds from each group were labelled with CellTracker™ Green CMFDA Dye and 
the scaffolds were imaged under a Leica DMI6000 B inverted confocal microscope. 
The scaffolds were then cultured for 6 weeks, with the medium being changed every 
4 - 5 days. Then, live cells on two of the scaffolds from each group were labelled with 
CellTracker™ Green CMFDA Dye and the scaffolds were imaged under a Leica 
DMI6000 B inverted confocal microscope. Scaffolds were then fixed in 10 % NBF for 
24 hours, before being paraffin embedded, sectioned and histologically stained with a 
Van Gieson’s, Picrosirius red and Von Kossa stain, to visualise tissue formation, 
collagen formation and mineralisation. 
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6.2.7 ADSCs treated with MI192 prior to seeding on 3D silk 
scaffolds (Expt 3) 
ADSCs in T175 tissue culture flasks were washed with 1x PBS and the medium was 
then replaced with medium containing MI192 (10 µM and 30 µM in 25 mL basal 
medium per flask), with untreated control flasks. After 48 hours, the flasks were 
carefully washed in 1x PBS. The ADSCs were then detached and were dynamically 
seeded (2.5 x 105 cells per scaffold) onto Am silk scaffolds for 48 hours, in 
MesenPRO RS™ growth medium. After seeding, the scaffolds were then cultured in 
the same medium for 24 hours. Then live cells on two of the scaffolds from each 
group were labelled with CellTracker™ Green CMFDA Dye and the scaffolds were 
imaged under a Leica DMI6000 B inverted confocal microscope. The scaffolds were 
then placed in culture medium; for the test groups (MI192 pre-treated scaffolds) and 
the osteogenic positive control groups was osteogenic mineralisation medium and the 
negative basal control group was changed to MesenPRO RS™ growth medium. The 
sample size was four for all groups (n=4). The scaffolds were then cultured for 6 
weeks, with the medium being changed every 4-5 days. Then, live cells on two of the 
scaffolds from each group were labelled with CellTracker™ Green CMFDA Dye and 
the scaffolds were imaged under a Leica DMI6000 B inverted confocal microscope. 
Scaffolds were then fixed in 10 % NBF for 24 hours. One scaffold from each group 
was imaged with environmental Scanning Electron Microscopy (SEM), with additional 
Energy Dispersive X-ray Spectroscopy (EDS) analysis. Scaffolds were then paraffin 
embedded, sectioned and histologically stained with a Van Gieson’s, Picrosirius red 
and Von Kossa stain, to visualise tissue formation, collagen formation and 
mineralisation. Sections were also stained with antibodies in immunohistochemical 
staining protocols for Runx2, Col1 and OCN. 
 
6.2.8 Immunohistochemical staining 
EnVision™ Detection Systems Peroxidase/DAB, Rabbit/Mouse (Dako, Cat. no: 
K406511) and a Thermo Scientific Shandon ® Sequenza Immunostaining Center with 
coverplates (Thermo Scentific Cat. no: 72110013) were utilised for 
immunohistochemical staining.  
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After being taken to water, slides were blocked for peroxidase with the ‘Dual 
Endogenous Enzyme Block’ from the EnVision™ kit for 10 minutes. Slides were then 
washed in a 1x PBS wash box for 5 minutes. For the Ocn and Col1 staining antigen 
retrieval was performed, where slides were immersed in a 37 ºC, pH 7.8, 0.1% 
chymotrypsin in 0.1% CaCl2 solution for 20 minutes. Slides were then washed in a 1x 
PBS wash box for 5 minutes before loading into coverplates and then the 
Immunostaining Centre. Slides were washed with 1x PBS for 5 minutes to ensure 
equal reagent flow through the coverplates. The slides were then incubated in normal 
goats serum (1:5 ratio in 1x PBS, Dako, Cat. no: X090710) for 30 minutes. The 
primary antibody (Table 6-1) was then applied, for the length of time specified below 
(Table 6-1). Antibody concentration refers to a dilution in PBS. After incubation with 
the primary antibody, the slides were washed with 1x PBS for 5 minutes. 2 drops from 
the bottle ‘Labelled Polymer’, the secondary antibody, from the EnVision™ kit were 
then loaded into each slide, and slides incubated at room temperature for 30 minutes. 
Slides were then washed in 1x PBS 5 minutes before removal from the coverplates. 
The stain was then developed for 5 – 10 minutes using the ‘DAB+ Chromogen’ in the 
provided ‘Substrate Buffer’, from the EnVision™ kit. Slides were then washed in a 
running tap water bath for 5 minutes, stained with Harris’s Haematoxylin for 30 
seconds, washed in a tap water bath for 2 minutes and developed in Scott’s tap water 
for 2 minutes. The slides were then immersed in a running tap water bath for 5 
minutes, and two 100 % EtOH baths, for 5 minutes each, and in xylene for 2 minutes 
before mounting in DPX. The stains were then observed under an Olympus BX50 
microscope.  
Table 6-1 – Antibodies for immunohistochemical staining and the conditions 
they were used in 
 
Protein 
Abcam Cat. 
no. 
Antigen 
retrieval? 
Concentration 
Length of time / 
temperature of application 
Runx2 ab6308 No 1/600 1 hour / room temp 
Collagen I ab6308 Yes 1/100 16 hours / 4 ºC 
Ocn ab13420 Yes 1/400 16 hours / 4 ºC 
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6.3 Results 
6.3.1.1 Assessment of cell viability and growth 
Am silk cell-scaffold constructs were labelled with CFMDA and EthD-1 to visualise the 
viable and dead cells on the 3D silk scaffolds. However, it was discovered that the 
Am silk scaffolds absorb the EthD-1, causing large background fluorescence, which 
can be observed in Figure 6.4, where a scaffold has been labelled with both CFMDA 
and EthD-1. This made imaging of dead cells vary hard. In Figure 6.4 A the scaffold 
architecture can be seen as dark, not fluorescing, and live cells can be seen. Figure 
6.4 B shows the scaffold fluorescing when exposed to the light usually utilised to 
visualise dead cells labelled with EthD-1 (excitation/emission maxima 528/617). 
When exposed to the same light, a scaffold not labelled with EthD-1 does not 
fluoresce, indicating this is not auto-fluorescence of the scaffold, but the scaffold itself 
somehow taking the label up. Figure 6.4 C shows the two previous images 
superimposed onto one another, showing that the darkness in the live cell image 
(Figure 6.4 A) follows the same architecture as the fluorescent image in the dead cell 
image (Figure 6.4 B). The fact the scaffold absorbs the dye and fluoresces means 
that imaging of dead cells was difficult, as the scaffold obscures the dead cells, 
resulting in false positive staining. Therefore, no dead dye was used in the rest of 
experiments detailed in this thesis. 
 
6.3.2 The effect of MI192 on ADSCs seeded onto 3D silk scaffolds 
prior to MI192 treatment (Expt 1) 
ADSCs were seeded onto Am scaffolds prior to the two days of pre-treatment with 
MI192, followed by osteogenic induction for 9 weeks.  
 
6.3.2.1 Assessment of cell viability and growth 
After 6 weeks of culture fluorescent images showed that viable cells were present on 
all scaffolds. Cells were quite dispersed and with variable morphologies. The density 
of viable cells in the osteogenic control scaffolds (Figure 6.5 A + B) was higher than 
those treated with MI192 (Figure 6.5 C + D). The cell density was too low in all 
samples to stop the experiment at the planned 6 week end point, so constructs were 
cultured for a further 3 weeks. 
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At 9 weeks, viable cells were observed on the scaffolds (Figure 6.6). The cell 
phenotype was similar in both groups: cells are typically aligned with one and other, 
although on top of this aligned pattern some randomly orientated cells can be 
observed (especially visible in Figure 6.6 B). The cell density was higher in both 
groups compared to the same group at 6 weeks (Figure 6.5). The cell density was 
similar in all groups and based on this the experiment was stopped and scaffolds 
were analysed with histology.  
  
6.3.2.2 Histological Analysis  
Negative control scaffolds, with no cells on, did not stick to the slides well and nothing 
was observable, presumably due to a lack of cells to support the scaffold structure or 
to bind to the slides. However, the scaffold is observed when cells are present, and 
the scaffold can be distinguished from the cells/tissues with some stains. Typically in 
histology, Harris’ haematoxylin and Eosin staining is utilised as a basic stain to 
observe tissue formation. However, the Am silk scaffolds strongly stain red with the 
eosin dye, making it difficult to differentiate between scaffold and cells. Furthermore, 
ADSCs in these studies did not absorb eosin dye well, and thus overall tissue 
identification was not good. Therefore, a Van Gieson’s stain for connective tissue was 
utilised, which stains the ADSCs strongly with a pink colour. The scaffold, when 
visible and not obscured by cells, stains yellow, or a different shade of pink with Van 
Gieson’s stain. 
 
In the osteogenic control scaffolds the tissue density was high in two of three 
scaffolds, with a lower tissue formation in the third (Figure 6.7 A, B and C). The silk 
scaffolds stained a yellow colour, thus the newly formed tissue can be distinguished 
from the scaffolds. In the higher cell density samples,   the scaffold architecture is 
difficult to observe, as it is obscured by the tissue.  
 
In the scaffolds treated with MI192, the staining/cell density was much lower than that 
of the osteogenic control group (Figure 6.7 D, E and F). Although a thick, strongly 
stained capsule appears to have formed around the edge all the scaffolds. Cell 
penetration and growth is low in the MI192 pre-treated groups compared to the 
osteogenic control group.  
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Due to the poor tissue formation in the test group (MI192 treatment group), further 
analysis was not carried out on the samples and alternative experimental designs 
were explored. 
 
 
Figure 6.4 – Live/Dead cell dye test. Fluorescent imaging of viable ADSCs (green 
colour) on Am silk scaffolds labelled with both the live (CFMDA) and the dead 
(EthD-1) markers 1 day after seeding.  A – Live marker alone; B – dead marker 
alone; C – superimposed images A and B. Scale bars = 100 µM. Yellow arrows 
indicate live cells growing aligned with the fibres of the scaffold.  
 
A 
 
B 
 
C 
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Figure 6.5 - Fluorescent imaging of viable ADSCs (green colour) on Am silk 
scaffolds 6 weeks after seeding, in Expt 1. A + B – Osteogenic control; C + 
D – pre-treated with 30 µM MI192. Scale bars = 100µM. 
 
Figure 6.6 - Fluorescent imaging of viable ADSCs (green colour) on Am silk 
scaffolds 9 weeks after seeding, in Expt 1. A + B – Osteogenic control; C + 
D – pre-treated with 30 µM MI192. Scale bars = 100 µM 
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Figure 6.7 – Van Gieson’s Stain of sections from ADSC-silk scaffold constructs after 9 weeks of in vitro culture (Exp1). A – C –  
Osteogenic control; D – F – Constructs treated with 30 µM MI192. Silk scaffold stained a yellow colour and the tissues were 
stained a pink colour. Arrows indicate the scaffold architecture.  Scale bars = 100 µM. 
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Figure 6.7 G – High magnification image of Figure 6.7 A. The black arrow indicates where layers of cells have formed on the outside 
of the scaffold. The green arrows show the cell structures growing along the architecture of the scaffold.  
 
 
 
 
G 
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6.3.3 The effect of MI192 treatment on ADSCs, which underwent 
osteogenic induction prior to seeding on 3D silk scaffolds 
(Expt 2) 
 
After being pre-treated with MI192 (10 µM and 30 µM) for two days, followed by 
culture in osteogenic medium for 7 days, ADSCs (2.5 × 105 cells per scaffold, 2.5 x 
higher than Expt 1) were seeded onto the Am scaffolds, followed by osteogenic 
induction for 6 weeks. 
 
6.3.3.1 Assessment of cell viability and growth 
24 hours after seeding live cell imaging of two scaffolds from each group labelled with 
with CFMDA showed that viable cells had attached to the silk scaffolds in all groups 
(Figure 6.8). In some scaffolds (Figure 6.8 A, B and E) the cell morphology was 
rounded, with very few cell processes. Other scaffolds had more expected cell 
morphology, with cell processes visible (Figure 6.8 C, D and F). This rounded 
morphology was different to what had been observed in previous experiments (e.g. 
Figure 6.5). These abnormal morphology cells were apparent in scaffolds across all 
treatment groups. Overall, the cell density was comparable to, or better than, the cell 
density after six weeks of culture in Expt 1 (Figure 6.5). The increased seeding 
density had the desired effect. 
 
After 6 weeks of culture two scaffolds from each group (the same scaffolds as at 24 
hours) were labelled for live cells again, to check if the tissue growth was sufficient to 
end the experiment (Figure 6.9). Viable cells were visible on all scaffolds from all 
groups labelled. In some scaffolds (Figure 6.9 C and F) the cell density had increased 
from the 24 hour time point, and there were large areas of confluent cells. However, 
other scaffolds had a lower cell density, (Figure 6.9 A, B D, E and F). In these lower 
density scaffolds, the cells had a rounded morphology. This cell density and the 
rounded morphology was the same as at the 24 hour time point (Figure 6.8). 
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6.3.3.2 Histological Analysis  
There were four scaffolds for each group processed for histology; however, 
consistent staining could not be observed in two scaffolds of each group. These 
corresponded to the scaffolds where abnormal cell morphology was observed in the 
live cell labelling experiments. In these samples, in sections from throughout the 
whole paraffin block and therefore scaffold, only minimal staining could be observed. 
Prior to staining, the scaffold could be seen attached to the slide, but as with the 
negative control scaffolds there was very little staining observed. What could be seen 
were rounded dots, which was abnormal compared to other samples. Examples of 
such staining can be seen in Figure 6.10 (Van Gieson’s stain, A + B). No collagen 
fibres could be seen when these were stained with Picrosirius red (Figure 6.10 C) and 
when stained with a Von Kossa stain (Figure 6.10 D) for mineralisation these dots 
appeared dark; however, they were not black as in the scaffolds with good cell 
formation (Figure 6.13), so this is probably not mineralisation.  
 
Those samples which could be stained yielded inconclusive results, and a low 
sample number means that conclusions could not be drawn. The tissue penetration 
was good in all scaffolds where staining could be achieved, with strong Van Gieson’s 
staining throughout the scaffolds, in both the osteogenic controls (Figure 6.11 A + B) 
and the groups with cells pre-treated with MI192 (10 µM - Figure 6.11 C + D and 30 
µM - Figure 6.11 E + F). 
 
Picrosirius red staining for collagen indicated strong staining for some samples 
(Figure 6.12 B, D + F); however, this varied across the groups and the other samples 
had much weaker staining. Results were inconsistent for this stain. 
 
Mineralisation close to the surface could be observed in all samples (Figure 6.13). 
The mineralisation was marginally higher in the two pre-treated groups (10 µM - 
Figure 6.13 C + D and 30 µM - Figure 6.13 E + F), compared to the osteogenic 
controls (Figure 6.13 A + B) indicating that MI192 pre-treatment had improved the 
mineralisation capacity of the ADSCs. The mineralisation in the treated samples 
seemed to occur in large zones, and was less spread around the same than the 
osteogenic control.  
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Figure 6.8 - Fluorescent imaging of viable ADSCs (green colour) on Am silk 
scaffolds 24 hours after seeding, in Expt 2. A + B – osteogenic control; C + 
D – ADSCs pre-treated with 10 µM MI192; E + F –  ADSCs pre-treated with 30 
µM MI192. Scale bars = 100 µM. 
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Figure 6.9 - Fluorescent imaging of viable ADSCs (green colour) on Am silk 
scaffolds 6 weeks after seeding, in Expt 2. A + B – osteogenic control; C + D 
– ADSCs pre-treated with 10 µM MI192; E + F –  ADSCs pre-treated with 30 µM 
MI192. Scale bars = 100 µM. 
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Figure 6.10 - Van Gieson’s, Picrosirius red and Von Kossa stain of sections 
from ADSC-silk scaffold constructs after 6 weeks of in vitro culture (Expt 
2). Example stains of samples where there was poor tissue formation, where 
cells and scaffold were not visible. A – Van Gieson’s stain of osteogenic control; 
B – Van Gieson’s stain of ADSCs pre-treated with 10 µM MI192; C – Picrosirius 
red stain Osteogenic control, A; D – Von Kossa stain of osteogenic control. 
Scale bars = 100 µM. 
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Figure 6.11 - Van Gieson’s stain of sections from ADSC-silk scaffold constructs 
after 6 weeks of in vitro culture (Expt 2). A + B – Osteogenic control; C + D – 
ADSCs pre-treated with 10 µM MI192; E + F –  ADSCs pre-treated with 30 µM 
MI192. Silk scaffold stained a yellow/pink colour and the tissues were stained a 
darker pink colour. Arrows indicate the scaffold architecture.  Scale bars = 100 
µM.    
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Figure 6.11 G – High magnification image of Figure 6.11 D. The black arrow 
indicates where layers of cells have formed on the outside of the scaffold. The green 
arrows show the cell structures growing along the architecture of the scaffold.  
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Figure 6.12 – Picrosirius red stain, with Weigert’s haematoxylin nuclei 
counterstain, of sections from ADSC-silk scaffold constructs after 6 
weeks of in vitro culture (Expt 2). A + B – Osteogenic control; C + D – 
ADSCs pre-treated with 10 µM MI192; E + F – ADSCs pre-treated with 30 µM 
MI192. Silk scaffold stained a yellow/grey colour, the tissues were stained red if 
collagen was present and the nuclei were stained black. Arrows indicate the 
scaffold architecture. Scale bars = 100 µM. 
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Figure 6.13 – Von Kossa staining, with a weak Van Gieson’s counter stain for 
tissue, of sections from ADSC-silk scaffold constructs after 6 weeks of in 
vitro culture (Expt 2). A + B – Osteogenic control; C + D – ADSCs pre-treated 
with 10 µM MI192; E + F – ADSCs pre-treated with 30 µM MI192. Mineral 
nodules stained black/dark brown, silk scaffold stained a pink/brown colour and 
the cell tissue stained pink. Arrows indicate strong areas of mineralisation in 
each scaffold. Scale bars = 100 µM. 
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Figure 6.13 G + H – High magnification image of Figure 6.12 E and F, 
respectively. The green arrows indicate some of the mineralisation.  
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6.3.4 The effect of MI192 treatment on ADSCs treated with MI192 
prior to seeding on 3D silk scaffolds and osteogenic 
induction (Expt 3) 
 
After being pre-treated with MI192 (10 µM and 30 µM) for two days, ADSCs (2.5 × 
105 cells per scaffold) were seeded onto the Am scaffolds, followed by osteogenic 
induction for 6 weeks. 
 
6.3.4.1 Assessment of cell viability and growth 
24 hours after seeding, imaging of live cells on two scaffolds from each group 
showed that viable cells had attached to the surface of the scaffolds in all groups 
(Figure 6.14). Cells in all groups had a normal morphology, with processes visible, 
indicating cell attachment and spreading. Cell density was similar across all labelled 
scaffolds. The density was comparable to, or better than the cell density after 24 
hours in experimental design 2 (Figure 6.8). None of the abnormal rounded cell 
morphology from Expt 2 was observed (Figure 6.10). 
 
After 6 weeks of culture, imaging of live cells on two scaffolds from each group (the 
same scaffolds as at 24 hours) was undertaken, to check if the tissue growth was 
sufficient to end the experiment (Figure 6.15). Viable cells were visible on all scaffolds 
from all groups labelled, with all scaffolds showing large areas of confluent cells. The 
cell density was comparable across all scaffolds. The morphology of the negative 
control ADSCs cultured in the basal MesenPRO RS™ growth medium (Figure 6.15 A 
+ B) were more elongated and the cells were more aligned, compared to the cells 
cultured in the osteogenic mineralisation medium (Figure 6.15 C – H). The cell 
density had increased from the 24 hour time point. 
 
6.3.4.2 SEM Analysis  
One scaffold from each group, along with unseeded negative control scaffolds, was 
analysed using SEM (Figure 6.16).  
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The negative control scaffold, with no cells seeded, has a highly porous structure, 
with no evidence of cells (Figure 6.16 -). The cell seeded scaffolds had only minimal 
scaffold architecture visible (Figure 6.16 A - H), compared to the negative control with 
no cells, as the pores are covered by cells. Cell processes could be observed in the 
lower magnification images (Figure 6.16 B, D, F + H). Cell density was highest in the 
basal MesenPRO RS™ growth medium negative control (Figure 6.16 A + B), where 
no scaffold is visible through the layer of cells. The other groups all had comparable 
cell density to each other, with the scaffold visible in places.   
 
The white deposition visible in the samples cultured in osteogenic medium (Figure 
6.16 C - H) is mineralisation. This appears white because of the higher molecular 
weight of the metallic elements compared to the carbon, oxygen and hydrogen, which 
make up the majority of the organic constituents of the scaffolds. There is no white 
mineral deposition visible in the basal MesenPRO RS™ growth medium negative 
control (Figure 6.16 A + B), compared to the osteogenic medium positive control 
(Figure 6.16 C - H). The highest level of mineralisation can be seen in the 30 µM pre-
treated ADSC sample (Figure 6.16 G). This visible mineralisation can be nodule like 
(Figure 6.16 F) or more spread out (Figure 6.16 H).  
 
The fact this was mineralisation, and not something else such as crystals of the 
fixative or frozen water on the samples, was confirmed by EDS analysis. Analysis of 
the minerals present showed the areas that were not white to mainly be carbon (red 
in Figure 6.17) and the white nodules to be comprised of phosphorus and calcium 
(green and blue in Figure 6.17). The basal control samples cultured in the 
MesenPRO RS™ basal growth medium had almost no calcium or phosphorus 
present (Figure 6.17 B). The mineralisation can be seen on a lower magnification 
scale (Figure 6.17 C + D) or at a high magnification (Figure 6.17 E, F, G + H).  
 
EDS can also produce quantitative analysis of the minerals present, taken from a low 
magnification to analyse this on a large area of the scaffold surface area. Histograms 
showing the elements present can be produced (Figure 6.18), clearly showing a 
calcium and a phosphorous peak present in the osteogenic control (Figure 6.18 B), 
and the MI192 pre-treated samples (Figure 6.18 C + D), but not in the MesenPRO 
RS™ basal growth medium sample (Figure 6.18 A). Quantification of this shows the 
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global levels of elements present (Table 6-2). The osteogenic control had the highest 
level of mineralisation, with a total calcium and phosphorus percentage of 20.93%, 
compared to only 1.09% for the negative, basal, control. The 10 µM pre-treated 
sample had a combined percentage of 16.93%, and the 30 µM pre-treated sample 
19.22 %. This indicates that the overall mineralisation is higher for the osteogenic 
control than the MI192 pre-treated groups. However, the mineralisation in 30 µM 
MI192 pre-treatment is very close to that of the osteogenic control. 
  
6.3.4.3 Histological Analysis  
Van Gieson’s histological staining showed the tissue penetration was high, and cells 
have penetrated completely every sample (Figure 6.19). The MesenPRO RS™ basal 
growth medium controls (Figure 6.19 A + B) had more layers of tissue formed around 
the outside of the scaffold, likely due to the increased proliferation capacity of cells in 
this medium. This has formed a thick, capsule like, layer of tissue. Cell density is 
lower at the surface of the other samples (Figure 6.19 C - L). The cell penetration was 
comparable across all groups. Cell density is similar in all scaffolds in the centre, 
which indicates that despite increased proliferative capacity of cells in the basal 
control, there is a maximum cell density in the scaffolds, which is still reached in the 
slower growing cell groups. 
 
Picrosirius red staining shows that collagen had formed in all samples, although the 
amount varies between groups (Figure 6.20). The capsule observable in the 
MesenPRO RS™ basal growth medium controls stains strongly red, indicating a high 
level of collagen is present. There is very little staining on the cells on the inside of 
the scaffold (Figure 6.20 A + B). The osteogenic control scaffolds have a several cell 
deep layer of staining close to the surface, showing the more mature cells located at 
the surface of the scaffold have laid down more collagen than the potentially less 
mature cells in the centre of the scaffold (Figure 6.20 C + D). The Picrosirius red 
staining is higher in the cells pre-treated with 10 µM of MI192 (Figure 6.20 E - H) than 
the osteogenic controls (Figure 6.20 C + D). The Picrosirius red staining can be 
observed strongly throughout the whole scaffold, especially in samples E and G. 
Staining is weaker in the samples with cells pre-treated with 30 µM of MI192 (Figure 
6.20 I – L) than the samples with cells pre-treated with 10 µM of MI192, but is 
comparable to the osteogenic medium controls (Figure 6.20 C + D). The samples 
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with cells pre-treated with 30 µM of MI192 (Figure 6.20 I – L) also have a strongly 
stained, thin capsule of cells at the surface.  
 
The Von Kossa’s staining for mineralisation showed no staining and thus no 
mineralisation of the MesenPRO RS™ basal growth medium control sections (Figure 
6.21 A + B), compared the other samples that were cultured in osteogenic 
mineralisation medium (Figure 6.21 C - L). Von Kossa’s staining was observed in the 
osteogenic mineralisation medium controls (Figure 6.21 C + D), showing that the 
osteogenic mineralisation medium induced mineralisation and the MesenPRO RS™ 
basal growth medium did not. The Von Kossa’s staining was stronger in both of the 
sample groups with cells pre-treated with MI192 (10 µM of MI192: Figure 6.21 E – H 
and 30 µM of MI192: Figure 6.21 I – L) than the osteogenic controls (Figure 6.21 C + 
D). The staining was comparable between the two groups of MI192 pre-treated cell 
scaffolds. In all groups cultured in osteogenic mineralisation medium, the 
mineralisation staining was found to be stronger closer to the surface of the 
constructs, where cells were more mature. 
 
6.3.5 Immunohistochemical staining 
Due to the high magnification needed to see staining with the Runx2 and Ocn 
staining, only one representative image is shown. For the collagen 1 staining, a high 
and a low magnification image from two different scaffolds are sown. 
 
6.3.5.1 Runx2 
Runx2 is a transcription factor, so should primarily only be seen in the nuclei of cells. 
Much optimisation was necessary to remove non-nuclear background staining. No 
Runx2 staining can be observed in the MesenPRO RS™ basal growth medium 
controls. Staining can be observed in the osteogenic control and both MI192 treated 
groups. Staining was largely the same in all three groups. Staining was located 
throughout the cells in the scaffold. 
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6.3.5.2 Col1 
Col1 staining mimicked that seen with the Picrosirius red staining for the osteogenic 
control and the MI192 treated cells. There was a low level of staining seen in the 
MesenPRO RS™ basal growth medium controls, despite the Picrosirius red staining, 
perhaps indicating the collagen formed when cells form a capsule like this is another 
type of collagen (likely type 2). Col1 staining was stronger in the two MI192 treated 
groups than the osteogenic controls, with the strongest staining visible in the 10 µM 
group. Staining was located most strongly at the cells on the surface of the scaffolds. 
 
6.3.5.3 Ocn 
No Ocn staining can be observed in the MesenPRO RS™ basal growth medium 
controls. Staining can be observed in the osteogenic control and both MI192 treated 
groups. Staining was largely the same in all three groups, although there was slightly 
stronger staining in the 30 µM MI192 group. Staining was located most strongly at the 
cells on the surface of the scaffolds. 
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Figure 6.14 – Fluorescent imaging of viable ADSCs (green colour) on Am silk 
scaffolds 24 hours after seeding, in Exp3. A + B – Untreated ADSCs, 
seeded onto the scaffolds; C + D – ADSCs pre-treated with 10 µM MI192; E + F 
– ADSCs pre-treated with 30 µM MI192. Scale bars = 100 µM. 
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Figure 6.15 – Fluorescent imaging of viable ADSCs (green colour) on Am silk 
scaffolds 6 weeks after seeding, in Exp3. A + B – basal medium control; C + 
D – osteogenic control; E + F – ADSCs pre-treated with 10 µM MI192; G + H – 
ADSCs pre-treated with 30 µM. Scale bars = 100 µM. 
A
 
  
 
E 
B
 
  
 
E 
C
 
  
 
E 
D
 
  
 
E 
E
 
  
 
E 
F
 
  
 
E 
G
 
  
 
E 
H
 
  
 
E 
230 
 
 
 
 
Figure 6.16 - SEM images of ADSCs on Am silk scaffolds 6 weeks after seeding, 
in Exp3. Low magnification images (scale bars = 1 mm) on the left, high 
magnification images (scale bars = 100 µm) on the right. A + B – Unseeded 
control scaffolds; C + D – basal control; E + F – osteogenic control; G + H – 
ADSCs pre-treated with 30 µM MI192; I + J – ADSCs pre-treated with 10 µM 
MI192. Arrows indicate some of the mineralisation. Magnification and scale 
indicated on the image. 
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Figure 6.17 - SEM images, with environmental EDS SEM images, of ADSCs on 
Am silk scaffolds 6 weeks after seeding, Exp3. In EDS images: Red = 
carbon, green = calcium and blue = phosphorus. A + B – basal control; C + D – 
osteogenic control; E + F – ADSCs pre-treated with 10 µM MI192; G + H – 
ADSCs pre-treated with 30 µM MI192. Magnification and scale indicated on the 
image. Magnification bars on left hand imagines = 100 µm, scale of right hand 
images is the same. 
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Figure 6.18 – Histograms showing elemental mapping of the elements present 
in the experimental Design 3 scaffolds. Maps taken at a low magnification to 
give indication of overall mineralisation levels. Labelled peaks show the 
Phosphorous and Calcium peaks. 
 
Table 6-2 - Element analysis of Design 3 scaffolds using EDS (% w.t.)  
 
Carbon 
% 
Nitrogen 
% 
Oxygen 
% 
Phosphorus 
% 
Calcium 
% 
Calcium : 
phosphorus 
ratio 
Basal control 47.79 13.45 37.67 0.41 0.68 1.66 
Osteogenic 
control 
38.13 9.71 31.82 6.42 14.51 2.26 
10 µM MI192 37.8 10.08 36.99 4.83 12.1 2.5 
30 µM MI192 26.68 8.31 37.29 9.06 10.16 1.12 
C: 10 µM MI192  
A: Basal control 
  
B: Osteogenic Control 
  
D: 30 µM MI192  
P 
  
Ca 
  
P 
Ca P Ca P 
Ca 
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Figure 6.19 – Van Gieson’s stain of sections from ADSC-silk scaffold constructs after 6 weeks of in vitro culture (Exp3). A + B – basal 
control; C + D – osteogenic control; E - H – ADSCs pre-treated with 10 µM MI192; I - L – ADSCs pre-treated with 30 µM MI192. Silk scaffold 
stained a yellow/pink colour and the tissues were stained a darker pink colour. Scale bars = 100 µM.    
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Figure 6.19 M + N – High magnification image of Figure 6.19 E and K, respectively. The green arrows indicate the cells growing along the 
scaffold.  
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Figure 6.20 – Picrosirius Red stain, with Weigert’s haematoxylin nuclei stain, of sections from ADSC-silk scaffold constructs after 6 
weeks of in vitro culture (Exp3). All samples labelling (A – L) same as Figure 6.19. Silk scaffold stained a yellow/grey colour, the tissues 
were stained red if collagen was present, with the nuclei counterstained black. Scale bars = 100 µM. 
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Figure 6.21 – Von Kossa staining, with a weak Van Gieson’s counter stain for tissue, of sections from ADSC-silk scaffold constructs 
after 6 weeks of in vitro culture (Exp3). All samples labelling (A – L) same as Figure 6.19. Mineral nodules stained black/dark brown, silk 
scaffold stained a pink/brown colour and the cell tissue stained pink. Arrows indicate some strong areas of mineralisation in each scaffold. 
Scale bars = 100 µM. 
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Figure 6.21 M + N – High magnification image of Figure 6.19 H and J, respectively. The green arrows indicate some of the mineralisation. 
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Figure 6.22 – Runx2 immunohistochemistry. Low magnification Runx2 
immunohistochemical staining (brown), with a weak Harris haematoxylin 
counter stain (purple) for tissue, of sections from ADSC-silk scaffold 
constructs after 6 weeks of in vitro culture (Exp3). A – basal control; B – 
osteogenic control; C – ADSCs pre-treated with 10 µM MI192; D – ADSCs 
pre-treated with 30 µM MI192. Arrows indicate some of the Runx2 staining. 
Scale bars = 100 µM. 
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Figure 6.23 – Col1 immunohistochemistry. High and low magnification collagen 
1 immunohistochemical staining (brown), with a weak Harris haematoxylin 
counter stain (purple) for tissue, of sections from ADSC-silk scaffold 
constructs after 6 weeks of in vitro culture (Exp3). A + B – basal control; C + 
D – osteogenic control; E + F – ADSCs pre-treated with 10 µM MI192; G +H– 
ADSCs pre-treated with 30 µM MI192. Arrows indicate some of the collagen 1 
staining. Scale bars = 100 µM. 
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Figure 6.24 – Ocn immunohistochemistry. Low magnification Ocn 
immunohistochemical staining (brown), with a weak Harris haematoxylin 
counter stain (purple) for tissue, of sections from ADSC-silk scaffold 
constructs after 6 weeks of in vitro culture (Exp3). A – basal control; B – 
osteogenic control; C – ADSCs pre-treated with 10 µM MI192; D – ADSCs 
pre-treated with 30 µM MI192 for two days. Arrows indicate Ocn staining. 
Scale bars = 100 µM. 
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6.4 Discussion  
In the previous chapter, the ability of MI192 to improve the osteogenic 
differentiation of ADSCs in monolayer was demonstrated, whereas in this chapter, 
this ability was investigated in 3D models. Am silk scaffolds were utilised as a 
scaffolds and three different experimental designs were explored (Figure 6.2). 
 
It is important to investigate how cells grow in 3D, as this is much more typical of 
how the cells actually exist and act in vivo (Baker & Chen 2012; Griffith & Swartz 
2006). Scaffolds are an integral part of bone tissue engineering, essential in guiding 
the formation of functional bone, providing a 3D environment to support cell 
attachment, growth (Baker & Chen 2012), and (in the case of stem cells), 
differentiation into bone forming cells (Amini et al. 2012; Ericka M. Bueno & 
Glowacki 2011). While in vivo models are the most effective way of investigating 
bone tissue engineering, due to ethical considerations and their financial cost, it is 
advisable to optimise experimental parameters in vitro before moving onto in vivo 
models (Beckmann & Kneuer 2007; Tremoleda et al. 2011). 
 
3D models have been utilised to explore how HDACis can influence bone tissue 
engineering, although studies are limited and some utilise the scaffolds without 
addition of cells in in vivo models, not in vitro. For example, Boer et al. (2006) 
investigated TSA and NaB with calcium phosphate ceramic granules in a 
subcutaneous mouse model (Boer et al. 2006). Lee et al. (2011) investigated 
Largazole with collagen sponge scaffolds and biphasic calcium phosphate scaffolds 
in rabbit calvaria bone defect models (Lee et al. 2011). The only study with much 
evidence of in vitro work was by Jung at al. (2010), where they investigated TSA 
with calcium sulphate scaffolds (by doping the scaffolds with the HDACis during the 
setting phase) both in vitro and in vivo (Jung et al. 2010). The final two of these 
three studies showed HDACis to improve bone tissue engineering outcomes.  
 
Am silk scaffolds were chosen due to their biocompatibility, abundance, 
biodegradability and because their ability to be successfully utilised in bone tissue 
engineering models have been demonstrated in the department and the literature 
(Saha et al. 2013; Sahu et al. 2015; Kundu et al. 2013). Due to the lack of 
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precedent in the literature for HDACis and scaffold studies, the best available 
scaffolds were chosen, rather than attempting to mimic what had already been 
done in the literature.  
 
The first experimental design (Expt 1) involved the treatment of the ADSCs with 
MI192 after they had been seeded onto the scaffold. Live/dead cell labelling is a 
technique used often to assess the attachment, spreading and viability of cells 
seeded onto scaffolds, and was used to assess all experimental design scaffolds at 
various time points (W. Lu et al. 2014; El-Gendy & Yang 2012). Unfortunately this 
technique did not give an idea of the effects of the MI192 treatment on the cell 
viability, because the dead marker did not work with these scaffolds (Figure 6.4). 
 
In Expt 1, the initial seeding density was too low (Figure 6.5). In line with the 
literature, 2.5 x 105 cells should have been seeded (Saha et al. 2013), but due to 
low cell availability at the time, a lower number (1 x 105) cells was seeded. Early live 
cell marking showed that cells had attached and were growing on the scaffold 
(Figure 6.5), but density was low. This was especially apparent in the MI192 treated 
scaffolds, where treatment with MI192 had caused a drop in cell numbers. In 
hindsight, a seeding density optimisation experiment should have been undertaken, 
and a higher density was likely necessary for the experiment. At 9 weeks it 
appeared cell density was much higher (Figure 6.6), with at least a confluent layer 
of cells on every scaffold, so it was believed that sufficient tissue would have 
formed and the effect of MI192 should still be apparent. 
 
Van Gieson’s staining showed tissue formation at the scaffold surface was thicker 
in the MI192 treated constructs (Figure 6.7 D – E), than the osteogenic control 
constructs (Figure 6.7 A – C). There was good cell penetration and growth inside 
the osteogenic controls, but less cell penetration in the MI192 treated constructs. 
The osteogenic controls had a cell density and capsule formation similar to that 
seen in a study with these scaffolds carried out previously (Saha et al. 2013). It is 
know that HDACi treatment halts the cell cycle and cellular proliferation (Zhang & 
Zhong 2014; Gabrielli et al. 2011; Bhaskara et al. 2009), which has been 
demonstrated previously with MI192 in the monolayer experiments. So here, the 
cells treated with MI192 may be less capable of growth and movement on the 
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scaffold, resulting in the thick cell capsule forming on the outside of the scaffold. 
Also, this lack of movement is in combination with the cytotoxic effect of MI192 
reducing cell numbers. Those cells that had survived may have been capable of 
laying down more extra cellular matrix, causing the higher density capsule to form. 
However, the MI192 is clearly having a negative effect on long term tissue 
formation, either by simply reducing cell numbers, or by also inhibiting cell 
movement and growth. In further experiments the cells were treated with MI192 
before being seeded onto the scaffolds, preventing a bias due to loss of cells. 
Aside, a higher more optimal cell seeding density was used on the other 
experiments (2.5 times the cells, 250,000 per scaffold). 
 
In experimental design 2 (Expt 2), the cells were pre-treated with MI192 for two 
days in monolayer, prior to undergoing osteogenic pre-seeding induction for 7 days 
before seeding. Cells were then seeded onto the scaffold for further osteogenic 
induction. This procedure mimicked that carried out in monolayer in Chapter 5: The 
Effects of MI192 on the Differentiation of Adipose Derived Stem Cells in 2D. 
 
Cell viability and density was checked earlier in Expt 2 than Expt 1, to ensure 
sufficient cells had been seeded. 24 hours after seeding it appeared that there were 
sufficient cells seeded onto the scaffold (Figure 6.8), with cell density being similar 
to at 6 weeks of the previous experiment. However, rounded cell morphology was 
observed in the cells on some of the scaffolds (Figure 6.8 A, B and E). It was 
believed that over 6 weeks of culture the cells may spread and behave more 
typically, so the scaffolds were left and cultured for 6 weeks. When assessed again 
at 6 weeks (Figure 6.9), the same atypical morphology was observed in the same 
scaffolds. This was unexpected and not comparable to the previous experiment. To 
assess more closely what had happened, the scaffolds were processed for 
histology.  
 
Histology of these scaffolds also yielded atypical results, where no cells with typical 
morphology could be observed (Figure 6.10). The cells were still seen as viable 
when labelled with the live cell marker (Figure 6.8 and Figure 6.9); therefore, the 
roundness is not caused by cell death. It could be a result of the differentiation the 
cells underwent before seeding, which may cause them to change morphology or 
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halt proliferation. However, in the scaffolds with the abnormal cell morphology, a 
range of cell phenotype would be expected if it was down to cell behaviour, and 
cells seeded from exactly the same batch in the same conditions did not display 
these properties. It could be a problem with the scaffolds, but these abnormalities 
were only every observed in this experiment, and the cells on the other half of the 
scaffolds behaved as expected. The reason for this behaviour remains unknown. 
 
The other scaffolds in the group had the expected cell morphology, comparable to 
Expt 1 and the literature (Saha et al. 2013), and had cell growth throughout the 
whole scaffold (Figure 6.11). Staining for collagen with Picrosirius red (Figure 6.12) 
and mineralisation with Von Kossa (Figure 6.13) gave good results. The collagen 
formation in the constructs seeded with the MI192 pre-treated cells (Figure 6.12 C – 
F) was comparable to the osteogenic medium alone controls (Figure 6.12 A + B). 
The mineralisation was greater in the MI192 pre-treated scaffolds (Figure 6.13 C – 
F) than the osteogenic medium alone controls (Figure 6.13 A + B). However, due to 
a low scaffold number (2), conclusions cannot be drawn with full confidence. Rather 
than repeat the experiment, a third experiment with a simpler experimental design 
was undertaken.  
 
A third experimental design, where cells were seeded straight after being treated 
with MI192 in monolayer for 2 days, was the final experimental design to be 
explored (Expt 3). In this experiment, a basal control scaffold group was also 
included, where the constructs were cultured in MesenPRO RS™ basal growth 
expansion medium, to act as a negative control for the osteogenic differentiation 
groups. 
 
24 hours after seeding, the cell-scaffold constructs showed a high density of viable 
cells (Figure 6.13), with high and normal cell attachment observed. Cell density was 
similar across all groups. There was no evidence of the rounded cell morphology, 
as in Expt 2. When labelled again after 6 weeks of culture the cell density was high 
in all scaffolds (Figure 6.15). There was a difference in cell morphology in the basal 
scaffold group (Figure 6.15 A + B), were cells were more elongated, with a more 
fibroblast like cell morphology. This mimics the results seen in the 2D morphological 
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analysis of the cells (Chapter 4: The General Effects of MI192 on Adipose Derived 
Stem Cells Cultured in Monolayer, Figure 4.3 - Figure 4.5). 
 
SEM analysis was carried out on the scaffolds, to further assess cell morphology 
and as an additional assessment of cell mineralisation. Compared to the highly 
porous negative control scaffold (Figure 6.15 A + B) cells could clearly be seen on 
all experimental scaffolds (Figure 6.15 C - J). Likely due to the increased 
proliferative capacity of the cells in the expansion medium, the highest cell density 
appeared to be in the basal control scaffolds (Figure 6.15 C + D). Compared to the 
basal control, mineralisation (the white deposition) could be seen in the osteogenic 
control (Figure 6.15 E + F), and both of the MI192 treated scaffolds (Figure 6.15 G 
– J). EDS analysis of this deposition showed this white deposition to comprise of 
calcium and phosphorous (Figure 6.16), the primary minerals found in bone. When 
quantified (Table 6-2), minimal mineralisation seen in the basal medium negative 
control (1.09 %). The highest total mineralisation was seen in the osteogenic 
control, with 20.93 %, compared to 16.93 % and 19.22 % for the samples with the 
10 µM and 30 µM pre-treated cells, respectively. This indicates that the overall 
mineralisation is higher for the osteogenic control than the MI192 pre-treated 
groups. The ratio of calcium and phosphorous was also calculated (Table 6-2). The 
typical calcium/phosphorous ratio in functional bone is between 1.95 and 2.07 
(Kourkoumelis et al. 2012). The osteogenic control has a ratio closest to this (2.26) 
and along with the 10 µM pre-treated sample (with a ratio of 2.5) had a higher level 
of calcium than typical of bone. The opposite was true for the 30 µM pre-treated 
sample, where the phosphorous levels were high and therefore the ratio low, at 
1.12.  
 
The MI192 treatment has clearly altered how the scaffolds mineralise, and this 
suggests it may have lowered the mineralisation ability of the cells. However, this 
was only a pilot study, primarily to check is the mineralisation being observed in the 
histology was true mineralisation. There was only data from one sample, and the 
analysis would need to be repeated with multiple samples for a full comparison. 
This also doesn’t analyse mineralisation below the surface of the scaffold. It has 
been demonstrated in Chapter 5: The Effects of MI192 on the Differentiation of 
Adipose Derived Stem Cells in 2D (Figure 5.13) that the MI192 may improve the 
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ability of the cells to form functional mineral nodules. Also, mineralisation below the 
surface may be different in the MI192 treatment constructs. 
 
Histological analysis of the scaffolds showed good cell growth and penetration in all 
scaffolds (Figure 6.19). Compared to those scaffolds cultured in osteogenic 
medium, the basal negative control scaffolds (Figure 6.19 A + B) had tissue forming 
thickly on the outside of the scaffold, indicating layers of cells growing on top of 
each other. The cell density in the centre of the basal control was similar to that of 
all the other scaffolds, so in proliferative promoting medium, the cell density cannot 
increase past a certain point inside the scaffolds. The osteogenic control (Figure 
6.19 C + D) and the scaffolds cultured with MI192 treated cells (Figure 6.19 E – L) 
had similar cell densities to each other.  
 
The thick layer of cells formed in the basal control scaffolds stained positive for 
collagen with a Picrosirius red stain (Figure 6.20 A + B). The osteogenic control 
scaffolds (Figure 6.20 C + D) and the scaffolds seeded with cells pre-treated with 
30 µM MI192 (Figure 6.20 I – L) showed a similar level of collagen staining, with the 
collagen mostly located nearer the surface of the scaffold. The more mature cells 
are located there, and they have the greatest concentration of any growth factors 
and osteogenic stimulating supplements from the medium, so this was expected. 
The scaffolds seeded with cells pre-treated with 10 µM of MI192 (Figure 6.20 E – H) 
showed high levels of collagen, with two of the scaffolds (Figure 6.20 E + G) 
showing strong staining throughout the scaffold. This may be an indicator these 
scaffolds are showing enhanced osteogenic differentiation capability.  
 
In the basal medium negative control scaffolds, the Von Kossa stain for 
mineralisation was negative (Figure 6.21 A + B), as expected. Mineralisation 
staining was observed in all of the osteogenic controls (Figure 6.21 C + D) and both 
groups of scaffolds seeded with MI192 pre-treated cells (Figure 6.21 A – L). The 
levels of mineralisation were similar in 3 of the 30 µM pre-treated cell scaffolds 
(Figure 6.21 I – K) to the osteogenic controls, with one showing much higher 
mineralisation (Figure 6.21 L). The mineralisation, especially deeper into the 
scaffolds, was higher in the 10 µM pre-treated cell scaffolds (Figure 6.21 E – H), 
indicating a greater level of mineralisation. 10 µM MI192 may be the preferred dose 
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for improving the osteogenic differentiation of ADSCs in long term 3D culture 
models.  
 
Runx2 and Ocn protein can be seen in the osteogenic controls and the MI192 
treated groups, but staining is quite weak and is comparable across all three groups 
grown in osteogenic medium. There was no staining in the basal controls, which is 
a good indicator staining is not a false positive. However, there’s no obvious 
increase or decrease in production of Ocn or Runx2 with MI192 treatment. Due to 
the reduction in OCN gene expression seen in Chapter 5: The Effects of MI192 on 
the Differentiation of Adipose Derived Stem Cells in 2D (Figure 5.10), the fact that 
Ocn protein is present in the MI192 treated cells is an interesting and important 
result, as this allays concerns that this protein may not be produced in the MI192 
treated cells, causing problems in the long term for these experiments. Collagen 1 
production is highest in the 10 µM treated cells, indicating that MI192 treatment may 
be improving the osteogenic differentiation of these cells. The staining in the 30 µM 
treated cells was weaker, so again 10 µM may be the preferred dose in the long 
term. 
 
The fact the cell density appears to plateau, not increased even in the proliferative 
medium, may affect the cells ability to differentiate into bone. The higher density 
cells found near the scaffold surface may be more suitable for differentiation down 
an osteogenic lineage, and therefore mineralise more highly and produce more 
osteogenic proteins. This may be because the cells are more mature, and the cells 
deeper into the scaffold have grown through after seeding and may differentiate 
further down an osteogenic lineage with more time. Finally, the cells nearer the 
surface have a greater access to minerals and growth factors from the culture 
medium, as they in contact with the medium and the cells in the middle must rely on 
diffusion of these through the cells closer to the surface. 
 
This study shows that the most suitable model for future studies is Experimental 
Design 3. MI192 treatment appears to increase the osteogenic differentiation of the 
ADSCs, especially when looking at the collagen deposition and the mineralisation. 
The results are better for the 10 µM MI192 dose, and this should be considered in 
the future work.                                                                                       .. 
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Chapter 7: The effect of MI192 treatment on ADSC gene 
expression 
The aim of this chapter was to investigate the effect of MI192 treatment on the gene 
expression of ADSCs, using 96 gene microfluidic TaqMan® Array cards. The gene 
expression in ADSCs before and after two days of MI192 treatment were 
investigated, to explore the potential mechanisms behind the alterations in 
differentiation potential seen in the ADSCs in previous chapters.  
 
7.1 Introduction 
The work in this chapter was carried out in conjunction with Sarah M. Churchman, 
from Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds. 
Cell culture was carried out by the author, RNA extraction was carried out jointly by 
the author and S. Churchman, qRT-PCR by S. Churchman (observed by the author), 
data collection and processing was carried out jointly and data analysis and 
presentation by the author. 
 
In previous work in this thesis, gene expression changes in cells treated with MI192 
during osteogenic and adipogenic differentiation culture have been explored; 
however, what happens to the gene expression immediately after the initial MI192 
pre-treatment has not been explored. This could answer questions about the 
pathways by which MI192 affects differentiation potential of ADSCs, along with 
potentially opening up other avenues for HDACi and MI192 research in the future. 
 
Custom 384-well, 96 gene microfluidic TaqMan® Array cards can be utilised to 
investigate a large number of genes from up to 4 samples at one time. The genes on 
the card were chosen as important in characterising MSCs by Churchmen et al. 
based on their previous work in characterisation of MSCs (Churchman et al. 2013; 
Churchman et al. 2012).  
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7.2 Materials and Methods 
7.2.1 MI192 treatment of ADSCs 
To account for donor variation, the effect of MI192 treatment on the gene expression 
of 6 different ADSC batches (4 single donors, and two samples with 6 and 8 donors) 
was tested. Full donor information can be found in Table 7-1. 
 
Table 7-1 - donor and passage information for the 6 batches of ADSCs  
Company (Catalogue number) 
Donor/Lot 
number 
Donor(s) age/sex/Tissue Location 
Life Technologies (R7788110) 2118 45/female/abdomen 
Life Technologies (R7788110) 2117 49/female/abdomen 
Life Technologies (R7788110) 2033 63/male/breast and abdomen 
Lonza (PT-5006) 407088 46/female/abdomen 
Zen Bio (ASC-F) ASC0046 
29-62 (average 50.7)/female/ abdomen, 
thigh and knee 
Zen Bio (ASC-F) ASC0049 
29-51 (average 44)/female/ abdomen, 
breast, flank, hip, thigh and knee 
 
ADSCs (passage 2) from each donor were seeded in 6 well plates (2.5 x 105 
cells/well) and cultured in basal medium. 2.5 x 105 ADSCs from each donor were 
placed directly into a lysis buffer (Norgen Biotek Corp, Cat. no: 24000) as the 
untreated controls. After 24 hours of initial culture, the medium was then replaced 
with MI192 containing medium (30 µM in 1 mL basal medium). After 48 hours 
induction, the cells were washed twice with 1x PBS and lysed in 500 µL lysis buffer 
for 20 minutes. Lysates were then stored at – 80 °C until RNA/DNA/Protein isolation. 
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7.2.2 Isolation of RNA/DNA/Protein 
The total RNA, genomic DNA and protein was purified from the samples using 
Norgen’s RNA/DNA/Protein Purification Kit (Norgen Biotek Corp, Cat 24000), 
following the manufacturer’s instructions. For each sample, the total RNA, genomic 
DNA and proteins were all purified using the same column. Purification is based on 
spin column chromatography using Norgen’s proprietary resin as the separation 
matrix. Before loading, the samples are washed with detergents and chaotropic 
denaturants that will inactive RNAses and proteases. Nucleic acids (the RNA and the 
DNA) are bound to the column, separate from the protein in the eluent. The column 
was then washed and the RNA eluted, while the DNA remains bound to the column. 
This was then washed and eluted in a separate solution. After this the proteins can 
be loaded and purified on the same column, using pH altering methods. RNA was 
then frozen and stored at - 80 °C. Genomic DNA and protein were stored at - 20 °C in 
case they were needed for any future/further studies.  
 
7.2.3 Reverse Transcription 
Reverse transcription was carried out as described in Chapter 2: General Materials 
and Methods, 2.7.2 Reverse Transcription.  
 
7.2.4 qRT-PCR 
Custom 384-well, 96 gene microfluidic TaqMan® Array Cards were used utilised to 
compare the gene expression difference between samples treated for 2 days with 
MI192, and untreated controls.  
 
200 ng of cDNA per port (4 ports/samples per card) was loaded onto a Custom 
TaqMan Array (format 96a; from Applied Biosystems). The cards are designed to not 
need technical repeats for samples, as each sample is loaded into a single port for all 
96 genes. Genes were selected for the custom card by Sarah Churchman and co-
workers to span a wide range of genes related to MSCs. Exon-spanning, ‘3 most’ 
TaqMan assays were selected for the array when possible. The full gene information 
can be found in Table 7-2.  
Amplification curves were obtained using an Applied Biosystems 7900HD sequence 
detection system with a 40 cycle standard Taqman protocol. Samples underwent a 
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10 minute 95 °C pre-incubation step, followed by 45 cycles of 10 seconds at 95 °C, 
30 seconds at 60 °C and 1 second at 72 °C. Samples were cooled to 40 °C at the 
end of the 40 cycles. 
 
Table 7-2 - Assay identification for microfluidic card.  
TaqMan assay 
identification 
Gene 
Symbol 
Description 
Hs00153936_m1 ACAN 
Aggrecan, cartilage-specific proteoglycan core 
protein (CSPCP) 
Hs00909449_m1 ACTA2 actin, alpha 2, smooth muscle, aorta 
Hs00244715_m1 ACVR1B activin A receptor, type IB 
Hs00155658_m1 ACVR2A activin A receptor, type IIA 
Hs00758162_m1 ALPL alkaline phosphatase 
Hs00181613_m1 ANGPT1 angiopoietin 1 
Hs01101127_m1 ANGPTL4 angiopoietin-like 4 
Hs03044164_m1 BAMBI BM activin membrane inhibitor homolog 
Hs00609452_g1 BGLAP PMF-bone gamma-carboxyglutamate(gla) protein/ 
osteocalcin 
Hs00154192_m1 BMP2 bone morphogenetic protein 2 
Hs00370078_m1 BMP4 bone morphogenetic protein 4 
Hs00234930_m1 BMP5 bone morphogenetic protein 5 
Hs00403062_m1 BMPER BMP binding endothelial regulator 
Hs00831730_s1 BMPR1A bone morphogenetic protein receptor, type IA 
Hs00156438_m1 CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) 
Hs00269972_s1 CEBPA CCAAT/enhancer binding protein (C/EBP), alpha 
Hs00154382_m1 CHAD chondroadherin 
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Hs00253550_m1 CLEC4M CD209 molecule,C-type lectin domain family 4, 
member M 
Hs00166657_m1 COL10A1 collagen, type X, alpha 1 
Hs01076777_m1 COL1A1 collagen, type I, alpha 1 
Hs01028971_m1 COL1A2 collagen, type I, alpha 2 
Hs00264051_m1 COL2A1 collagen, type II, alpha 1 
Hs00164359_m1 COMP cartilage oligomeric matrix protein 
Hs00426981_m1 CSPG4 chondroitin sulfate proteoglycan 4 
Hs00171022_m1 CXCL12 chemokine (C-X-C motif) ligand 12/ stromal cell-
derived factor 1 
Hs00601975_m1 CXCL2 chemokine (C-X-C motif) ligand 2 
Hs00322497_m1 DAAM2 dishevelled associated activator of 
morphogenesis 2 
Hs00178815_m1 DDR2 discoidin domain receptor tyrosine kinase 2 
Hs00182901_m1 DVL2 dishevelled, dsh homolog 2  
Hs00358886_m1 EFNA1 ephrin-A1 
Hs00174752_m1 EPHB4 EPH receptor B4 
Hs00191912_m1 EPYC epiphycan 
Hs00609791_m1 FABP4 fatty acid binding protein 4, adipocyte 
Hs00170454_m1 FGF5 fibroblast growth factor 5 
Hs00241111_m1 FGFR1 fibroblast growth factor receptor 1  
Hs00179829_m1 FGFR3 fibroblast growth factor receptor 3  
Hs00173503_m1 FRZB frizzled-related protein/ secreted frizzled-related 
protein 3 
Hs00268943_s1 FZD1 frizzled homolog 1  
Hs00201853_m1 FZD4 frizzled homolog 4  
Hs00275833_s1 FZD7 frizzled homolog 7  
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Hs00259040_s1 FZD8 frizzled homolog 8  
Hs00268954_s1 FZD9 frizzled homolog 9  
Hs99999905_m1 GAPDH glyceraldehyde-3-phosphate dehydrogenase 
Hs00231119_m1 GATA2 GATA binding protein 2 
Hs00167060_m1 GDF5 growth differentiation factor 5 
Hs01075601_m1 GHR growth hormone receptor 
Hs00748445_s1 GJA1 gap junction protein, alpha 1, 43kDa/ Connexin 43 
Hs00157103_m1 HAPLN1 hyaluronan and proteoglycan link protein 1 
Hs99999909_m1 HPRT1 hypoxanthine phosphoribosyltransferase 1* 
Hs99999041_m1 IFNG interferon, gamma, 
Hs01005963_m1 IGF2 insulin-like growth factor 2 (somatomedin A),INS-
IGF2 
Hs00181211_m1 IGFBP3 insulin-like growth factor binding protein 3 
Hs00961622_m1 IL10 interleukin 10 
Hs00174202_m1 IL7 interleukin 7 
Hs01070036_m1 JAG1 jagged 1 
Hs00174492_m1 LEPR leptin receptor 
Hs01012571_m1 LPL lipoprotein lipase 
Hs00174838_m1 MCAM melanoma cell adhesion molecule/ CD146 
Hs00427183_m1 MSX1 msh homeobox 1 
Hs02379661_g1 MT2A metallothionein 2A 
Hs00159522_m1 MYH9 myosin, heavy chain 9, non-muscle 
Hs02387400_g1 NANOG Nanog homeobox 
Hs00707120_s1 NES nestin 
Hs00918411_s1 NGFRAP1 nerve growth factor receptor (TNFRSF16) 
associated protein 1 
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Hs00182120_m1 NGFR nerve growth factor receptor (TNFR superfamily, 
member 16)/ CD271 
Hs00271352_s1 NOG noggin 
Hs00192325_m1 OMD osteomodulin 
Hs00190682_m1 PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 
2 
Hs00170179_m1 PCOLCE procollagen C-endopeptidase enhancer 
Hs00998018_m1 PDGFRA platelet-derived growth factor receptor, alpha 
polypeptide 
Hs00185122_m1 PDGFRL platelet-derived growth factor receptor-like 
Hs01370291_g1 PHOSPHO1 phosphatase, orphan 1 
Hs00999632_g1 POU5F1 POU class 5 homeobox 1 (Oct 4) 
Hs01115513_m1 PPARG peroxisome proliferator-activated receptor gamma 
Hs00160431_m1 PRELP proline/arginine-rich end leucine-rich repeat 
protein 
Hs00231079_m1 RUNX1 runt-related transcription factor 1  
Hs00231692_m1 RUNX2 runt-related transcription factor 2 
Hs00173499_m1 S1PR1 sphingosine-1-phosphate receptor 1 
Hs00610060_m1 SFRP1 secreted frizzled-related protein 1 
Hs00180066_m1 SFRP4 secreted frizzled-related protein 4 
Hs00361747_m1 SORT1 sortilin 1 
Hs01053049_s1 SOX2 SRY (sex determining region Y)-box 2 
Hs00165814_m1 SOX9 SRY (sex determining region Y)-box 9  
Hs00541729_m1 SP7 Sp7 transcription factor/ osterix 
Hs00277762_m1 SPARC secreted protein, acidic, cysteine-rich/ osteonectin 
Hs00959010_m1 SPP1 osteopontin/ secreted phosphoprotein 1/ bone 
sialoprotein I 
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Hs00559661_m1 TGFBR2 transforming growth factor, beta receptor II 
(70/80kDa) 
Hs00234257_m1 TGFBR3 transforming growth factor, beta receptor III 
Hs01113602_m1 TNFAIP6 tumor necrosis factor, alpha-induced protein 6 
Hs00900360_m1 TNFRSF11B tumor necrosis factor receptor superfamily, 
member 11b/ osteoprotegerin 
Hs00361186_m1 TWIST1 twist homolog 1  
Hs00382379_m1 TWIST2 twist homolog 2  
Hs01097550_m1 UGDH UDP-glucose 6-dehydrogenase 
Hs00900058_m1 VEGFA vascular endothelial growth factor A 
Hs01099206_m1 VEGFC vascular endothelial growth factor C 
Hs00183662_m1 WIF1 WNT inhibitory factor 1 
*HPRT, reference gene. 
 
7.2.5 Ct Value Calculations  
Once all samples had been run, (multiple cards were necessary due to there being a 
4 sample limit per card), data from all cards was pooled in RQ Manager Software 
(Life Technologies) and analysed together in one project file, ensuring equal 
treatment and relative expression levels for all samples. A threshold was 
automatically generated by the software. The amplification curves of any flagged 
values were individually scrutinised in SDS v2.3 software to deduce if the result was 
genuine amplification or an automatic machine error in the curve detection. Samples 
were measured against a background standard and a ROX stable fluorescent 
marker, and flagged values were compared to these. Any questionable results were 
not included in the final analysis; any genes with consistently flagged results were 
noted as potentially erroneous results in Table 7-11.  
 
The comparative Ct method (2-∆∆Ct) was utilised to quantify gene expression levels, 
with the results normalised to the reference gene HPRT. Once Ct values for all 
samples had been generated, the fold difference between untreated and treated 
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samples was calculated for each donor. An average fold change for each gene was 
then produced.  
 
Samples where expression had increased from an undetectable/undetermined value 
to a detected value, or from a value to an undetectable/undetermined value were not 
included in statistical analysis, as creating false values (e.g. 0 for “undetermined”) can 
lead to inaccuracies in statistics. Undetermined just means not detected within the 
confines of this experiment and does not mean that there is no expression, or 
subsequent change of expression, for the gene. 
 
7.2.6 Statistical Analysis 
Fold changes for each gene, indicating up or down regulation (where a positive 
number is fold up-regulation and a negative number is fold down-regulation), were 
analysed in GraphPad Prism 5.0 using the non-parametric Wilcoxon paired signed 
rank test. n = 6. P value equal or below 0.05 was considered statistically significant 
(*). 
 
7.2.7 Data Presentation 
Tables of fold changes have been produced, indicating up or down regulation and if 
the result is significant. Transcripts were grouped based on their function. Graphs 
indicating the trend of up-regulation or down-regulation between treated and 
untreated cells have been produced on a log scale, with indication of if the result was 
significant. Those genes with potentially erroneous results, or with vast (500 fold plus) 
variance between donors are analysed separately (Table 7-11). The one gene not 
determined in either treated or untreated samples was also indicated separately.  
 
For each gene, a graph depicting the fold change for each donor on a logarithmic 
scale was produced, showing the difference between untreated and MI192 treated 
ADSCs. The average fold change, standard deviation and the statistical significance 
(P value) for each gene was also calculated and is in tabular form.  
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7.3 Results  
The 96 transcripts investigated have been grouped into physiologically relevant 
categories. An increase or decrease in expression with MI192 treatment refers to an 
increase or decrease of expression compared to the untreated control cells. 
 
7.3.1.1 The effect of MI192 treatment on the expression of Wnt related 
transcripts in ADSCs  
MI192 treatment significantly up-regulated FRZB, SFRP1 and FZD9 gene expression 
(15.5 fold, 20.2 fold and 6.7 fold, P ≤ 0.05) in treated ADSCs (Table 7-3).  
 
In the MI192 treatment groups, the expression levels of FZD1, FZD7 and FZD8 were 
down-regulated (3.57 fold, P > 0.05; 4.19 fold, P ≤ 0.05 and 1.32 fold, P > 0.05, 
respectively). Of these, only FZD7 showed a strong down-regulation between donors, 
FZD1 and FZD8 had a poor level of consistency between donors.  
 
DVL2, SRFP4, FDZ4, NANOG and POU5F1 had inconclusive changes in expression, 
with mixed results between donors (Figure 7.1) and expression changes below 2 fold 
up and down-regulation (Table 7-3).   
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Table 7-3 – Fold changes in expression of Wnt related transcripts in ADSCs 
treated with MI192 for 2 days 
Gene Fold Change Significance 
FRZB 15.51 * 
SFRP1 20.23 * 
SFRP4 0.12 ns 
DAAM2 -15.95 * 
DVL2 -1.23 ns 
FZD1 -3.57 ns 
FZD4 0.88 ns 
FZD7 -4.19 * 
FZD8 -1.32 ns 
FZD9 6.73 * 
NANOG -0.03 ns 
POU5F1 0.85 ns 
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Figure 7.1 - Graphical depictions of gene expression changes between treated 
and untreated cells in Wnt pathway related transcripts. Graphs on a 
logarithmic scale and results expressed as fold changes (n=6). * = P ≤ 0.05 
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7.3.2 The effect of MI192 treatment on the expression of early 
cartilage and bone related transcripts in ADSCs 
BMP2 and BMP4 transcript levels were significantly up-regulated (32.76 and 12.3 
fold, P ≤ 0.05, both strongly in all donors, Table 7-4 and Figure 7.2) in the MI192 
treated ADSCs. IGF2 was 30.14 fold up-regulated (P > 0.05), with 5 out of 6 donors 
showed up-regulation.  
 
Transcript levels of BMPER were down regulated (4.63 fold, although not statistically 
significantly, P > 0.05), with five out of six donors showing down-regulation. GDF5 
was down-regulated 26.05 fold in all donors but not statistically significant (P > 0.05). 
IGFBP3, ACVR1B, ACVR2A and RUNX2 were all uniformly  and statistically 
significantly down-regulated in all donors (8.05 fold, 3.33 fold, 2.42 fold and 3 fold P ≤ 
0.05). TWIST1 was down-regulated 10 fold (P > 0.05), although it was up-regulated in 
2 donors. Finally, TWIST2 and DDR2 were down-regulated (10 fold and 18.9 fold P ≤ 
0.05), in all donors. 
 
Results were less conclusive, with varying results between donors, (P > 0.05) for 
SOX9 (1.48 fold up-regulated), BMPR1A (3.55 fold down-regulated), BMPER (4.63 
fold down-regulated) and NOG (0.35 fold up-regulated). 
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Table 7-4 - Fold changes in expression of early cartilage and bone related 
transcripts in ADSCs treated with MI192 for 2 days 
Gene Fold Change Significance 
BMP2 32.762 * 
BMPR1A -3.55 ns 
BMP4 12.29 * 
GDF5 -26.05 ns 
BMPER -4.64 ns 
NOG 0.35 ns 
SOX9 1.48 ns 
IGF2;INS-IGF2 30.14 ns 
IGFBP3 -8.05 * 
ACVR1B -3.32 * 
ACVR2A -2.42 * 
RUNX2 -3.09 * 
TWIST1 -9.97 ns 
TWIST2 -10.06 * 
DDR2 -18.86 * 
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Figure 7.2 - Figure 7.3 - Graphical depictions of gene expression changes 
between treated and untreated cells in early cartilage and bone related 
transcripts. Graphs on a logarithmic scale and results expressed as fold 
changes (n=6). * = P ≤ 0.05 
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7.3.3 The effect of MI192 treatment on the expression of bone 
related transcripts in ADSCs 
In this study, in MI192 treated ADSCs the transcript levels of ALPL and PMF-BGLAP 
had a trend of down-regulation (both ~3.5 fold, P > 0.05) but with mixed results 
between donors (Table 7-5 and Figure 7.4). SPP1 and PHOSPHO1 were both up-
regulated strongly, SPP1 in all donors and PHOSPHO1 in 5 out of 6 (35 fold, P ≤ 
0.05, and 59 fold, P > 0.05, respectively). 
 
SPARC, TNFRSF11B, CDH11, COL1A1 and COL1A2 were all strongly down-
regulated in all donors (P ≤ 0.05, 11 fold, 52 fold, 11 fold, 22 fold and 11 fold 
respectively). EPHB4 and TGFBR3 had variable and mixed results between donors, 
with small, below 2 fold, down-regulation (P > 0.05). 
 
Table 7-5 – Fold changes in expression of markers of osteogenic differentiation 
in ADSCs treated with MI192 for 2 days 
Gene Fold Change P Value 
ALPL -3.53 ns 
SPARC -11.71 * 
BGLAP;PMF-
BGLAP 
-3.34 ns 
TNFRSF11B -52.28 * 
CDH11 -11.00 * 
EPHB4 -1.80 ns 
TGFBR3 -0.33 ns 
COL1A1 -22.29 * 
SPP1 35.31 * 
PHOSPHO1 58.59 ns 
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Figure 7.4 - Graphical depictions of gene expression changes between treated 
and untreated cells in later stage bone related transcripts. Graphs on a 
logarithmic scale and results expressed as fold changes (n=6). * = P ≤ 0.05.
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7.3.4 The effect of MI192 treatment on the expression of early 
stage cartilage, and cartilage and bone extracellular matrix 
related transcripts in ADSCs 
 
TNFAIP6 was statistically significantly (P ≤ 0.05) up-regulated 7.4 fold, in all 6 
donors. EPYC was up-regulated 5.3 fold, although not statistically significantly (P > 
0.05), likely because one donor showed down-regulation. 
  
Expression of COL2A1 was up-regulated in MI192 pre-treated cells (2.5 fold); 
however, in 3 donors expression went from an undetected level to a detected level, 
and the other three donors all had the expression up-regulated, indicating a strong 
up-regulation. CHAD had similar results (8 fold up-regulation overall, P > 0.05), with 
3 donors showing up-regulation, one down-regulation and two with expression 
initially undetermined become determined from, therefore with strong indication of 
up-regulation. 
 
Transcription levels of PCOLCE, PAPSS2, UGDH and COL10A1 were all down-
regulated (P ≤ 0.05) in MI192 treated cells, (8.1 fold, 6.1 fold, 6.3 fold and 10.36 fold 
respectively) in all donors (Figure 7.5 and Table 7-6). HAPL1 was also down-
regulated (47.8 fold, P > 0.05, with 5 out of 6 donors having down-regulation). 
 
COMP was down-regulated by 0.45 fold, but was not statistically significant (P > 
0.05), as the expression was actually up-regulated in 2 donors. ACAN had mixed 
and inconclusive results. Results were also mixed for PRELP, where 2 donors 
showed down-regulation, one donor had expression initially undetermined become 
determined, and up-regulation (45, 18 and 2.27 fold) in 3 donors. Overall it showed 
an up-regulation of 12.6 fold, although this was not statistically significantly (P > 
0.05).  
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Table 7-6 – Fold changes in expression of cartilage and bone extracellular 
matrix related transcripts in ADSCs treated with MI192 for 2 days 
Gene Fold Change P Value 
PCOLCE -8.11 * 
PAPSS2 -6.07 * 
UGDH -6.32 * 
COL10A1 -10.36 * 
HAPLN1 -47.83 ns 
COMP -0.45 ns 
COL2A1 2.45 ns 
TNFAIP6 7.43 * 
EPYC 5.31 ns 
PRELP 12.55 ns 
CHAD 7.97 ns 
ACAN -9.06 ns 
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Figure 7.5 - Graphical depictions of gene expression changes between treated 
and untreated cells in cartilage and bone extracellular matrix related 
transcripts. Graphs on a logarithmic scale and results expressed as fold 
changes (n=6). * = P ≤ 0.05.  
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7.3.4.1 The effect of MI192 treatment on the expression of adipogenic 
transcripts in ADSCs 
CEBPA expression in MI192 treated cells was statistically significantly up-regulated 6 
fold (P ≤ 0.05) in all 6 donors. FABP4 expression in MI192 treated cells was up-
regulated (P > 0.05), with up-regulation in 3 donors (22 fold, 1230 fold and 1817 fold), 
and from undetermined to determined in 3 donors.  
 
LEPR expression in MI192 treated cells down-regulated 4.2 fold, although not 
statistically significantly (P > 0.05), with up-regulation in 1 of 6 donors. PPARγ was 
down-regulated in MI192 treated cells (Figure 7.6), although this was not statistically 
significant (P > 0.05), as the down-regulation was only 1.1 fold over all, and was 
actually up-regulated in 2 donors (Table 7-7).  
 
LPL expression in the MI192 treated and untreated ADSCs was flagged as 
unreliable, and results varied massively between donors.  The expression of TGFBR2 
was also variable between donors, so no conclusion could be drawn from that data. 
BAMBI expression in MI192 treated cells was up-regulated 2.7 fold (P > 0.05), also 
with mixed results between donors. 
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Table 7-7 – Fold changes in expression of adipogenic transcripts in ADSCs 
treated with MI192 for 2 days 
Gene Fold Change P Value 
PPARG -1.14 ns 
FABP4 1023.56 ns 
BAMBI 2.65 ns 
CEBPA 6.00 * 
LEPR -4.16 ns 
TGFBR2 -0.134 ns 
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Figure 7.6 - Graphical depictions of gene expression changes between treated 
and untreated cells in adipogenic transcripts. Graphs on a logarithmic scale 
and results expressed as fold changes (n=6). * = P ≤ 0.05
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7.3.5 The effect of MI192 treatment on the expression of stromal 
related transcripts in ADSCs 
7.3.5.1 Angiogenesis related transcripts 
Expression of ANGPTL4 in MI192 treated cells was up-regulated 29.75 fold (P ≤ 0.05, 
Table 7-8) in all 6 donors (Figure 7.7). VEGFA, VEGFC and ANGPT1 expression in 
MI192 treated cells was strongly down-regulated (9.5 fold, 6.6 fold and 10 fold 
respectively P ≤ 0.05), in all donors. Expression of EPHB4 in MI192 treated cells is 
varied between donors and overall was not significantly (P > 0.05) down-regulated 
(1.8 fold) with MI192 treatment cells (shown previously in Figure 7.4 and Table 7-5). 
 
7.3.5.2 Pericyte related transcripts 
MCAM was 4.79 fold up-regulated (P > 0.05, Table 7-8) with MI192 treatment, with 
one donor showing down-regulation (Figure 7.7). PDGFRL was 14.5 fold up-
regulated in MI192 treated ADSCs, although not significantly (P > 0.05), and results 
were inconclusive as in 3 donors it was actually down-regulated. CSPG4, ANGPT1, 
ACTA2 and PDGFRA expression was down-regulated 2.9 fold, 10 fold, 13 fold and 
8.53 fold (P ≤ 0.05, Table 7-8) in MI192 treated ADSCs in all 6 donors.  
 
7.3.5.3 Hematopoietic related transcripts 
CXCL2 expression in MI192 treated cells was 86 fold significantly up-regulated, (P ≤ 
0.05), with a strong up-regulation visible in all 6 donors. With MI192 treatment, 
expression of GJA1 was statistically significantly (P ≤ 0.05, Table 7-8) down-
regulated (6 fold) in all 6 donors (Figure 7.8). RUNX1 was down-regulated 4.5 fold (P 
> 0.05), with most donors showing very little change in expression with MI192 
treatment. Also minimally altered with MI192 treatment was JAG1 (up-regulated, 0.35 
fold, P > 0.05), where results were mixed between donors. CXCL12, GATA2, IL7 and 
IL10 all had mixed results between donors, both with fold changes all less than 2 fold, 
and nothing statistically significantly (P > 0.05).  
 
7.3.5.4 Muscle related 
ACTA2 and MSX1 expression in MI192 treated cells was significantly down-regulated 
13 fold and 3 fold (P ≤ 0.05) in all 6 donors. 
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Figure 7.7 - Graphical depictions of gene expression changes between treated 
and untreated cells in half of the stromal related transcripts. Graphs on a 
logarithmic scale and results expressed as fold changes (n=6). * = P ≤ 0.05 
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Figure 7.8 - Graphical depictions of gene expression changes between treated 
and untreated cells in the other half of the stromal related transcripts. 
Graphs on a logarithmic scale and results expressed as fold changes (n=6). * = 
P ≤ 0.05 
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Table 7-8 – Fold changes in expression of stromal related transcripts in ADSCs 
treated with MI192 for 2 days 
Gene Fold Change P Value 
VEGFA -9.54 * 
VEGFC -6.64 * 
ANGPT1 -10.04 * 
ANGPTL4 29.75 * 
CSPG4 -2.92 * 
MCAM 4.79 ns 
ACTA2 -13.01 * 
PDGFRA -8.53 * 
PDGFRL 14.51 ns 
GJA1 -5.96 * 
RUNX1 -4.50 ns 
JAG1 0.35 ns 
CXCL12 -0.90 ns 
GATA2 0.94 ns 
CXCL2 86.19 * 
IL7 1.52 ns 
IL10 -2.54 ns 
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7.3.6 The effect of MI192 treatment on the expression of 
Neural/nerve related transcripts in ADSCs 
NGFR expression in MI192 treated was up-regulated 36.8 fold (P > 0.05, Table 
7-9), with measurable up-regulation in 5 donors and from undetermined to 
determined in 1 donor (Figure 7.9). SORT1 was also strongly up-regulated in all 
donors (6.63 fold, P ≤ 0.05). NGFRAP1 and NES expression changes were mixed 
between donors and largely unaffected (0.21 and 0.86 fold down-regulation overall 
P > 0.05), with MI192 treatment. 
 
Table 7-9 - Fold changes in expression of neural/nerve related transcripts in 
ADSCs treated with MI192 for 2 days 
Gene Fold Change P Value 
NGFR 36.79 ns 
NGFRAP1 -0.21 ns 
NES -0.86 ns 
SORT1 6.63 * 
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Figure 7.9 - Graphical depictions of gene expression changes between 
treated and untreated cells in neural/nerve related transcripts. Graphs on 
a logarithmic scale and results expressed as fold changes (n=6). * = P ≤ 0.05. 
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7.3.7 The effect of MI192 treatment on the expression of 
miscellaneous transcripts in ADSCs 
FGFR3 was significantly up-regulated 38 fold (P ≤ 0.05), with strong up-regulation 
in all donors. MYH9 was slightly down-regulated in 5 donors, although only 1.78 
fold in total and not significantly (P > 0.05). Change in expression of FGFR1, FGF5, 
SOX2 and GHR with MI192 treatment were minimal and varied between donors 
(Figure 7.10). 
 
Table 7-10 – Fold change in expression of miscellaneous transcripts in 
ADSCs treated with MI192 for 2 days 
Gene Fold Change P Value 
FGFR1 -0.71 ns 
FGF5 0.90 ns 
FGFR3 38.30 * 
SOX2 1.68 ns 
GHR 1.34 ns 
MYH9 -1.78 ns 
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Figure 7.10 - Graphical depictions of gene expression changes between 
treated and untreated cells in miscellaneous transcripts. Graphs on a 
logarithmic scale and results expressed as fold changes (n=6). * = P ≤ 0.05. 
 
 
7.3.8 Genes that were flagged due to potentially erroneous 
results or non-expression  
Some genes (Table 7-11) were flagged by the software as having Ct values that 
were questionable. The questionable Ct values and thus fold changes often 
resulting in very, and very variable between donors large fold changes. These were 
noted as being inconclusive and these results were not analysed further. 
 
Finally, BMP5 was undetermined in all samples both before and after MI192 
treatment, so no conclusions could be drawn other than ADSCs must have a low 
expression of BMP5.  
 
 
 
 
 
277 
 
 
Table 7-11 - Genes that were flagged due to potentially erroneous results. No 
transcripts were significantly up or down-regulated.  
Gene Fold Change P Value Notes 
CLEC4M; 
CD209 
14.40 ns 
Up-regulated 14.4 fold in one donor, from 
undetermined to determined in 4 donors and 
down regulated from determined to 
undetermined in 1 donor. 
 
LPL 43.39 ns 
Very varied expression changes, including up 
and down regulations. Data not reliable at all. 
 
WIF1 -1655.11 ns 
Overall trend of up-regulation, however with 
one donor with a huge down-regulation, and 
overall widely variable changes. 
 
SP7 -1317.68 ns 
Overall trend of down-regulation, but with 
widely variable changes and with one donor 
having no expression in MI192 treated and 
untreated samples. 
 
OMD -1307.61 ns 
Varied expression changes, including up and 
down regulations. Down-regulation from 
determined to undetermined from 3 donors. 
Overall trend of down-regulation. 
 
IFNG -448.23 ns 
Very varied expression changes, including up 
and down regulations. Data not reliable at all. 
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Figure 7.11 – Up-regulated fold changes grouped. Graph indicating the average 
fold change for every up-regulated transcript with MI192 treatment. HPRT 
reference gene is set to 1. A number greater than 1 indicates an up-
regulation. Statistical significant (P ≤ 0.05) indicated on the graph with a *. 
Any gene with a donor number less than 4, or with abnormal amplification 
curves were removed from the graph.  
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Figure 7.12- Down-regulated fold changes grouped. Graph indicating the 
average fold change for every down-regulated transcript with MI192 
treatment. HPRT reference gene is set to 1. A number less than 1 indicates a 
down-regulation. Statistical significant (P ≤ 0.05) indicated on the graph with a 
*. Any gene with a donor number less than 4, or with abnormal amplification 
curves were removed from the graph. 
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7.4 Discussion 
Those genes in which a noticeable change with MI192 treatment will be discussed. 
Where relevant, those where no change was observed will be discussed, otherwise 
the results won’t be discussed for conciseness.  
 
7.4.1 The effect of MI192 treatment on the expression of Wnt 
related transcripts in ADSCs 
MI192 had a strong effect on several transcripts linked to the Wnt/β-catenin 
pathway. The Wnt/β-catenin pathway is a key pathway in MSC differentiation, with 
complicated and wide ranging effects. When activated, Wnt ligands combine with 
frizzled receptors and co-receptors, such as lipoprotein receptors, to facilitate β-
catenin accumulation. This inhibits glycogen synthase kinase-3β (GSKβ3), and the 
β-catenin enters the nucleus, regulating many proteins and subsequent pathways. 
Related to this investigation, Wnt signalling is an upstream activator of BMP2 
expression in osteoblasts, and the cross talk that occurs between Wnt and BMP2 
signalling is essential for both osteogenic differentiation and skeletal maintenance. 
Increasing Wnt signalling causes MSCs to begin to differentiate into osteoblasts, 
and continued signalling triggers these pre-osteoblast cells to develop into mature 
osteoblasts, leading to ALP activation and mineralisation, which also needs Wnt 
and BMP signalling (Zhang et al. 2013; Enomoto-Iwamoto et al. 2002). It is known 
that some osteogenic differentiation altering methods, such as mechanical loading, 
affect the Wnt pathway, one way or another (Vrtačnik et al. 2013). Interestingly, 
activated Wnt signalling can also result in both the degradation of adult cartilage, 
the chondrogenic differentiation of MSCs and inhibition can cause the apoptosis of 
adult chondrocytes. In addition to this, Wnt signalling maintains the undifferentiated 
states of human and mouse ESCs (Sato et al. 2004). Furthermore, Wnt/β-catenin 
signalling is known to enhance neuronal differentiation (Yu et al. 2013).  
 
Burba et al. (2011) found VPA to treatment of CD34+ HSCs up-regulated the 
expression of Wnt pathway transcripts WNT1 and FZD1. They suggested that this 
could be a sign of the enhanced self-renewal, as these pathways are a key 
regulator of stem cells in the stem cell niche (Burba et al. 2011).  
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7.4.1.1 The effect of MI192 treatment on the expression of Wnt 
modulating FRZB, SFRP1, SRFP4, DAAM2 and DVL2 transcripts  
FRZB, which was up-regulated with MI192 treatment, encodes for a Wnt 
modulating protein key to bone and cartilage development, regulating 
skeletalgenesis, long bone formation and chondrocyte maturation. It is thought that 
the increased levels of this are linked to an increase in chondrogenic differentiation 
(Thysen et al. 2015).  
 
Secreted frizzled-related proteins (SFRPs) act as modulators of Wnt signalling. 
There was a large up-regulation of SFRP1 and a very small down-regulation of 
SRFP4. SFRP1 is a Wnt transcript, which modulates the Wnt pathway linked to 
bone, cartilage and osteoblast differentiation and inhibition of osteoclasts (Thysen 
et al. 2015). SFRP4 is a member of the SFRP family that contains a cysteine-rich 
domain homologous to the putative Wnt-binding site of frizzled proteins. The 
expression of SFRP4 in ventricular myocardium correlates with apoptosis related 
gene expression. SFRP4 is a Wnt pathway antagonist, inhibiting the pathway, while 
lowering BMP2 levels (Wagner et al. 2005).  
 
Up-regulation of FRZB and SFRP1, combined with down-regulation of SFRP4, may 
(partially at least) explain the pathway by which MI192 improves osteogenic 
differentiation potential of ADSCs. FRZB and SFRP1 are involved in chondrogenic 
and osteogenic Wnt related pathways. An increase in the transcript levels of SRFP1 
indicates an increase in Wnt signalling potential. Also, the decreased levels of 
SRFP4 and increased levels of FRZD proteins are associated with undifferentiated 
MSCs. Down-regulation of the antagonist SFRP4 allows for increase Wnt signalling 
in the cells (Wagner et al. 2005; Thysen et al. 2015). 
 
DAAM2 encodes dishevelled associated activator of morphogenesis 2 protein, 
which is known to amplify Wnt signalling. It is possibly related to spinal cord 
development and general cell actin cytoskeleton function (Lee et al. 2015), and the 
strong down-regulation of this indicates the MI192 treated cells are not being 
amplified for this. 
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7.4.1.2 The effect of MI192 pre-treatment on the expression of Wnt 
receptor transcripts FZD1, FZD4, FZD7, FZD8 and FZD9  
FZD1, FZD4, FZD7, FZD8 and FZD9 are all transcripts for Wnt receptors, and their 
individual functions are not very well understood. They act as part of the Wnt/β-
catenin pathway (Burba et al. 2011; Reya et al. 2001).  
 
FZD7 was down-regulated with MI192 treatment, and FZD9 up-regulated, which 
may give more insight into which receptors are involved in these Wnt signalling 
pathways. In the literature, for example, FZD1 is up-regulated in HSCs treated with 
VPA (Burba et al. 2011). Here, only FZD9 expression is up-regulated with MI192 
treatment, perhaps indicating it the key receptor of these in the Wnt pathway when 
activated by HDAC2 and HDAC3 inhibition, or by the other Wnt related proteins 
potentially increased with MI192 treatment. For the other receptors (FZD1, FZD8 
and FZD4) the responses to MI192 treatment were mixed between donors. 
 
7.4.1.3 The effect of MI192 treatment on the expression of Wnt Targets 
NANOG, POU5F1, and SOX2 
NANOG and POU5F1 encode proteins (Nanog homeobox and POU domain, class 
5, transcription factor 1, also known as Oct-4, octamer-binding transcription factor 
4)). They are transcription factors related to the pluripotency of ESCs and are two of 
the four famous key factors utilised in generation of pluripotent stem cells from adult 
cell sources (Takahashi et al. 2007). They are key Wnt targets and can be utilised 
as markers for undifferentiated cells, and are essential for maintaining the self-
renewing undifferentiated state. NANOG acts to bind SMADs, regulators of BMP, 
blocking BMP function and preventing mesoderm differentiation (Gaarenstroom & 
Hill 2014). In this study, both NANOG and POU5F1 transcript levels are almost 
unchanged in the MI192 treated cells (P > 0.05). It has been suggested in the 
literature that treatment with HDACis (here TSA and VPA) decreases the levels of 
NANOG and POU5F1 in cell lines of malignant testicular germ cell tumour cells 
(Schweyer 2013). However, here there is a lack of change in NANOG and POU5F1 
expression with HDAC inhibition. SOX2 encodes Sox2, a transcription factor that is 
essential for maintaining self-renewal, or pluripotency, of undifferentiated ESCs. 
This was also unchanged with MI192 treatment.  
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This blanket lack of change in these transcripts indicates that the pluripotency, or 
ESC like capacity, of the ADSCs cells is maintained, and certainly not decreased, 
with MI192 treatment. 
 
7.4.2 The effect of MI192 treatment on the expression of early 
cartilage and bone related transcripts in ADSCs 
Markers linked to the early stages of bone and cartilage differentiation have been 
grouped together. The change in expression of these genes may account for why 
pre-treatment of ADSCs with MI192 leads to an increased sensitivity to osteogenic 
differentiation protocols.  
 
7.4.2.1 BMP2, BMPR1a, BMP4, BMPER, NOG and GDF5 
A key finding from this study was finding that fact BMP2 was significantly up-
regulated with MI192 treatment. BMP2 encodes for bone morphogenetic protein 2 
(BMP2), and is perhaps the most explored protein in the osteogenic differentiation 
pathway, due to investigations into its potential clinical application (Carragee et al. 
2011). BMP2 binds to BMPR1a and 1b, but also interacts with many targets, 
especially in osteogenic differentiation linked signalling pathways (Jang et al. 2012). 
Unfortunately BMPR1B was not on the card, but the expression of BMPR1A was 
found to be slightly down-regulated. The BMP2 pathway crosstalks with the 
aforementioned Wnt pathway, and it is believed Wnt signalling is an upstream 
regulator of BMP signalling (Zhang et al. 2013). Despite its bone-related name, 
BMP2 acts in many pathways, such as cardiac differentiation (van Wijk et al. 2007), 
and not just in osteogenic differentiation pathways. Here, the BMP2 pathway seems 
to be up-regulated with MI192 treatment. 
 
BMP4 is responsible for early chondrogenesis, and can induce MSCs down a 
chondrogenic lineage (Karamboulas et al. 2006; Hatakeyama et al. 2004). BMP4 
was up-regulated in MI192 treated ADSCs, and this is similar to findings in the 
literature, where TSA treated P19 embryonic carcinoma cell line cells showed 
increased levels of BMP4 (Karamboulas et al. 2006). BMPER encodes BMP 
binding endothelial regulator (BMPER), which is a BMP4 inhibiting protein (Moser et 
al. 2003). BMPER was down-regulated with MI192 treatment. NOG encodes for 
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Noggin, another BMP pathway inhibiting protein (Zhang et al. 2013), which was 
unaffected with MI192 treatment. 
 
BMP2 and BMP4 encode proteins key to the promotion of osteogenic differentiation 
of stem cells. The observed increase of Wnt signalling in the MI192 treated cells 
may account for their elevated transcription, as increased Wnt signalling in cells is 
known to lead to an increase in BMP2 and BMP4 levels (Zhang et al. 2013). The 
fact BMP2 and BMP4 are significantly up-regulated with MI192 treatment, with 
BMPER encoding an inhibitor for these pathways, significantly down-regulated is 
very interesting.  
 
Finally, GDF5 encodes growth/differentiation factor-5, a member of the TGF-β 
super family, is responsible for later stage chondrogenesis (following on from BMP4 
in the pathway), and promotes chondroprogenitor cell aggregation (Hatakeyama et 
al. 2004). GDF5 was down-regulated in all donors, so the fact this was not 
significant is unusual, and there is a definite trend of down-regulation. GDF5 is 
involved downstream in chondrogenic differentiation to BMP4, indicating that MI192 
treatment might be inducing the earlier stages of chondrogenic differentiation.  
 
7.4.2.2 IGF2 and IGFBP3 
IGF2 and IGFBP3 may also be linked to osteogenic differentiation. MI192 treatment 
had the opposite effect on these transcripts, largely up-regulating IGF2 but down-
regulating IGFBP3. IGF2 encodes insulin-like growth factor 2, which is thought to 
trigger osteogenic differentiation in MSCs and ESCs (Ding et al. 2015; Kang et al. 
2012). Insulin-like growth factor-binding protein 3 (IGFBP3) is a binder and a 
blocker of BMP2 and BMP4 (Zhong et al. 2011), and is thought to regulate and 
inhibit bone formation (Silha et al. 2003). An increase in IGF2 and a decrease in 
IGFBP3 with MI192 treatment may help account for the increased osteogenic 
potential of these cells. The down-regulation of IGFBP3 fits the picture with the up-
regulation of BMP2 and BMP4.  
 
7.4.2.3 ACVR1B and ACVR2A 
ACVR1B encodes activin receptor type-1B, a growth factor part of the transforming 
growth factor-beta (TGF-beta) superfamily of structurally related signalling proteins. 
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ACVR1B can bind to activin receptor type-2A, a receptor type protein encoded by 
ACVR2A. Both of these were statistically significantly (P ≤ 0.05) down-regulated 
with MI192 treatment. They transmit signals to receptor-regulated SMAD2 and 
SMAD3, resulting in the transcription of genes that function as inhibitory regulators 
of proliferation. This acts differently to BMP signalling, which through other 
receptors such as BMPR1a, transmit their signals through SMAD1, SMAD5 and 
SMAD8, initiating osteogenic differentiation. These two signalling pathways have 
compete for binding of a co-SMAD, SMAD4, interfering in signalling with each 
other. Inhibition of SMAD2/3 activates SMAD1/5/8 signalling, and therefore 
increasing osteogenic differentiation. It is believed that it is the targeting and 
inhibition of ACVR1B by microRNA miRNA-210, which results in the improved 
osteogenic differentiation seen when this mRNA is utilised (Mizuno et al. 2009; 
Maeda et al. 2004). Here MI192 treatment results in the down-regulation of 
ACVR1B and ACVR2A, which may act in the same way as miRNA-210, inhibiting 
the TGF-β/activin signalling pathway, resulting in more SMAD4 being available to 
take part in BMP signalling pathways, in turn, resulting in increased osteogenic 
differentiation. Alternatively, the up-regulation of BMP2 and BMP4 may be 
accounting for the increase in these transcripts. Either way this is part of an overall 
explanation for the increased osteogenic differentiation potential observed with 
MI192 treatment.  
 
7.4.2.4 RUNX2, TWIST1, TWIST2 and DDR2 
Runx2, encoded by RUNX2, is the key bone transcription factor, activated by Wnt 
and BMP signalling, known to form a complex with HDAC3 (Schroeder et al. 2004). 
Here, inhibition of RUNX2 expression was demonstrated with MI192 treatment. 
RUNX2 expression was also investigated in Chapter 5: 5.3.4, where the inhibition of 
RUNX2 at an early stage was also seen, the reasons for this were extensively 
discussed.  
 
TWIST1 and TWIST2 encode for twist transcription factor proteins, which are 
antagonists of Runx2 (Bialek et al. 2004). TWIST2 is clearly down-regulated with 
MI192 treatment, while TWIST1 is down-regulated in 4 of 6 donors, so there is a 
trend of down-regulation, but it is inconclusive. The up-regulation of these two 
genes with MI192 treatment could have accounted for the down-regulation of 
RUNX2; however, this is clearly not the case here. It may be that this whole 
pathway is down-regulated with HDAC2/HDAC3 inhibition. TWIST-1 and TWST-2 
286 
 
 
proteins transiently inhibit Runx2 proteins during osteogenic differentiation, and 
their inhibition is necessary for osteoblast differentiation to take place (Bialek et al. 
2004). A down-regulation of these genes does indicate an increased osteogenic 
differentiation potential, and it may be that this down-regulation allows a later 
increase in the Runx2 levels and osteogenic differentiation potential of the MI192 
treated cells.  
 
DDR2 encodes discoidin domain-containing receptor 2, a receptor tyrosine kinase 
(RTK) linked to bone, a key osteoblast regulator. It is a cell surface receptor, with 
fibrillar collagen as a ligand, which regulates cell differentiation, cell migration, cell 
proliferation and remodelling of the extracellular matrix. It is required for normal 
bone and cartilage development and regulates osteoblast differentiation and 
chondrocyte maturation via the activation of Runx2 (Y. Zhang et al. 2011). 
Increased levels of DDR2 protein leads to an increase of Runx2 activity, and in the 
MI192 treated ADSCs, DDR2 expression is significantly down-regulated, which 
would be expected given the down-regulation of Runx2. 
 
The decrease in the expression of RUNX2 and Runx2 antagonist TWIST1 and 
TWIST2, along with the down-regulation of DDR2 that can activate Runx2, 
indicates that this pathway is not being engaged when the cells are inhibited with 
MI192. This gives some clues as to the pathway by which HDAC3/2 inhibition is 
improving the osteogenic differentiation of these cells, likely through BMP2 and 
BMP4 and not through GDF5 or direct activation of Runx2. The activation of the 
BMP and Wnt pathways may later lead to a later than 2 day increase in RUNX2, 
and other osteogenic transcripts. 
 
7.4.2.5 Chondrogenic transcription factors – SOX9, RUNX2 and DDR2 
Chondrogenic transcription factor Sox9 is expressed by proliferative, but not 
hypertrophic, chondrocytes. It is used as a marker of early chondrogenic 
differentiation of MSCs, and forced over expression induces chondrogenesis in 
MSCs (Tsuchiya et al. 2003). Sox9 induces expression of components of cartilage 
matrix such as  collagen type II (Lefebvre & Smits 2005). However here, expression 
of SOX9 varied between donors and results were inconclusive. 
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The aforementioned down-regulated transcription factor Runx2 is also an important 
transcription factor in cartilage development. In hypertrophic cartilage Runx2 
activates hypertrophic chondrocyte genes, such as COL10A1, which encodes 
collagen type X. Runx2 and Sox9 interact, and Runx2 is repressed by Sox9 (Zhou 
et al. 2006). Another marker of early chondrogenic differentiation mentioned earlier 
is DDR2 protein, which regulates chondrocyte maturation via the activation of 
Runx2 (Y. Zhang et al. 2011). DDR2 expression was down-regulated in the MI192 
treated cells, in line with the reduction also seen in RUNX2.  
 
7.4.2.6 The Wnt/β-catenin pathway 
In MI192 treated cells secreted Wnt pathway antagonist Frzb-1 (FRZB) is up-
regulated 15.5 fold.  Frzb-1 is expressed by prehypertrophic chondrocytes and is 
likely to act as an endogenous modulator of Wnt’s effects on chondrocyte 
maturation (Enomoto-Iwamoto et al. 2002). It is a modulator of the Wnt pathway 
and over expression will inhibit the Wnt pathway, preventing chondrocyte 
maturation and processes such as endochondral ossification. Up-regulation of this 
gene indicates that these MI192 treated cells may be becoming less mature 
cartilage cell like, and more cartilage progenitor cell like, an early chondrocyte cell 
type (Mackie et al. 2008). 
 
7.4.3 The effect of MI192 treatment on the expression of later 
stage bone related transcripts in ADSCs 
The increase in the osteogenic differentiation potential of the ADSCs treated with 
MI192 for two days is known and proven in previous chapters. This may be as a 
result of the up-regulation of some of the transcripts affected by MI192 pre-
treatment explored with this experiment. The up-regulation of several early markers 
of osteogenic differentiation has been seen, so later markers of bone differentiation, 
key to osteoblastic differentiation and those involved in biomineralisation, have 
been grouped together for discussion. 
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7.4.3.1 The down-regulated later stage markers of osteogenic 
differentiation - ALPL, SPARC, PMF-BGLAP, TNFRSF11B, 
CDH11, COL1A1 and COL1A2  
The majority of the later stage markers of osteogenic differentiation investigated 
were down-regulated with MI192 treatment of ADSCs, compared to control cells 
untreated with MI192. 
 
ALPL is the gene responsible for alkaline phosphatase, a key enzyme to cell 
mineralisation and discussed at length in Chapter 5: 5.3.4. The initial down-
regulation of ALPL is likely as a result of the down-regulation of other osteogenic 
markers, such as RUNX2, and is in line with the previous results, where ALP was 
also down-regulated at an early time point after MI192 treatment. Also explored in 
Chapter 5: 5.3.4 was PMF-BLGAP (encoding for BGLALP/Osteocalcin/OCN). In 
this study it was down-regulated 3.5 fold (although not statistically significant, there 
was a down regulation in 5 of the 6 donors), which is also in line with the data on 
early expression of PMF-BLGAP in ADSCs, where MI192 treatment lead to a drop 
in PMF-BLGAP expression. 
 
Collagen production is another sign of the medium to late stages of osteogenic 
differentiation, with collagen being a key organic structural component of bone 
(Junqueira et al. 1979; Donald L. Bartel et al. 2006; Pocock & Richards 2006). In 
this study, the transcript levels of COL1A1 and COL1A2 were down-regulated 
highly in the MI192 treated cells, (22 and 11 fold respectively, P ≤ 0.05). This 
matches the results from Chapter 5: 5.3.4, where the expression of COL1A1 was 
found to be down-regulated at the early (day 3) time point of the MI192 treated 
cells. That study found it was down-regulated below even the basal control. The 
combined results of these two studies indicate that MI192 treatment inhibits genes 
linked to collagen formation. 
 
Other later stage markers of osteogenic differentiation in MSCs on the card were 
proteins found in mature osteoblasts, including SPARC (encoding for 
Osteonectin/ON), TNFRSF11B (encoding for OPG/Osteoprotegrin) and CDH11 
(encoding Cadherin-11). They were all statistically significantly (P ≤ 0.05) down-
regulated by MI192 pre-treatment.  
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The decrease in these genes related to the later stage markers of osteogenic 
differentiation, along with the increase in so many earlier stage markers of 
osteogenic differentiation, may indicate that the cells are becoming more primed 
and with a greater osteogenic potential, rather than actually starting down the 
osteogenic differentiation potential process itself. After all, this is after only two days 
of treatment, the later stages of differentiation should not be expressed 
prematurely. Previous work (in  Chapter 5: 5.3.4) suggests that, ADSCs still need 
osteogenic medium/stimulus to begin osteogenic differentiation; treatment with 
MI192 alone does not result in osteogenic differentiation. These results provide an 
explanation of that.  
 
7.4.3.2 The up-regulated later stage markers of osteogenic 
differentiation - SPP1, PHOSPHO1 
Not all later stage markers of osteogenic differentiation were down-regulated; SPP1 
and PHOSPHO1 were both found to be up-regulated with MI192 treatment. 
 
SPP1 encodes osteopontin (OPN), which is found in osteoblasts and is an 
extracellular structural protein forming part of the organic component of bone. In 
this study, the expression was convincingly up-regulated in 6 donors with MI192 
treatment. The results are conflicting, as previously, in Chapter 5: 5.3.4, the 
expression of SPP1 was down-regulated with MI192 treatment (across all time 
points). A full discussion of the role of osteopontin, especially with regards to 
mineralisation, was undertaken there. The differences in these results may arise 
due to the additional growth in osteogenic medium the cells underwent in the other 
study. The initial increase of SPP1 expression may indicate an un-readiness of the 
cells to mineralise yet, preventing mineralisation and fitting the picture of the cells 
become more osteo-progenitor like, and less like more mature osteogenic cells. 
 
Furthermore, expression of PHOSPHO1, encoding phosphoethanolamine/ 
phosphocholine phosphatase, a protein that plays a role in inorganic phosphate cell 
formation was up-regulated with MI192 treatment. Since the expression of SPP1 
and PHOSPHO1 are linked, and PHOSPHO1 is regulated by OPN, so if one is up-
regulated, so should the other be (Yadav et al. 2014). These mineralisation linked 
genes are up-regulated earlier than others mineralisation genes in the MI192 
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treated cells, which may indicate the pathway by which ADSCs display an 
increased mineralisation potential when treated with MI192.  
 
7.4.4 The effect of MI192 treatment on the expression of cartilage 
and bone extracellular matrix formation related transcripts 
in ADSCs 
The effect of MI192 on the expression genes related to the extracellular matrix 
formed in bone and cartilage (although also many other tissues) was investigated.  
 
7.4.4.1 Down-regulated extracellular matrix (ECM) related transcripts – 
PCOLCE, PAPSS2, HAPL1, UGDH and COL10A 
PCOLCE encodes procollagen C-endopeptidase enhancer 1, a pre-collagen protein 
is involved in collagen formation (Bourhis et al. 2013), down-regulated by MI192 
pre-treatment. Similarly, PAPSS2 was also down-regulated, which encodes a 
sulfation protein, with wide reaching roles, known to be a key extracellular matrix 
protein linked to osteochondral tissue formation. It was reported that silencing of 
PAPSS2 expression significantly decreased ALP activity and mineralization, 
inhibiting OPN and COL1 expression, while over expression lead to osteoblast 
development and mineralisation in osteoclast like cells (Wang et al. 2012). Another 
gene down-regulated with MI192 treatment was HAPL1, which encodes hyaluronan 
binding link protein, a cartilage proteoglycan link protein key to cartilage and bone 
structure (Mundlos et al. 1991). UDP-glucose 6-dehydrogenase (UGDH), another 
extracellular matrix linked gene, was down-regulated 6.3 fold in MI192 treated cells. 
UGDH is an enzyme key in GAG formation, known to enhance chondrogenesis in 
models of cartilage formation (C. E. Clarkin et al. 2011; Claire E. Clarkin et al. 
2011). Finally, COL10A1 which encodes for collagen, type X was statistically 
significantly down-regulated in the MI192 treated cells. Type X collagen is key in 
endochondral ossification, in new bone formation (Shen 2005). DDR2 acts as a 
receptor for type X Collagen (Leitinger & Kwan 2006), and the down-regulation of 
DDR2 was mentioned earlier; their combined down-regulation is likely linked.  
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7.4.4.2 Up-regulated extracellular matrix (ECM) related transcripts – 
COL2, TNFAIP6, EPYC, CHAD and PRELP  
Collagen 2, encoded by COL2, is the key collagenous component of cartilage 
(Kessler & Grande 2008), and was strongly up-regulated with MI192 treatment. 
Collagen 1 gene expression levels are down-regulated in the MI192 treated cells, 
so the cells are being primed for collagen II and not collagen I formation. This could 
indicate that these cells are stimulated to undergo an endochondral ossification 
type pathway (Chen et al. 2012), although without the initial involvement of the 
down-regulated of type X collagen. 
 
TNFAIP6 and EPYC were also, although not strongly, up-regulated with MI192 
treatment. TNFAIP6 encodes tumour necrosis factor alpha induced protein 6, which 
is related to binding of hyaluronan and protects against cartilage matrix destruction 
(Blundell et al. 2003). EPYC, which was up-regulated although not significantly, 
encodes epiphycan, a proteoglycan that regulates fibrillogenesis, playing a role in 
ECM formation of bone and cartilage (Kurita et al. 1996; Wang et al. 2009). CHAD 
encodes chondroadherin protein, which is known to mediate adhesion of isolated 
cells, and may be central for maintaining the adult chondrocyte phenotype and 
cartilage homeostasis (Haglund et al. 2011). MI192 treatment also resulted in up-
regulation of CHAD expression in ADSCs. PRELP encodes proline arginine-rich 
end leucine-rich repeat protein, which is found in connective tissue extracellular 
matrix. It binds collagen type I and type II and the basement membrane heparan 
sulfate proteoglycan perlecan (Bengtsson et al. 2002). When gene expression in 
tissues was analysed, there were high levels of this gene found in adult cartilage 
and low levels in juvenile cartilage, so it can be utilised as a late stage marker of 
chondrogenesis (Grover et al. 1996). PRELP was also up-regulated (although not a 
completely true picture only in 4 of 6 donors). 
 
The up-regulation of these specific ECM related genes could indicate by which 
pathways the early stage osteogenic/endochondral ossification related transcripts 
act. They may be as a direct result of MI192 treatment (i.e. HDAC2 or HDAC3 
inhibition).  
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7.4.5 The effect of MI192 treatment on the expression of 
adipogenic transcripts in ADSCs 
Adipogenic differentiation was always thought of as the classical opposite of 
osteogenic differentiation; however, some genes control aspects of both (Ducy et 
al. 2000). It has been proven in Chapter 5: 5.3.7 that MI192 pre-treatment strongly 
inhibits future adipogenic differentiation. In this chapter, the results aim to answer 
the question of the how the adipogenic related genes were initially affected when 
the cells were treated with MI192.  
 
7.4.5.1 PPARγ, FABP4, CEBPA and LEPR 
The expression of PPARγ was found to be down-regulated in Chapter 5: 5.3.7, 
even with cultured in  medium containing a PPARγ activator, where its function as 
an adipogenic transcription factor was discussed extensively. Unfortunately the 
results from this study were inconclusive regarding PPARγ, which was due to the 
varied response across different donors. 
 
FABP4 is another adipogenic related transcript, coding for fatty acid binding protein, 
and used as a marker of late stage adipogenic differentiation. It is PPARγ 
responsive and in the literature HDAC3 inhibition was found to increase levels of 
FABP4 expression (Jiang et al. 2013). In this study FABP4 expression in MI192 
treated cells was up-regulated; however, the results were not statistically significant 
(P > 0.05), likely due to only 3 donors having been analysed. However, the trend of 
up-regulation is still clear. However, a study by Catalioto et al. found that HDAC 
inhibition by MS-275, SAHA and VPA (Catalioto et al. 2009), strongly reduced 
FAB4 levels in human white preadipocytes, opposite to the results of treatment with 
MI192. CD271+ sorted cells were also found to have high levels of FABP4 
expression, indicating a steady-state engagement with adipogenesis, which may be 
the same with the MI192 treated cells (Churchman et al. 2012). The links between 
CD271+ cells and MI192 treated cells are discussed at length later (in 7.4.8). 
 
CEBPA, encodes for CCAAT/enhancer-binding protein alpha, a protein involved in 
body weight homeostasis, with increased levels found in adipogenic differentiation 
of MSCs (Sekiya et al. 2004). CEBPA was strongly up-regulated with MI192 
treatment.  
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LEPR, which was down-regulated with MI192 treatment, encodes leptin receptor. 
Leptin is a small polypeptide hormone secreted primarily by adipocytes, which is 
involved in control of body weight, and is linked to obesity. However, it also is an 
important regulator of bone mass, and controls the balance between bone and fat in 
the bone marrow (Ducy et al. 2000), although this can be time frame dependent 
(Gordeladze et al. 2002). The down-regulation of LEPR in MI192 treated cells may 
indicate a reduction in cells in susceptibility to Leptin. This may result in a reduction 
of the osteogenic differentiation potential of these cells, as leptin is known to 
increase bone formation, while it is also associated with adipogenic lineages.  
 
The results from several of the genes (BAMBI, PPARγ, LPL and TGFBR2) were 
also inconclusive, so the complete effect of MI192 on the adipogenic potential of 
these cells remains unclear. Although with the increases in FABP4 and CEBPA 
expression, along with the decrease in LEPR would suggest an overall increase in 
adipogenic differentiation potential of these cells. This does not really explain why 
when pre-treated with MI192 and then cultured in adipogenic medium there is a 
large decrease in adipogenic differentiation of these cells. 
 
7.4.6 The effect of MI192 treatment on the expression of stromal 
related transcripts in ADSCs 
The effect of MI192 on some markers connected with muscle, connective, blood 
and bone marrow like tissue in ADSCs was also measured.  
 
7.4.6.1 Angiogenesis transcription factors – VEGFA, VEGFC and 
ANGPT1 
Both VEGFA and VEGFC (vascular endothelial growth factors A and C) are part of 
the VEGF family, and are down-regulated with MI192 treatment. This family of 
transcription factors encode proteins that control a large number of processes, 
including angiogenesis, vasculogenesis and endothelial cell growth (Gerber et al. 
1999). VEGFA and VEGFC proteins also act as are promoters of cell migration, 
inhibitors of apoptosis and are important in the later stages of cartilage formation, 
as well as for vasculature growth in bone (Zelzer et al. 2004; Kozhemyakina et al. 
2015). VEGFA is produced in osteoblasts in response to BMP2, BMP4 and BMP6 
signalling and is key to angiogenesis of bone (Deckers et al. 2002). However, here 
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it seems the elevated levels of BMP2 and BMP4 have not resulted in elevated 
levels of VEGFA (levels were down with MI192 treatment). This may be because 
the cells have not had time to response to these increases yet. Another 
transcription factor down-regulated with MI192 treatment is ANGPT1, which 
encodes Angiopoietin-1. Angiopoietin-1 belongs to the angiotrophic family, and is 
key to vasculature maturation, through pericyte recruitment, as well we being 
involved in the second stage of angiogenesis (Kosacka et al. 2006; Thurston 2003).  
 
Strongly up-regulated on treatment with MI192 treatment, and also from the 
angiotrophic family ANGPTL4. This encodes for angiopoietin-like 4, a protein 
expressed highly in adipose tissue, liver, and placenta, repressed by leptin and 
activated by ligands of peroxisome-activated receptors (e.g. PPARγ) (Ge et al. 
2005). It has actually been found to inhibit angiogenesis in in vitro models (Okochi-
Takada et al. 2014).   
 
The down-regulation of ANGPT1, VEGFA and VEGFC, along with the up-regulation 
of ANGPTL4, indicates treatment with the MI192 may inhibit angiogenesis, which 
could have effects on the formation of tissue such as bone in the long term. If 
MI192 was considered for long term use, or even with the pre-treatment of cells for 
bone formation, the effect on the ability of the bone to vascularise would need to be 
investigated.  
 
7.4.6.2 Pericyte transcripts - CSPG4, MCAM, ANGPT1, ACTA2, 
PDGFRA and PDGFRL 
Pericytes are the cells that wrap around the endothelial cells of capillaries and 
vasculature. CSPG4 (chondroitin sulfate proteoglycan 4), ANGPT1 (encoding 
angiopoietin-1), ACTA2 (encoding for smooth muscle actin), and PDGFRA 
(encoding for alpha-type platelet-derived growth factor receptor) were all down-
regulated (Churchman et al. 2012). The majority of the pericyte markers identified 
by Churchman et al. were down-regulated, statistically significantly (P ≤ 0.05) after 
treatment with MI192. The exceptions were PDGFRL, encoding platelet-derived 
growth factor receptor-like, which had inconclusive results and MCAM, which was 
up-regulated, although not statistically significantly (It was up-regulated in 5 of 6 
donors, P > 0.05) 
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Apart from the increase in MCAM, the down-regulation of all of these markers 
indicates the cells are becoming less pericyte like. MCAM is highly expressed in 
blood vessels, smooth muscles and pericytes, although its function is not well 
understood and is a commonly used marker of multipotent mesenchymal stromal 
cells. MCAM is also known as CD146 and the expression of this was found to be 
increased on ADSCs treated with MI192 for two days in Chapter 4: 4.3.7. These 
results complement each other. This increase in surface marker can be accounted 
for by this increase in gene expression. MCAM is thought to be involved in 
interactions of MSCs and other cells with endothelial cells (Robey 2011; Covas et 
al. 2008). The up-regulation of this is interesting and may be indicative of these 
cells becoming more multipotent and less committed to a lineage, such as the 
pericytes lineage.  
 
7.4.6.3 Hematopoietic stem cell (HSC) related transcripts - GJA1, 
RUNX1, JAG1, CXCL12 and GATA2 
GJA1 encodes gap junction protein alpha 1, which is also known as connexin 43 
(Cx43). This protein is found in high levels in osteoblasts, a population of osteo-
progenitor cells and HSCs, and is key to the communication of these cells, 
especially homing of cells, in the bone marrow niche (Gonzalez-Nieto et al. 2012). 
The down-regulation of GJA1 with MI192 treatment may indicate the cells becoming 
less mature, as they are key to the maturation of several tissue types such as the 
blood (Montecino-Rodriguez et al. 2000). 
 
Also down-regulated, RUNX1 encodes Runx1, a transcription factor that regulates 
the differentiation of HSCs into mature blood cells, and is widely expressed in 
mature hematopoietic cells, so is possible required for HSC maturation (Huang et 
al. 2008). A down-regulation of this may indicate an increasing naivety and more 
stem cell like profile being adopted by the MI192 treated cells, becoming less adult 
regarding hematopoietic lineages. However, conclusions cannot be fully drawn as 
this trend is only strongly observed in one donor, and several remain unchanged. 
 
Changes in JAG1, CXCL12 and GATA2 expression with MI192 treatment were 
minimal and inconclusive. GATA2 encodes GATA binding protein 2, a transcription 
factor that is expressed in hematopoietic progenitors, and also in ESCs. 
Interestingly, research has shown that HDAC3 associates with GATA2, repressing 
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GATA2 transcription (Ozawa et al. 2001). Inhibiting HDAC2 and HDAC3, with 
MI192, at least in the short term, appears to have had had no effect on the 
expression of GATA2 in the ADSCs. 
 
The down-regulation of RUNX1 and GJA1 may indicate movement away from 
hematopoietic cell type, although related genes JAG1, CXCL12 and GATA2 are 
relatively unaffected. 
 
7.4.6.4 CXCL12 and CXCL2 
CXCL2 is a human chemokine that is known to bind the CXCR2 receptor and is 
involved in the mobilisation of human hematopoietic stem and progenitor cells 
(Pelus et al. 2002). Chemokine receptors such as these can be activated in 
peripheral blood stem cell transplants. There has been studies showing that 
HDACis can promote the self-renewal of hematopoietic stem cells This study has 
shown that with MI192 treatment CXCL12 expression is unaffected. However, the 
expression of CXCL2 with MI192 treatment was massively increased, 86 fold 
(statistically significantly, P ≤ 0.05); it was the largest increase in expression seen in 
all genes investigated. The huge increase in CXCL2 expression is an interesting 
result regarding HSCs. HDACis are known to increase the mobilisation/self-renewal 
of human HSCs, and it may be that they act to increase the expression of CXCL2, 
as MI192 does in these ADSCs.  
 
7.4.6.5 Muscle differentiation cell related transcripts - ACTA2, DVL2 
and MSX1 
ACTA2 encodes smooth muscle actin, which can be used as a myofibroblast 
differentiation marker and is found in linked to muscle, liver and stromal lineages 
(Ozgurll et al. 1990). ACTA2 expression down-regulated strongly with MI192 
treatment, indicating the cells are not moving down a muscle lineage. However, 
conversely, the Wnt regulator DVL2, discussed earlier, inhibits myogenesis 
(Yamaguchi et al. 2012), and was slightly down-regulated in most samples that 
might have indicated a readiness for muscle formation, although conflicting with the 
down-regulation of ACTA2.   
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The muscle segment homeobox gene (MSX1) encodes for a protein essential for 
cell proliferation and differentiation of several cell types, and is key in normal tooth, 
limb development and craniofacial bone development (Vastardis et al. 1996). When 
knocked down (with a siRNA) in mouse dental MSCs, down-regulated MSX1 
expression could promote the expression of ALP, COL1A1, OCN, RUNX2, DSPP, 
and DMP1, and increase ALP activity and mineralised nodule formation (Feng et al. 
2013). MSX1 is known to be essential for BMP4 induction in embryonic mouse 
models of tooth development (Chen et al. 1996). MSX1 was down-regulated in the 
MI192 treated cells, although interestingly, this down-regulation has not had a 
negative effect on BMP4 transcription levels (which has a large up-regulation in the 
MI192 treated cells). This down-regulation is especially interesting, when 
considering that the knockdown of this can improve the osteogenic differentiation of 
mouse dental MSCs (Feng et al. 2013). This may, at least in part, account for the 
increased osteogenic potential of the ADSCs on treatment with MI192. 
 
7.4.7 The effect of MI192 treatment on the expression of 
Neural/nerve related transcripts in ADSCs 
7.4.7.1 NGFR, NGFRAP1, ANGPT1 and NES 
Low-Affinity Nerve Growth Factor Receptor (CD271/p75 neurotrophin 
receptor/p75NTR), encoded by the NGFR gene, was strongly up-regulated with MI192 
treatment. NGFR, as well as potentially being a useful stem cell marker (for a 
specific discussion of this see ahead to 7.4.8) is a receptor involved in mediating 
survival and cell death in the neurons (Barrett & Bartlett 1994), depending on the 
developmental stage, expressed in situations such as injury to the nervous system 
(Ibáñez & Simi 2012). NGFRAP1, nerve growth factor receptor associated protein 1 
(NADE), was unaffected by MI192 treatment. The up-regulation of the receptor but 
not one of proteins known to interact with the receptor is interesting, perhaps 
indicating another, alternative role of NGFR, discussed in the next section. 
 
Previously mentioned down-regulated gene ANGPT1, encoding Ang-1 of the 
angiotrophic family, is involved in the activation of nerve growth factor receptor. A 
down-regulation of this indicates an inhibition of any neurite growth, a shift away 
from any nervous system role of the MI192 treated cells (Kosacka et al. 2006). NES 
encodes Nestin, a filament protein that is found in the peripheral and central 
nervous system, which can be used as a marker of neural stem cells, was 
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unaffected by MI192 treatment (Michalczyk & Ziman 2005; Cattaneo & McKay 
1990). 
 
Based on these results, MI192 treated ADSCs don’t appear to be being induced to 
play a role in nervous or neural systems. However, the up-regulation of NGFR may 
indicate differently, although it is also a marker of MSCs, and is not only linked to 
the nervous/neural systems. 
 
7.4.7.2 SORT1 
SORT1 encodes for a neurotensin receptor involved in the neurotensin-induced 
migration of human microglia, especially found in inflammatory responses of the 
brain (Martin et al. 2003). SORT1 expression was found to be 6 fold, statistically 
significantly (P ≤ 0.05) up-regulated in the MI192 treated ADSCs.  
 
7.4.8 The effect of MI192 treatment on the expression of NGFR 
(CD271) in ADSCs and a comparison of the transcription 
profile to CD271+ cells 
The aforementioned NGFR encodes a protein also known as CD271, a potentially 
useful stem cell marker. CD271 sorting has been suggested as a method of 
isolating clinically useful pure populations MSCs, with excellent differentiation 
potential, especially down an osteogenic lineage (Cuthbert et al. 2015). As 
mentioned in the previous section, this was up-regulated with MI192 treatment. 
 
CD271 positive cells sorted from bone marrow were found by Churchman et al. to 
have a transcriptional profile comparable to bone marrow MSCs, with regards to the 
potential to commit to multiple fates (including osteogenic, adipogenic, pericytic, 
and haematopoietic). CD271 is down-regulated in MSCs that have been expanded 
in tissue culture and has low expression in hematopoietic-lineage cells. 
 
Positive sorting for CD271 in combination with negative sorting for PDGFRA has 
been suggested as a method of isolating a close to pure population of human 
MSCs with multi-function potential (Li et al. 2014). MI192 treatment results in an up-
regulation of CD271 and a down-regulation of PDGFRA (8.5 fold, statistically 
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significantly, P ≤ 0.05) so in a way is acting as in the sorting work by Li et al., 
increasing the percentage of cells with a stromal stem/progenitor cell like 
properties, similar to the pure cells in the adult human bone marrow. It is worth 
noting that Churchman et al. found expression of PDGFRA to be higher in the 
CD271+ cells isolated from bone marrow than hematopoietic-lineage cells 
(Churchman et al. 2012), different to the MI192 treated cells, so the population of 
cells created by the MI192 pre-treatment is different to the just CD271+ cells 
(Churchman et al. 2012).  
 
When compared to cultured MSCs, CD271+ cells expressed certain transcriptional 
activities differently, perhaps most notable Wnt-related genes FRZB and WIF1. The 
MI192 pre-treated cells in this study showed FRZB to be up-regulated 15.5 fold (P ≤ 
0.05). WIF1 was up-regulated very highly in two donors (161 fold and 554 fold), 
slightly in one donor (2.5 fold), from not determined to determined in 2 donors and 
in one donor it was down-regulated (7337 fold). This has skewed the average 
results in favour of down-regulated, despite an overall trend of up-regulation. 
SFRP1 and SRFP4 were also found to be highly up-regulated in the CD271+ cells. 
Comparatively, in the MI192 pre-treated cells SFRP1 was up-regulated, while 
SRFP4 was not affected. This transcriptional picture fits that of the CD271+ cells, 
where the cells are more Wnt active, and ready for Wnt pathway activation and 
regulation. 
 
Other genes with increased transcriptional activity in CD271 sorted cells include an 
increased pericyte-like transcription profile. However, in contrast to the CD271 
sorted cells, the MI192 pre-treated cells have only MCAM expression increased, 
with other pericytes related genes such as ANGPT1, ACTA2 and PDGFRA being 
down-regulated.  
 
CD271+ cells also had a higher expression of haematopoiesis-supporting cytokines 
CXCL12 and IL7, whereas the expression was up and down-regulated in different 
donors on MI192 treatment, with no real conclusion to be drawn about these 
transcripts. Expression in CD271+ cells of adipogenic transcripts PPARG, LPL, and 
FABP4 was increased and osteogenic transcripts SP7, SPARC, SPP1 and BGLAP-
OCN indicating a steady stage engagement with adipogenic and osteogenesis. In 
the MI192 treated cells, results for PPARG and LPL were inconclusive, while 
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FABP4 was up-regulated. SP7 and BGLAP were down-regulated, although not 
consistently between donors or significantly, while SPARC and SPP1 were up-
regulated. So the transcription profile of the MI192 treated cells is similar to the 
CD271+ cells; however the expression of some genes in the M192 treated cells 
drops when it would be expected to rise if the selection was making them more 
CD271+ cell like. Another example of this is in that expression of NANOG and 
POU5F1 were higher in CD271 cells, whereas in the MI192 treated cells the 
expression of these was virtually unchanged with treatment.  
 
One key point in the Churchmen et al. CD271 study was that to the author’s 
knowledge, no native MSCs with a higher expression of BMP2, and IGF2 over 
cultured MSCs had been found. They believe this makes CD271+ sorted cells a 
strong potential candidate for injectable stem cell therapies for bone healing. 
Interestingly, the MI192 cells show increased expression of BMP2 and IGF2 over 
the untreated counterparts, making them a similarly improved cell population for 
that purpose.  
 
7.4.9 The effect of MI192 treatment on the expression of 
miscellaneous transcripts in ADSCs 
The card contained three fibroblast growth factor related genes; FGFR1, encoding 
fibroblast growth factor receptor 1 and FGF5, encoding fibroblast growth factor 5 
were both unaffected by MI192 treatment, and FGFR3 was strongly up-regulated 
with treatment. 
 
FGF5 is involved in many cellular processes, including embryonic development and 
cell growth (Haub & Goldfarb 1991), and is not highly expressed in adult tissue, it is 
primarily expressed during embryonic development and in the nervous system 
(Allerstorfer et al. 2008). FGF5 signals are predominantly target for FGFR1 (Ornitz 
et al. 1996), so it is unsurprising that if one of these was unaffected by MI192 
treatment, the same was seen in the other. 
 
FGFR3 is crucial to bone and cartilage development, and mutations in this gene 
lead to a range of short-limb dwarfism in humans, along with other skeletal 
conditions such as Muenke and Crouzon syndromes. FGFR3 plays a number of 
301 
 
 
roles endochondral ossification, it initially enhances proliferation of immature 
chondrocytes (Iwata et al. 2000); however, at a later stage acts to inhibit 
chondrocyte proliferation and differentiation (Naski et al. 1998). Therefore, an 
increase in FGFR3 expression must be looked at within the context of other genes. 
Here the increase of FGFR3 may help these cells to advance on an endochondral 
ossification type pathway of osteogenic differentiation. Interestingly, FGFR3 is 
known to down-regulated BMP4 expression (Naski et al. 1998); however, BMP4 is 
also up-regulated in the MI192 treated cells. 
 
7.4.10 Discussion summary  
The increased osteogenic differentiation potential of these cells has been proven, in 
several models, so the effect of MI192 on many genes was explored in an effort to 
explain this, along with other effects such as increased stem cell markers and a 
decrease in adipogenic differentiation potential of the cells. 
 
Some key Wnt transcripts, FRZB and SFRP1 were up-regulated, along with the 
down-regulation of SFRP4. Also up-regulated were BMP2 and BMP4, and BMP 
pathway inhibitor BMPER was down-regulated. The BMP and Wnt pathway are 
interconnected, and it appears that the treatment for two days with MI192 increases 
the activation of these pathways, perhaps explaining the increase osteogenic 
differentiation potential of these cells. The increased osteogenic potential may also 
be mediated by the IGF pathways, as the up-regulation of IGF2 and down-
regulation of IGFBP3 also indicates a priming for osteogenic differentiation (Zhong 
et al. 2011; Silha et al. 2003; Ding et al. 2015; Kang et al. 2012). The down-
regulation of ACVR1B and ACVR2A, which can compete with BMP signalling to 
inhibit osteogenic differentiation, also contributes to overall picture of increased 
BMP signalling (Mizuno et al. 2009; Maeda et al. 2004). Also down-regulated with 
MI192 treatment, with down-regulation linked to improved osteogenic differentiation 
in the literature (Feng et al. 2013), was MSX1.  
 
Most later markers of osteogenic differentiation, for example ALPL, SPARC, PMF-
BGLAP, COL1A1 and COL1A2 were down-regulated. The treatment of cells with 
MI192 alone does not increase the osteogenic differentiation of the ADSCs, it 
appears to only increase the potential; osteogenic stimulation is also required. The 
cells appear to be being primed for osteogenic differentiation, they are not 
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beginning the osteogenic differentiation process with MI192 treatment. Runx2 is an 
early stage bone transcription factor and its up-regulation was expected, given the 
increased osteogenic potential of these cells. However, this was not the case, 
which mirrored the results seen in Chapter 5: 5.3.4. This may also require 
osteogenic stimulus, and/or time for the effects of the BMP/Wnt pathways to kick in. 
Although, of the osteogenic transcripts, mineralisation linked genes SPP1 and 
PHOSPHO1 were up-regulated. An increase in SPP1 actually also indicates that 
the cells are becoming more mature, as SPP1 controls and prevents mineralisation. 
 
No direct increase in chondrogenic potential was seen with MI192 treatment of 
ADSCs (there was no increase in SOX9 expression, and DDR2 and RUNX2 down-
regulated). However, some genes perhaps linked to endochondral ossification such 
as FRZB, COL2, CHAD and FGFR3, were up-regulated, so the cells may be being 
primed to form tissue in the areas where bone and cartilage interact, or just bone 
formation via an endochondral ossification pathway. Associated closely with 
cartilage formation, but often all types of extracellular matrix formation in other 
tissues, the up-regulation of some specific ECM related genes (COL2, TNFAIP6, 
EPYC, CHAD and PRELP) was also discovered. These genes may be as a result 
of the increase of the early stage transcription factors linked to bone and 
endochondral ossification, or as a direct result of the MI192 treatment.  
 
Moving on from bone and cartilage, a key question in this experiment was what 
effect would MI192 treatment have on adipogenic gene expression. The results for 
these genes were mostly unclear, with mixed results with donors. However, there 
was an increase in FABP4 and CEBPA expression, and a decrease in LEPR 
expression, indicating a trend to increased adipogenic differentiation of the MI192 
treated cells. However, this doesn’t match the results from Chapter 5: 5.3.6. FABP4 
is also linked to control of bone formation. The reason for the decrease in 
adipogenic potential of the MI192 pre-treated ADSCs remains unanswered from 
this specific study. 
 
As bone is a vascularised tissue, angiogenesis may be key in new bone formation. 
However, it was concluded that MI192 treatment decreased the angiogenic 
potential of these cells, which may have long term consequences. This may be 
important to investigate in the future. Also decreased were most pericyte related 
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markers, meaning MI192 treatment does not seem to improve the stromal tissue 
like properties of these cells. The treatment of ADSCs with MI192 didn’t appear to 
increase the neural/nervous or muscle differentiation potential of these cells, 
although only a small number of genes in these areas were investigated.  
 
The expression of two genes encoding for stem cell markers, NGFR (CD271) and 
MCAM (CD146) were up-regulated. The increased expression of CD146 was 
already seen in Chapter 4:4.3.7, and may indicate an increase in the stem cell-like 
potential of these cells. CD271 expression was not measured, but this has also 
been linked with stem cell like properties of cells. While individual groups of gene 
expression may be affected with MI192, there may be an increase in the stem cell 
like properties of the cells when treated with MI192. NANOG, SOX2 and POU5F1 
was not altered with MI192, so the treated cells may have properties closely linked 
to adult stem cells, such as bone marrow MSCs or HSCs, not ESCs that these are 
markers of. RUNX1 and GJA1 are hematopoietic markers, and they were down-
regulated with MI192 treatment, so the cell may be forming more immature cell 
versions. Another HSC marker, CXCL2 is known to mobilise HSCs and this may 
account for the massive increase in expression of CXCL2 with MI192 treatment, as 
HDACis are known to increase mobilisation of HSCs. Overall, MI192 treatment 
clearly has an effect on HSC like properties of the ADSCs, perhaps making them 
more transcriptionally similar. Further investigation of this effect may yield 
interesting results.  
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Chapter 8: General Discussion, Conclusions and Future Work 
 
This final chapter includes a general discussion of the findings of the thesis, placing 
them in context of the literature, summarising the results from each chapter and 
linking them together. Following that, the conclusions of the study are collated, and 
finally, potential future work for the study is outlined.  
 
8.1 General Discussion  
Researchers can approach the huge clinical demand for generating organs and 
tissues with a ‘from scratch’ tissue engineering approach, combining the key 
elements of cells, scaffolds, environmental stimuli and chemical cues (Naderi et al. 
2011; Payne 2013). The cells utilised are typically stem cells, and poor control of how 
these differentiate into tissue specific cells is a key limitation of the field. More 
specifically, currently bone tissue engineering is a key target for researchers, largely 
because of the huge clinical need, and limitations of current technologies in practice. 
Although many advances have been made in recent years, there is still much work to 
be done to successfully bring bone tissue engineering to the clinic (Amini et al. 2012).  
 
As discussed extensively in the literature review, it has been highlighted that HDACis 
can have an effect on stem cell differentiation potential (Tollervey & Lunyak 2012; 
Kretsovali et al. 2012b; Maroni et al. 2012). There is the potential to harness this, 
utilising HDACis, to control stem cell fate to assist in the formation of functional tissue 
and organs in tissue engineering. This study sits alongside those where the potential 
of a HDACi to improve the osteogenic differentiation of cells is demonstrated. For 
example, this has been demonstrated with TSA (Hu et al. 2014; Hu et al. 2013), NaB 
(Xu et al. 2009) and MS-275 (Kim et al. 2012; H.-N. Kim et al. 2011). The most 
relevant comparisons are to those where HDACis, such as VPA and TSA have been 
shown to improve the osteogenic differentiation of specifically ADSCs (Xu et al. 2009; 
Kurihara & Suzuki 2014; Maroni et al. 2012). 
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The design of next generation, isoform specific HDACis, provides researchers with a 
whole new set of tools to investigate the effect of HDACis on stem cell differentiation. 
MI192 was designed to be a Class 1 specific HDACi, and was found to be specific for 
HDAC2 and HDAC3 (Boissinot et al. 2012). It is believed to be the only HDACi of its 
kind, and no evidence of studies can be found where the effects of inhibiting HDAC2 
and HDAC3 together in stem cells is explored. MI192 has so far only been explored 
as an anti-cancer agent, and in rheumatoid arthritis research (Boissinot et al. 2012; 
Gillespie et al. 2012).  
 
To date, the vast majority of studies with regards to stem cells have only investigated 
HDAC2 and HDAC3 individually (Schroeder & Westendorf 2005; Schroeder et al. 
2004; Razidlo et al. 2010; McGee-Lawrence et al. 2013; Hesse et al. 2010; Lamour et 
al. 2007; Choo et al. 2009; Shen et al. 2002; Paino et al. 2014). The most similar 
studies to this, exploring inhibitors in bone tissue engineering, are with MS-275, 
which is believed to inhibit HDAC1, HDAC2 and HDAC3 (although reports of the 
exact isoform specificity are conflicting (Bradner et al. 2010; H.-N. Kim et al. 2011)) 
where MS-275 was found to improve the differentiation of osteoblasts (Kim et al. 
2012; H.-N. Kim et al. 2011). The results with MI192 were similar to these studies, 
providing further evidence that inhibiting Class 1 HDAC isoforms is a valuable tool for 
bone tissue engineering. 
 
Furthermore, this study explores new ground by investigating the effect of HDACis on 
the osteogenic differentiation of ADSCs in 3D. To date, studies in this fields have 
been limited, with only a few examples (Boer et al. 2006; Lee et al. 2011; Jung et al. 
2010). Finally, there has also never been such a comprehensive exploration of the 
effect of a HDACi on the gene expression profile of cells. The effect on gene 
expression of ADSCs by MI192 was extensively explored (Chapter 7: The effect of 
MI192 treatment on ADSC gene expression), which yielded some very interesting 
results, opening avenues for exploration of both MI192 and the specific inhibition of 
HDAC2 and HDAC3 isoforms in the future. The specifics of what were achieved in 
this study will be discussed, within the context of the literature.  
 
In this study, MI192 was synthesised and characterised using NMR spectroscopy. 
The final step of the MI192 synthesis involves a relatively dangerous and difficult to 
perform step using allene gas, and improvements to the synthesis route were limited 
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by the cost and the availability of this gas, and if the scale up of MI192 was ever 
sought this may need to be addressed with an alternative reaction route.  
 
Just before this study was begun, a commercial partnership with Cancer Research 
Technologies was established by Professor Ron Grigg, attempting to commercialise 
MI192 for the use in cancer medicaments. There is a patent application on-going, 
with the intention of filing further patents for further medical use claims in the future, if 
anything else was discovered (such as may result from this study). Consequently, the 
scale up of MI192 has likely been explored by Cancer Research Technologies, 
especially as since then MI192 has become available commercially through Abcam 
(Abcam Cat. no: ab146817). If the scale up of MI192 was necessary in the future, 
speaking to the commercial partners already in place would be the best course of 
action, as they may have circumnavigated the need for allene gas. Alternatively, 
while it is expensive at £360 for 5 mg, MI192 could just be purchased commercially. 5 
mg is a large amount of inhibitor at the small doses that these studies are carried out 
at. 
 
It was discovered that MI192 clearly had a cytotoxic effect on cells, as well as 
decreasing cell viability. This effect is undesirable, but does not totally prevent use if 
used in the right way or for a short enough length of time. This lead to the pre-
treatment strategy being adopted, which minimises (although does not totally 
eliminate) the negative effects of inhibitor, while still being able to explore the effects 
of MI192 on the differentiation potential of the cells. The basis for this strategy was 
found in the literature (see a summary in Table 5-4) (Xu et al. 2009; Cho et al. 2005; 
Maroni et al. 2012). MI192 was also shown to inhibit the HDAC activity of ADSCs, 
although the study undertaken was limited and the effect of this was not explored 
further due to the expensive assay kit and limited test values. It was thought enough 
for this study to assume that the HDAC inhibitory effect was taking place.  
 
It was also found that MI192 halted the cell cycle of ADSCs, at least to some degree, 
in the G2/M phase. The cell cycle is essential to normal cell function, and controls cell 
proliferation (Majdzadeh et al. 2008; Jiang & Hsieh 2014). It is well known in the 
literature that the HDAC enzymes are key to normal cell cycle function, with HDAC3 
especially key to cells progressing past the G2/M checkpoint in the cell cycle 
(McGee-Lawrence et al. 2011; Petruccelli et al. 2011). As MI192 inhibits HDAC3, it 
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would follow that this is the mechanism by which MI192 is halting the cell cycle of the 
ADSCs. This cell cycle halting effect may be linked to the cytotoxic effect of the 
MI192, as cells are unable to repair any DNA damage as a result of treatment at this 
checkpoint, which may result in apoptosis. The study was limited because there was 
a high standard deviation for the later time point samples, and further time points and 
doses of MI192 could have been explored. It would be interesting to explore if 
proteins, such as the cyclin-dependent kinase inhibitors (CKIs) p21CIP1 and p27KIP1 
(Park et al. 2011), linked to the cell cycle are also affected, and establish the full link 
between the HDAC inhibition and the cell cycle halting effect. The halting of the cell 
cycle is likely responsible for a decrease in cellular proliferation, and thus lower cell 
migration seen in MI192 treated cells through scaffolds in Chapter 6:.  
 
Also investigated was the effect of MI192 on stem cell markers. The results from this 
were especially interesting, because there are no studies of its kind in the literature, 
with only the pluripotency markers explored with HDACi treatment (Y. Kim et al. 
2013). With MI192 treatment there was a rise in expression of CD34 and CD146, with 
a decrease in expression of CD29, CD44, CD73, CD105 and CD166. There was no 
change in the expression of CD45 and CD90. This study was limited in that it only 
analysed a small number of markers, but it provided an interesting result none the 
less. When the 96 different gene expression changes were measured in Chapter 7:, 
the expression of MCAM, which encodes for CD146, was found to be up-regulated 
with MI192 treatment. The results from the different experiments were consistent. The 
only other stem cell marker related gene tested in the panel was NGFR, or CD271. 
This was also found to be up-regulated with MI192 treatment.  
 
This study found that pre-treating ADSCs with MI192 improved the osteogenic 
differentiation potential of ADSCs, while also decreasing the cell’s adipogenic 
differentiation potential. MI192 was found to elevate ALPSA in cells, especially when 
the cells were pre-treated for two days. A 30 µM dose for two days of treatment was 
found to be the optimal pre-treatment strategy, with a good balance between cell 
death and increased ALP levels. Measurement of ALPSA was also utilised to show 
that there was no difference in MI92 pre-treatment on 4 different ADSC donors, that 
the effect was seen with two different types of osteogenic induction media, that the 
effect was seen across multiple time points and that there was no difference in effect 
with two different batches of MI192. The effect of pre-treatment with TSA was also 
investigated and compared to MI192, as it was found in the literature that pre-
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treatment with TSA would increase the osteogenic differentiation of ADSCs (Maroni 
et al. 2012), but was found to have a much smaller effect on ADSCs ALP levels 
compared to MI192. It was also demonstrated that MI192 treatment alone, without 
osteogenic induction, did not increase ALP levels; at least some osteogenic induction 
is needed.   
 
MI192 pre-treatment increased expression of RUNX2, BMP2, ALP and COL1 over 
osteogenic controls at certain time points, although expression often peaked and was 
lower than controls at other time points. There was an initial, at day 3, increase in 
BMP2 expression, which is followed by a spike in ALP expression at day 5, COL1 at 
day 7, and RUNX2 expression at days 7 and day 14. It appears that the initial 
increase in BMP2 expression may be responsible for this. Interestingly, the MI192 
pre-treatment was found to reduce the expression of OCN/BGLAP (responsible for 
osteocalcin production) in the ADSCs, which may result in problems in long term 
osteogenic differentiation studies. The decrease in SPP1/OPN expression 
(responsible for osteopontin production) was also interesting, as there was a 
significant down-regulation of the gene in both the osteogenic control and the MI192 
pre-treated cells, but the down-regulation was greater in the MI192 pre-treated cells.  
 
The expression of these changes was also investigated when the effect of MI192 
treatment on gene expression changes, without osteogenic differentiation was 
explored in Chapter 7:. In that study, there was a large increase in the expression of 
BMP2, while COL1 and RUNX2 expression were both down-regulated with MI192 
treatment. This matches the data seen in Chapter 5:, where at day 3 the expression 
pattern was similar. The results for OCN and ALP were inconclusive, with mixed 
results between donors (although there was an overall trend of down-regulation, 
matching the decrease in expression at day 3 seen in this experiment). The only 
conflicting result was with SPP1, where expression was increased with MI192 
treatment before osteogenic induction, but was found to be decreased throughout the 
experiment here. The effect of the osteogenic medium has clearly had a strong effect 
on the expression of SPP1 in these cells. Also investigated before MI192 induction 
were Wnt related genes, and other genes related or down-stream of BMP2. In 
hindsight, it may have been useful to investigate genes such as these during the 
differentiation process.. 
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Importantly there was an increase in functional mineralisation in the MI192 pre-
treated cells seen with a Von Kossa stain. This study was limited in that it only 
investigates the mineralisation at one, quite late time point. It would have been 
interesting to investigate the mineralisation over time, with earlier time points. MI192 
may have also resulted in the quicker mineralisation of the ADSCs. This may have 
been due to the decrease in SPP1 expression and this Opn formation, allowing more 
free and less controlled mineralisation. 
 
A decrease in adipogenic differentiation potential was seen in the cells pre-treated 
with MI192. With adipogenic differentiation induction, the lipid accumulation and 
adipogenic gene expression was seen to be greatly decreased in the cells pre-treated 
with MI192. The inhibition of HDAC2 and HDAC3 in combination appears to have a 
negative effect on the adipogenic differentiation potential of the ADSCs. This is 
countered with a large increase in the osteogenic differentiation potential of these 
cells. This was in contrast to reports that HDAC inhibition would promote the 
adipogenic differentiation of cells, (Yoo et al. 2006) (Jiang et al. 2013), although these 
were with a 3T3-L1 mouse fibroblast/adipocyte cell line. The most relevant study 
found that HDAC3 inhibition inhibited  PPARγ expression in ADSCs (Maroni et al. 
2012), so the findings of this study corroborate the findings of Maroni et al. The 
addition of a HDAC2 inhibitory effect does not seem to have an impact on the 
adipogenic differentiation of the ADSCs. This adipogenic inhibitory effect must be 
considered when using MI192, as it could be a detrimental side effect of using the 
compound in a physiological setting. These results were actually in contrast with the 
results seen in Chapter 7:, where the adipogenic potential was seen to increase. This 
only goes to highlight how changes in gene expression cannot be used in isolation to 
draw conclusions. 
 
The effect of MI192 on ADSCs was also investigated in a number of 3D culture 
models. Three different experimental designs were investigated, so the best design 
could be found for any future work. While all three were not carried out at the same 
time, so they are not a direct comparison, the conclusions are clear. The strategy with 
the best outcome was experimental design 3, where cells were pre-treated for two 
days in 2D before seeding, in equal numbers, onto the scaffolds. In hindsight this is 
much more informative of the effects of MI192 on the differentiation potential of the 
cells than experimental design 1, as this allows for a fairer test with the cell numbers 
(at least at the time of seeding) being equal. 
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The treatment with MI92 was shown to increase the mineralisation of the ADSCs, and 
increase collagen production in 3D. The mineralisation and collagen production was 
highest in the scaffolds seeded with the 10 µM MI192 pre-treated cells, not those pre-
treated with 30 µM of MI192 which was expected due to the results seen in the 2D 
studies. This may be a sign that in the long term a lower than initially optimal dose of 
MI192 may be the best. These results matched those found in monolayer (Chapter 
5:); there was an increase in COL1 expression found in cells pre-treated with MI192, 
and the Von Kossa and Alizarin Red staining indicated that mineralisation potential 
was increased with MI192 treatment. 
 
MI192 treatment didn’t lower or raise levels of bone proteins Ocn and Runx2 over 
osteogenic controls, despite the indication from monolayer gene expression 
quantification. However, collagen 1 levels were increased in the MI192 treated cells, 
which matched the increased Sirius red for collagen staining seen, and the increase 
in COL1 expression (Chapter 5:). These results combined with the increase in 
mineralisation and collagen staining indicates promising results for the utilisation of 
MI192 to improve bone tissue engineering in long term 3D models. 
 
Exploring the gene expression changes without any osteogenic induction yielded 
some interesting results. The BMP and Wnt pathway are interconnected, and key 
genes related to increase in the activity of these pathways were up and down-
regulated (BMP2, BMP4, FRZB and SFRP1, as well as the down-regulation of 
SFRP4, ACVR1B and ACVR2A) (Zhang et al. 2013; Enomoto-Iwamoto et al. 2002; 
Mizuno et al. 2009; Maeda et al. 2004). It was found that that the treatment for two 
days with MI192 increases the activation of these pathways, which may in turn 
account for a down-stream increase in osteogenic differentiation pathways. 
Furthermore, up-regulated of IGF2 and down-regulation of IGFBP3 and MSX1 also 
indicates a priming for osteogenic differentiation (Ding et al. 2015; Kang et al. 2012; 
Zhong et al. 2011; Feng et al. 2013). A large proportion of genes linked to 
endochondral ossification were also up-regulated (e.g. FRZB, COL2, CHAD and 
FGFR3), which may also aid in the general increased osteogenic potential of the 
cells.  
 
Many of the later stage osteogenic differentiation marker genes, such as ALP, 
SPARC, PMF-BGLAP, COL1A1 and COL1A2 were down-regulated, highlighting the 
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already demonstrated need for osteogenic induction; MI192 treatment alone is not 
enough to induce osteogenic differentiation in these cells.  
 
8.1.1 Summary  
The aim of this study was to investigate the effect of MI192 on ADSC behaviour. The 
study has investigated a wide range of effects of the HDAC2 and HDAC3 specific 
HDACi MI192 on ADSCs, including how it affects cell viability, the cell cycle, stem cell 
markers and gene expression. MI192 was found to be cytotoxic and affect cell 
viability in doses as low as 10 µM. Treatment with MI192 also halted the cells in the 
G2/M phase of the cell cycle and altered the expression of stem cell markers on the 
ADSCs. The second part of the aim was to investigate this with regards to bone 
tissue engineering. MI192 was found to improve the osteogenic differentiation of the 
ADSCs, in several 2D and a 3D model of differentiation. The opposite was found with 
regards to adipogenic differentiation, MI192 treatment greatly reduced the adipogenic 
potential of the cells. Due to the cytotoxic and cell viability reducing effects of MI192, 
a pre-treatment strategy was employed, where cells are typically only exposed to 
MI192 for 2 days. Cells pre-treated with MI192 were found to have improved 
osteogenic differentiation seen with increased ALP expression, osteogenic gene 
expression and mineralisation in 2D. Effects were similar in 3D, with an increase in 
collagen production and mineralisation in constructs seeded with cells pre-treated 
with MI192 observed. 
 
The mechanism by which MI192 improves the osteogenic differentiation potential of 
the cells was investigated. The increase in CD34 and CD146 stem cell markers 
indicates that the cells are taking on a new profile. Halting the cell in the G2/M phase 
may be part of the priming effect that MI192 is having on the cells, as cells that are 
undergoing differentiation are not proliferating. This may also account for a decrease 
in proliferation and the cytotoxic effect seen with MI192 treatment. The gene 
expression studies indicate that before osteogenic induction, some key Wnt related 
genes, as well as other key osteogenic genes such as BMP2 were up-regulated. 
These are key osteogenic transcripts and the proteins these encode for are likely 
responsible for the increase in osteogenic differentiation potential of the cells. 
However, it was demonstrated that osteogenic induction is needed to see the cells 
actually differentiate down an osteogenic lineage. During differentiation there is a 
spike (a higher expression than the osteogenic control) in BMP2 expression seen 
initially at day 3, followed by spikes in ALP, COL1 and RUNX2 expression. All of 
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these are classic genes in osteogenic differentiation and spikes in these clearly result 
in the increased differentiation potential seen by the MI192 pre-treatment. The down-
regulation of SPP1 may account for the increased mineralisation potential of the cells. 
Mechanistically speaking this combined goes someway to explaining why MI192 has 
the effects seen on ADSCs. 
 
Summary of key conclusions:  
 MI192 had a cytotoxic and cell viability reducing effect on ADSCs. 
 MI192 inhibited the HDAC activity of ADSCs. 
 MI192 halted the cell cycle in the G2/M phase.  
 MI192 altered stem cell markers expressed on cells, with a rise in expression 
of CD34 and CD146, a decrease in expression of CD29, CD44, CD73, 
CD105, CD166 and no change in the expression of CD45 and CD90. 
 MI192 pre-treatment increased the ALP expression of ADSCs. 
 MI192 pre-treatment altered the osteogenic gene expression patterns of 
ADSCs, with increases in RUNX2, BMP2, ALP and COL1 and decreases in 
OCN/BGLAP and SPP1 expression over osteogenic controls. 
 MI192 pre-treatment increased the mineralisation of ADSCs, increasing 
calcium accumulation and mineral nodule formation.  
 MI192 pre-treatment reduced the adipogenic potential of ADSCs, reducing 
lipid droplet accumulation and adipogenic gene expression. 
 MI192 pre-treatment of cells for 2 days prior to seeding on Am silk scaffolds 
increased the osteogenic differentiation of ADSCs in long term (6 week) 3D 
tissue culture models of osteogenic differentiation.  
 M192 treatment of cells altered the transcriptional profile of the cells, with 
some key early osteogenic pathway related genes being increased. 
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8.2 Conclusion  
Pre-treatment of ADSCs with the HDAC2 and HDAC3 specific HDAC inhibitor MI192 
was found to increase the osteogenic differentiation potential and decrease the 
adipogenic differentiation potential of ADSCs. This was while having a cytotoxic and 
viability decreasing effect on ADSCs, along with altering expression of stem cell 
markers and halting the cell cycle in the G2/M phase. MI192 pre-treatment was also 
found to increase the osteogenic differentiation of ADSCs in 3D culture models 
utilising Am silk scaffolds. Finally, MI192 treatment of ADSCs for two days was found 
to alter the gene expression profile of ADSC, with some key early osteogenic 
pathway related genes being increased. 
 
8.3 Future Work  
An alternative synthetic route for M192 may be worth exploring to allow the scale up 
of MI192. This may be necessary if any large scale studies were undertaken in the 
future. Cancer Research Technologies, the commercial partner who provided a 
sample for the comparison of MI192 batches experiment, have synthesised MI192 in 
their laboratories, and may have alternative routes accessible to save time and 
resources.  
 
In terms of improving upon experiments already undertaken; the effect of MI192 on 
the HDAC activity of the ADSCs could be explored with a greater dose response and 
with more time points, to investigate fully how and how quickly MI192 acts on the 
ADSCs; cell sorting to isolate the potentially formed subpopulation of cells and 
comparison to the other population of the MI192 treated cells, and untreated cells 
would be interesting; assessing the marker expression of more stem cell markers on 
the treated cells would give a better picture of the cells after MI192 treatment; further 
experiments investigating the mineralisation would be useful for drawing full 
conclusions, longer and shorter time points would provide a better picture; and finally, 
further assessment of the 3D studies, with longer time points and more conclusive 
immunohistochemical studies would be interesting.  
 
Further experiments could include work with siRNAs. siRNAs are another tool utilised 
by researchers to target specific HDAC isoforms and can knock down specific genes, 
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thereby affecting enzyme levels in the cell. However, siRNAs only degrade mRNAs, 
preventing the formation of new proteins, so don't inhibit the already formed proteins 
in the cells. These have been utilised to knock down HDAC1 and HDAC3 in 
combination in ADSCs, which improved the osteogenic potential of the cells (Maroni 
et al. 2012). No studies have investigated the effect of knocking both HDAC2 and 
HDAC3 down with siRNAs, except with relation to the cell cycle (Ye et al. 2013).  An 
interesting future study would be to explore the knock down of HDAC2 and HDAC3, 
with siRNAs, and to see if it has the same effect on ADSCs as treatment with MI192. 
This may help explain the mechanism behind the improvement to osteogenic 
differentiation seen with MI192 treatment.  
 
To best explore the effect of a compound such as MI192 on the differentiation of cells 
is in an in vivo model. In vivo models have been used to investigate how HDACis 
effect cells in vivo in a limited number of studies, there are definite gaps in the 
knowledge in the literature. The scaffolds from experimental design 3 in the 3D 
chapter could be implanted in in vivo models to investigate how the cells react under 
more realistic physiological conditions than in vitro culture conditions. The scaffolds 
could be implanted in a diffusion chamber, which separates the scaffold from the host 
tissue and cells, but still provides a physiological relevant model better than a tissue 
culture incubator, as growth factors, minerals, nutrients etc are able to diffuse into the 
chamber (W. Lu et al. 2014; Yang et al. 2003).  Subcutaneous implantation model 
could also be used, where the scaffolds are in contact with host cells as well. 
Alternatively, or after conclusions are drawn from a diffusion chamber model, 
scaffolds can be implanted in a defect models (such as those utilised  by Lee et al, 
where Largazole demonstrated bone-forming activity in mouse calvaria defect models 
(Boer et al. 2006)). These provide a model of bone healing, investigating if the 
scaffolds aid bone healing. If the constructs with cells pre-treated with MI192 
provided a better healing of a bone defect, the conclusion that MI192 improves the 
osteogenic differentiation of ADSCs would be more concrete. An alternative model to 
investigate the effect of MI192 on bone healing would be to implant scaffolds soaked 
in MI192 medium, with no cells seeded, into defects. This would indicate if MI192 
could be incorporated in simpler models of bone healing and just aid the host cells in 
the process. 
 
With regards to the more general effects of MI192 on ADSCs, there could be more 
exploration of the apoptotic effects of MI192. How the cells are dying and if this could 
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be prevented could be explored. The levels of stress markers, cytokines or DNA 
fragmentation in the cells could be measured to indicate pathways by which this is 
happening. Comparison of different morphological, biochemical, and cell-cell 
interaction changes can indicate if the cells are dying from apoptosis, autophagy or 
necrosis (Krysko et al 2008).  
 
Furthermore, the cells which detached on MI192 treatment were assumed to be 
apoptotic dead cells and were never investigated. There was no guarantee that these 
cells were in fact dead, and MI192 may merely have affected their adhesion 
properties. Further characterisation of these cells, to either confirm cell death or 
attachment, should be carried out.   
 
The effect of MI192 on the angiogenic potential of these cells has not been explored, 
and it would be interesting to link this to the results from the effect of MI192 on the 
stem cell markers. This may be best undertaken in vivo. Sorting for certain markers 
after MI192 treatment could lead to the isolation of an interesting subpopulation of 
cells, perhaps with increased osteogenic differentiation potential.  
 
While the effect of MI192 was explored on osteogenic and adipogenic differentiation, 
the third part of the classical trilineage test of differentiation is chondrogenic 
differentiation. Chondrogenic differentiation and osteogenic differentiation are closely 
linked in the body, as can be seen in processes such as endochondral ossification. It 
was demonstrated that with MI192 treatment came an increase in expression of 
genes such as Wnt pathway promoters and BMP4, so MI192 may increase 
chondrogenic differentiation of the ADSCs. This could be explored through pellet 
culture or scaffold studies. Furthermore, only ADSCs were explored in this study. 
While they are an abundant and very promising source of MSCs for use in the clinic, 
there are alternative benefits to utilising bone marrow MSCs. They are more 
commercially explored and more studies have been undertaken with them, giving a 
wider knowledge base. The effect of MI192 on those, or other MSCs (with their own 
plethora of advantages and disadvantages) would be very interesting.                             
 
The work in this study was only carried out on ADSCs. As discussed extensively in 
the Introduction, ADSCs are a useful and plentiful source of MSCs. However, they 
only represent one source of stem cells. For future commercialisation, it may be 
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useful to explore alternative sources of stem cells. ADSCs are most comparable to 
other MSCs such as bone marrow MSCs (Wagner et al. 2005). Therefore, it would be 
useful from a translational perspective to compare the effects of MI192 on bone 
marrow MSCs to ADSCs, especially to see if the same increased osteogenic 
differentiation potential was observed. If the results could be translated into all types 
of MSCs, or even other sources of stem cells, then the potential usefulness of MI192 
would be greatly increased. Bone marrow MSCs are the best characterised and 
commercialised MSCs, so a compatibility with those cells would be a great advantage 
in commercialisation of MI192. 
 
Finally, the actual commercialisation of MI192 need to be explored. Based on the 
results obtained in this study, MI192 could be utilised as part of a pre-treatment 
strategy to improve the osteogenic potential of ADSCs (or maybe all MSCs) in vitro. It 
could be sold in medium as part of a media package, where a pre-treatment medium 
is used with the cells prior to full differentiation. Or further work with lower doses may 
indicate it could be included as a component of medium for use with the cells the 
‘whole time’. Alternatively, it could be sold as a supplement in powder form and 
researchers optimise their own treatment strategies with.  
 
Further, ADSCs treated (or “primed”) with MI192 could be sold as a cell source 
capable of osteogenic differentiation. The cells could be treated with MI192, frozen, 
packaged and sold ready for use. If the cells were not grown in any osteogenic 
medium, and only primed, then researchers/clinicians could tailor differentiation 
protocols to suit their needs. Presently, this research has focused on osteogenic 
differentiation, and there looks to be potential to utilise them with scaffolds. If this 
work was to be continued, such scaffolds could be implanted in bone defects, such 
as those created when fractures are too large to heal alone (critical-size defects). 
This would work best for hard bone, but could potentially be applied in reconstruction 
of craniofacial bone. Standardisation of protocols and full characterisation of the 
treated cells would be key if this was the case, to meet regulatory standards.  
 
Without further work, nothing can be concluded about its potential usefulness in other 
scenarios, such as incorporation in scaffolds. Intellectual property on the compound 
is owned by the Grigg group, and a patent application is pending for MI192 for in 
cancer treatment. Further patent applications could be filed with second medical use 
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type claims, where the patent claimed the compound for use as a tool for improving 
the osteogenic differentiation of stem cells.                                         . 
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Appendix A 
Supplementary Lab Data 
A.1 - NMR Spectra 
Full NMR spectra for the compounds synthesised in Chapter 3: The Chemical 
Synthesis of MI192 follows. The peaks are described in 3.3: Results.  
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Figure A.1 - NMR spectrum for compound 1 (4-(4,6-Dimethoxy-1,3,5-triazin-2-
yl)-4-methylmorpholinium tetrafluoroborate. 
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Figure A.2 - NMR spectrum for compound 2 (((Tert-
butoxycarbonylamino)methyl)benzoic acid). 
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Figure A.3 - NMR spectrum for compound 3 (tert-Butyl 4-(2-
aminophenylcarbamoyl)benzylcarbamate). 
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Figure A.4 - NMR spectrum for compound 4  (4-(Aminomethyl)-N-(2-
aminophenyl)benzamide). 
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Figure A.5 – NMR spectrum for MI192. 
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A2 - Confirmation of tri-linage differentiation potential of 
ADSCs 
 
The ADSCs were capable of mineralised nodule formation, indicating osteogenic 
differentiation, after 28 days growth in osteogenic induction medium, with calcium 
mineralisation stained red by Alizarin Red staining (Figure A.6 A). The 
mineralisation stain was much stronger than in the negative basal control, where no 
staining was observed.  
 
The ADSCs were capable of lipid droplet accumulation, indicating adipogenic 
differentiation, after 14 days growth in adipogenic induction medium (Figure A.6 B). 
The lipid droplet stain was much stronger than in the negative basal control, where 
no staining was observed.  
 
The ASCSs were also capable of producing Glycosaminoglycans (GAGs) (stained 
blue with an Alcian blue stain) and a collagenous capsule around a pellet (stained 
red with a Sirius red stain), indicating chondrogenic differentiation, after 21 days 
growth in a pellet culture model in chondrogenic induction medium (Figure A.6  C). 
The collagen and GAG staining was much stronger than in the negative basal 
control, where weak staining was observed. 
 
 
 
 
 
 
xliii 
 
 
 
 
Figure A.6 – Confirmation of tri-lineage differentiation potential of ADSCs. A: 
Osteogenic differentiation: ADSCs capable of mineralisation after 28 days 
growth in osteogenic induction medium, stained red for calcium by Alizarin 
Red staining; B: Adipogenic differentiation: ADSCs capable of lipid droplet 
formation after 14 days growth in adipogenic induction medium, stained red 
for lipid droplets by oil red O staining; C: Chondrogenic differentiation: ADSCs 
capable of forming cartilage like pellets after 21 days growth in a pellet model 
and chondrogenic induction medium, stained blue for GAGs by Alcian Blue 
staining and red for collagen by Sirius Red staining. Scale bars = 100 µM. 
 
      
   
 
 
A 
B 
C 
Basal controls 
 
Induction medium 
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A3 - Investigation of the effect off 1% – 0.01% DMSO has on 
ADSC cell number and viability 
 
To ensure that MI192 dissolved, a stock solution was first made up with DMSO, 
which was then further diluted in culture medium, resulting in cells being exposed to 
potentially harmful DMSO. A summary of the equivalent DMSO percentages cells 
would be exposed to with the relevant doses of MI192 can be seen in Table A 0-1. 
To investigate the effect DMSO has on ADSCs, ADSCs were cultured with a 
relevant range of DMSO concentrations and the effect investigated. 
 
PicroGreen® was used to assess the effect on total cell number DMSO had on 
ADSCs (Figure A.7). Total DNA content at a range of DMSO concentrations, across 
three days, was compared to a basal, untreated, negative control. These dose 
ranges and times cover every dose in this thesis. After one day of treatment with a 
range of DMSO concentrations, DNA content similar was the same as the negative 
basal control. At day 2 and day 3 the 1% DMSO dose showed a reduced cell 
number, presumably DMSO was having a cytotoxic effect on the cells. All other 
doses (0.5% - 0.01%) showed a total DNA content similar to the negative basal 
control.  
 
The cell viability was investigated after 2 days of culture with DMSO (the most 
common dose length for experiments in this thesis) with the CellGlo® ATP 
measuring cell viability assay (Figure A.8). Cell viability was found to be in the 
range of the negative basal control at all concentrations of DMSO. This was not 
normalised to cell number, but the cell numbers should be the same across the 
groups according to the PicoGreen® results (Figure A.7), except the 1% DMSO 
group, which would only be increased by normalisation to cell number, bringing it 
closer to the negative basal control.  
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Table A 0-1 - The equivalent DMSO percentage which cells will be exposed to 
when dosed with MI192 
 
MI192 dose Equivalent DMSO % 
100 µM 1 % 
50 µM 0.5 % 
40 µM 0.4 % 
30 µM 0.3 % 
20 µM 0.2 % 
10 µM 0.1 % 
1µM 0.01 % 
 
0.0
0.5
1.0
1.5
Effect of DMSO on total cell number
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1% DMSO
0.5% DMSO
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Figure A.7- DMSO effect on cell numbers. Quant-iT™ PicoGreen® analysis of 
ADSCs treated for 1 day, 2 days and 3 days with a range of concentrations of 
DMSO (1% - 0.01%), normalised to a 0% basal sample for each time point. 
Results expressed as mean ± SD (n=3). Dotted line represents the negative, 
basal control normalised to 1. 
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Figure A.8 - CellTiter-Glo® analysis of ADSCs treated with a range of 
concentrations of DMSO (1% - 0.01%) for 2 days. Results expressed as 
mean ± SD (n=3).  
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A4 - Effect of MI192 on ADSC Stem Cell Markers: FACs plots 
and autofluorescence comparison histograms 
 
The expression of 9 commonly used stem cell markers (see Table 4-1 for full 
details) was investigated in ADSCs treated with MI192 (30 µM for 2 days), 
compared to untreated basal medium controls. Markers were assessed as a group 
of three (CD29/CD73/CD90) and three groups of two (CD34/CD45, CD44/CD166 
and CD146/CD105).  
 
Representative dot plots of the events (after gating for intact cells) were produced 
for the groups of markers for both the untreated (Figure A.9) and the MI192 treated 
ADSCs (Figure A.10). Also shown are histograms showing the expression of the 
marker compared to the autofluorescence of the cells, for both untreated (Figure 
A.8) and the MI192 treated ADSCs (Figure A.9). This was to account 
autofluorescence when analysing the markers, and to ensure there was no overlap 
with the expressing populations. Any differences in peak size/areas is due to 
variations in the event counts.  
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Figure A.9 – Representative FACs plots showing flow cytometric analysis of 
stem cell markers in untreated ADSCs. A – CD29/CD73; B – CD34/CD45; 
C – CD44/CD166; D – CD73/CD90; E – CD90/CD29 and F – CD146/CD105. 
Markers plotted in pairs, with the first marker listed on the Y Axis.  
E. CD90 / CD29 F. CD146 / CD105 
D. CD73 / CD90 C. CD44 / CD166 
B. CD34 / CD45 A. CD29 / CD73 
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Figure A.1010 - Representative FACs plots showing flow cytometric analysis 
of stem cell markers in MI192 treated ADSCs. A – CD29/CD73; B – 
CD34/CD45; C – CD44/CD166; D – CD73/CD90; E – CD90/CD29; F – 
CD146/CD105. Markers plotted in pairs, with the first marker listed on the Y 
Axis. 
F. CD146 / CD105 E. CD44 / D166 
D. CD90 / CD29 C. CD73 / CD90 
B. CD34 / CD45  A. CD29 / CD73 
l 
 
 
 
Figure A.111 - Representative histograms showing flow cytometric analysis 
of stem cell markers in untreated ADSCs. A – CD29, B – CD34, C – CD44, 
D – CD45, E – CD73, F – CD90, G – CD105, H – CD146, I – CD166. 
Histograms showing count for each marker (green colour) compared to a 
negative control (blue colour) and for each marker alone (red). 
 
C. CD44 
I. CD166 
B. CD34 A. CD29 
D. CD45 
E. CD73 F. CD90 
G. CD105 H. CD146 
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Figure A.12 - Representative histograms showing flow cytometric analysis of 
stem cell markers in MI192 treated ADSCs. A – CD29, B – CD34, C – 
CD44, D – CD45, E – CD73, F – CD90, G – CD105, H – CD146, I – CD166. 
Histograms showing count for each marker (green colour) compared to a 
negative control (blue colour) and for each marker alone (red). 
A. CD29 B. CD34 
D. CD45 C. CD44 
F. CD90 E. CD73 
H. CD146 
G. CD105 
I. CD166 
G. CD105 
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A5 – qRT-PCR choice of housekeeping gene and standard 
curves 
A5.1 - Choice of Housekeeping Gene for qRT-PCR Assays 
 
For all qRT-PCR experiments, it is standard practice to use a housekeeping to 
normalise the expression of target genes. An endogenous control housekeeping 
gene should expressed at a constant level in the samples, and is essential to act as 
a reference to reduce possible errors (Rubie et al. 2005; Ragni et al. 2013). 
 
The more stable the housekeeping gene, the better for determining the change in 
expression of other genes. GAPDH is a commonly used housekeeping gene; 
however, there is an argument there are even more stable genes available. 
Previous work in the department, and a journal article on the topic (Ragni et al. 
2013), suggested that YWHAZ may be a more stable gene, especially for 
differentiation protocols.  
 
A comparative study between Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase 
Activation Protein (YWHAZ) was undertaken to determine the most stable 
housekeeping gene. For four different conditions from the adipogenic differentiation 
experiment outlined 5.3.7: Assessment of the effect of MI192 pre-treatment on the 
adipogenic gene expression of ADSCs in Chapter 5: The Effects of MI192 on the 
Differentiation of Adipose Derived Stem Cells in 2D. The expression of the two 
genes was calculated, in biological triplicate and with three technical repeats for a 
total of n = 18 for each condition. Graphs of the mean ± SE was plotted (Figure 
A.13) and the statistical significance was determined by Kruskal-Wallis 1 way 
ANOVA test, using Graphpad Version 5 of variance between the Ct values. 
Calculated was a p value of 0.0016 for YWHAZ (**, P ≤ 0.01) and 0.0005 for 
GAPDH (***, P ≤ 0.001) The lower variance with the YWHAZ housekeeping gene 
between samples resulted in this being selected for all qRT-PCR experiments.  
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Figure A.12 – Housekeeping gene comparison. CT values for expression of 
YWHAZ (A) and GAPDH (B) derived from 13 samples, in triplicate, from the 
adipogenic differentiation experiment (5.3.7: Assessment of the effect of 
MI192 pre-treatment on the adipogenic gene expression of ADSCs) 
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A5.2 - Standard Curves for qRT-PCR Assays 
 
qRT-PCR was performed using TaqMan gene expression assays (Life 
Technologies) and the full list of genes and assays can be found in 4.2: Materials 
and Methods for Chapter 4: The General Effects of MI192 on Adipose Derived 
Stem Cells Cultured in Monolayer. Optimal cDNA concentration for assays, and 
probe efficiency was investigated by plotting standard curves for each probe using 
known cDNA concentrations, from a day 0 sample of cells, against generated Ct 
values for reactions where all other variables (water, master mix and probe used) 
all stayed the same. Standard curves allow the user to check that the primer/probe 
sets are running efficiently. Serial dilutions of cDNA were run with each 
primer/probe set to produce the standard curves. No template controls were also 
run to check for unwanted reactions. All reactions were run in triplicate and the 
average Ct value for each Log10 concentration of cDNA was plotted, to give the 
standard curve (Figure A.14).  
 
Probe efficiency for all genes of interest was satisfactory, as all lines had an R2 
value of 0.97 or over. ADIPOQ was the exception, as no Ct value was generated for 
any concentration of cDNA. However, with samples which had undergone 
adipogenic expression, transcripts could be detected, and the probe worked well 
within the context of the experiment, so it was used and assumed to be efficient as 
all of the other Taqman probes were. 
 
A reaction of 5 ng of cDNA was deemed to be acceptable, allowing changes of 
gene expression to be observed while using a lower amount of RNA from samples 
with a low RNA yield. 
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Figure A.14 – Standard curves. Generated from serial dilutions of a day 0 P5 
untreated/differentiated ADSC sample, for the amplification of target genes 
(RUNX2, BMP2, ALP, OCN, COL1, OPN and PPARG) and YWHAZ 
housekeeping gene.  
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Appendix B 
List of conference presentations and publications 
B.1  Oral Presentations 
 The Effect of a Novel HDACi on Osteogenic and Adipogenic Differentiation 
of Human Adipose Derived Stem Cells. CDT/DTC Joint Conference, 10th 
July 2015.  
 The Effect of a Novel HDACi on Osteogenic and Adipogenic Differentiation 
of Human Adipose Derived Stem Cells. Leeds School of Dentistry 
postgraduate research day, 8th July 2015. (First place – oral presentation 
awarded) 
 A NOVEL HDACI CAN IMPROVE OSTEOGENIC DIFFERENTIATION OF 
HUMAN ADIPOSE DERIVED STEM CELLS. Biomaterials & Tissue 
Engineering Group 16th Annual White Rose Work in Progress Meeting 
(BITEG), 22nd December 2014. 
 A novel HDACi can improve osteogenic differentiation of human adipose 
derived stem cells. Leeds School of Dentistry postgraduate research day, 
9th July 2014. 
B.2  Poster Presentations 
 The Effect of a Novel HDACi on Osteogenic Differentiation of Human 
Adipose Derived Stem Cells. Small-molecule potentiation and differentiation 
of stem cells: a growth area? Royal Society of Chemistry Symposium, 20 
April 2015. 
 A novel HDACi can improve osteogenic differentiation of human adipose 
derived stem cells. Tissue & Cell Engineering Society (TCES) annual 
conference, July 2nd - 4th July 2014 
 A novel HDACi can improve osteogenic differentiation of human adipose 
derived stem cells. CDT/DTC Joint Conference, 11th July 2014. 
 THE EFFECT OF HDAC INHIBITORS ON HUMAN DENTAL PULP 
STROMAL CELLS FOR CHONDROGENESIS IN VITRO Biomaterials & 
Tissue Engineering Group 15th Annual White Rose Work in Progress 
Meeting (BITEG), 19th December 2013. 
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 The effect of HDAC inhibitors on stem cell behaviour. Leeds School of 
Dentistry postgraduate research day, 9th July 2014. 
 The effect of HDAC inhibitors on stem cell behaviour – the potential of using 
HDACis for bone tissue engineering. CDT/DTC Joint Conference, 12th July 
2013.  
 The effect of HDAC inhibitors on stem cell behaviour. Leeds School of 
Dentistry postgraduate research day, 9th July 2013. 
 The effect of HDAC inhibitors on stem cell behaviour – the potential of using 
HDIs for bone tissue engineering. CDT/DTC Joint Conference, 20th July 
2012.  
B.3  Book Chapter 
Lawlor, L., Grigg, R. and Yang, X. 2014 In Vivo Imaging of Bone. In: In Vivo 
Imaging: New Research. eBook: Nova Science Publishers Inc. ISBN-10: 
1629486337 
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Appendix C 
Rights Permissions for Figures from Journal Articles 
Rights for reuse in a thesis were obtained for the images seen in Figure 1.1, 1.2, 
1.4, 1.8 and 6.1. Details below. 
 
 
 
 
